metronidazole has been researched along with Infections, Helicobacter in 1814 studies
Metronidazole: A nitroimidazole used to treat AMEBIASIS; VAGINITIS; TRICHOMONAS INFECTIONS; GIARDIASIS; ANAEROBIC BACTERIA; and TREPONEMAL INFECTIONS.
metronidazole : A member of the class of imidazoles substituted at C-1, -2 and -5 with 2-hydroxyethyl, nitro and methyl groups respectively. It has activity against anaerobic bacteria and protozoa, and has a radiosensitising effect on hypoxic tumour cells. It may be given by mouth in tablets, or as the benzoate in an oral suspension. The hydrochloride salt can be used in intravenous infusions. Metronidazole is a prodrug and is selective for anaerobic bacteria due to their ability to intracellularly reduce the nitro group of metronidazole to give nitroso-containing intermediates. These can covalently bind to DNA, disrupting its helical structure, inducing DNA strand breaks and inhibiting bacterial nucleic acid synthesis, ultimately resulting in bacterial cell death.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Inpatients with peptic ulcer complications who were not able to take oral medicine were randomly assigned to three groups: triple therapy (esomeprazole, levofloxacin, metronidazole) and dual therapy (esomeprazole, levofloxacin/metronidazole) for 7 days." | 9.69 | Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study. ( Chen, J; Gui, Q; Liang, X; Lu, H; Su, W; Yu, D; Zhang, W; Zhu, C, 2023) |
| "To assess the efficacy and safety of omeprazole given with the new single capsule of bismuth, metronidazole and tetracycline (OBMT) compared with quadruple treatment consisting of omeprazole, bismuth, amoxicillin and clarithromycin (OBAC) for Helicobacter pylori eradication in duodenal ulcer patients." | 9.27 | New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro ( Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G, 2018) |
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 9.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 9.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 9.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 9.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin)." | 9.10 | [Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. ( Firsanova, VIu; Kolomiets, EV; Vasil'ev, IuV; Zvenigorodskaia, LA, 2002) |
| "One hundred and forty-nine consecutive patients with active duodenal ulcer were randomized to receive omeprazole (20 mg b." | 9.10 | Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. ( Amberiadis, P; Archavlis, E; Chiotakakou, E; Christoforidis, P; Kourtessas, D; Mantzaris, GJ; Petraki, K; Triantafyllou, G, 2002) |
| "This multicenter, randomized, active-controlled trial assessed efficacy of bismuth-based quadruple therapy with omeprazole, bismuth biskalcitrate, metronidazole, and tetracycline (OBMT) using a single-triple capsule of BMT compared with triple therapy with omeprazole, amoxicillin, and clarithromycin (OAC) in treatment of patients with Helicobacter pylori infection and duodenal ulcers." | 9.10 | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a ( El-Zimaity, H; Hunt, R; Laine, L; Nguyen, B; Osato, M; Spénard, J, 2003) |
| " pylori-positive patients with active gastric ulcer were randomized to receive pantoprazole (40 mg) (P) and two of three antibiotics: clarithromycin (500 mg) (C), metronidazole (500 mg) (M) or amoxicillin (1000 mg) (A)." | 9.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 9.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| "To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer." | 9.09 | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. ( Bayerdörffer, E; Bradette, M; Farley, A; Leddin, D; Lind, T; O'Morain, C; Sinclair, P; Sipponen, P; Spiller, RC; Unge, P; Wrangstadh, M; Zanten, SJ; Zeijlon, L, 1999) |
| " pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CBP, 100 mg qid (group 2) for 2 weeks, then continued CBS, 240 mg, or CBP, 200 mg bid for a further 2 weeks." | 9.09 | Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. ( Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H, 1999) |
| " Our main objective was to study the outcome of a non-metronidazole and omeprazole-based antibiotic regimen in eradicating Helicobacter pylori in patients with duodenal ulcer." | 9.09 | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. ( Abdulle, AM; Adeyemi, EO; Benedict, S; Danial, MF; Helal, T, 1999) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 9.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 9.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| "A total of 59 consecutive Helicobacter pylori infected non-ulcer dyspepsia patients were randomly selected to receive either one of two triple therapy regimens, including metronidazole, amoxycillin plus ranitidine bismuth citrate (RAM group) or omeprazole (OAM group)." | 9.09 | Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia. ( Chuang, CH; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB, 2001) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 9.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| "Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b." | 9.09 | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( Barthélemy, P; Caekaert, A; Fléjou, JF; Laurent, J; Mégraud, F, 2001) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 9.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 9.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 9.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 9.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 9.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "This double-blind, randomized, phase III clinical trial was carried out in two parallel groups to assess the efficacy of ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene) amino]-4-thiazolyl]methyl]thio]ethyl]amino] methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) 400 mg and ranitidine 300 mg given in single evening dose, combined with amoxicillin 750 mg and metronidazole 500 mg three times daily for 14 days, in the eradication of Helicobacter pylori in patients with duodenal ulcer." | 9.08 | Efficacy of ebrotidine and ranitidine combined with amoxicillin and metronidazole in the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Fillat, O; Herrero, E; Karcz, D; Kulig, J; Márquez, M; Ortiz, JA; Popiela, T; Tabor, J; Torres, J, 1997) |
| "In patients with active duodenal ulcer, a 10-day course of amoxycillin-clarithromycin-based triple therapy without additional acid suppression is highly effective in eradicating H." | 9.08 | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. ( Archambault, A; Archimandritis, A; Bazzoli, F; Fedorak, R; Hentschel, E; Megraud, F; Mora, P; Rodrigo, L; Rokkas, T; Skandalis, N; Stamler, D; Wurzer, H, 1997) |
| "To estimate and compare the efficacy of 'triple' 1-week regimens--omeprazole, clarithromycin and a nitroimidazole (metronidazole or ornidazole)--followed by omeprazole, for an additional 3 weeks, on Helicobacter pylori eradication and duodenal ulcer (DU) healing, in a country with a high resistance rate of H." | 9.08 | One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. ( Archimandritis, A; Balatsos, V; Davaris, P; Delis, V; Kanellopoulou, E; Manika, Z; Skandalis, N; Souyioultzis, S; Tzivras, M, 1997) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 9.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 9.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| " In study II 22 duodenal ulcer patients were given bismuth subnitrate, oxytetracycline, and metronidazole (triple therapy) for 2 weeks to eradicate H." | 9.07 | Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients. ( Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K, 1994) |
| "To determine the distribution of Helicobacter pylori in the antral and duodenal mucosa of patients with duodenal ulcers refractory to 12 wk of treatment with cimetidine and to evaluate the effect of adding antimicrobial agents to cimetidine on the healing of refractory duodenal ulcers." | 9.07 | Helicobacter pylori and refractory duodenal ulcers: cross-over comparison of continued cimetidine with cimetidine plus antimicrobials. ( Boyd, EJ; Boyd, HK; Chinzon, D; Eisig, JN; Iriya, K; Laudanna, AA; Zaterka, S, 1994) |
| "A total of 152 patients with recurrent peptic ulcer disease were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 9.07 | Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. ( Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I, 1994) |
| "A controlled, prospective clinical trial of colloidal bismuth subcitrate (CBS), ranitidine and ranitidine plus metronidazole for the treatment of duodenal ulcer (DU) is reported here, with evaluation of the possible pathogenic role of Helicobacter pylori (HP) on DU in a six-month follow-up." | 9.07 | Colloidal bismuth subcitrate, ranitidine, and ranitidine plus metronidazole in the treatment of duodenal ulcer and Helicobacter pylori infection: a controlled and prospective study. ( Chen, GH; Huang, CK, 1993) |
| " pylori agents and ranitidine was superior to ranitidine alone for duodenal ulcer healing." | 9.07 | Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. ( Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM, 1991) |
| "Seventy-two patients with Helicobacter pylori-associated chronic gastritis were randomized to a 3-week oral treatment with furazolidone 0." | 9.06 | The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial. ( Jiang, SJ; Liu, WZ; Wang, RN; Xia, DH; Xiao, SD; Xu, WW; Zhang, ZH, 1990) |
| " We attempted to investigate the role of clarithromycin with tinidazole on Helicobacter pylori-related gastritis from the aspects of clinical effect and COX-2 expression." | 8.02 | Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression. ( He, C; Kong, F; Liu, Y; Wang, K; Zhao, W; Zhu, X, 2021) |
| "Use of metronidazole has been suggested to be associated with an increased risk of acute pancreatitis in case reports." | 7.73 | Metronidazole and risk of acute pancreatitis: a population-based case-control study. ( Jacobsen, J; Nørgaard, M; Pedersen, L; Ratanajamit, C; Skriver, MV; Sørensen, HT, 2005) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 7.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 7.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "Omeprazole heals most duodenal ulcers after 4 weeks of treatment but relapse is common." | 7.68 | Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. ( Beattie, S; Collins, R; Hamilton, H; McCarthy, CJ; O'Morain, C, 1993) |
| "The histamine concentration of the oxyntic mucosa was determined in Helicobacter pylori-positive patients with duodenal ulcer before and after antimicrobial therapy and in H." | 7.68 | Histamine content of the oxyntic mucosa from duodenal ulcer patients: effect of Helicobacter pylori eradication. ( Coelho, LG; Cunha-Melo, JR; Lima Júnior, GF; Mendes, EN; Moura, SB; Oliveira, CA; Passos, MC; Queiroz, DM; Resende, LM; Rocha, GA, 1993) |
| "pylori on the recurrence of duodenal ulcer, we treated 104 patients with H." | 6.67 | Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. ( Brandstätter, G; Dragosics, B; Hentschel, E; Hirschl, AM; Nemec, H; Schütze, K; Taufer, M; Wurzer, H, 1993) |
| "Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities." | 5.91 | Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice. ( Cao, M; Chen, Q; He, Z; Huang, M; Qing, L; Wu, C; Yan, X; Yu, Z; Zhang, X; Zhao, J; Zhao, Q, 2023) |
| "Inpatients with peptic ulcer complications who were not able to take oral medicine were randomly assigned to three groups: triple therapy (esomeprazole, levofloxacin, metronidazole) and dual therapy (esomeprazole, levofloxacin/metronidazole) for 7 days." | 5.69 | Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study. ( Chen, J; Gui, Q; Liang, X; Lu, H; Su, W; Yu, D; Zhang, W; Zhu, C, 2023) |
| "Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 5.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 5.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "To assess the efficacy and safety of omeprazole given with the new single capsule of bismuth, metronidazole and tetracycline (OBMT) compared with quadruple treatment consisting of omeprazole, bismuth, amoxicillin and clarithromycin (OBAC) for Helicobacter pylori eradication in duodenal ulcer patients." | 5.27 | New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro ( Chen, Y; Du, Y; Li, Y; Liu, D; Lv, N; Pan, X; Wang, H; Wang, J; Wu, K; Xie, Y; Xu, J; Zeng, Z; Zhang, G, 2018) |
| " Helicobacter pylori associated gastritis patients were randomized to 2 groups: group 1 (n=100) was tailored triple therapy with placebo (esomeprazole 20 mg bid, clarithromycin 500 mg bid or metronidazole 400 mg tid if clarithromycin resistance and amoxicillin 1000 mg bid), and group 2 was tailored triple therapy plus pretreatment with probiotic containing yogurt." | 5.20 | Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial. ( Dechsukhum, C; Kaewpitoon, N; Kaewpitoon, S; Leeanansaksiri, W; Loyd, RA; Matrakool, L; Panpimanmas, S; Tongtawee, T, 2015) |
| "Levofloxacin-tinidazole-based triple therapy was highly effective and safe as a first-line regimen in Indian patients with gastroduodenal ulcer disease associated with H." | 5.17 | Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India. ( Gulzar, GM; Javid, G; Khan, BA; Khan, MA; Saif, R; Shah, A; Shoukat, A; Sodhi, JS; Teli, F; Yattoo, GN; Zargar, SA, 2013) |
| "One hundred and eight patients with pangastritis were assigned to either lansoprazole 30 mg once a day (n=54) or bismuth 240 mg bis in die (n=54) for 14 days combined, for the first week, with amoxicillin 1g plus metronidazole 250 mg tris in die." | 5.14 | High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis. ( Abdullahi, M; Annibale, B; Capoccia, D; Leonetti, F; Marcheggiano, A; Osborn, J; Severi, C; Tari, R; Vannella, L, 2009) |
| "Patients with proven peptic ulcer or duodenitis were randomized into three groups: OAB-M-F; metronidazole (M) (500 mg bid) for the first 5 days, followed by furazolidone (F) (200 mg bid) for the second 5 days; OAC-P; clarithromycin (C) (500 mg bid) for 10 days; and OAB-C-F; clarithromycin (500 mg bid) for the first 5 days and furazolidone (200 mg bid) for the second 5 days." | 5.14 | Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial. ( Agah, S; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Pourshams, A; Riahizadeh, S; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2010) |
| "Treatment of H pylori can enhance the efficacy of ferrous succinate therapy in IDA patients with H pylori-positive chronic gastritis." | 5.12 | Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis. ( Chen, LH; Luo, HS, 2007) |
| " pylori-positive patients with non-ulcer dyspepsia were randomized into one of two regimens: (i) bismuth subsalicylate 300 mg q." | 5.12 | The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori. ( Bagci, S; Ilgan, S; Kadayifci, A; Safali, M; Uygun, A, 2007) |
| "Adult Helicobacter pylori-positive patients by 13C-urea breath test with uninvestigated dyspepsia symptoms were randomized to 1-week eradication treatment with omeprazole, metronidazole and clarithromycin (OMC) vs." | 5.11 | Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia. ( Armstrong, D; Barkun, A; Chiba, N; Escobedo, S; Grace, E; Lee, J; Sinclair, P; Thomson, AB; Veldhuyzen Van Zanten, SJ, 2004) |
| "The purpose of this study was to compare the efficacy of tinidazole- versus clarithromycin-based triple regimens for eradication of Helicobacter pylori in North Indian patients of peptic ulcer disease, and to correlate the outcome with in vitro antibiotic susceptibility." | 5.11 | Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity. ( Ahuja, V; Bal, C; Bhatia, V; Das, B; Sharma, MP, 2004) |
| "248 patients with Hp-associated active duodenal ulcer confirmed by endoscopy, 193 males and 55 females, were randomized to receive OAC(250): omeprazole (0." | 5.11 | [Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study]. ( , 2004) |
| " pylori positive peptic ulcer disease or functional dyspepsia were treated with two-day quadruple therapy (lansoprazole 30 mg twice daily, and colloidal bismuth subcitrate 120 mg, tetracycline 250 mg and metronidazole 250 mg, all eight times a day)." | 5.11 | The influence of pretreatment on cure rates of Helicobacter pylori eradication. ( de Boer, WA; Jansen, JB; Janssen, MJ; Laheij, RJ, 2004) |
| "To investigate the effect of Helicobacter pylori eradication on endothelin-1 (ET-1) and nitric oxide (NO) in duodenal ulcer (DU) patients." | 5.11 | Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication. ( Chang, FY; Chen, CY; Lee, SD; Lu, CL; Lu, RH; Luo, JC, 2005) |
| " pylori-positive peptic ulcer were randomly divided into two groups, and accepted triple therapy with omeprazole 20 mg, amoxicillin 1000 mg and either clarithromycin 500 mg (OAC group, n = 58) or metronidazole 400 mg (OAM group, n = 45)." | 5.11 | Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients. ( Cao, DZ; Fu, XL; Hu, JM; Ou, XL; Su, H; Sun, WH; Sun, YL; Yu, Q; Yu, T; Zhu, F, 2005) |
| "Comparison of two treatment regimens of eradication treatment of duodenal ulcer (DU) associated with Helicobacter pylori based on fromilid (clarithromycin)." | 5.10 | [Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)]. ( Firsanova, VIu; Kolomiets, EV; Vasil'ev, IuV; Zvenigorodskaia, LA, 2002) |
| "To assess and compare the efficacy and safety of two triple regimes: A) metronidazole, amoxicillin and omeprazole, which is still widely used in Russia, and B) azithromycin, amoxicillin and omeprazole in healing active duodenal ulcer and H." | 5.10 | Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer. ( Bondarenko, OY; Fedchenko, VI; Grigoriev, PY; Gulyaev, PV; Ivashkin, VT; Lapina, TL; Sklanskaya, OA; Vasiliev, YV; Yakovenko, EP, 2002) |
| " pylori positive patients with non-ulcer dyspepsia were randomised to one of the following four treatment groups: omeprazole 20 mg + clarithromycin 500 mg + amoxycillin 1000 mg (OCA); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + amoxycillin 1000 mg (RBCCA); omeprazole 20 mg + clarithromycin 500 mg + metronidazole 500 mg (OCM); ranitidine bismuth citrate 400 mg + clarithromycin 500 mg + metronidazole 500 mg (RBCCM)." | 5.10 | The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial. ( Bago, J; Bevanda, M; Bilić, A; Halle, ZB; Jandrić, D; Kućisec, N; Strinić, D; Tomić, M, 2002) |
| " pylori associated gastritis were randomly divided into pantoprazole triple regimen group (pantoprazole 40 mg, amoxicillin 1 g, and metronidazole 400 mg, bid,for 1-week or 2-weeks) and omeprazole triple regimen (omeprazole 20 mg, amoxicillin 1 g, and metronidazole 400 mg, bid, for 1-week or 2-weeks)." | 5.10 | [Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection]. ( Cui, M; Hu, F; Jiang, H; Zheng, X, 2002) |
| "One hundred and forty-nine consecutive patients with active duodenal ulcer were randomized to receive omeprazole (20 mg b." | 5.10 | Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study. ( Amberiadis, P; Archavlis, E; Chiotakakou, E; Christoforidis, P; Kourtessas, D; Mantzaris, GJ; Petraki, K; Triantafyllou, G, 2002) |
| "This multicenter, randomized, active-controlled trial assessed efficacy of bismuth-based quadruple therapy with omeprazole, bismuth biskalcitrate, metronidazole, and tetracycline (OBMT) using a single-triple capsule of BMT compared with triple therapy with omeprazole, amoxicillin, and clarithromycin (OAC) in treatment of patients with Helicobacter pylori infection and duodenal ulcers." | 5.10 | Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a ( El-Zimaity, H; Hunt, R; Laine, L; Nguyen, B; Osato, M; Spénard, J, 2003) |
| " pylori-positive patients with active gastric ulcer were randomized to receive pantoprazole (40 mg) (P) and two of three antibiotics: clarithromycin (500 mg) (C), metronidazole (500 mg) (M) or amoxicillin (1000 mg) (A)." | 5.10 | Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies. ( Bohuschke, M; Gatz, G; Kirchner, T; Kist, M; Leodolter, A; Malfertheiner, P; Peitz, U; Strobel, S, 2003) |
| "To determine the value of Helicobacter pylori (Hp) serology in diagnosis of active Hp infection in patients with documented duodenal ulcer (DU) and to directly compare the efficacy and side-effects profiles of metronidazole or tinidazole in a triple therapy regimen to eradicate active Hp infection." | 5.10 | Diagnosis and eradication of Helicobacter pylori in patients with duodenal ulceration in the community. ( Abbas, AB; Abbas, SZ; Crawshaw, A; Dalton, HR; English, J; McGovern, D; Shaw, S; Vivian, G, 2003) |
| "We used data from a randomized placebo-controlled clinical trial to examine the relationship between Helicobacter pylori and reflux symptoms in nonulcer dyspepsia patients randomly assigned anti-Helicobacter pylori triple therapy alone, calcium carbonate alone, or in combination with triple therapy, tetracycline, or placebo." | 5.10 | Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment. ( Correa, P; Feldman, M; Fischbach, LA; Fontham, E; Goodman, KJ; Jain, R; Priest, E, 2003) |
| "Clinical efficiency and safety of Epigam containing antibodies to histamine in ultralow doses were studied during the therapy of patients with exacerbation of peptic ulcer disease of the stomach and duodenum associated with Helicobacter pylori infection." | 5.10 | Clinical efficiency of Epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum. ( Bakumov, PA; Dugina, YL; Epstein, OI; Sergeeva, SA; Shchepotkin, IV, 2003) |
| "To compare the short-term (7-day) safety and efficacy of two triple-therapy regimens using pantoprazole with those of two dual-therapy regimens (one with pantoprazole and one without), for Helicobacter pylori eradication in patients with peptic ulcer disease." | 5.10 | Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies. ( Bochenek, WJ; Davis, KD; El-Zimaity, HM; Fraga, PD; Graham, DY; Mack, ME; Osato, MS; Peters, S; Wang, W, 2003) |
| "To investigate the efficacy of two omeprazole triple therapies for the eradication of Helicobacter pylori, ulcer healing and ulcer relapse during a 6-month treatment-free period in patients with active duodenal ulcer." | 5.09 | The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy. ( Bayerdörffer, E; Bradette, M; Farley, A; Leddin, D; Lind, T; O'Morain, C; Sinclair, P; Sipponen, P; Spiller, RC; Unge, P; Wrangstadh, M; Zanten, SJ; Zeijlon, L, 1999) |
| " pylori-positive duodenal ulcer were allocated randomly to receive one of four regimens: metronidazole, 200 mg; amoxicillin, 250 mg; and colloidal bismuth subcitrate (CBS), 120 mg (group 1), or CBP, 100 mg qid (group 2) for 2 weeks, then continued CBS, 240 mg, or CBP, 200 mg bid for a further 2 weeks." | 5.09 | Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer. ( Dai, S; Du, H; Li, Q; Li, Y; Nie, Y; Sha, W; Wang, H; Wu, H, 1999) |
| " All patients belong to a low socioeconomic strata, had multifocal atrophic gastritis documented by gastric biopsies, and had been treated previously and unsuccessfully for 2 weeks with bismuth subsalicylate (262 mg four times a day), amoxicillin (500 mg three times a day), and metronidazole (400 mg three times a day)." | 5.09 | Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed. ( Bravo, LE; Correa, P; DeLany, JP; Mera, R; Realpe, JL, 1999) |
| " pylori infection and duodenal ulcer, gastric ulcer or non-ulcer dyspepsia were randomly assigned to a 1 week course of either famotidine 80 mg b." | 5.09 | Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial. ( Brandstätter, G; Dragosics, B; Gschwantler, M; Hentschel, E; Hirschl, AM; Klimpfinger, M; Oberhuber, G; Pasching, E; Schütze, K; Weiss, W; Wimmer, M; Wurzer, H, 1999) |
| " Our main objective was to study the outcome of a non-metronidazole and omeprazole-based antibiotic regimen in eradicating Helicobacter pylori in patients with duodenal ulcer." | 5.09 | The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate. ( Abdulle, AM; Adeyemi, EO; Benedict, S; Danial, MF; Helal, T, 1999) |
| "We conducted a prospective, uncontrolled study of a consecutive series of 21 peptic ulcer patients with failure of 1-week lansoprazole, amoxicillin, and clarithromycin." | 5.09 | Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases. ( Ducóns, JA; Ferrero, M; García Cabezudo, J; Gomollón, F; Guirao, R; Montoro, M; Simón, MA, 1999) |
| "To compare two lansoprazole-based non-clarithromycin triple therapies and one dual therapy in a prospective double-blind placebo-controlled study of Helicobacter pylori eradication and duodenal ulcer healing." | 5.09 | Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study. ( Carpio, RE; Fock, KM; Ho, J; Hu, FL; Hu, PJ; Huang, NX; Kachintorn, U; Kullavanijaya, P; Lam, SK; Lesmana, L; Li, YY; Manan, C; Perez, JY; Phornphutkul, K; Qian, SC; Wong, BC; Xiao, SD, 2000) |
| "To compare the eradication rates of Helicobacter pylori, ulcer healing rates and side-effects of three regimens of omeprazole triple therapy in patients with duodenal ulcer from South-East Asia and to study the impact of metronidazole resistance." | 5.09 | Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. ( Chelvam, P; Fock, KM; Lim, SG, 2000) |
| "To compare the efficacy of either omeprazole or ranitidine in a second-line quadruple regimen in patients with duodenal ulcer or erosive duodenitis." | 5.09 | Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens. ( Balta, A; Bouzakis, H; Broutet, N; Kralios, N; Michopoulos, S; Tsibouris, P; Vougadiotis, J, 2000) |
| " pylori eradication and duodenal ulcer healing in this region despite the high metronidazole resistance rate." | 5.09 | Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study. ( Adamthwaite, D; Davidson, G; Katelaris, PH; Lambert, J; Midolo, P; Yeomans, ND, 2000) |
| "For this open study, 331 patients with duodenal ulcer were screened and randomly allocated to either pantoprazole 40 mg b." | 5.09 | Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens. ( Daake, H; Frevel, M; Janisch, HD; Kellner, HU; Krezdorn, HG; Tanneberger, D; Wack, R, 2000) |
| "The aim of this study was to compare in an open, controlled and prospective trial the efficacy of one-week regimen using either lansoprazole (2 x 30 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group I, 60 cases) or ranitidine bismuth citrate (2 x 400 mg) + 2 x 500 mg metronidazole + 2 x 250 mg clarithromycin (group II, 61 cases) on the eradication of Hp infection in duodenal ulcer patients." | 5.09 | [Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer]. ( Buzás György, M; Illyés, G; Székely, E; Széles, I, 2000) |
| " pylori alone with the present bismuth-based triple therapy in patients with duodenal ulcer hemorrhage did not result in significant reduction in further bleeding episodes, although a trend was seen for the group that was given triple therapy." | 5.09 | Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage--a long-term randomized, controlled study. ( Ching, CK; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Wong, BC; Wong, WM, 2000) |
| "Patients with active duodenal ulcer were randomized either to omeprazole, 20 mg twice daily until healing, followed by omeprazole, 20 mg/ day for 1 year, or to eradication therapy (metronidazole, amoxicillin, and omeprazole for 2 weeks) followed by placebo for 1 year." | 5.09 | Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group. ( Aalykke, C; Bekker, C; Bonnevie, O; Bytzer, P; Eriksen, J; Gjørup, T; Hansen, J; Justesen, T; Kjaergaard, J; Kromann-Andersen, H; Rask-Madsen, J; Rune, S; Teglbjaerg, PS; Vilien, M; Vyberg, M; Weywadt, L, 2000) |
| "Ninety patients with established peptic ulcer and NUD (with previously proven ulcer) were randomly assigned to receive either bismuth-subcitrate, amoxycillin and metrnidazole (BAM) or lansoprasole, clarithromycine and metronidazole (LCM) for 7 days." | 5.09 | The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication. ( Avidan, B; Bar-Meir, S; Keller, N; Melzer, E, 2001) |
| "A total of 59 consecutive Helicobacter pylori infected non-ulcer dyspepsia patients were randomly selected to receive either one of two triple therapy regimens, including metronidazole, amoxycillin plus ranitidine bismuth citrate (RAM group) or omeprazole (OAM group)." | 5.09 | Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia. ( Chuang, CH; Lin, XZ; Sheu, BS; Wu, JJ; Yang, HB, 2001) |
| "Subjects in the tetracycline and triple therapy groups, but not the calcium carbonate only group, showed a reduction in inflammation and epithelial damage vs." | 5.09 | Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer. ( Bravo, JC; Bravo, LE; Casabon, AL; Collazos, T; Correa, P; Fischbach, LA; Ramirez, H; Realpe, JL; Ruiz, B; Schmidt, BA, 2001) |
| "Non-ulcer dyspepsia patients (n=199), with a normal upper endoscopy and a positive (13)C-urea breath test (UBT) were randomly assigned to either pantoprazole, clarithromycin and metronidazole (PCM) or pantoprazole, clarithromycin and eicosapen (PCE) for 7 days." | 5.09 | Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication. ( Drewe, J; Geiser, HR; Meier, R; Wettstein, A, 2001) |
| "A total of 122 consecutive patients with peptic ulcer and Helicobacter pylori infection were treated with omeprazole 20 mg b." | 5.09 | Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment. ( Brullet, E; Calvet, X; Campo, R; Garcia, N; Gené, E; Sanfeliu, I, 2001) |
| "To investigate Helicobacter pylori eradication in duodenal ulcer patients with a new regimen, lansoprazole 30 mg daily for one or four weeks plus twice daily tetracycline 500 mg, clarithromycin 250 mg, and metronidazole 400 mg." | 5.09 | Quadruple therapy for symptomatic spontaneous duodenal ulcer disease. ( Bateson, MC, 2001) |
| " pylori positive duodenal ulcer were enrolled and randomly allocated into one of the five treatment groups: 1) group A: received lansoprazole 30 mg once daily for 2 weeks plus amoxicillin (AM) 500 mg and metronidazole (MZ) 500 mg twice daily for one week in the first week; 2) group B: the AM in group A was replaced by clarithromycin (CM) 250 mg; 3) group C: the MZ in group A was replaced by CM 250 mg; 4) group D: the AM and CM in group C was used for 2 wk; 5) group E: the CM in group D was doubled to 500 mg twice daily." | 5.09 | A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy. ( Hsu, CT; Kuo, CF; Wang, CS; Wang, TH; Yang, JC; Yang, KC, 1999) |
| "Helicobacter pylori-positive patients (n=323) with non-ulcer dyspepsia were randomized to receive one of four 1-week regimens consisting of omeprazole, 20 mg b." | 5.09 | A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia. ( Barthélemy, P; Caekaert, A; Fléjou, JF; Laurent, J; Mégraud, F, 2001) |
| "pylori positive (histology and/or culture) ulcer disease (n = 17; acute ulcer: n = 11) or functional dyspepsia (n = 13) were treated over one week with pantoprazole 40 mg bd, clarithromycin 250 mg bd and metronidazole 400 mg bd." | 5.08 | [Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori]. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1995) |
| " The aim of this controlled, randomized, prospective study was to compare the effect of these two regimens and a further regimen for metronidazole-resistant patients on duodenal ulcer healing, H." | 5.08 | Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized ( Dehbashi, N; Etaati, H; Fattahi, M; Javan, A; Massarrat, S; Saberi-Firoozi, M; Zare, S, 1995) |
| "To establish the efficacy of omeprazole combined with two antibiotics for Helicobacter pylori eradication and duodenal ulcer relapse." | 5.08 | Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M; Maconi, G; Minguzzi, M, 1995) |
| " pylori infection and gastric ulcers unrelated to the use of nonsteroidal antiinflammatory drugs, one week of antibacterial therapy without acid suppression heals the ulcers as well as omeprazole and reduces the rate of their recurrence." | 5.08 | Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. ( Cheng, AF; Chung, SC; Leung, VK; Li, AK; Li, MK; Ling, TK; Ng, EK; Sung, JJ; Yung, MY, 1995) |
| " pylori infection and peptic ulcer disease (n = 64) or functional dyspepsia (n = 16), with similar demographic and clinical characteristics, were treated for 1 week with either omeprazole 20 mg once in the morning and clarithromycin 250 mg and metronidazole 400 mg twice daily (OCM; n = 40) or with omeprazole 20 mg once in the morning and clarithromycin 250 mg and tetracycline 500 mg twice daily (OCT; n = 40)." | 5.08 | One-week low-dose triple therapy for the eradication of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Rühl, GH; Sollböhmer, M; Stolte, M; Tillenburg, B, 1995) |
| ") in eradicating Helicobacter pylori in patients with duodenal ulcer successfully healed with omeprazole or ranitidine; second, to examine the influence of the eradication on duodenal ulcer recurrence rate after 12 months." | 5.08 | Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up. ( Archimandritis, A; Balatsos, V; Delis, V; Kastanas, K; Mentis, A; Scandalis, N, 1995) |
| "Eradication of Helicobacter pylori from the stomach by triple therapy with bismuth, tetracycline, and metronidazole cures peptic ulcer disease." | 5.08 | Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. ( de Boer, W; Driessen, W; Jansz, A; Tytgat, G, 1995) |
| "In this double-blind trial, conducted in 19 hospitals, 119 patients with symptomatic duodenal ulcer disease were randomized to receive either 14 days treatment with omeprazole 40 mg daily, amoxycillin 500 mg t." | 5.08 | Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial. ( Axon, AT; Bate, CM; Bell, GD; Emmas, CE; Green, JR; Kerr, GD; Taylor, MD; Tildesley, G, 1995) |
| "The combined therapy with amoxycillin, metronidazole, and omeprazole is highly effective in both HP eradication and prevention of duodenal ulcer recurrence." | 5.08 | Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence. ( Alvisi, C; Bargiggia, S; Bianchi Porro, G; Cesana, B; Fiocca, R; Franceschi, M; Lazzaroni, M; Luinetti, O; Maconi, G; Perego, M; Solcia, E; Trespi, E; Villani, L, 1996) |
| "The aim of this study was to assess the effect of colloidal bismuth subcitrate (CBS) and metronidazole on Helicobacter pylori eradication and on the course of symptoms due to functional dyspepsia." | 5.08 | Eradication of Helicobacter pylori and long-term outcome of functional dyspepsia. A clinical endoscopic study. ( Bargiggia, S; Bianchi Porro, G; Boldorini, M; Lazzaroni, M; Maconi, G; Sangaletti, O, 1996) |
| " Sixty duodenal ulcer patients were randomised to receive either standard triple therapy (tripotassium dicitrato bismuthate 120 mg qds+tetracycline 500 mg qds+metronidazole 400 mg qds), quadruple therapy A (triple therapy+omeprazole 20 mg od) or quadruple therapy B (triple therapy+omeprazole 40 mg od), for 7 days." | 5.08 | One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy. ( Griffiths, AE; Halliday, D; Jacyna, MR; Phull, PS, 1995) |
| "To determine the effect of Helicobacter pylori eradication with omeprazole and amoxycillin, with or without metronidazole, on the 12-month course of duodenal ulcer disease." | 5.08 | Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole. ( Axon, AT; Bate, CM; Bell, GD; Martin, JL; Richardson, PD; Taylor, MD; Tildesley, G, 1996) |
| " pylori-positive gastritis with or without peptic ulcer, and compared with the classic 'Bazzoli regimen' (OCT: omeprazole, clarithromycin, tinidazole) in 60 matched patients." | 5.08 | Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori. ( Alvisi, V; Caselli, M; Gasbarrini, G; Gaudenzi, P; Luzzi, I; Ruina, M; Sartori, S; Trevisani, L; Tursi, A, 1997) |
| " After 2 weeks duodenal ulcer healing was confirmed in 91% (95% CI = 80-100%) of patients treated with omeprazole and in 76% (95% CI = 60-91%) in the placebo group (P = 0." | 5.08 | One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. ( Adamek, RJ; Börsch, G; Idström, JP; Labenz, J; Peitz, U; Tillenburg, B, 1997) |
| "Eighty patients with endoscopically proven active duodenal ulcer were randomized to take ranitidine or lansoprazole for 4-8 wk, together with clarithromycin 250 mg b." | 5.08 | Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer. ( Bargiggia, S; Bianchi Porro, G; Lazzaroni, M, 1997) |
| "Eighty-two patients with severe peptic ulcer disease and concurrent Helicobacter pylori infection were treated with a two week regimen of omeprazole (40 mg once daily), amoxycillin (750 mg t." | 5.08 | Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. ( Jönsson, KA; Sörberg, M; Ström, M, 1997) |
| "In this prospective controlled study conducted in a single center, 78 symptomatic peptic ulcer patients were treated for 4 wk with omeprazole 40 mg o." | 5.08 | Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients? ( Anania, MC; Annibale, B; D'Ambra, G; Delle Fave, G; Iannoni, C; Luzzi, I; Marcheggiano, A; Marignani, M; Paoletti, M, 1997) |
| "This double-blind, randomized, phase III clinical trial was carried out in two parallel groups to assess the efficacy of ebrotidine (N-[(E)-[[2-[[[2-[(diaminomethylene) amino]-4-thiazolyl]methyl]thio]ethyl]amino] methylene]-4-bromo-benzenesulfonamide, CAS 100981-43-9, FI-3542) 400 mg and ranitidine 300 mg given in single evening dose, combined with amoxicillin 750 mg and metronidazole 500 mg three times daily for 14 days, in the eradication of Helicobacter pylori in patients with duodenal ulcer." | 5.08 | Efficacy of ebrotidine and ranitidine combined with amoxicillin and metronidazole in the eradication of Helicobacter pylori in patients with duodenal ulcer. ( Fillat, O; Herrero, E; Karcz, D; Kulig, J; Márquez, M; Ortiz, JA; Popiela, T; Tabor, J; Torres, J, 1997) |
| "A randomised, double blind placebo controlled trial was performed to study the efficacy of an antibiotic only regimen consisting of 300 mg metronidazole, 500 mg amoxycillin, and 250 mg clarithromycin, each given four times daily for two weeks, in the healing of duodenal ulcer as assessed by endoscopy." | 5.08 | Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study. ( Chan, CK; Ching, CK; Lai, CL; Lai, KC; Lam, SK; Ong, L; Wong, BC, 1997) |
| "Patients with active HP infection and peptic ulcer, a history of peptic ulcer, or nonulcer dyspepsia were randomized to either lansoprazole 30 mg b." | 5.08 | Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial. ( Barnett, JL; Chey, WD; DelValle, J; Elta, GH; Fisher, L; Hasler, WL; Nostrant, T; Scheiman, JM, 1997) |
| "In patients with active duodenal ulcer, a 10-day course of amoxycillin-clarithromycin-based triple therapy without additional acid suppression is highly effective in eradicating H." | 5.08 | Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group. ( Archambault, A; Archimandritis, A; Bazzoli, F; Fedorak, R; Hentschel, E; Megraud, F; Mora, P; Rodrigo, L; Rokkas, T; Skandalis, N; Stamler, D; Wurzer, H, 1997) |
| " pylori-infected patients with endoscopically documented duodenal ulcer either currently or within the past year were randomized to 14 days of (1) lansoprazole, 30 mg bid, plus amoxicillin, 1 gm tid; (2) lansoprazole, 30 mg tid, plus amoxicillin, 1 gm tid; (3) lansoprazole, 30 mg tid alone; or (4) amoxicillin, 1 gm tid alone." | 5.08 | Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection. ( Arora, A; Graham, D; Haber, M; Harford, W; Lanza, F; Rose, P; Siepman, N; Weissfeld, A, 1996) |
| " Patients (n = 787) with proved duodenal ulcer disease were randomized to treatment twice daily for 1 week with omeprazole, 20 mg (O), plus either placebo (P) or combinations of two of the following antimicrobials: amoxicillin, 1 gm (A), clarithromycin, 250 or 500 mg (C250, C500), or metronidazole, 400 mg (M)." | 5.08 | Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study. ( Bardhan, KD; Bayerdörffer, E; Bradette, M; Cederberg, C; Chiba, N; Idström, JP; Lind, T; O'Morain, C; Spiller, R; Unge, P; Veldhuyzen van Zanten, S; Wrangstadh, M, 1996) |
| " pylori-positive peptic ulcer received omeprazole 20 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 500 mg twice daily for seven days." | 5.08 | One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit? ( Bhutta, AS; Bindel, H; Cunnane, K; Loane, J; O'Connor, HJ, 1997) |
| " The aim of this study was to determine whether the carbon 13-labeled urea breath test (UBT) can be used in children by evaluating: (1) its sensitivity and specificity compared with either culture or both rapid urease test and histologic examination, (2) whether a test meal or a prolonged fast is required, (3) the usefulness after treatment for H." | 5.08 | Carbon 13-labeled urea breath test for the diagnosis of Helicobacter pylori infection in children. ( Daly, LE; Drumm, B; Durnin, M; Gormally, S; Hetherington, C; Lambert, I; Rowland, M; Thomas, JE, 1997) |
| "To estimate and compare the efficacy of 'triple' 1-week regimens--omeprazole, clarithromycin and a nitroimidazole (metronidazole or ornidazole)--followed by omeprazole, for an additional 3 weeks, on Helicobacter pylori eradication and duodenal ulcer (DU) healing, in a country with a high resistance rate of H." | 5.08 | One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer. ( Archimandritis, A; Balatsos, V; Davaris, P; Delis, V; Kanellopoulou, E; Manika, Z; Skandalis, N; Souyioultzis, S; Tzivras, M, 1997) |
| "To compare the efficacy of two "new" one-week triple therapies (with omeprazole, metronidazole and clarithromycin or amoxycillin) for the eradication of Helicobacter pylori and healing duodenal ulcer." | 5.08 | [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. ( Abraira, V; Boixeda, D; García Plaza, A; Gisbert, JP; Martín de Argila, C; Moreno, L; Redondo, C, 1998) |
| " pylori-positive peptic ulcer received lansoprazole 30 mg twice daily in combination with metronidazole 400 mg twice daily and clarithromycin 250 mg twice daily for 5 days." | 5.08 | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? ( Cunnane, K; Kelly, S; Laundon, J; McLoughlin, R; O'Connor, HJ, 1998) |
| "In an open study 66 consecutive infected patients with ulcer disease or non-ulcer dyspepsia were treated with 4-day quadruple therapy after 3 days of lansoprazole pretreatment." | 5.08 | Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection. ( de Boer, WA; Schneeberger, PM; van Etten, RJ, 1998) |
| " pylori-associated gastritis, received seven days of lansoprazole, bismuth, tetracycline and metronidazole after three days of lansoprazole pretreatment." | 5.08 | Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection. ( Bolin, TD; Engelman, JL; Korman, MG; Nicholson, FB, 1998) |
| "Ninety patients with active duodenal ulcer disease and H pylori infection, proven with the 13C-urea breath test and CLO test (Campylobacter-like organism test) were treated randomly in three therapeutic groups: Group A, DeNol 120 mg, amoxicillin 500 mg and metronidazole 250 mg four times a day orally for 14 days; Group B, omeprazole 20 mg plus clarithromycin 500 mg twice a day and amoxicillin 500 mg four times a day for 14 days; Group C, omeprazole 20 mg, clarithromycin 250 mg and metronidazole 500 mg twice a day for seven days." | 5.08 | New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection. ( Ho, AS; Hsu, CT; Huang, WH; Lee, MM; Lee, SC; Shyu, RY, 1998) |
| "Rabeprazole is a new fast acting proton pump inhibitor that has recently been proven to be effective in the treatment of peptic ulceration and reflux esophagitis." | 5.08 | Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration. ( Atherton, JC; Cockayne, A; Hawkey, CJ; Jenkins, D; Knifton, A; Stack, WA; Thirlwell, D, 1998) |
| "We performed a randomized, placebo-controlled trial comparing the efficacy of treatment for two weeks with 20 mg of omeprazole orally twice daily, 500 mg of amoxicillin three times daily (with 500 mg of tetracycline three times daily substituted for amoxicillin in patients allergic to penicillin), and 400 mg of metronidazole three times daily (160 patients) with that of omeprazole alone (158 patients) for resolving symptoms of dyspepsia in patients with H." | 5.08 | Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia. ( Dickson, A; El-Nujumi, A; El-Omar, E; Hilditch, T; Kelman, A; Knill-Jones, R; McColl, K; Murray, L; Penny, C; Wirz, A, 1998) |
| "Three hundred seventy four patients with duodenal ulcers and Helicobacter pylori infections were given a four-week treatment of bismuth or ranitidin." | 5.08 | [The treatment of chronic duodenal ulcer with accompanying Helicobacter pylori infection]. ( Kabala, A; Pawłowski, W; Petsch, B, 1998) |
| "Two 4-week triple-therapy treatment regimens, metronidazole+tetracycline+bismuth subcitrate and omeprazole+amoxycillin+bismuth subcitrate, were compared in a randomly allocated double-blind trial for their efficacy in eradicating Helicobacter pylori from the gastric mucosa of patients with gastritis and/or peptic ulcer disease." | 5.07 | Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease. ( Hahm, JS; Kim, HJ; Park, KN, 1994) |
| "Seventy-four patients with three endoscopically verified duodenal ulcers during the past 2 years received triple treatment consisting of bismuth subnitrate, oxytetracycline, and metronidazole for 14 days." | 5.07 | Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori. ( Berstad, A; Wilhelmsen, I, 1994) |
| " In study II 22 duodenal ulcer patients were given bismuth subnitrate, oxytetracycline, and metronidazole (triple therapy) for 2 weeks to eradicate H." | 5.07 | Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients. ( Aase, S; Andersen, KJ; Mowinckel, P; Schrumpf, E; Vetvik, K, 1994) |
| "The goals of this study were to assess the effectiveness of a new triple therapy consisting of amoxicillin and metronidazole with plaunotol in the eradication of Helicobacter pylori infection in humans, and to determine whether this treatment regimen reduces the rate of recurrence of gastric ulcer in patients infected with H." | 5.07 | Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate. ( Karita, M; Morshed, MG; Okita, K; Ouchi, K, 1994) |
| " Forty-six consecutive patients (suffering from either peptic ulcer or non-ulcer dyspepsia) with helicobacter pylori infection were randomly allocated to one of the following two groups: group 1 (n = 23) 2 weeks of treatment with bismuth subcitrate tablets (120 mgx4) + amoxycillin capsules (500 mgx4) + metronidazole tablets (250 mgx4); group 2 (n = 23) 2 weeks of treatment with amoxycillin capsules (500 mgx4) + metronidazole tablets (250 mgx4)." | 5.07 | Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection. ( Corinaldesi, R; De Giorgio, R; Gasperoni, S; Paparo, GF; Poli, L; Stanghellini, V; Tucci, A; Varoli, O, 1994) |
| "To determine the distribution of Helicobacter pylori in the antral and duodenal mucosa of patients with duodenal ulcers refractory to 12 wk of treatment with cimetidine and to evaluate the effect of adding antimicrobial agents to cimetidine on the healing of refractory duodenal ulcers." | 5.07 | Helicobacter pylori and refractory duodenal ulcers: cross-over comparison of continued cimetidine with cimetidine plus antimicrobials. ( Boyd, EJ; Boyd, HK; Chinzon, D; Eisig, JN; Iriya, K; Laudanna, AA; Zaterka, S, 1994) |
| "A total of 152 patients with recurrent peptic ulcer disease were treated with bismuth subnitrate, oxytetracycline and metronidazole." | 5.07 | Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease. ( Berstad, A; Berstad, K; Hausken, T; Hundal, O; Weberg, R; Wilhelmsen, I, 1994) |
| " Patients presenting because of major upper gastrointestinal hemorrhage from peptic ulcer and whose ulcers healed in a study in which they were randomized to receive ranitidine alone or triple therapy plus ranitidine were followed up regularly with endoscopy." | 5.07 | Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease. ( Graham, DY; Hepps, KS; Lew, GM; Ramirez, FC; Saeed, ZA, 1993) |
| " pylori-positive duodenal ulcers were randomized to receive either triple therapy for 1 wk plus omeprazole for 4 wk (Triple+OMP) (n = 78), or omeprazole alone (OMP) for 4 wk (N = 77)." | 5.07 | One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori. ( Cheng, AF; Chung, SC; Hosking, SW; Li, AK; Ling, TK; Sung, JJ; Yung, MY, 1994) |
| "A total of 104 patients with recurrent duodenal ulcer were treated with either ranitidine plus amoxicillin plus metronidazole or ranitidine plus placebo." | 5.07 | Kinetics of specific IgG antibodies for monitoring the effect of anti-Helicobacter pylori chemotherapy. ( Brandstätter, G; Dragosics, B; Hentschel, E; Hirschl, AM; Kundi, M; Rotter, ML; Schütze, K; Taufer, M, 1993) |
| "A controlled, prospective clinical trial of colloidal bismuth subcitrate (CBS), ranitidine and ranitidine plus metronidazole for the treatment of duodenal ulcer (DU) is reported here, with evaluation of the possible pathogenic role of Helicobacter pylori (HP) on DU in a six-month follow-up." | 5.07 | Colloidal bismuth subcitrate, ranitidine, and ranitidine plus metronidazole in the treatment of duodenal ulcer and Helicobacter pylori infection: a controlled and prospective study. ( Chen, GH; Huang, CK, 1993) |
| "In this study, 26 patients with duodenal ulcers refractory to treatment with H2-receptor antagonists for 8-12 weeks were randomly assigned to eight weeks of treatment with colloidal bismuth subcitrate (120 mg four times a day) alone (N = 12) or in combination with tetracycline hydrochloride (500 mg four times a day, days 0-14) and metronidazole (500 mg three times a day, days 15-28)." | 5.07 | Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates. ( Hatzis, A; Mantzaris, GJ; Petraki, K; Spiliades, C; Tamvakologos, G; Triadaphyllou, G, 1993) |
| "A one week regimen of bismuth, tetracycline, and metronidazole is safe and effective in eradicating H pylori and reduces the number of duodenal ulcers four weeks after completing treatment." | 5.07 | Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. ( Cheng, A; Chung, SC; Hosking, SW; Leung, JW; Li, AK; Ling, TK; Yung, MY, 1992) |
| " pylori-positive patients with (n = 42) or without (n = 42) duodenal ulcer were randomized to receive ranitidine, bismuth, or bismuth plus antibiotics." | 5.07 | Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication. ( Corbishley, CM; Goggin, PM; Jackson, PA; Marrero, JM; Northfield, TC; Spychal, RT, 1992) |
| "The probability of recurrence for patients who received triple therapy plus ranitidine was significantly lower than that for patients who received ranitidine alone: for patients with duodenal ulcer, 12% (95% CI, 1% to 24%) compared with 95% (CI, 84% to 100%); for patients with gastric ulcer, 13% (CI, 4% to 31%) compared with 74% (44% to 100%)." | 5.07 | Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. ( Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Saeed, ZA, 1992) |
| " pylori-associated gastritis were allocated to one of the following four therapeutic schedules: 1) omeprazole 40 mg/d for 4 weeks (n = 13); 2) bismuth subsalicylate (BSS) 3 x 600 mg for 4 weeks (n = 12); 3) omeprazole plus BSS for 4 weeks (n = 13); 4) triple therapy (BSS for 4 weeks, amoxicillin 3 x 750 mg and metronidazole 3 x 400 mg for 10 days) (n = 12)." | 5.07 | The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection. ( Bär, W; Gebel, M; Haruma, K; Lange, P; Müller, MJ; Schorn, T; Soudah, B; Varrentrapp, M; Wagner, S, 1991) |
| " pylori agents and ranitidine was superior to ranitidine alone for duodenal ulcer healing." | 5.07 | Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial. ( Evans, DG; Evans, DJ; Graham, DY; Klein, PD; Lew, GM, 1991) |
| "Seventy-two patients with Helicobacter pylori-associated chronic gastritis were randomized to a 3-week oral treatment with furazolidone 0." | 5.06 | The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial. ( Jiang, SJ; Liu, WZ; Wang, RN; Xia, DH; Xiao, SD; Xu, WW; Zhang, ZH, 1990) |
| " pylori eradication is achieved; (5) the eradication rates seem to be higher in peptic ulcer than in nonulcer dyspepsia; (6) in areas where the prevalence of metronidazole resistance is high, triple therapy including a PPI, clarithromycin, and amoxicillin is the best option, and (7) quadruple therapy (PPI, bismuth, tetracycline, and metronidazole) is the recommended second-line therapy after PPI-clarithromycin-amoxicillin failure, although replacing the PPI and the bismuth compound by ranitidine bismuth citrate achieves also good results." | 4.81 | Helicobacter pylori therapy: first-line options and rescue regimen. ( Gisbert, JP; Pajares, JM, 2001) |
| " We attempted to investigate the role of clarithromycin with tinidazole on Helicobacter pylori-related gastritis from the aspects of clinical effect and COX-2 expression." | 4.02 | Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression. ( He, C; Kong, F; Liu, Y; Wang, K; Zhao, W; Zhu, X, 2021) |
| " Metronidazole resistance in peptic ulcer patients was significantly higher." | 3.83 | A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis. ( Bian, H; Fang, Y; Hu, B; Kong, M; Miao, Y; Olszewski, MA; Wang, S; Wu, Y; Xu, L; Yang, C; Zhang, Y; Zhao, F; Zhao, H, 2016) |
| " pylori culture positive dyspeptic patients (64 patients with peptic ulcer, PU) completed a 2-week treatment with omeprazole, amoxicillin and metronidazole and underwent endoscopy again 6-8 weeks after the end of therapy." | 3.78 | Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection. ( Figura, N; Giordano, N; Langone, F; Moretti, E; Vaglio, L; Vernillo, R; Vindigni, C, 2012) |
| " pylori eradication in peptic ulcer patients treated with pantoprazole in Polish Caucasian peptic ulcer patients administered pantoprazole, amoxicillin, and metronidazole." | 3.76 | Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole. ( Bielicki, D; Droździk, M; Gawrońska-Szklarz, B; Kurzawski, M; Marlicz, W; Siuda, A, 2010) |
| "Patients with peptic ulcer who failed with first-line triple eradication therapy containing clarithromycin received quadruple therapy with omeprazole (20 mg, twice daily), amoxicillin (750 mg, twice daily), metronidazole (500 mg, twice daily) and ecabet sodium (1000 mg, twice daily) for 14 days." | 3.76 | Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study). ( Ae, T; Azuma, M; Higuchi, K; Ishido, K; Katada, C; Koizumi, W; Nakatani, K; Nakayama, N; Nishimura, K; Saigenji, K; Sasaki, T; Tanabe, S, 2010) |
| "Use of metronidazole has been suggested to be associated with an increased risk of acute pancreatitis in case reports." | 3.73 | Metronidazole and risk of acute pancreatitis: a population-based case-control study. ( Jacobsen, J; Nørgaard, M; Pedersen, L; Ratanajamit, C; Skriver, MV; Sørensen, HT, 2005) |
| "46 patients having exacerbation of duodenal ulcer in the presence of Helicobacter pylori (HP) were studied for efficacy of HP eradication treatment which comprised omeprazole (40 mg/day), colloid bismuth subcitrate (480 mg/day) and metronidazole (1000 mg/day) for 2 weeks." | 3.72 | [Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens]. ( Nurbaev, FE; Orziev, ZM; Rakhimova, GSh, 2003) |
| " pylori isolates from patients with peptic ulcer disease reporting for clinical management to the Post Graduate Institute of Medical Education and Research, Chandigarh; All India Institute of Medical Sciences, New Delhi; Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow; Deccan College of Medical Sciences and Allied Hospitals, Hyderabad; and hospitals in Chennai in collaboration with the Dr ALM Post Graduate Institute of Basic Medical Sciences were analyzed for their levels of antibiotic susceptibility to metronidazole, clarithromycin, amoxycillin, ciprofloxacin and tetracycline." | 3.72 | Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study. ( Ayyagari, A; Bhasin, D; Das, BK; Dharmalingam, S; Habibullah, CM; Khan, AA; Naik, SR; Rajasambandam, P; Ramathilagam, B; Rao, UA; Ray, P; Sharma, MP; Thyagarajan, SP, 2003) |
| "Six captive cheetahs (Acinonyx jubatus) with severe gastritis diagnosed by gastric endoscopy and mucosal histopathology were treated with omeprazole, metronidazole, and amoxicillin for 3 wk." | 3.72 | Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis. ( Burroughs, R; Lane, E; Lobetti, R, 2004) |
| " pylori infection in active peptic ulcer in Korea (30 mg of lansoprazole, 250 mg of clarithromycin, and 400 mg of metronidazole, all twice daily)." | 3.70 | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. ( El-Zimaity, HM; Graham, DY; Kim, JG; Osato, MS; Perng, CL, 1998) |
| "We describe a 54-year-old man with Helicobacter pylori (+) duodenal ulcer who developed Clostridium difficile associated colitis, 5 days after commencing a 'triple' regimen consisting of omeprazole 20 mg b." | 3.70 | Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori. ( Archimandritis, A; Katsorida, M; Souyioultzis, S; Tzivras, M, 1998) |
| " pylori to clarithromycin and metronidazole, as well as the sensitivity and specificity of H." | 3.70 | [Profile of the resistance to macrolides and imidazoles of Helicobacter pylori in a sample of the Portuguese population]. ( Caetano, JA; Caetano, JM; da Silva, JA; Marote, G; Pessanha, MA; Rosário, M, 1998) |
| "One hundred eight patients with cultured H pylori-positive gastritis or peptic ulcer were treated with three regimens: quadruple treatment without proton pump inhibitors (n = 25), dual treatment with omeprazole and amoxicillin (INN, amoxicilline) (n = 26), and triple treatment with omeprazole, amoxicillin, and clarithromycin (n = 57)." | 3.70 | CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori. ( Aoyama, N; Kasuga, M; Kita, T; Komada, F; Okumura, K; Shirakawa, K; Tanigawara, Y, 1999) |
| " pylori-infected patients with duodenal ulcer were treated with either omeprazole or famotidine plus two antibiotics for 2 wk." | 3.70 | The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country. ( Acevedo, C; Duarte, I; Figueroa, C; Fuster, F; Giancaspero, R; Hola, K; Rollan, A; Schulz, M, 2000) |
| " Given the histology and the fact that rapid urease test results were positive, chronic active gastritis with H." | 3.70 | Iron-deficiency anemia associated with Helicobacter pylori gastritis. ( Imai, T; Konno, M; Muraoka, S; Takahashi, M, 2000) |
| " One hundred and thirty two patients with endoscopically confirmed H pylori positive, duodenal ulcer or antral gastritis were treated with triple therapy (colloidal bismuth/metronidazole/amoxicillin) for two weeks." | 3.69 | High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. ( Bujanover, Y; Gilat, T; Hallak, A; Konikoff, FM; Moshkowitz, M; Peled, Y; Santo, M; Tiomny, E, 1995) |
| " pylori-positive duodenal ulcer patients before and 6 weeks after 'triple therapy' with bismuth, tetracycline and metronidazole." | 3.69 | Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation. ( Dhillon, AP; Fraser, AG; Pounder, RE; Sankey, EA; Sim, R, 1994) |
| " pylori-positive patients with recurrent peptic ulcer diseases, 29 of whom were given triple therapy (amoxycillin and metronidazole for 1 week and plaunotol for 4 weeks)." | 3.69 | Evaluation of a new bismuth-free triple therapy in nude mice and humans. ( Karita, M; Nakazawa, T; Okita, K; Sugiyama, T; Tsuda, M, 1995) |
| " pylori infection and peptic ulcer disease or functional dyspepsia were treated with either omeprazole 20 mg b." | 3.69 | One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection. ( Becker, T; Börsch, G; Labenz, J; Peitz, U; Stolte, M; Tillenburg, B, 1996) |
| "Thirty-nine Helicobacter pylori (HP) positive chronic duodenal ulcer patients completed the 4 weeks treatment of triple therapy (Denol, Metronidazole and Amoxil)." | 3.69 | Triple therapy in duodenal ulcer healing--a follow up study. ( Ahmed, W; Qureshi, H; Zuberi, SJ, 1996) |
| " Sixty-six patients (with nonulcer dyspepsia, inactive ulcer, or active ulcer) were given lansoprazole (30 mg, h." | 3.69 | Endoscopic topical therapy for the treatment of Helicobacter pylori infection. ( Ishino, Y; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Takimoto, T; Taniguchi, Y; Yamamoto, H; Yoshida, Y, 1996) |
| "Fifty-two patients with peptic ulcer disease and antral biopsies containing Helicobacter pylori sensitive to metronidazole were given a 7-day course of treatment: omeprazole 20 mg b." | 3.69 | A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice. ( Scott, BB; Vautier, G, 1997) |
| " and omeprazole 20 mg daily for one week, followed by 20 mg omeprazole daily for further 3 weeks) in a prospective study of 36 patients with Helicobacter pylori-associated ulcers (10 gastric ulcers, 26 duodenal ulcers)." | 3.69 | [Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease]. ( Kobler, E; Reinhart, WH; Werth, B; Wüst, W, 1997) |
| " Helicobacter pylori status and the histology of the antral and oxyntic mucosa were evaluated in 25 patients with duodenal ulcer treated with a triple schedule of furazolidone, metronidazole and amoxicillin, and in 16 patients treated only with cimetidine." | 3.68 | Histology of the mucosa of gastric antrum and body before and after eradication of Helicobacter pylori. ( Barbosa, AJ; Castro, LP; Coelho, LG; Lima Júnior, GF; Mendes, EN; Oliveira, CA; Passos, MC; Queiroz, DM; Resende, LM; Rocha, GA, 1993) |
| "Omeprazole heals most duodenal ulcers after 4 weeks of treatment but relapse is common." | 3.68 | Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics. ( Beattie, S; Collins, R; Hamilton, H; McCarthy, CJ; O'Morain, C, 1993) |
| "25 patients with Helicobacter pylori-associated active duodenal ulcer disease (bleeding: n = 5, penetrating: n = 1, stenosis of the bulb: n = 4, frequent ulcer relapse: n = 18) were treated with 3 x 600 mg bismuth subsalicylate (BSS), 3 x 400 mg metronidazole and 3 x 500 mg tetracycline in addition to 300 mg ranitidine." | 3.68 | [Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease]. ( Börsch, G; Gyenes, E; Labenz, J; Rühl, GH, 1993) |
| "The histamine concentration of the oxyntic mucosa was determined in Helicobacter pylori-positive patients with duodenal ulcer before and after antimicrobial therapy and in H." | 3.68 | Histamine content of the oxyntic mucosa from duodenal ulcer patients: effect of Helicobacter pylori eradication. ( Coelho, LG; Cunha-Melo, JR; Lima Júnior, GF; Mendes, EN; Moura, SB; Oliveira, CA; Passos, MC; Queiroz, DM; Resende, LM; Rocha, GA, 1993) |
| " Thirty-two consecutive patients (suffering from either peptic ulcer or nonulcer dyspepsia) with Helicobacter pylori infection received omeprazole (40 mg) + bismuth subcitrate (240 mg x 4) + amoxicillin suspension (2000 mg x 4) + metronidazole (500 mg x 4), for only one day." | 3.68 | One-day therapy for treatment of Helicobacter pylori infection. ( Barbara, L; Biasco, G; Corinaldesi, R; Gasperoni, S; Paparo, GF; Ricci-Maccarini, M; Stanghellini, V; Tucci, A; Varoli, O, 1993) |
| " pylori-associated gastritis from the gastric tissue following different drug regimens in inoculated nude mice, we evaluated the effectiveness of each regimen, including a new drug, plaunotol." | 3.68 | Evaluation of new therapy for eradication of H. pylori infection in nude mouse model. ( Karita, M; Li, Q; Okita, K, 1993) |
| "Thirty-six patients with nonhealing or recurrent duodenal ulcers (DU) were treated with omeprazole; 20 mg/day for one month followed by triple therapies (metronidazole, 400 mg three times a day, tetracycline, 500 mg four times a day with either colloidal bismuth, 120 mg four times a day or sucralfate 1 g four times a day." | 3.68 | Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori. ( Jaskiewicz, K; Louw, JA; Marks, IN, 1993) |
| "Forty-eight patients with endoscopically proven duodenal ulcer (DU) and Helicobacter pylori infection detected by 14C-urea breath test (BT) were assigned to 5 days of treatment with furazolidone, metronidazole, and amoxicillin in addition to eventual classical anti-ulcer agents if necessary." | 3.68 | Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study. ( Brandao, MJ; Castro, LP; Chausson, Y; Coelho, LG; Costa, EL; Maia, AF; Passos, MC; Rodrigues, DC, 1992) |
| "Thirty consecutive patients with endoscopically proven duodenal ulceration who had Helicobacter pylori infection on culture and histology, were treated with tripotassium dicitrato bismuthate (1 tablet q." | 3.68 | Short report: short-term triple therapy for H. pylori-associated duodenal ulcer disease. ( Beattie, S; Keane, C; O'Morain, C; Patchett, S, 1992) |
| "We have performed a retrospective study of 103 patients with either peptic ulcer or non-ulcer dyspepsia, infected with metronidazole-sensitive strains of Helicobacter pylori (H." | 3.68 | Does a previous course of tripotassium dicitrato bismuthate affect the subsequent chances of successful Helicobacter pylori eradication? ( Bell, GD; Burridge, SM; Gant, PW; Harrison, G; Jones, PH; Powell, K; Trowell, JE; Weil, J, 1992) |
| "Nine patients with Helicobacter pylori-related antral gastritis and history of duodenal ulceration were studied before and at 1 and 7 months after eradication of the infection by a 4-week course of tripotassium dicitrato bismuthate, metronidazole, and amoxycillin." | 3.68 | Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects. ( Chittajalu, R; Dahill, SW; el Nujumi, AM; Fullarton, GM; Hilditch, TE; MacDonald, AM; McColl, KE, 1991) |
| "pylori infection and penicillin allergy." | 3.30 | New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial. ( Li, C; Lu, H; Ren, X; Song, Z; Suo, B; Tian, X; Yao, X; Zhang, H; Zhang, Y; Zhou, L, 2023) |
| " Twenty-three children reported at least one adverse event (63." | 3.01 | Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children. ( Bontems, P; Cadranel, S; Kotilea, K; Mahler, T; Miendje Deyi, VY; Nguyen, J; Salame, A; Verset, L, 2021) |
| " Adverse events were reported by 32." | 2.87 | The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice. ( Bazzoli, F; Conigliaro, R; Eusebi, LH; Farinati, F; Grande, G; Gravina, AG; Ierardi, E; Maconi, G; Panarese, A; Romano, M; Romiti, A; Savarino, E; Stasi, E; Zagari, RM, 2018) |
| " Adverse events were recorded by patients in specially developed diaries." | 2.87 | Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection. ( Andreev, DN; Dicheva, DT; Maiev, IV; Partzvania-Vinogradova, EV; Yurenev, GL, 2018) |
| "pylori eradication in patients with type 2 diabetes." | 2.84 | Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes. ( Chang, WL; Chen, WY; Cheng, HC; Lin, CH; Lu, CC; Ou, HY; Sheu, BS; Wu, CT; Yang, HB; Yang, YJ, 2017) |
| " pylori treatment or lookalike placebos together with a single dosage of omeprazole and bismuth." | 2.82 | A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication. ( Bajbouj, M; Classen, M; Gerhard, M; Guan, WX; Li, M; Liu, RY; Liu, WD; Ma, JL; Pan, KF; Quante, M; Schmid, R; Suchanek, S; Ulm, K; Vieth, M; Wang, JX; Wang, LH; You, WC; Zhang, L; Zhang, LF; Zhang, Y; Zhou, T, 2016) |
| " The present study was designed to evaluate efficacy of 10-day sequential therapy (SQT) and 14-day standard triple therapy (STT) with four- times-daily dosing of amoxicillin for H." | 2.82 | Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospecti ( Bhanthumkomol, P; Chonprasertsuk, S; Mahachai, V; Phiphatpatthamaamphan, K; Pornthisarn, B; Siramolpiwat, S; Tangaroonsanti, A; Vilaichone, RK, 2016) |
| "Vonoprazan (TAK-438) is a novel potassium-competitive acid blocker that inhibits gastric H(+), K(+)-ATPase." | 2.82 | Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study. ( Hasegawa, S; Nakamura, K; Nishimura, A; Okamoto, H; Sakurai, Y; Shiino, M, 2016) |
| " There were no significant differences between the groups in regard to the eradication rates and adverse events." | 2.80 | Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea. ( Hong, SN; Kim, JJ; Lee, H; Lee, JH; Lee, YC; Min, BH; Rhee, PL, 2015) |
| "Clarithromycin resistance was an independent risk factor predicting eradication failure in standard triple group (P < 0." | 2.80 | A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection. ( Chen, A; Chen, WC; Cheng, JS; Chuah, SK; Hsu, PI; Kao, SS; Lai, KH; Peng, NJ; Tsay, FW; Wang, HM; Wu, DC; Yu, HC, 2015) |
| "In standard regimens for Helicobacter pylori infection, amoxicillin is dosed twice daily, although the bactericidal effect of amoxicillin depends on the %time-above-MIC." | 2.79 | Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy. ( Furuta, T; Ichikawa, H; Osawa, S; Sahara, S; Sugimoto, K; Sugimoto, M; Umemura, K; Uotani, T; Watanabe, H; Yamada, T; Yamade, M, 2014) |
| "Metronidazole resistance was observed in 16/49 (32." | 2.79 | Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori. ( Delchier, JC; Malfertheiner, P; Thieroff-Ekerdt, R, 2014) |
| "SUMMARY Eradikacion therapy at patients with chronic pancreatitis and combined with Helicobacter associated erosive gastropathy in a month after treatment appeared successful at 75% patients which accepted therapy of the first line--pantoprazol, amoksicillin, klaritromicin." | 2.79 | [Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy]. ( Kotsiubniak, LA; Koval', VIu; Moskal', OM, 2014) |
| "To estimate risk of H." | 2.78 | Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities. ( Anderson, GL; Baker, LH; Bravo, LE; Chey, WD; Correa, P; Crowley, JJ; Dominguez, RL; Ferreccio, C; Goodman, GE; Greenberg, ER; Herrero, R; Lazcano-Ponce, EC; Martínez, ME; Meza-Montenegro, MM; Morgan, DR; Peña, EM; Peña, R; Salazar-Martínez, E; Sexton, R; Torres, J; Valdivieso, M, 2013) |
| "Metronidazole resistance was 96." | 2.78 | Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study. ( Liang, X; Liu, W; Lu, H; Sun, Q; Xiao, S; Xu, X; Zhang, W; Zheng, Q, 2013) |
| "Lafutidine is an H2-receptor antagonist with gastroprotective action through capsaicin-sensitive afferent neurons and relatively inexpensive compare to proton-pump inhibitors (PPIs)." | 2.77 | Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study. ( Ando, T; Fujinami, H; Hosokawa, A; Kudo, T; Murakami, J; Nishikawa, J; Ogawa, K; Orihara, T; Sugiyama, T; Takahara, T, 2012) |
| "Ecabet sodium has an anti-H." | 2.76 | Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection. ( Asaka, M; Furukawa, K; Furuta, T; Inaba, T; Ishii, N; Kamoshida, T; Kato, M; Konda, Y; Nomura, H; Sasaki, M; Shirai, T; Sugimoto, M; Tomita, T, 2011) |
| "Gastritis was assessed according to the updated Sydney classification for activity, chronic inflammation, gastric glandular atrophy, intestinal metaplasia, and H." | 2.74 | Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial. ( Bijlsma, JW; Bloemena, E; Boers, M; De Leest, HT; Dijkmans, BA; Houben, HH; Janssen, M; Kostense, PJ; Kuipers, EJ; Lems, WF; Steen, KS; Van de Laar, MA, 2009) |
| "Treatment with metronidazole is as effective as that with tinidazole in terms of efficacy." | 2.73 | Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy. ( Astegiano, M; Berrutti, M; De Angelis, C; Fagoonee, S; Leone, N; Morgando, A; Pellicano, R; Repici, A; Rizzetto, M; Saracco, G; Smedile, A, 2008) |
| "Furazolidone has been effective against Helicobacter pylori in Iran, with no resistance, but with intolerable side effects in the second week." | 2.73 | Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease. ( Agah, S; Ajvadi, Y; Ali-Asgari, A; Ebrahimi-Dariani, N; Khatibian, M; Malekzadeh, R; Massarrat, S; Mikaeli, J; Nasseri-Moghaddam, S; Pourshams, A; Sotoudehmanesh, R; Vahedi, H; Zendehdel, N, 2007) |
| "Famotidine treatment including metronidazole-amoxicillin as second-line therapy provided a high eradication rate similar to lansoprazole therapy." | 2.72 | Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection. ( Fujioka, T; Inoue, K; Kodama, M; Miyajima, H; Murakami, K; Okimoto, T; Ono, M; Otsu, S; Sato, R; Watanabe, K, 2006) |
| "Levodopa was prescribed for groups 1 and 3." | 2.72 | Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial. ( Alizadeh, M; Arj, A; Bagheri-Lankarani, K; Bahri-Najafi, R; Dehbashi, N; Emami, MH; Esmaeili, A; Fattahi, MR; Geramizadeh, B; Kaviani, MJ; Saberfiroozi, MM; Taghavi, AR, 2006) |
| " pylori eradication rate in both metronidazole-sensitive and -resistant strains following quadruple therapy using single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole." | 2.71 | Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study. ( Borody, T; Dallaire, C; De Boer, WA; Fallone, CA; Farley, A; Mégraud, F; O'Morain, C; Piotrowski, J; Schuman, R; Spénard, J; Tytgat, G, 2003) |
| "Furazolidone has recently shown promising efficacy in H." | 2.71 | The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy. ( Bahrami, H; Ebrahimi-Dariani, N; Haghpanah, B; Mansour-Ghanaei, F; Mirmomen, S; Noormohammadpoor, P; Sotodehmanesh, R, 2003) |
| "Rabeprazole is a new proton pump inhibitor, which has been reported to induce a faster acid suppression than other drugs of the same category." | 2.71 | Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study. ( Bilardi, C; Dulbecco, P; Gambaro, C; Iiritano, E; Mansia, C; Savarino, V; Usai, P; Vigneri, S; Zentilin, P, 2003) |
| "Among the 18 new cases of gastric cancers that developed, no overall reduction was observed in participants who received H pylori eradication treatment (n = 7) compared with those who did not (n = 11) (P =." | 2.71 | Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. ( Chen, JS; Ching, CK; Feng, RE; Fong, DY; Ho, J; Hu, WH; Lai, KC; Lam, SK; Leung, SY; Wong, BC; Wong, WM; Yuen, ST; Zheng, TT, 2004) |
| "Treatment with metronidazole, tetracycline and bismuth for 10 days failed to eradicate H." | 2.71 | Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination. ( Berge, T; Berstad, A; Henriksen, TH; Lerang, F; Lia, A; Ragnhildstveit, E; Schøyen, R; Thoresen, T; Tveten, Y, 2004) |
| "Peptic ulcer was found in 6." | 2.71 | Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients. ( Färkkilä, M; Sarna, S; Sipponen, P; Valtonen, V, 2004) |
| "Lansoprazole (LAN) is a proton pump inhibitor drug (PPI) metabolized by the P-450 liver cytochrome (CYP-450) system." | 2.71 | Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test. ( Bellotti, M; Botta, F; Chiarbonello, B; Cotelessa, T; Emanuela, T; Fumagalli, A; Giannini, E; Malfatti, F; Milazzo, S; Podestà, E; Polegato, S; Testa, R, 2005) |
| "A urea breath test was performed 1-2 months after eradication." | 2.71 | Eradication rate of Helicobacter pylori in dyspeptic patients. ( Amini, M; Khedmat, H; Yari, F, 2005) |
| "The aim was to confirm which was the better regimen for second-line therapy after treatment failure with a standard triple therapy in Japan, a high dosage of levofloxacin- or metronidazole-based therapy." | 2.71 | Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan. ( Aoyama, N; Kasuga, M; Matsumoto, Y; Miki, I; Mitani, T; Miyachi, H; Morita, Y; Shirasaka, D; Tamura, T; Toyoda, M; Watanabe, Y, 2005) |
| "Metronidazole had a lower limit CI of 74% for C(max)." | 2.71 | Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication. ( Aumais, C; Brunet, JS; Grace, M; Lefebvre, M; Massicotte, J; Spénard, J; Tremblay, C, 2005) |
| " A therapeutical scheme (omeprazole, metronidazole, amoxicilline) obtained a further pathogenetic substantiation of B type CG patient treatment with additional antioxidant vitamin E use at the dosage of 300 mg/day for three weeks." | 2.71 | [Lipid peroxidation and antioxidant system in treatment dynamics of patients with chronic gastritis]. ( Postavnyĭ, VE, 2005) |
| "Duodenal ulcers were healed in nine of 10 (90%) patients in the BTF group and in all patients (12/12) (100%) in the OBTM group (P = N." | 2.70 | Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole. ( Domareva, I; Ganskaya, Z; Isakov, V; Koudryavtseva, L; Maev, I, 2002) |
| "Helicobacter pylori gastritis is usually a lifelong disease which can cause different topographical inflammatory reactions and induce divergent effects on acid secretion in humans." | 2.70 | Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia. ( Färkkilä, M; Koskenpato, J; Sipponen, P, 2002) |
| "Eight children with type 1 diabetes and H." | 2.70 | Effect of Helicobacter pylori eradication in the glycemia of children with type 1 diabetes: a preliminary study. ( Bégué, RE; Compton, T; Gómez, R; Vargas, A, 2002) |
| "and metronidazole 500 mg b." | 2.70 | Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication. ( Doulgeroglou, V; Kamberoglou, D; Patra, E; Polymeros, D; Sanidas, I; Savva, S; Tzias, V, 2001) |
| " Sixty-eight patients received 30 mg of lansoprazole once daily, 500 mg of amoxicillin and 250 mg of metronidazole thrice daily for 2 weeks (LAM group), while the other 67 patients received the same dosage of those agents plus 18,000 tyrosine units of pronase thrice daily for 2 weeks (LAMP group)." | 2.70 | Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori. ( Akamatsu, T; Gotoh, A; Ikeno, T; Ishida, K; Kaneko, T; Katsuyama, T; Kawakami, Y; Kiyosawa, K; Ota, H; Shimizu, T; Shimodaira, K; Sugiyama, A, 2002) |
| "Metronidazole resistance was found in 32 of 65 (49%) patients in whom H." | 2.69 | Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance. ( Collins, BJ; Coombs, GW; Forbes, GM; McCullough, CA; Robins, PD, 1998) |
| "Pretreatment with omeprazole did not reduce the cure rate for this new quadruple therapy." | 2.69 | A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate. ( Maeda, K; Nishimura, H; Oda, K; Ohkuma, K; Okabe, N; Okada, M; Oki, K; Seo, M; Shirotani, T, 1998) |
| "pylori recurrence rate." | 2.69 | [Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment]. ( Iijima, K; Kato, K; Ohara, S; Sekine, H, 1999) |
| " Further study may permit development of optimal once-daily dosing and enhance eradication rates." | 2.69 | Once-daily therapy for H. pylori infection: a randomized comparison of four regimens. ( Cheybani, K; Estrada, R; Laine, L; Neil, G; Smith, S; Trujillo, M; Yeramian, P, 1999) |
| "pylori-related gastritis, have focused mainly on medium and long-term change following eradication therapies." | 2.69 | Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy. ( Chadwick, VS; Chen, W; Shu, D; Tie, A; Wilson, IR, 1999) |
| "In order to improve the efficacy and simplicity of the FDA-approved regimen of ranitidine bismuth citrate (RBC) and clarithromycin dual therapy, we added an inexpensive antibiotic (metronidazole), changed the dosage scheme to twice daily dosing, and decreased the duration of therapy to 1 week." | 2.69 | Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication. ( Cave, DR; Hoffman, JS; Katz, LM, 1999) |
| "pylori functional dyspepsia is prevalent in people over 60 years old." | 2.69 | Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments. ( Bentivegna, C; Branciforte, G; Brogna, A; Catalano, F; Chodash, HB; Dawson, BK; Luca, S; Michalos, A; Terranova, R, 1999) |
| "Metronidazole resistance was present in 29." | 2.69 | Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies. ( Are, BM; Atzei, A; Carta, M; Cugia, L; Dore, MP; Graham, DY; Maida, A; Manca, A; Massarelli, G; Mura, I; Piana, A; Realdi, G, 1999) |
| " Pre-treatment with a proton pump inhibitor, higher doses or more frequent dosing may be necessary to increase the cure rate of short duration regimens." | 2.69 | Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen. ( Cross, R; Grimley, CE; Illing, RC; Lismore, JR; Loft, DE; Nwokolo, CU; O'sullivan, M; Penny, A; Shebani, M, 1999) |
| "Clarithromycin resistance was uncommon." | 2.69 | The OAC and OMC options. ( Unge, P, 1999) |
| "pylori eradication rate and ulcer recurrence rate were compared." | 2.69 | Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study. ( Chen, J; Chen, SY; Wang, JY; Zhang, SS; Zhang, XD, 1999) |
| " Other factors reported to affect compliance included the frequency of dosing and the number of pills." | 2.69 | A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy. ( Canning, A; Egan, C; Farraye, FA; Kemp, JA; Lee, M; Tataronis, G, 1999) |
| "The ulcer recurrences appeared in patients with H." | 2.69 | [Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication]. ( Mach, T; Zahradnik-Bilska, J, 1999) |
| "While addition of metronidazole to the omeprazole-amoxycillin combination has been shown to be advantageous, the optimal dosage and drug distribution of the antimicrobials has not been sufficiently evaluated." | 2.69 | Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. ( Bayerdörffer, E; Burman, CF; Díete, U; Dité, P; Domján, L; Kisfalvi, I; Lonovics, J; Mégraud, F; Pap, A; Sipponen, P; Zeijlon, L, 1999) |
| " The aim of this study was to determine the optimal dose and duration of lansoprazole (LA) administration in combination with amoxicillin (AMPC) and metronidazole (MNZ)." | 2.69 | Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy. ( Asaka, M; Ishizuka, J; Kagaya, H; Katagiri, M; Kato, M; Komatsu, Y; Kudo, M; Kudo, T; Nishikawa, K; Sugiyama, T; Sukegawa, M; Takeda, H; Toyota, J, 1999) |
| "Metronidazole resistance was found in 44% of pre-treatment cultures of H." | 2.69 | Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily. ( Axon, AT; Bardhan, KD; Braun, W; Cooper, BT; Dillon, J; Gatz, G; Tildesley, G; Wyatt, JI, 2000) |
| "After eradication, 51 out of 53 treated rosacea patients became Hp negative." | 2.69 | Helicobacter pylori and its eradication in rosacea. ( Bielański, W; Karczewska, E; Konturek, SJ; Pytko-Polonczyk, J; Sliwowski, Z; Szlachcic, A, 1999) |
| "We therefore assessed the incidence of GERD among comparable patients having undergone successful versus failed H." | 2.69 | Is Helicobacter pylori eradication associated with gastroesophageal reflux disease? ( Barkun, AN; Beech, R; Best, L; Fallone, CA; Friedman, G; Joseph, L; Loo, V; Mayrand, S, 2000) |
| " However, eradication rates with different dosages and dosing vary, and data on the impact of resistance are sparse." | 2.69 | The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection. ( Bardhan, K; Bayerdörffer, E; Burman, CF; Delchier, JC; Gromark, P; Hellblom, M; Lind, T; Mégraud, F; Stubberöd, A; Veldhuyzen Van Zanten, SJ; Zeijlon, L, 2000) |
| "Omeprazole can enhance efficacy of single and double antibiotic protocols and is particularly effective when combined with clarithromycin and a nitroimidazole." | 2.68 | Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori. ( Andrews, P; Bae, H; Borody, TJ; Brandl, S; Fracchia, G; Shortis, NP, 1995) |
| "Treatment with bismuth subsalicylate and metronidazole resulted in symptomatic improvement in 61-66% of non-ulcer dyspepsia patients regardless of initial or post-treatment H." | 2.68 | Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients. ( Appelman, HD; Barnett, JL; Behler, EM; Crause, I; Elta, GH; Nostrant, TT; Scheiman, JM, 1995) |
| "Healing of gastric ulcer is rapid and recurrence is infrequent after successful H pylori eradication." | 2.68 | Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group. ( Gormsen, MH; Kivilaakso, E; Pikkarainen, P; Seppälä, K; Sipponen, P, 1995) |
| "To determine the 12-month posttherapy recurrence (recrudescence) of Helicobacter pylori in patients with healed duodenal ulcer after apparent eradication of the organism with anti-H." | 2.68 | Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens. ( Beattie, S; Gilvarry, J; Hamilton, H; Keane, CT; O'Morain, CA; Sweeney, EC; Xia, HX, 1995) |
| "Dyspepsia was assessed on the frequency and severity of six symptoms [epigastric pain (night and day), nausea and vomiting, upper abdominal discomfort, and regurgitation] where each symptom was scored from 0 to 4." | 2.68 | Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia. ( Beattie, S; Collins, RM; Keane, C; McCarthy, C; O'Morain, C; Patchett, S, 1995) |
| "Duodenal ulcers were healed in 44 of 49 (89." | 2.68 | Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. ( Cheng, AF; Chung, SC; Lau, JY; Leung, VK; Li, AK; Ling, TK; Suen, R; Sung, JJ, 1996) |
| "91%)." | 2.68 | Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients. ( Acuña, R; Albornoz, V; Figueroa, G; Portell, DP; Toledo, MS; Troncoso, M; Vigneaux, J, 1996) |
| "Cure of HP infection reduces the recurrence of peptic ulcer and of rebleeding from ulcer disease more effectively than does long-term maintenance therapy." | 2.68 | Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients. ( Cantero, J; Gómez-Cedenilla, A; Grávalos, RG; Pajares, JM; Santander, C, 1996) |
| "Some recent studies have reported high recurrence rates after apparent cure." | 2.68 | Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy. ( De Boer, WA; Driessen, WM; Geuskens, LM; Lai, JY, 1996) |
| "Metronidazole is an important component of combination antimicrobial therapies used in the eradication of Helicobacter pylori, a recognized cause of gastritis and duodenal ulcer." | 2.68 | A liquid chromatography assay for the study of serum and gastric juice metronidazole concentrations in the treatment of Helicobacter pylori. ( Pollak, PT, 1996) |
| "Shallow duodenal ulcers were noted in three patients at 1-year follow-up, two of whom admitted to taking non-steroidal anti-inflammatory drugs (NSAIDs); H." | 2.68 | Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up. ( Goh, KL; Navaratnam, P; Peh, SC, 1996) |
| "Metronidazole resistance was induced in 8 out of 16 with a sensitive strain." | 2.68 | One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection. ( de Boer, WA; Ouwehand, ME; Schade, RW; Schneeberger, PM; Tytgat, GN; van Etten, RJ; van Unnik, AJ, 1997) |
| "Clarithromycin is a new macrolide antibiotic which is known to be highly effective in eradicating Helicobacter pylori (H." | 2.68 | Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease. ( Lee, SD; Lin, HJ; Lo, WC; Perng, CL; Wang, K, 1997) |
| "In this random study, the efficacy of either colloidal bismuth subcitrate (CBS) or metronidazole in combination with an H2-antagonist in the treatment of various gastric pathologies was evaluated, along with the trends in antibody levels." | 2.68 | Comparison of colloidal bismuth subcitrate and metronidazole, both in combination with an H2-antagonist as therapy for Helicobacter pylori. ( Albano, A; Baffone, W; Barbieri, E; Belbusti, F; Bruscolini, F; Fabi, MT; Pianetti, A; Salvaggio, L, 1997) |
| "The co-administration of ranitidine bismuth citrate plus clarithromycin at low dosage and metronidazole in twice daily doses for 1 week is a short, effective and well-tolerated regimen for the eradication of H." | 2.68 | A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics. ( Bisso, G; Caroli, M; Celle, G; Mansi, C; Mela, GS; Mele, MR; Olivieri, A; Saggioro, A; Savarino, V; Termini, R; Tosatto, R; Vigneri, S, 1997) |
| " Possibly, 14-day therapy or a higher dosage of metronidazole provide better results with metronidazole-resistant H." | 2.68 | Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. ( el-Zimaity, HM; Graham, DP; Graham, DY; Hoffman, J; Osato, M, 1997) |
| "Lansoprazole has superior anti-Helicobacter activity in vitro and possibly also in vivo; therefore we investigated quadruple therapy with lansoprazole." | 2.68 | Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection. ( de Boer, WA; Driessen, WM; Lai, JY; Schneeberger, PM; van de Wouw, BA; van Etten, RJ, 1996) |
| "Rapid recurrence of H." | 2.68 | Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University. ( Carrazco, J; Checkley, W; Cordero, L; Gilman, RH; Leon-Barua, R; McDonald, J; Ramirez-Ramos, A; Recavarren-Arce, S; Salazar, G; Valdez, Y; Watanabe, J, 1997) |
| " pylori than ranitidine when given with amoxicillin plus metronidazole for the treatment of duodenal ulcer, as both early reinfection and ulcer recurrence are diminished." | 2.68 | Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer. ( Blanco, M; Carpintero, P; Pajares, JM, 1997) |
| "The LCM1 regimen consisting of 30 mg lansoprazole once daily, 200 mg clarithromycin twice daily, and 250 mg metronidazole twice daily (the regular doses in ordinary use in Japan) is a highly effective and safe regimen for Japanese patients." | 2.68 | The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients. ( Ido, K; Kihira, K; Kimura, K; Saifuku, K; Satoh, K; Seki, M; Takimoto, T; Taniguchi, Y; Yoshida, Y, 1997) |
| "Pre-treatment metronidazole resistance was encountered in 34/63 (54." | 2.68 | Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection? ( Cheah, PL; Chin, SC; Chuah, SY; Goh, KL; Lo, YL; Parasakthi, N, 1997) |
| "To detect DU recurrence, the gastroscopy was performed at 6, 12, 18, and 24 months after therapy." | 2.67 | The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence--a 24 month follow-up study. ( Choi, JH; Jung, MH; Kim, NY; Lee, KH; Oh, HS; Wee, SH, 1994) |
| "pylori) eradication and duodenal ulcer recurrence." | 2.67 | Eradication of Helicobacter pylori infection and the recurrence of duodenal ulcers. ( Chen, CY; Chen, LT; Jan, CM; Lin, SR; Liu, CS; Perng, DS; Wang, WM, 1993) |
| "Metronidazole resistance was defined as a minimal inhibitory concentration (MIC) of metronidazole of > 8 micrograms/ml." | 2.67 | [Eradication of metronidazole-resistant Helicobacter pylori: is omeprazole/amoxicillin a therapeutic alternative?]. ( Ammann, R; Bauer, S; Flury, R; Meyenberger, C; Wirth, HP; Wüst, J; Zala, G, 1994) |
| "To evaluate two triple-therapy (TT) regimens of colloidal bismuth subcitrate (CBS), metronidazole, and tetracycline HCl in eradicating Helicobacter pylori, with particular attention to the frequency of resulting adverse effects of the two therapies." | 2.67 | Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori. ( Andrews, P; Borody, TJ; Brandl, S; Ferch, N; Hyland, L; Jankiewicz, E, 1994) |
| "Treatment with amoxicillin and omeprazole resulted in encouraging Helicobacter pylori eradication rates in pilot studies that included medium term follow up." | 2.67 | Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. ( Börsch, G; Gyenes, E; Labenz, J; Rühl, GH, 1993) |
| "pylori on the recurrence of duodenal ulcer, we treated 104 patients with H." | 2.67 | Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. ( Brandstätter, G; Dragosics, B; Hentschel, E; Hirschl, AM; Nemec, H; Schütze, K; Taufer, M; Wurzer, H, 1993) |
| "Metronidazole resistance has become an increasing problem that has severely limited the usefulness of the original triple therapy." | 2.67 | Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth. ( Genta, RM; Graham, DY; Klein, PD; Lew, GM; Malaty, HM; Ramirez, FC, 1993) |
| "Duodenal ulcer recurrence and gastritis are reduced with successful Helicobacter pylori treatment." | 2.67 | Patient factors affecting Helicobacter pylori eradication with triple therapy. ( Cutler, AF; Schubert, TT, 1993) |
| " Substitution of doxycycline for tetracycline HCl offers advantages of less frequent dosing and extrarenal excretion." | 2.67 | Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy. ( Andrews, P; Borody, TJ; Brandl, S; Devine, M; George, LL; Lenne, J; Moore-Jones, D; Walton, M, 1992) |
| "Metronidazole is an antiprotozoal drug used to treat a broad spectrum of infectious diseases, including Helicobacter pylori (H pylori) infections." | 2.61 | Metronidazole for Helicobacter pylori eradication therapy among children and adolescents in Japan: Overcoming controversies and concerns. ( Kakiuchi, T; Kikuchi, S; Lin, Y; Okuda, M; Wang, C, 2019) |
| "pylori eradication therapy to prevent gastric cancer." | 2.58 | World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat. ( Mori, H; Suzuki, H, 2018) |
| " In addition, sensitivity analyses ascertained the effects of treatment schedule, dosage and duration on cure rates." | 2.53 | Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment. ( Baylina, M; Calvet, X; Cohen, H; Dacoll, C; García-Iglesias, P; Gisbert, JP; López-Gongora, S; Muñoz, N; Puig, I; Sánchez-Delgado, J; Suarez, D, 2016) |
| " No significant differences in adverse events were noted among hybrid therapy, sequential therapy, and concomitant therapy ((RR: 1." | 2.52 | Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis. ( Lv, ZF; Wang, B; Wang, H; Wang, YH; Xie, Y; Xiong, HF; Yang, Y, 2015) |
| "Most gastroduodenal ulcers are due to HP infection." | 2.52 | [What is new in treating Helicobacter pylori infection?]. ( Fischbach, W; Glocker, E; Malfertheiner, P; Scherübl, H, 2015) |
| "pylori associated diseases such as gastric cancer is expected." | 2.50 | [Expanded indication of National Health Insurance for H. pylori associated gastritis]. ( Kato, M, 2014) |
| "Levofloxacin is an adequate substitute for clarithromycin and is recommended in second-line regimens." | 2.50 | Helicobacter pylori. ( Malfertheiner, P; Selgrad, M, 2014) |
| "As clarithromycin is a key antibiotic in the eradication of H." | 2.49 | A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication). ( Gisbert, JP; Marin, AC; McNicholl, AG, 2013) |
| "All patients with peptic ulcer disease, gastric cancer, and MALT lymphoma should be tested for Hp." | 2.47 | Diagnosis and treatment of Helicobacter pylori infection. ( Bytzer, P; Dahlerup, JF; Eriksen, JR; Jarbøl, DE; Rosenstock, S; Wildt, S, 2011) |
| " Although dosing regimens of clarithromycin triple therapy were quite consistent between trials, dosing regimens varied considerably for bismuth quadruple therapy." | 2.46 | Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability. ( Chey, WD; Higgins, PD; Luther, J; Moayyedi, P; Schoenfeld, PS; Vakil, N, 2010) |
| "Clarithromycin resistance is a growing problem in many countries." | 2.44 | Helicobacter pylori treatment: is sequential or quadruple therapy the answer? ( Vakil, N, 2008) |
| " dosing of levofloxacin (81%[95% CI: 78%-89%]vs 84%[95% CI: 66%-97%])." | 2.43 | Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis. ( Chey, WD; Kim, HM; Saad, RJ; Schoenfeld, P, 2006) |
| "The aetiology of dyspepsia is unknown in the majority of patients." | 2.43 | Role of Helicobacter pylori in functional dyspepsia. ( O'Morain, C, 2006) |
| " Adherence and adverse events for quadruple therapy were similar to currently recommended triple therapies." | 2.42 | Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies. ( Dickason, J; Fischbach, LA; van Zanten, S, 2004) |
| "pylori infection and idiopathic thrombocytopenic purpura (ITP)." | 2.42 | [Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients]. ( Hirashima, N; Ito, K; Kato, A; Kato, H; Kondo, H; Matsunaga, S; Nukaya, H; Sakakibara, K; Sakamoto, T; Tanaka, Y, 2004) |
| "Metronidazole resistance was significantly associated with female sex (P < 0." | 2.41 | Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999. ( Bhattacharyya, H; Hopkins, RJ; King, EC; Meyer, JM; Morris, D; Siepman, NY; Silliman, NP; Sugg, JE; Wang, W; Zhang, J, 2002) |
| "The lowest costs and recurrence rates were achieved by 3 regimens: standard triple therapy (a combination of bismuth subsalicylate, metronidazole, and tetracycline hydrochloride) for 14 days ($223, with 18% recurrence); a combination of clarithromycin, metronidazole, and a proton pump inhibitor for 7 days ($235, with 15% recurrence); and standard triple therapy with a proton pump inhibitor for 7 days ($236, with 14% recurrence)." | 2.40 | Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori. ( Freston, JW; Murphy, K; Taylor, JL; Zagari, M, 1997) |
| "Peptic ulcer is now recognized as a chronic gastric infectious disease." | 2.40 | [Helicobacter pylori infection and ulcer]. ( Blum, AL; Malfertheiner, P, 1998) |
| "Clarithromycin seems to be a better choice than amoxycillin to achieve this goal." | 2.40 | Clinical relevance of resistant strains of Helicobacter pylori: a review of current data. ( Doermann, HP; Mégraud, F, 1998) |
| "Eradication rate of Helicobacter pylori in dual therapy (omeprazole/amoxicillin) are reported in the range of 28-91%, side effect such as loose stool and skin reaction are reported 3." | 2.40 | [Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy]. ( Iwasaki, A, 1999) |
| "The treatment of duodenal ulcer has evolved from ineffective medical treatments through an era of surgical management, back to increasingly effective medical treatment." | 2.39 | Duodenal ulcer treatment: progress from pH to HP. ( Reilly, TG; Walt, RP, 1994) |
| "pylori infection." | 2.39 | May Helicobacter pylori be important for dermatologists? ( Drago, F; Parodi, A; Rebora, A, 1995) |
| "pylori infection decreases recurrence rates and facilitates healing, antibiotic therapy is indicated for all H." | 2.39 | Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology. ( Soll, AH, 1996) |
| "14C-urea breath test was the "gold standard" and the specificity of the biopsy urease test in diagnosing H." | 2.39 | Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway. ( Bergseth, M; Berstad, A; Berstad, K; Hundal, O; Olafsson, S; Tefera, S; Wilhelmsen, I, 1996) |
| " Dosing was lower than recommended for PPI (A: 49%, B: 41%) and amoxicillin (A: 6%, B: 56%)." | 1.91 | Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry. ( Barrio, J; Bontems, P; Cabral, J; Cilleruelo Pascual, ML; Homan, M; Kalach, N; Koletzko, S; Kori, M; Kotilea, K; Le Thi, TG; Lima, R; Misak, Z; Tavares, M; Urbonas, V; Urruzuno, P; Werkstetter, K, 2023) |
| " The adverse event rates were 8." | 1.91 | Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly. ( Chuah, SK; Liang, CM; Loke, SS; Ma, TL; Tai, WC; Yao, CC, 2023) |
| "Levofloxacin resistance was higher (38." | 1.91 | Geographic distribution of antibiotic resistance of Helicobacter pylori: A study in Bulgaria. ( Boyanova, L; Gergova, G; Gergova, R; Kandilarov, N; Markovska, R; Yordanov, D, 2023) |
| " Treatment success is affected by treatment choice, correct dosing of medications, and adherence." | 1.91 | Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children. ( Bontems, P; Iliadis, E; Kotilea, K; Mahler, T; Miendje Deyi, VY; Nguyen, J; Salame, A, 2023) |
| "Urolithin B (UB) is an additional major intestinal metabolite of ellagic acid (EA), which has been shown to possess anti-inflammatory, antioxidant, and antiapoptotic biological activities." | 1.91 | Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice. ( Cao, M; Chen, Q; He, Z; Huang, M; Qing, L; Wu, C; Yan, X; Yu, Z; Zhang, X; Zhao, J; Zhao, Q, 2023) |
| "005)] and a regimen including 4-times-daily dosing of amoxicillin (2 grams/day) [OR 3." | 1.91 | Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial). ( Aumpan, N; Graham, D; Issariyakulkarn, N; Mahachai, V; Vilaichone, RK; Yamaoka, Y, 2023) |
| "A sensitive and selective method needs to be developed and validated for simultaneous determination of four drugs (amoxacillin, tinidazole, naproxen and lansoprazole), used for treating Helicobacter pylori infection, in their combined dosage forms." | 1.72 | RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method. ( Hassib, ST; Mostafa, EA; Sharf, MG; Taha, EA, 2022) |
| "Clarithromycin resistance was more frequently observed in the H." | 1.72 | Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure. ( Florholmen, JR; Goll, R; Halvorsen, FA; Johnsen, KM; Melby, KK; Moayeri, B; Nestegard, O; Paulssen, E; Sørbye, SW; Tønnesen, T, 2022) |
| "Metronidazole resistance was found in 18 (18." | 1.72 | Effect of metronidazole resistance on Helicobacter pylori eradication regimens. ( Celiberto, F; D'attoma, B; De Bellis, M; Di Leo, A; Iannone, A; Ierardi, E; Losurdo, G; Pricci, M; Rendina, M; Riezzo, G; Russo, F, 2022) |
| " The adverse events were predictable and reported as frequent adverse events during triple-antibiotic therapy." | 1.62 | Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects. ( Jeon, JY; Kim, B; Kim, MG; Kim, SY; Lee, J; Moon, SJ; Oh, K; Song, GS, 2021) |
| "Gold nanoparticles were synthesized by the Turkevich method." | 1.62 | Construction of metronidazole capped in gold nanoparticles against ( Ali Rahdar, H; Amini, M; Azimi, A; Davarpanah, M; Fateh, R; Ghasemi, F; Javadi, A; Kardan-Yamch, J; Mohammadzadeh, R, 2021) |
| "Clarithromycin use was lower in postrevised guideline period (P = 0." | 1.62 | Low Adherence to Society Guidelines for the Management of Helicobacter Pylori Among Pediatric Gastroenterologists. ( Bonilla, S; Mansuri, I; Mitchell, PD, 2021) |
| " Adverse drug effects were found in 36 patients from the twice a day group and 50 patients from the four times a day group (P = ." | 1.56 | Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication. ( Kim, JH; Kim, JY; Lee, SY; Park, HS; Sung, IK, 2020) |
| "Cultured gastric cancer cell line SGC-7901 was infected with H." | 1.56 | Helicobacter pylori Infection Facilitates the Expression of Resistin-like Molecule Beta in Gastric Carcinoma and Precursor Lesions. ( Fang, EH; Li, HJ; Tong, QS; Wang, JQ; Zheng, LD, 2020) |
| "Clarithromycin resistance is an important contributor to eradication failure, and metronidazole is recommended as second-line treatment in such cases." | 1.56 | Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan. ( Ando, T; Handa, O; Horie, R; Imamoto, E; Itoh, Y; Murakami, T; Ose, T; Sendo, R; Suzuki, N, 2020) |
| "Metronidazole resistance was 81% followed by levofloxacin resistance (8." | 1.56 | Population-based study of Helicobacter pylori infection and antibiotic resistance in Bhutan. ( Aumpan, N; Mahachai, V; Ratanachu-Ek, T; Tshering, L; Uchida, T; Vilaichone, RK; Yamaoka, Y, 2020) |
| " The aim of this study was to evaluate the compliance, adverse effects and effectiveness of this treatment with the new galenic three-in-one capsule formulation containing bismuth subcitrate, metronidazole and tetracycline (Pylera®)." | 1.51 | Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera®) to eradicate Helicobacter pylori infection in 200 patients. ( Castro Fernández, M; Grande Santamaría, L; Keco Huerga, A; Lamas Rojas, E; Llorca Fernández, R; Pabón Jaén, M; Rojas Feria, M; Romero García, T, 2019) |
| "Clarithromycin resistance was 24% (167/686) in females and 15% (11/753) in males (p=0." | 1.51 | Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study. ( Álvarez-Argüelles, ME; Armesto, E; Duque, JM; Melón, S; Morilla, AM; Villar, H, 2019) |
| " Adverse events occurred in 55 patients (15." | 1.48 | Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study. ( Allegretta, L; Baldassarre, G; Brandimarte, G; Cassieri, C; De Bastiani, R; Di Mario, F; Elisei, W; Ferronato, A; Franceschi, M; Licci, C; Miraglia, C; Penna, A; Picchio, M; Pranzo, G; Rizzo, GL; Savarino, E; Scida, S; Tursi, A, 2018) |
| "Clarithromycin-resistance was detected in 29 samples (31." | 1.48 | Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa. ( Berger, Z; Castro, VG; Escandar, S; Gonzalez-Hormazabal, P; Jara, L; Lanzarini, E; Musleh, M; Valladares, H, 2018) |
| "Clarithromycin resistance was higher amongst women than men, 13% vs." | 1.46 | Antibiotic susceptibility of Helicobacter pylori in Iceland. ( Bjornsson, ES; Gudjonsson, H; Gunnarsdottir, AI; Hardardottir, H; Jonsdottir, KD, 2017) |
| " Here, we present an eradication regimen consisting of four-times-daily dosing (q." | 1.46 | Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan. ( Andoh, A; Ban, H; Furuta, T; Ichikawa, H; Kagami, T; Otsuka, T; Sahara, S; Sugimoto, M, 2017) |
| " Recently, a new treatment strategy has been developed to overcome the problem by using natural products in combination with antibiotics to enhance the treatment efficacy." | 1.43 | In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates. ( Berchová, K; Hassan, ST; Majerová, M; Pokorná, M; Švajdlenka, E, 2016) |
| "pylori gastritis were examined from medical centers in four different geographic regions of the USA." | 1.43 | Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA. ( Arnold, CA; Coss, E; Cryer, B; Doern, CD; Dunbar, KB; Lam-Himlin, DM; Mitui, M; Okwara, C; Park, JY; Thung, I; Valasek, MA, 2016) |
| "The cumulative 5-year incidences of gastric cancer were 3." | 1.43 | Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication. ( Fukayama, M; Hayakawa, Y; Hirata, Y; Koike, K; Niikura, R; Shichijo, S; Ushiku, T; Yamada, A, 2016) |
| "Low clarithromycin resistance was surprising since Pakistan is considered a hot bed of drug-resistant bacteria." | 1.43 | Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin. ( Ahmed, W; Arif, A; Bibi, S; Khan, A; Siddiqui, TR, 2016) |
| "pylori-induced gastric cancer, irrespective of the timing of antibiotic administration." | 1.42 | Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model. ( Aponte-Pieras, JR; Lee, DS; Morrissey, R; Moss, SF; Rogers, AB; Zhang, S, 2015) |
| "Curcumin was filtered using Lipinski's rule of five and the druglikeness property for evaluation of pharmacological properties." | 1.42 | In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation. ( Roy, BK; Shukla, HS; Srivastava, AK; Tewari, M, 2015) |
| "The linezolid MIC50 value was 31." | 1.42 | Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance. ( Boyanova, L; Evstatiev, I; Gergova, G; Mitov, I; Yaneva, P, 2015) |
| " Four times daily dosing (q." | 1.40 | Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion. ( Furuta, T; Ichikawa, H; Sahara, S; Sugimoto, K; Sugimoto, M; Uotani, T; Yamade, M, 2014) |
| "Clarithromycin resistance was 1." | 1.39 | Living in Sofia is associated with a risk for antibiotic resistance in Helicobacter pylori: a Bulgarian study. ( Boyanova, L; Evstatiev, I; Gergova, G; Ilieva, J; Mitov, I; Nikolov, R, 2013) |
| "Levofloxacin resistance was significantly associated with the male sex (OR: 11." | 1.38 | High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy. ( Castelli, V; Fiorini, G; Gatta, L; Holton, J; Ricci, C; Ridola, L; Saracino, IM; Vaira, D; Zaccaro, C; Zullo, A, 2012) |
| "Metronidazole is a significant antibiotic used for eradication of Helicobacter pylori infections and it is of notice that metronidazole-resistant clinical isolates have been found in high rates worldwide." | 1.37 | Assessing the role of the RND efflux pump in metronidazole resistance of Helicobacter pylori by RT-PCR assay. ( Akbari, B; Daryani, NE; Eshraghi, S; Mehrabadi, JF; Shirazi, MH; Sirous, M, 2011) |
| " Seventeen patients experienced mild adverse events." | 1.37 | Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy. ( Choi, JH; Hyun, JJ; Jung, SW; Kim, JH; Kim, SY; Koo, JS; Kwon, BS; Lee, SK; Lee, SW; Park, JY; Yim, HJ, 2011) |
| "Clarithromycin resistance was associated with macrolide use for any indication during the previous year (p = 0." | 1.36 | Antibiotic resistance of Helicobacter pylori in Israeli children. ( Levy, I; Samra, Z; Shmuely, H; Yahav, J; Zevit, N, 2010) |
| "Pre-existing nonerosive gastroesophageal reflux disease, smoking, and older age are important predictors of de novo development of erosive esophagitis." | 1.36 | De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study. ( Jonaitis, L; Kiudelis, G; Kupčinskas, J; Kupčinskas, L, 2010) |
| "Chronic urticaria is a persistent urticaria lasting longer than 6 weeks, affecting 20% of the general population." | 1.35 | Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies. ( Abdou, AG; Elnaidany, NF; Elshayeb, EI; Farag, AG, 2009) |
| "Clarithromycin resistance was very high even in strains from paediatric patients not previously treated for H." | 1.35 | [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]. ( Agudo, S; Alarcón, T; Cibrelus, L; López-Brea, M; Martínez, MJ; Urruzuno, P, 2009) |
| "Metronidazole resistance was present in 37." | 1.35 | Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status? ( Fitzgerald, N; Murphy, P; Nami, A; O'Connor, A; O'Connor, H; O'Morain, C; Qasim, A; Taneike, I, 2009) |
| "pylori eradication is early gastric cancer in addition to the previous indications of peptic ulcer including scar and Marginal zone B cell lymphoma (MALT type)." | 1.35 | [Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea]. ( Choe, YH; Chung, IS; Kim, HS; Kim, JI; Kim, JJ; Kim, N, 2009) |
| "Although the possibility of preventing gastric cancer by eradicating H." | 1.35 | The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer. ( Hirata, Y; Kawabe, T; Maeda, S; Mitsuno, Y; Ogura, K; Ohmae, T; Okamoto, M; Omata, M; Shibata, W; Watabe, H; Yamaji, Y; Yanai, A; Yoshida, H, 2008) |
| "The study included 100 youth with type 1 diabetes and seropositive for Hp (European Caucasians: n=49; Moghrabin Caucasians: n=51)." | 1.34 | [Helicobacter pylori infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes]. ( Dorchy, H; Khalil, T; Melot, C; Scaillon, M, 2007) |
| "Levofloxacin resistance was also more frequent in those strains with either clarithromycin or metronidazole resistance." | 1.34 | Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. ( Hassan, C; Morini, S; Perna, F; Ricci, C; Saracino, I; Vaira, D; Zullo, A, 2007) |
| "Seventy-one H." | 1.33 | Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients. ( Castro-Fernández, M; Cosme, A; Gisbert, JP; Gómez, B; Herrerías, JM; Luna, M; Monés, J; Olivares, D; Pajares, JM; Sánchez-Pobre, P, 2006) |
| "pylori-positive chronic idiopathic thrombocytopenic purpura (ITP)." | 1.33 | [Successful platelet recovery after the second eradication of Helicobacter pylori with metronidazole in two patients with chronic idiopathic thrombocytopenic purpura]. ( Hatao, K; Takahashi, T; Yamada, K, 2006) |
| "Chronic gastritis was evaluated according to sydney system." | 1.33 | [Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori]. ( Ben Ayed, M; Ben Khelifa, H; Chedly-Debbiche, A; Gargouri, D; Ghorbel, AJ; Kharrat, J; Khayat, O; Kilani, A; Souissi, A; Zeddini, A, 2006) |
| "Amoxicillin resistance was 2." | 1.33 | Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children. ( Doratotaj, D; Fallahi, GH; Khatami, GR; Mirnaseri, MM; Safari, F; Siavoshi, F, 2006) |
| "Metronidazole resistance was demonstrated in isolates from 155 (44%) persons, clarithromycin resistance from 108 (31%) persons, amoxicillin resistance from 8 (2%) persons, and 0 for tetracycline resistance." | 1.33 | Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003. ( Berg, DE; Bruce, MG; Bruden, DL; Hennessy, TW; Hurlburt, DA; Martinez, P; McMahon, BJ; Morris, J; Parkinson, AJ; Parks, D; Peters, H; Reasonover, A; Sacco, F; Swenson, M, 2006) |
| "Gastric metaplasia was endoscopically and histologically evaluated before and after eradication of this bacterium." | 1.32 | Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori. ( Sano, T; Urakami, Y, 2003) |
| "Metronidazole resistance was significantly more common in women (P < 0." | 1.32 | Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001. ( Baldwin, L; Bell, GD; Cameron, EAB; Jones, P; Powell, KU; Williams, SGJ, 2004) |
| "Although profound hypochlorhydria is considered to be an important risk factor for development of gastric cancer, long-term effect of Helicobacter pylori eradication on its reversibility remains uncertain." | 1.32 | Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria. ( Iijima, K; Imatani, A; Koike, T; Ohara, S; Sekine, H; Shimosegawa, T, 2004) |
| "Metronidazole resistance was detected in 10 (20%) isolates." | 1.32 | Antibiotic resistance in Helicobacter pylori: is it a problem in New Zealand? ( Ahmed, D; Barbezat, G; Brooks, H; McConnell, M, 2004) |
| "Levofloxacin has been proposed as an alternative for these refractory infections." | 1.32 | High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy. ( Branca, G; Cammarota, G; Fadda, G; Gasbarrini, A; Gasbarrini, GB; Schito, AM; Spanu, T, 2004) |
| "Metronidazole is a good substitute for clarithromycin as the second-line option for children." | 1.32 | Results of triple eradication therapy in Japanese children: a retrospective multicenter study. ( Iinuma, K; Kato, S; Konno, M; Maisawa, S; Nakayama, Y; Shimizu, T; Tajiri, H; Toyoda, S; Yoshimura, N, 2004) |
| "The post-treatment recurrence rate of H." | 1.32 | Long-term recurrence rate after treatment of Helicobacter pylori infection in children and adolescents in Estonia. ( Maaroos, HI; Oona, M; Rägo, T, 2004) |
| "Clarithromycin was also transferred with acid but was then rapidly degraded." | 1.31 | Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats. ( Atherton, JC; Barrett, DA; Jenkins, D; Jordan, N; Shaw, PN; Sherwood, PV; Spiller, RC; Wibawa, JI, 2002) |
| "pylori induces de novo GERD symptoms in ulcer patients." | 1.31 | Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease. ( Dickson, A; El-Nujumi, A; El-Omar, E; Kelman, A; McColl, KE, 2000) |
| "pylori treatment on MALT lymphoma and chronic gastritis at the histologic and molecular levels." | 1.31 | Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases. ( Begum, S; Endo, H; Kawamata, H; Sano, T; Urakami, Y, 2000) |
| "Metronidazole is an important component in most eradication regimens." | 1.31 | Metronidazole-resistant Helicobacter pylori in an urban Asian population. ( Fock, KM; Khor, CJ; Ng, TM; Tan, AL; Teo, EK, 2000) |
| "Trough steady state serum levels of lansoprazole or ranitidine, amoxycillin, clarithromycin and metronidazole were monitored in 232 patients during the last dosing interval of a 5-day quadruple H." | 1.31 | Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori. ( Ammon, S; Kees, F; Klotz, U; Treiber, G, 2000) |
| "Metronidazole resistance is a common problem in most Asian countries, and clarithromycin has been widely used in Hong Kong." | 1.31 | High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. ( Berg, DE; Cho, CH; Fung, FM; Hu, WH; Hui, WM; Lai, KC; Lam, SK; Mukhopadhyay, AK; Wang, WH; Wong, BC, 2000) |
| "Pre-treatment metronidazole resistance was encountered in 57/74 strains (77." | 1.31 | Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients. ( Cheah, P; Chin, S; Goh, K; Parasakthi, N; Ranjeev, C; Rosmawati, M; Tan, Y, 2000) |
| "pylori eradication on low-grade gastric MALT lymphoma and to investigate the whitish mucosa that appeared with regression of the lesions." | 1.31 | Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori. ( Begum, S; Endo, H; Kawamata, H; Oki, Y; Sano, T; Urakami, Y, 2000) |
| "Metronidazole resistance was commoner in younger patients (P = 0." | 1.31 | Antibiotic resistance in Helicobacter pylori. ( Cullen, DJ; McGechie, DB; Mollison, LC; Stingemore, N; Wake, RA, 2000) |
| "Metronidazole resistance was estimated to be 35." | 1.31 | Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia. ( Al-Quorain, AA; Al-Qurashi, AR; El-Morsy, F, 2001) |
| "Metronidazole resistance was 39% by Etest and 21." | 1.31 | Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States. ( Graham, DY; Malaty, HM; Osato, MS; Penland, RL; Reddy, R; Reddy, SG, 2001) |
| "1 year after drug therapy the recurrence of CDU is revealed in 16." | 1.31 | [Current principles of the use of laparoscopic surgery in gastroduodenal ulcer]. ( Fedorov, AV; Sazhin, VP, 2001) |
| "We determined late recrudescence rates, true reinfection, and ulcer recurrence." | 1.31 | Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. ( Ahmad, MM; Arefin, MS; Bardhan, P; Bauerfeind, P; Beglinger, C; Glatz-Krieger, K; Gyr, N; Hasan, M; Hildebrand, P; Khan, AK; Parvin, S; Rahman, A; Rossi, L; Terracciano, L, 2001) |
| "Treatment with clarithromycin, metronidazole and pantoprazole eradicated H." | 1.31 | Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole. ( Kaddu, S; Kränke, B; Mayr-Kanhäuser, S; Müllegger, RR, 2001) |
| "Therefore, the recurrence rate of H." | 1.31 | Six-year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease. ( Kleibeuker, JH; Thijs, JC; van der Wouden, EJ; van Zwet, AA, 2001) |
| "We evaluated the effect of optimized doses and dosing schedules of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline (BMT) triple therapy with only 1 day of dosing on Helicobacter pylori SS1 titers in a mouse model." | 1.31 | Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model. ( Amsler, KM; Foster, LA; Merrill, JJ; Modzelewski, TC; Quispe, JD; Sizemore, CF; Slee, AM; Stevenson, DA, 2002) |
| "Metronidazole resistance was associated with female gender." | 1.31 | Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. ( Affonso de Oliveira, C; Aguiar Rocha, G; Camargos Rocha, AM; Campos Barbosa, DV; De Magalhães Queiroz, DM; Martins Teixeira, L; Nogueira Mendes, E; Prazeres Magalhães, P; Santos, A; Valle Corrêa, PR, 2002) |
| "Metronidazole J(M-->S) was measured with the mucosal pH at 2." | 1.30 | In vitro assessment of gastric mucosal transfer of anti-Helicobacter therapeutic agents. ( Goddard, AF; Spiller, RC, 1997) |
| "Lactoferrin (Lf) is an iron-binding glycoprotein present in milk, lacrimae, saliva, and gastroduodenal secretions." | 1.30 | Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation. ( Ikemura, N; Imoto, I; Misaki, M; Nakao, K; Shibata, T; Taguchi, Y; Takaji, S; Yamauchi, K; Yamazaki, N, 1997) |
| "Endoscopy after ER detected no new gastric cancers in these patients." | 1.30 | Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer. ( Haruma, K; Kajiyama, G; Mashiba, H; Mukai, T; Okamoto, S; Sasaki, N; Sumii, K; Taniyama, K; Uemura, N; Yamaguchi, S, 1997) |
| " pylori strain in vivo required a higher dosage than eradication of a metronidazole-sensitive H." | 1.30 | Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains. ( Ikeda, F; Karita, M; Matsumoto, S; Matsumoto, Y; Tawara, S; Washizuka, Y; Yokota, Y, 1997) |
| "Gastritis was scored according to Sydney criteria." | 1.30 | Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy. ( Angelucci, D; Cellini, L; Di Campli, E; Diodoro, MG; Grossi, L; Marzio, L, 1998) |
| "For metronidazole there was a significantly higher resistance seen in women compared to men (53." | 1.30 | [Antibiotic resistance among strains of Helicobacter pylori in Gothenburg. Bacteria resistant to metronidazole]. ( Brandberg, A; Jaup, BH; Norrby, A; Stenquist, B, 1998) |
| "Treatment with amoxicillin, metronidazole, and famotidine may not be effective in eradicating gastric infections with Helicobacter spp in dogs." | 1.30 | Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs. ( Cornetta, AM; Gleed, RD; McDonough, PL; Simpson, KW; Strauss-Ayali, D, 1998) |
| "Metronidazole resistance was determined by E-test after subculture." | 1.30 | Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients. ( Bradbury, R; Katelaris, PH; Ngu, MC; Nguyen, TV; Robertson, GJ, 1998) |
| " Discouraging the use of over-the-counter H2 antagonists, ruling out long-term use of nonsteroidal anti-inflammatory drugs before selecting the treatment regimen, and considering expected treatment compliance are important aspects of PUD management that emerged from this case." | 1.30 | Understanding peptic ulcer disease pharmacotherapeutics. ( Navuluri, R; Yue, S, 1999) |
| "Metronidazole resistance was found in 6." | 1.30 | Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. ( Chang, YS; Cheng, KS; Lin, CW; Wu, SC, 1998) |
| "All patients had abnormal gastro-oesophageal reflux before anti-H." | 1.30 | The effect of Helicobacter pylori eradication on gastro-oesophageal reflux. ( Berstad, A; Hatlebakk, JG; Tefera, S, 1999) |
| "Metronidazole was completely stable for up to 24 h in SGF." | 1.30 | Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection. ( Amiji, M; Patel, V; Qaqish, R; Shah, S, 1999) |
| " Primary metronidazole resistance may reduce its effectiveness, but an increased daily dosing of metronidazole may partly overcome this problem." | 1.30 | Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection. ( Bardhan, KD; Bayerdörffer, E; Delchier, JC; Díte, P; Lind, T; Mégraud, F; O'Morain, C; Sipponen, P; Spiller, R; Veldhuyzen van Zanten, S; Zeijlon, L, 1999) |
| "After 1 year, no patient had H." | 1.30 | Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study. ( Annibale, B; D'Ambra, G; Delle Fave, G; Marcheggiano, A; Martino, G; Paoletti, M, 1999) |
| "Metronidazole resistance was shown for 84 isolates (32%) and clarithromycin resistance for 18 isolates (6." | 1.30 | Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit. ( Fraser, AG; Hackett, M; Hollis, B; Moore, L, 1999) |
| "This shows that recurrence of H pylori infection is probably caused by recrudescence and that the discriminatory power of randomly amplified polymorphic DNA fingerprinting is a practicable and discriminatory typing scheme for H pylori." | 1.29 | Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting. ( Keane, CT; Marshall, DG; O'Morain, CA; Smyth, CJ; Windle, HJ; Xia, HX, 1995) |
| "There was no recurrence of ulcer in 17 H." | 1.29 | Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. ( Chen, CY; Chen, LT; Jan, CM; Lin, SR; Liu, CS; Perng, DS; Wang, WM, 1994) |
| "pylori recurrence." | 1.29 | Long-term Helicobacter pylori recurrence after successful eradication with triple therapy. ( Cutler, AF; Schubert, TT, 1993) |
| "Its relationship to gastritis has not been studied." | 1.29 | Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease. ( Beattie, AD; Curry, GW; Morton, R; Park, RH; Taha, AS, 1996) |
| "Pre-treatment metronidazole susceptible H pylori were significantly more likely to respond to the triple therapy used than those with the metronidazole resistant ones (14 of 15 v five of 10) (p = 0." | 1.29 | Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong. ( Ching, CK; Lai, CL; Lai, KC; Lam, SK; Leung, KP; Wong, BC; Yung, RW, 1996) |
| "One hundred and thirty patients with proven H pylori infection (by at least two tests) were treated with low dose triple therapy (DeNol 1 qid, tetracycline 250 mg qid and metronidazole 200 mg qid for 2 weeks; dosing with meals and at night); 83 were given a standard prescription for triple therapy (dispensed in bottles) and 47 were given a medication pack with times of dosing clearly marked." | 1.29 | An audit of low dose triple therapy for eradication of Helicobacter pylori. ( Ali, MR; Chua, LE; Fraser, AG; Hollis, B; Little, SV; Moore, L, 1996) |
| "Chronic urticaria is a disease of unknown etiology." | 1.29 | [Connection between Helicobacter pylori infection and chronic gastrointestinal urticaria]. ( Daróczy, J; Ferenczi, K; Kalas, D; Pálos, G; Prónai, L, 1996) |
| "Lansoprazole has a cytotoxic action against this organism, the MIC being 2." | 1.29 | Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication. ( Kawano, S; Murakami, M; Saita, H; Tsuji, S, 1996) |
| "The ferrets were monitored for recrudescence by repeated cultures of endoscopic gastric mucosal biopsies." | 1.29 | Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets. ( Batchelder, M; Fox, JG; Hayward, A; Murphy, JC; Palley, L; Shames, B; Yan, L, 1996) |
| "pylori and cured DU, there has been no recurrence of ulcer, regardless of smoking status." | 1.28 | Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication. ( Andrews, P; Borody, TJ; Brandl, S; George, LL; Jankiewicz, E; Ostapowicz, N, 1992) |
| "No ampicillin was detected in gastric juice." | 1.28 | Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori. ( Goldie, J; Hollingsworth, J; Hunt, RH; Richardson, H; Silletti, C; van Zanten, SJ, 1992) |
| "A 30-year-old man with AIDS presented with symptoms of fever, epigastric pain and weight loss, together with histological findings of Helicobacter pylori-induced gastritis." | 1.28 | Severe Helicobacter pylori infection in a patient with AIDS. ( Blackwell, N; Khoo, SH, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 592 (32.64) | 18.2507 |
| 2000's | 587 (32.36) | 29.6817 |
| 2010's | 444 (24.48) | 24.3611 |
| 2020's | 191 (10.53) | 2.80 |
| Authors | Studies |
|---|---|
| Katsura, Y | 1 |
| Tomishi, T | 1 |
| Inoue, Y | 1 |
| Sakane, K | 1 |
| Matsumoto, Y | 4 |
| Ishikawa, H | 1 |
| Takasugi, H | 1 |
| Kaakoush, NO | 1 |
| Asencio, C | 1 |
| Mégraud, F | 27 |
| Mendz, GL | 2 |
| Lai, CH | 3 |
| Rao, YK | 1 |
| Fang, SH | 1 |
| Sing, YT | 2 |
| Tzeng, YM | 1 |
| Chang, CS | 2 |
| Liu, JF | 1 |
| Lin, HJ | 2 |
| Lin, CD | 1 |
| Tang, CH | 1 |
| Lu, DY | 1 |
| Chen, LY | 1 |
| Kao, MC | 1 |
| Kuo, SC | 1 |
| Tseng, YY | 1 |
| Liou, JM | 13 |
| Hsu, TL | 1 |
| Cheng, WC | 1 |
| Wu, MS | 15 |
| Wong, CH | 1 |
| Ma, Z | 2 |
| He, S | 1 |
| Yuan, Y | 2 |
| Zhuang, Z | 1 |
| Liu, Y | 3 |
| Wang, H | 4 |
| Chen, J | 8 |
| Xu, X | 2 |
| Ding, C | 1 |
| Molodtsov, V | 1 |
| Lin, W | 1 |
| Robertson, GT | 1 |
| Weiss, WJ | 1 |
| Pulse, M | 1 |
| Nguyen, P | 1 |
| Duncan, L | 1 |
| Doyle, T | 1 |
| Ebright, RH | 1 |
| Lynch, AS | 1 |
| Ang, TL | 5 |
| Lim, KW | 1 |
| Ang, D | 2 |
| Wong, YJ | 1 |
| Tan, M | 1 |
| Yih Wong, AS | 1 |
| Gisbert, JP | 52 |
| Alcedo, J | 2 |
| Amador, J | 2 |
| Bujanda, L | 8 |
| Calvet, X | 21 |
| Castro-Fernández, M | 11 |
| Fernández-Salazar, L | 4 |
| Gené, E | 6 |
| Lanas, Á | 2 |
| Lucendo, AJ | 4 |
| Molina-Infante, J | 13 |
| Nyssen, OP | 8 |
| Pérez-Aisa, A | 12 |
| Puig, I | 7 |
| Zurita, J | 1 |
| Sevillano, G | 1 |
| Paz Y Miño, A | 1 |
| Zurita-Salinas, C | 1 |
| Peñaherrera, V | 1 |
| Echeverría, M | 1 |
| Navarrete, H | 1 |
| Schubert, JP | 4 |
| Warner, MS | 3 |
| Rayner, CK | 4 |
| Roberts-Thomson, IC | 4 |
| Mangoni, AA | 3 |
| Costello, S | 2 |
| Bryant, RV | 4 |
| Wang, L | 3 |
| Zhang, J | 7 |
| Hu, M | 1 |
| Pang, X | 1 |
| Cho, JH | 1 |
| Jin, SY | 1 |
| Park, S | 1 |
| He, C | 1 |
| Kong, F | 2 |
| Zhu, X | 3 |
| Zhao, W | 2 |
| Wang, K | 2 |
| Dutta, AK | 1 |
| Phull, PS | 2 |
| Hassib, ST | 1 |
| Taha, EA | 1 |
| Sharf, MG | 1 |
| Mostafa, EA | 1 |
| Huang, JG | 1 |
| Lim, SYS | 1 |
| Aw, MM | 1 |
| Quak, SH | 1 |
| Kuang, S | 1 |
| Xu, J | 2 |
| Chen, M | 2 |
| Zhang, Y | 6 |
| Shi, F | 1 |
| Lu, X | 2 |
| Spiegel, M | 1 |
| Krzyżek, P | 3 |
| Dworniczek, E | 1 |
| Adamski, R | 1 |
| Sroka, Z | 1 |
| Lee, YC | 14 |
| Dore, MP | 14 |
| Graham, DY | 53 |
| Nemr, N | 1 |
| Kishk, RM | 1 |
| Salem, A | 1 |
| Abdalla, MO | 1 |
| Abd El-Fadeal, NM | 1 |
| Soliman, NM | 1 |
| Seo, SI | 1 |
| Lim, H | 4 |
| Bang, CS | 3 |
| Yang, YJ | 6 |
| Baik, GH | 8 |
| Lee, SP | 1 |
| Jang, HJ | 1 |
| Kae, SH | 1 |
| Kim, J | 3 |
| Kim, HY | 2 |
| Shin, WG | 5 |
| Yokota, K | 1 |
| Osaki, T | 2 |
| Hayashi, S | 1 |
| Yokota, SI | 1 |
| Takeuchi, H | 1 |
| Rimbara, E | 4 |
| Ojima, H | 1 |
| Sato, T | 2 |
| Yonezawa, H | 1 |
| Shibayama, K | 1 |
| Tokunaga, K | 6 |
| Kamiya, S | 2 |
| Murakami, K | 17 |
| Kato, M | 13 |
| Sugiyama, T | 8 |
| Huang, TH | 1 |
| Yang, SC | 2 |
| Tai, WC | 6 |
| Liang, CM | 5 |
| Kuo, CM | 5 |
| Yao, CC | 2 |
| Wu, CK | 1 |
| Kuo, YH | 3 |
| Chou, YP | 3 |
| Lee, CH | 6 |
| Wu, KL | 4 |
| Chuah, SK | 10 |
| Woodman, RJ | 1 |
| Costello, SP | 2 |
| Losurdo, G | 3 |
| D'Abramo, FS | 1 |
| Piazzolla, M | 1 |
| Rima, R | 1 |
| Continisio, A | 1 |
| Pricci, M | 2 |
| Ierardi, E | 7 |
| Di Leo, A | 4 |
| Windham, IH | 1 |
| Merrell, DS | 2 |
| Migdał, P | 1 |
| Grande, R | 2 |
| Gościniak, G | 3 |
| Jiang, F | 1 |
| Guo, CG | 1 |
| Cheung, KS | 2 |
| Li, B | 1 |
| Law, SYK | 1 |
| Leung, WK | 9 |
| Nestegard, O | 1 |
| Moayeri, B | 2 |
| Halvorsen, FA | 1 |
| Tønnesen, T | 2 |
| Sørbye, SW | 1 |
| Paulssen, E | 1 |
| Johnsen, KM | 1 |
| Goll, R | 1 |
| Florholmen, JR | 1 |
| Melby, KK | 2 |
| Tian, L | 1 |
| Yao, Y | 2 |
| Yin, L | 1 |
| An, Z | 2 |
| Kang, L | 1 |
| Ru, C | 1 |
| Li, J | 3 |
| Geng, T | 1 |
| Yu, ZS | 1 |
| Zhou, XX | 1 |
| Liu, B | 1 |
| Zhang, HH | 1 |
| Li, ZY | 2 |
| Abouwarda, AM | 1 |
| Ismail, TA | 1 |
| Abu El-Wafa, WM | 1 |
| Faraag, AHI | 1 |
| Veenendaal, RA | 6 |
| Woudt, SHS | 1 |
| Schoffelen, AF | 1 |
| de Boer, MGJ | 2 |
| van den Brink, G | 1 |
| Molendijk, I | 1 |
| Kuijper, EJ | 2 |
| Ho, JJC | 1 |
| Navarro, M | 2 |
| Sawyer, K | 1 |
| Elfanagely, Y | 1 |
| Moss, SF | 10 |
| Shawky, D | 1 |
| Salamah, AM | 1 |
| Abd-Elsalam, SM | 1 |
| Habba, E | 1 |
| Elnaggar, MH | 1 |
| Elsawy, AA | 1 |
| Baiomy, N | 1 |
| Bahaa, MM | 1 |
| Gamal, RM | 1 |
| Kouhsari, E | 1 |
| Sadeghifard, N | 1 |
| Khadiv, A | 1 |
| Sayadi, H | 1 |
| Amiriani, T | 1 |
| Ghafourian, S | 1 |
| Valadbeigi, H | 1 |
| Krutova, M | 1 |
| Zhou, Y | 6 |
| Zhong, Z | 1 |
| Hu, S | 2 |
| Wang, J | 4 |
| Deng, Y | 2 |
| Li, X | 7 |
| Chen, X | 4 |
| Tang, Y | 3 |
| Hao, Q | 2 |
| Liu, J | 6 |
| Sang, T | 1 |
| Bo, Y | 2 |
| Bai, F | 1 |
| Wang, Y | 9 |
| Wu, S | 2 |
| Liu, D | 2 |
| Fu, Y | 1 |
| Xie, Y | 4 |
| Wasielica-Berger, J | 1 |
| Gugnacki, P | 1 |
| Mlynarczyk, M | 1 |
| Rogalski, P | 1 |
| Swidnicka-Siergiejko, A | 1 |
| Antonowicz, S | 1 |
| Krzyzak, M | 1 |
| Maslach, D | 1 |
| Dabrowski, A | 1 |
| Daniluk, J | 1 |
| Sousa Sampaio, PN | 1 |
| Calado, CRC | 1 |
| Karbalaei, M | 1 |
| Talebi Bezmin Abadi, A | 3 |
| Keikha, M | 1 |
| Boyanova, L | 11 |
| Kandilarov, N | 2 |
| Hadzhiyski, P | 1 |
| Gergova, R | 2 |
| Gergova, G | 7 |
| Markovska, R | 3 |
| Sau, R | 1 |
| Niolu, C | 1 |
| Abbondio, M | 1 |
| Tanca, A | 1 |
| Bibbò, S | 3 |
| Loria, M | 2 |
| Pes, GM | 3 |
| Uzzau, S | 1 |
| Shao, Y | 4 |
| Lin, Y | 3 |
| Wang, B | 4 |
| Miao, M | 1 |
| Ye, G | 2 |
| Tang, X | 2 |
| Wang, Z | 3 |
| Shen, Y | 2 |
| Song, X | 2 |
| Benghezal, M | 2 |
| Marshall, BJ | 4 |
| Tang, H | 2 |
| Li, H | 5 |
| Kim, SJ | 3 |
| Jee, SR | 1 |
| Park, MI | 4 |
| Jung, K | 3 |
| Kim, GH | 4 |
| Lee, MW | 1 |
| Lee, J | 6 |
| Jang, JS | 1 |
| Koh, M | 1 |
| Essaidi, I | 1 |
| Bounder, G | 1 |
| Jouimyi, RM | 1 |
| Boura, H | 1 |
| Elyounsi, I | 1 |
| Kheir, FZ | 1 |
| Benomar, H | 1 |
| Badre, W | 1 |
| Zerouali, K | 1 |
| Maachi, F | 1 |
| Kumar, S | 1 |
| Mehrotra, T | 1 |
| Talukdar, D | 1 |
| Verma, J | 1 |
| Chandra Karmakar, B | 1 |
| Paul, S | 1 |
| Chaudhuri, S | 1 |
| Kumari Pragasam, A | 1 |
| Bakshi, S | 1 |
| Kumari, S | 1 |
| Chawla, M | 1 |
| Purohit, A | 1 |
| Porey Karmakar, S | 1 |
| Mutreja, A | 1 |
| Banerjee, S | 2 |
| Ray, A | 1 |
| Ramamurthy, T | 2 |
| Mukhopadyay, AK | 1 |
| Das, B | 2 |
| Azrad, M | 2 |
| Vazana, D | 1 |
| On, A | 3 |
| Paritski, M | 1 |
| Rohana, H | 1 |
| Roshrosh, H | 1 |
| Agay-Shay, K | 1 |
| Peretz, A | 3 |
| Zeng, J | 1 |
| Xie, C | 1 |
| Zhang, L | 11 |
| Liu, X | 2 |
| Chan, MTV | 1 |
| Wu, WKK | 1 |
| Chen, H | 3 |
| Imane, E | 1 |
| Ghizlane, B | 1 |
| Reda, JM | 1 |
| Hasna, B | 1 |
| Ilhame, E | 1 |
| Hakima, B | 1 |
| Wafa, B | 1 |
| Khalid, Z | 1 |
| Fatima, M | 1 |
| Correia, C | 1 |
| Almeida, N | 3 |
| Leal, C | 1 |
| Branquinho, D | 2 |
| Fernandes, A | 1 |
| Gravito-Soares, E | 1 |
| Calhau, C | 1 |
| Bastos, I | 1 |
| Vasconcelos, H | 1 |
| Figueiredo, P | 1 |
| Howden, CW | 6 |
| Trevino, E | 1 |
| Weissfeld, A | 3 |
| Hunt, B | 1 |
| Smith, N | 1 |
| Leifke, E | 1 |
| Chey, WD | 9 |
| Li, T | 1 |
| Shu, X | 2 |
| Ye, D | 1 |
| Hu, C | 1 |
| Peng, K | 1 |
| Zhao, H | 3 |
| Jiang, M | 1 |
| De Bellis, M | 1 |
| Celiberto, F | 1 |
| Russo, F | 1 |
| Riezzo, G | 1 |
| D'attoma, B | 1 |
| Iannone, A | 2 |
| Rendina, M | 1 |
| Le Thi, TG | 2 |
| Werkstetter, K | 2 |
| Kotilea, K | 6 |
| Bontems, P | 11 |
| Cabral, J | 3 |
| Cilleruelo Pascual, ML | 3 |
| Kori, M | 2 |
| Barrio, J | 11 |
| Homan, M | 2 |
| Kalach, N | 12 |
| Lima, R | 2 |
| Tavares, M | 1 |
| Urruzuno, P | 6 |
| Misak, Z | 3 |
| Urbonas, V | 2 |
| Koletzko, S | 5 |
| Tian, XL | 2 |
| Suo, BJ | 1 |
| Zhang, H | 3 |
| Lu, HP | 1 |
| Li, CL | 1 |
| Zhang, YX | 1 |
| Ren, XL | 1 |
| Yao, XY | 1 |
| Zhou, LY | 4 |
| Song, ZQ | 1 |
| Miendje Deyi, VY | 6 |
| Ntounda, R | 3 |
| Louis, H | 3 |
| Kahegeshe, NL | 3 |
| Nkuize, M | 4 |
| Burette, A | 3 |
| Gossum, MV | 3 |
| Delhaye, M | 3 |
| Lee, JW | 8 |
| Kim, N | 32 |
| Choi, SI | 2 |
| Jang, JY | 5 |
| Song, CH | 2 |
| Nam, RH | 8 |
| Lee, DH | 31 |
| Yang, J | 4 |
| Gu, Y | 2 |
| Xiao, Y | 2 |
| Chu, N | 2 |
| Luo, H | 2 |
| Wang, Q | 2 |
| Ragab, MAA | 2 |
| Maher, HM | 2 |
| Tarek, S | 2 |
| Mahgoub, H | 2 |
| Jiang, XT | 1 |
| Chen, CC | 16 |
| Luo, JC | 9 |
| Bair, MJ | 8 |
| Chen, PY | 6 |
| Chou, CK | 1 |
| Fang, YJ | 9 |
| Chen, MJ | 9 |
| Lee, JY | 13 |
| Yang, TH | 7 |
| Yu, CC | 1 |
| Kuo, CC | 1 |
| Chiu, MC | 1 |
| Chen, CY | 8 |
| Shun, CT | 7 |
| Hu, WH | 11 |
| Tsai, MH | 1 |
| Hsu, YC | 6 |
| Tseng, CH | 6 |
| Chang, CY | 8 |
| Lin, JT | 14 |
| El-Omar, EM | 7 |
| Doctor, S | 1 |
| Abraham, P | 1 |
| Desai, D | 1 |
| Dhoble, P | 1 |
| Gupta, T | 1 |
| Joshi, A | 1 |
| Cui, MY | 1 |
| Cui, ZY | 1 |
| Zhao, MQ | 1 |
| Zhang, MJ | 1 |
| Jiang, QL | 1 |
| Wang, JJ | 1 |
| Lu, LG | 1 |
| Lu, YY | 1 |
| Ma, TL | 1 |
| Loke, SS | 1 |
| Adachi, K | 1 |
| Kato, S | 7 |
| Koshino, A | 1 |
| Nagao, K | 1 |
| Yoshimine, T | 1 |
| Yamaguchi, Y | 2 |
| Izawa, S | 1 |
| Ohashi, W | 1 |
| Ebi, M | 1 |
| Funaki, Y | 1 |
| Ogasawara, N | 1 |
| Sasaki, M | 2 |
| Kasugai, K | 1 |
| Suzuki, S | 1 |
| Ishibashi, F | 1 |
| Gotoda, T | 1 |
| Zhang, W | 9 |
| Gui, Q | 1 |
| Yu, D | 1 |
| Su, W | 1 |
| Zhu, C | 1 |
| Liang, X | 13 |
| Lu, H | 21 |
| Yordanov, D | 3 |
| Song, Z | 5 |
| Suo, B | 4 |
| Tian, X | 3 |
| Ren, X | 3 |
| Xue, Y | 3 |
| Niu, Z | 1 |
| Zhou, L | 6 |
| Braendli, T | 1 |
| Schindler, V | 1 |
| Braun, DL | 1 |
| Murray, FR | 1 |
| Hente, JM | 1 |
| Pohl, D | 1 |
| Vu, TB | 1 |
| Tran, TNQ | 1 |
| Tran, TQA | 1 |
| Vu, DL | 1 |
| Hoang, VT | 1 |
| de Moraes Andrade, PV | 1 |
| Monteiro, YM | 1 |
| Chehter, EZ | 1 |
| Ding, ZH | 1 |
| Huang, Y | 7 |
| Chen, JN | 1 |
| Luo, LS | 1 |
| Ayaş, M | 1 |
| Gürol, Y | 1 |
| Yao, X | 2 |
| Li, C | 2 |
| Kakiuchi, T | 2 |
| Örsten, S | 1 |
| Yılmaz, E | 1 |
| Akyön, Y | 2 |
| Macedo Silva, V | 1 |
| Lima Capela, T | 1 |
| Freitas, M | 1 |
| Boal Carvalho, P | 2 |
| Magalhães, J | 2 |
| Cotter, J | 2 |
| Antunes, R | 1 |
| Oleastro, M | 3 |
| Nogueira, JP | 1 |
| Lopes, AI | 3 |
| Puca, V | 1 |
| Yang, W | 1 |
| Shi, R | 1 |
| Hou, Z | 1 |
| Hu, J | 1 |
| Zhang, X | 4 |
| Yong, H | 2 |
| Wang, P | 1 |
| Li, F | 1 |
| Qi, H | 1 |
| Wang, X | 3 |
| Jin, L | 1 |
| Cui, T | 1 |
| Yang, B | 1 |
| Yu, Y | 1 |
| Ma, B | 1 |
| Fu, L | 1 |
| Tang, N | 1 |
| You, Y | 1 |
| Guo, J | 2 |
| Yu, X | 2 |
| Yao, L | 1 |
| Gao, R | 1 |
| Li, Y | 8 |
| Xin, R | 1 |
| Cao, Z | 2 |
| Ma, L | 1 |
| Ma, S | 1 |
| Cao, Y | 1 |
| Mu, R | 1 |
| Niu, M | 1 |
| Su, X | 1 |
| Gao, H | 2 |
| Ding, Z | 2 |
| Zeng, X | 2 |
| Xu, F | 1 |
| Han, Y | 2 |
| Hu, L | 1 |
| Ai, Q | 1 |
| Liu, C | 1 |
| Chen, Y | 5 |
| Liu, L | 4 |
| Li, GQ | 1 |
| Guo, Y | 1 |
| Xu, P | 1 |
| Yan, J | 2 |
| Panigrahi, MK | 1 |
| Chouhan, MI | 1 |
| Hallur, VK | 1 |
| Makashir, MS | 1 |
| Kumar, C | 1 |
| Sethi, S | 1 |
| Nayak, HK | 1 |
| Padhy, BM | 1 |
| Samal, SC | 1 |
| Gong, Y | 2 |
| Dong, Y | 1 |
| Sun, J | 1 |
| Milivojevic, V | 1 |
| Babic, I | 1 |
| Kekic, D | 1 |
| Rankovic, I | 1 |
| Sagdati, S | 1 |
| Panic, N | 1 |
| Spasic, IS | 1 |
| Krstic, M | 2 |
| Milosavljevic, T | 2 |
| Moreira, L | 1 |
| O' Morain, C | 1 |
| Gisbert, J | 2 |
| Asaad, AM | 1 |
| El-Azab, G | 1 |
| Abdelsameea, E | 1 |
| Elbahr, O | 1 |
| Kamal, A | 1 |
| Abdel-Samiee, M | 1 |
| Abdelfattah, A | 1 |
| Abdallah, H | 1 |
| Maher, D | 1 |
| El-Refaie, A | 1 |
| Ghanem, SE | 1 |
| Ansari, S | 1 |
| Awad, SM | 1 |
| Lee, SY | 4 |
| Kim, JH | 13 |
| Sung, IK | 2 |
| Park, HS | 2 |
| Du, J | 1 |
| Zhang, D | 1 |
| Jin, C | 1 |
| Mei, T | 1 |
| Fu, K | 1 |
| Qian, Q | 1 |
| Pang, T | 1 |
| Lu, K | 1 |
| Lang, C | 1 |
| Zou, X | 1 |
| Zang, L | 1 |
| Sang, W | 1 |
| Feng, Q | 1 |
| Mu, Y | 1 |
| Xu, C | 1 |
| Zhao, J | 3 |
| Ismail, M | 1 |
| Majaliwa, ND | 1 |
| Vale, FF | 1 |
| Cumbana, R | 1 |
| Sumbana, JJ | 1 |
| Muchongo, A | 1 |
| Nassone, E | 1 |
| Loforte, M | 1 |
| Mondlane, L | 1 |
| Botão, E | 1 |
| Taviani, E | 1 |
| Carrilho, C | 1 |
| Vítor, JMB | 1 |
| Sacarlal, J | 1 |
| Riaz, MS | 1 |
| Shapiro, JM | 1 |
| Cerezo, C | 1 |
| Herzlinger, M | 1 |
| Kwon, YH | 5 |
| Jeon, SW | 7 |
| Nam, SY | 3 |
| Lee, DW | 3 |
| Park, JH | 4 |
| Bae, HJ | 1 |
| Iliadis, E | 1 |
| Nguyen, J | 2 |
| Salame, A | 3 |
| Mahler, T | 2 |
| Gómez-Ruiz de Arbulo, M | 1 |
| Tamayo, E | 1 |
| Mendibil, L | 1 |
| Mendiola, J | 1 |
| Cilla, G | 1 |
| Montes, M | 2 |
| Huang, X | 1 |
| Wu, B | 1 |
| Chen, Q | 8 |
| Ji, X | 1 |
| Zhou, X | 1 |
| Lin, Z | 1 |
| Zheng, X | 2 |
| Nguyen, TC | 1 |
| Le, GKN | 1 |
| Pham, DTH | 1 |
| Pham, BV | 1 |
| Nguyen, LTH | 1 |
| Che, TH | 1 |
| Nguyen, HT | 1 |
| Truong, DQ | 1 |
| Robert, A | 1 |
| Nguyen, PNV | 1 |
| Yang, T | 1 |
| Bonilla, S | 2 |
| Goldsmith, J | 1 |
| Mitchell, P | 1 |
| Bousvaros, A | 1 |
| Buyuk, F | 1 |
| Karakaya, E | 2 |
| Akar, M | 2 |
| Kayman, T | 2 |
| Tarhane, S | 1 |
| Ozcan, HE | 1 |
| Celebi, O | 1 |
| Saticioglu, IB | 1 |
| Anuk, T | 1 |
| Abay, S | 2 |
| Otlu, S | 1 |
| Aydin, F | 2 |
| Yu, Z | 1 |
| Zhao, Q | 1 |
| Yan, X | 1 |
| Wu, C | 1 |
| Qing, L | 1 |
| He, Z | 1 |
| Huang, M | 1 |
| Cao, M | 1 |
| Quach, DT | 1 |
| Vilaichone, RK | 11 |
| Luu, MN | 1 |
| Lee, YY | 1 |
| Miftahussurur, M | 4 |
| Aye, TT | 1 |
| Basir, DN | 1 |
| Vutha, K | 1 |
| Vannarath, S | 2 |
| Sollano, JD | 2 |
| Mahachai, V | 12 |
| Lin, K | 1 |
| Huang, L | 1 |
| Li, K | 1 |
| Ye, Y | 1 |
| Yang, S | 1 |
| Li, A | 1 |
| Kucharska, M | 1 |
| Zdanowicz, K | 1 |
| Daniluk, T | 1 |
| Bucki, R | 1 |
| Lebensztejn, DM | 1 |
| Daniluk, U | 1 |
| Ingram, PR | 1 |
| Zhao, P | 1 |
| Shi, H | 1 |
| Meng, F | 2 |
| Yang, N | 2 |
| Dong, L | 2 |
| Gong, J | 1 |
| Garvey, E | 1 |
| Rhead, J | 1 |
| Suffian, S | 1 |
| Whiley, D | 1 |
| Mahmood, F | 1 |
| Bakshi, N | 1 |
| Letley, D | 1 |
| White, J | 1 |
| Atherton, J | 1 |
| Winter, JA | 1 |
| Robinson, K | 1 |
| Shmuely, H | 5 |
| Shvartsman, Y | 1 |
| Berdinstein, R | 2 |
| Yahav, J | 6 |
| Melzer, E | 3 |
| Mubarak, AG | 1 |
| Abd-Elhafeez, HH | 1 |
| Mohamed, HMA | 1 |
| Aumpan, N | 2 |
| Issariyakulkarn, N | 1 |
| Graham, D | 4 |
| Yamaoka, Y | 10 |
| Prieto de Paula, JM | 1 |
| García Colodro, JÁ | 1 |
| Prieto Dehesa, M | 1 |
| Franco Hidalgo, S | 1 |
| Salis, R | 1 |
| Manca, A | 4 |
| Kim, BJ | 2 |
| Lee, H | 6 |
| Kim, HS | 3 |
| Sung, JK | 2 |
| Kim, HU | 1 |
| Choi, IJ | 3 |
| Yoon, SM | 1 |
| Kim, SW | 2 |
| Kim, JI | 6 |
| Kim, SG | 6 |
| Kim, JG | 7 |
| Kim, JJ | 11 |
| Jha, SK | 1 |
| Mishra, MK | 1 |
| Saharawat, K | 1 |
| Jha, P | 1 |
| Purkayastha, S | 1 |
| Ranjan, R | 1 |
| Arévalo, A | 1 |
| Otero, WA | 1 |
| Trespalacios, AA | 2 |
| Chang, CM | 1 |
| Hsu, WF | 4 |
| Chen, YN | 3 |
| Wu, JY | 10 |
| Lu, TP | 1 |
| Chuang, EY | 1 |
| Di Stefano, M | 1 |
| Pagani, E | 1 |
| Pesatori, EV | 1 |
| Bergonzi, M | 1 |
| Figura, N | 3 |
| Corazza, GR | 1 |
| Di Sabatino, A | 1 |
| Papaefthymiou, A | 1 |
| Liatsos, C | 1 |
| Georgopoulos, SD | 5 |
| Apostolopoulos, P | 3 |
| Doulberis, M | 1 |
| Kyriakos, N | 1 |
| Giakoumis, M | 1 |
| Papadomichelakis, M | 1 |
| Galanopoulos, M | 1 |
| Katsinelos, P | 1 |
| Rokkas, T | 6 |
| Kountouras, J | 1 |
| Pichon, M | 1 |
| Broutin, L | 1 |
| Touroult-Jupin, P | 1 |
| Cremniter, J | 1 |
| Plouzeau, C | 1 |
| Faure, JP | 1 |
| Olivier, R | 1 |
| Burucoa, C | 3 |
| Pellicano, R | 8 |
| Farhoud, NS | 1 |
| Ibrahim, OM | 1 |
| Ezzat, SE | 1 |
| Pan, J | 1 |
| Shi, Z | 1 |
| Lin, D | 1 |
| Lin, L | 1 |
| Jin, Z | 1 |
| Zhou, Q | 1 |
| Wu, J | 4 |
| Chu, A | 1 |
| Wang, D | 1 |
| Guo, Q | 1 |
| Lv, Z | 1 |
| Hu, Y | 3 |
| Zhu, Y | 4 |
| Lu, NH | 4 |
| Valencia, ME | 1 |
| Montejano, R | 1 |
| Moreno, V | 1 |
| Martín Carbonero, L | 1 |
| Bernardino, JI | 1 |
| Serrano, L | 1 |
| Lin, TF | 1 |
| Wu, DC | 19 |
| Tsay, FW | 10 |
| Tsai, KW | 4 |
| Tsai, TJ | 4 |
| Peng, NJ | 6 |
| Kao, SS | 7 |
| Chen, WC | 3 |
| Chen, YH | 5 |
| Hsu, PI | 18 |
| Ye, Z | 2 |
| Tang, Z | 1 |
| Yan, W | 1 |
| Jiang, Y | 1 |
| Luo, L | 1 |
| Ji, Y | 3 |
| Yu, L | 3 |
| Ekmektzoglou, K | 2 |
| Georgopoulos, S | 3 |
| Chounta, E | 1 |
| Theofanopoulou, A | 1 |
| Kalantzis, C | 2 |
| Vlachou, E | 2 |
| Tsibouris, P | 3 |
| Alexandrakis, G | 2 |
| Kim, JY | 3 |
| Beheshtirouy, S | 1 |
| Eyvazi, S | 1 |
| Tarhriz, V | 1 |
| Yoon, K | 3 |
| Yoon, H | 8 |
| Shin, CM | 14 |
| Park, YS | 16 |
| Li, HJ | 1 |
| Fang, EH | 1 |
| Wang, JQ | 1 |
| Zheng, LD | 1 |
| Tong, QS | 1 |
| Kao, JY | 3 |
| Kuo, CH | 10 |
| Wang, HM | 6 |
| Shie, CB | 2 |
| Guevara, B | 1 |
| Cogdill, AG | 1 |
| Tepes, B | 6 |
| Rodrigo-Sáez, L | 2 |
| Romero, PM | 2 |
| Lucendo, A | 3 |
| Phull, P | 1 |
| Ortuño, J | 2 |
| Areia, M | 2 |
| Brglez Jurecic, N | 2 |
| Huguet, JM | 4 |
| Alcaide, N | 2 |
| Voynovan, I | 2 |
| María Botargues Bote, J | 1 |
| Modolell, I | 5 |
| Pérez Lasala, J | 1 |
| Ariño, I | 2 |
| Jonaitis, L | 3 |
| Dominguez-Cajal, M | 2 |
| Buzas, G | 1 |
| Lerang, F | 8 |
| Perona, M | 3 |
| Bordin, D | 2 |
| Axon, T | 1 |
| Gasbarrini, A | 6 |
| Marcos Pinto, R | 1 |
| Niv, Y | 6 |
| Kupcinskas, L | 4 |
| Tonkic, A | 4 |
| Leja, M | 2 |
| Shvets, O | 1 |
| Venerito, M | 3 |
| Bytzer, P | 3 |
| Goldis, A | 1 |
| Simsek, I | 1 |
| Lamy, V | 1 |
| Przytulski, K | 1 |
| Kunovský, L | 1 |
| Capelle, L | 1 |
| Caldas, M | 2 |
| Garre, A | 3 |
| O'Morain, C | 22 |
| Jeong, HM | 1 |
| Choi, JH | 6 |
| Soh, JS | 2 |
| Kang, HS | 2 |
| Hong, JT | 2 |
| Shin, SP | 2 |
| Suk, KT | 3 |
| Lee, JJ | 3 |
| Kim, DJ | 3 |
| Horie, R | 1 |
| Handa, O | 1 |
| Ando, T | 3 |
| Ose, T | 1 |
| Murakami, T | 1 |
| Suzuki, N | 2 |
| Sendo, R | 1 |
| Imamoto, E | 1 |
| Itoh, Y | 1 |
| Thieu, H | 1 |
| Bach Dat, B | 1 |
| Nam, NH | 1 |
| Reda, A | 1 |
| Duc, NT | 1 |
| Alshareef, A | 1 |
| Nguyen, JG | 1 |
| Ngoc, NM | 1 |
| Tien Huy, N | 1 |
| Ratanachu-Ek, T | 2 |
| Uchida, T | 2 |
| Tshering, L | 1 |
| Sustmann, A | 1 |
| Iwanczak, B | 4 |
| Pehlivanoglu, E | 1 |
| Casswall, T | 2 |
| Martinez Gomez, MJ | 1 |
| Papadopoulou, A | 1 |
| Roma, E | 1 |
| Dolinsek, J | 1 |
| Rogalidou, M | 1 |
| Chong, S | 1 |
| Kindermann, A | 1 |
| Miele, E | 2 |
| Rea, F | 1 |
| Cseh, Á | 1 |
| Beer, A | 1 |
| Hudler, H | 1 |
| Hader, M | 1 |
| Kundi, M | 2 |
| Hudler, S | 1 |
| Täuber, V | 1 |
| Schachner, H | 1 |
| Gruber, S | 1 |
| Hirschl, AM | 7 |
| Kain, R | 1 |
| Makristathis, A | 2 |
| Saracino, IM | 8 |
| Pavoni, M | 4 |
| Zullo, A | 14 |
| Fiorini, G | 8 |
| Saccomanno, L | 1 |
| Lazzarotto, T | 1 |
| Antonelli, G | 1 |
| Cavallo, R | 1 |
| Borghi, C | 1 |
| Vaira, D | 19 |
| Kono, Y | 1 |
| Kusumoto, C | 1 |
| Kiguchi, T | 1 |
| Okada, H | 1 |
| Lu, J | 1 |
| Miao, S | 1 |
| Sun, H | 1 |
| Rodrigo, L | 6 |
| Castro, M | 5 |
| Mata Romero, P | 1 |
| Modollel, I | 1 |
| Gomez, B | 2 |
| Gomez Rodriguez, BJ | 3 |
| Varela, P | 1 |
| Jimenez-Moreno, M | 1 |
| Pozzati, L | 2 |
| Burgos, D | 1 |
| Hinojosa, J | 1 |
| Di Maira, T | 1 |
| Ferrer, L | 1 |
| Figuerola, A | 1 |
| Tito, L | 6 |
| de la Coba, C | 2 |
| Gomez-Camarero, J | 2 |
| Fernandez, N | 2 |
| Resina, E | 1 |
| Zhang, S | 2 |
| Wise, MJ | 1 |
| He, Y | 1 |
| Liu, A | 1 |
| Huang, H | 3 |
| Young, S | 1 |
| Tay, CY | 1 |
| Chua, EG | 1 |
| Cisarò, F | 2 |
| Pizzol, A | 1 |
| Calvo, PL | 1 |
| Gudra, D | 1 |
| Pupola, D | 1 |
| Skenders, G | 1 |
| Radovica-Spalvina, I | 1 |
| Gorskis, H | 1 |
| Vangravs, R | 1 |
| Fridmanis, D | 1 |
| Lyu, T | 1 |
| Ni, L | 1 |
| Mu, P | 1 |
| Yang, Q | 1 |
| Lyu, Z | 1 |
| Guo, H | 1 |
| Seto, WK | 2 |
| Asim, M | 1 |
| Baqai, K | 1 |
| Abbas, Z | 1 |
| Laique, N | 1 |
| Samejo, SA | 1 |
| Ji, CR | 1 |
| Li, YY | 2 |
| Qiao, C | 1 |
| Qu, JY | 1 |
| Hu, JN | 1 |
| Lin, MJ | 1 |
| Ji, R | 1 |
| Li, LX | 1 |
| Zuo, XL | 1 |
| Li, YQ | 1 |
| Chang, YL | 1 |
| Tung, YC | 1 |
| Tu, YK | 2 |
| Yeh, HZ | 2 |
| Yang, JC | 5 |
| Kim, SE | 5 |
| Wu, MF | 1 |
| Liou, WS | 1 |
| Shiu, SI | 1 |
| Lee, GH | 5 |
| Lee, KM | 1 |
| Shin, SJ | 1 |
| Kang, JK | 1 |
| Noh, CK | 1 |
| Lim, SG | 2 |
| Arslan, M | 1 |
| Balamtekin, N | 1 |
| Günal, A | 1 |
| Tang, G | 1 |
| Pan, L | 1 |
| Zhu, H | 1 |
| Zhou, S | 1 |
| Wei, Z | 1 |
| Hofreuter, D | 1 |
| Behrendt, J | 1 |
| Franz, A | 1 |
| Meyer, J | 1 |
| Jansen, A | 1 |
| Bluemel, B | 1 |
| Eisele, B | 1 |
| Koken, M | 1 |
| Glocker, EO | 1 |
| Topaz, S | 1 |
| Alix, C | 1 |
| Charron, P | 1 |
| Bénéjat, L | 1 |
| Ducournau, A | 1 |
| Bessède, E | 1 |
| Lehours, P | 1 |
| Kim, JL | 1 |
| Cho, SJ | 2 |
| Chung, SJ | 2 |
| Lee, A | 3 |
| Choi, J | 2 |
| Chung, H | 1 |
| Tepes, K | 1 |
| Espada Sanchez, M | 1 |
| Perez Nyssen, O | 1 |
| Pih, GY | 1 |
| Choi, KD | 5 |
| Gong, EJ | 2 |
| Na, HK | 1 |
| Ahn, JY | 3 |
| Lee, JH | 7 |
| Jung, KW | 1 |
| Kim, DH | 2 |
| Song, HJ | 5 |
| Jung, HY | 5 |
| Papastergiou, V | 3 |
| Ortuñ, J | 1 |
| Gomez-Rodriguez, BJ | 2 |
| Pinto, RM | 1 |
| Nuñez, O | 1 |
| Romano, M | 5 |
| Gravina, AG | 2 |
| Fernandez-Bermejo, M | 6 |
| Malfertheiner, P | 18 |
| Fernanadez-Salazar, L | 1 |
| Gehlert, J | 1 |
| Yozgat, A | 1 |
| Kasapoğlu, B | 1 |
| Demirci, S | 1 |
| Coşkun Sökmen, F | 1 |
| Laudanno, O | 1 |
| Ahumarán, G | 1 |
| Gollo, P | 1 |
| Khoury, M | 1 |
| Thomé, M | 1 |
| González, P | 1 |
| Bonoso Criado, R | 1 |
| Pérez Citores, L | 1 |
| Pérez Millán, AG | 1 |
| Montero Moretón, Á | 1 |
| González de Castro, E | 1 |
| Cabezudo Molleda, L | 1 |
| García Castro, MA | 1 |
| Moreira Da Silva, BA | 1 |
| Maestro Antolín, S | 1 |
| Santos Santamarta, F | 1 |
| Barcenilla Laguna, J | 1 |
| Mestrovic, A | 1 |
| Perkovic, N | 1 |
| Bozic, J | 1 |
| Pavicic Ivelja, M | 1 |
| Vukovic, J | 1 |
| Kardum, G | 1 |
| Puljiz, Z | 1 |
| Vologzhanina, L | 1 |
| Jurecic, NB | 1 |
| Perez-Lasala, J | 1 |
| Vujasinovic, M | 2 |
| Abdulkhakov, R | 1 |
| Hwang, JY | 1 |
| Kim, C | 1 |
| Lee, JE | 1 |
| Seo, AN | 1 |
| Han, MH | 1 |
| Ouyang, Y | 1 |
| Argueta, EA | 1 |
| Alsamman, MA | 2 |
| D'Agata, EMC | 1 |
| Nakase, K | 1 |
| Nakanishi-Yamasaki, M | 1 |
| Harada, K | 1 |
| Koizumi, J | 1 |
| Yamada, T | 6 |
| Ikoshi, H | 1 |
| Nakaminami, H | 1 |
| Noguchi, N | 3 |
| Jeon, JY | 1 |
| Kim, SY | 7 |
| Moon, SJ | 1 |
| Oh, K | 2 |
| Kim, B | 1 |
| Song, GS | 1 |
| Kim, MG | 1 |
| Kim, YI | 1 |
| Kim, CG | 2 |
| Park, B | 1 |
| Park, JY | 6 |
| Kodama, M | 9 |
| Okimoto, T | 11 |
| Mizukami, K | 1 |
| Hirashita, Y | 1 |
| Wada, Y | 1 |
| Fukuda, M | 1 |
| Matsunari, O | 1 |
| Okamoto, K | 2 |
| Ogawa, R | 1 |
| Fukuda, K | 1 |
| Kudo, Y | 1 |
| Kawahara, Y | 1 |
| De Francesco, V | 7 |
| Manta, R | 2 |
| Gatta, L | 9 |
| Jia, J | 1 |
| Zhang, C | 2 |
| Bai, Y | 1 |
| Hang, X | 1 |
| Zeng, L | 1 |
| Zhu, D | 1 |
| Bi, H | 1 |
| Sue, S | 1 |
| Maeda, S | 2 |
| Li, SY | 1 |
| Dong, XH | 1 |
| Teng, GG | 1 |
| Cheng, H | 3 |
| Gao, W | 1 |
| Dai, Y | 1 |
| Zhang, XH | 1 |
| Wang, WH | 8 |
| Fateh, R | 1 |
| Javadi, A | 1 |
| Kardan-Yamch, J | 1 |
| Ali Rahdar, H | 1 |
| Amini, M | 4 |
| Ghasemi, F | 1 |
| Azimi, A | 1 |
| Davarpanah, M | 1 |
| Mohammadzadeh, R | 1 |
| Moreno Márquez, C | 1 |
| Fernández Álvarez, P | 1 |
| Valdés Delgado, T | 1 |
| Castro Laria, L | 2 |
| Argüelles Arias, F | 2 |
| Caunedo Álvarez, Á | 2 |
| Khan, SF | 1 |
| Teng, JC | 1 |
| Holmes, JA | 1 |
| Perera, C | 1 |
| Prendergast, L | 1 |
| Waring, L | 1 |
| Cadranel, S | 3 |
| Verset, L | 1 |
| Vanderpas, J | 2 |
| Buset, M | 1 |
| Gomez-Galdon, M | 1 |
| Delforge, M | 1 |
| Miendje-Deyi, VY | 1 |
| Muls, V | 1 |
| De Wit, S | 1 |
| Van Thieu, H | 1 |
| Duc, NM | 1 |
| Nghi, BTD | 1 |
| Van Bach, N | 1 |
| Khoi, HH | 1 |
| Tien, VNT | 1 |
| Bang, MTL | 1 |
| Ngoc, TLC | 1 |
| Li, XH | 1 |
| Huang, YY | 1 |
| Lu, LM | 1 |
| Zhao, LJ | 1 |
| Luo, XK | 1 |
| Li, RJ | 1 |
| Dai, YY | 1 |
| Qin, C | 1 |
| Huang, YQ | 1 |
| Bricker-Ford, R | 1 |
| Choi, Y | 1 |
| Tang, SY | 1 |
| Wu, IT | 2 |
| Mitchell, PD | 1 |
| Mansuri, I | 1 |
| Shafahi Tilaki, S | 1 |
| Fattahi, G | 1 |
| Safarnejad, S | 1 |
| Gunnarsdottir, AI | 1 |
| Gudjonsson, H | 2 |
| Hardardottir, H | 1 |
| Jonsdottir, KD | 1 |
| Bjornsson, ES | 1 |
| Akpinar, Z | 1 |
| Akay, S | 1 |
| Unsal, B | 1 |
| Dias de Castro, F | 1 |
| Rosa, B | 1 |
| Ribaldone, DG | 1 |
| Astegiano, M | 5 |
| Saracco, G | 3 |
| Ozturk, O | 1 |
| Doganay, L | 1 |
| Colak, Y | 1 |
| Yilmaz Enc, F | 1 |
| Ulasoglu, C | 1 |
| Ozdil, K | 1 |
| Tuncer, I | 1 |
| Castro Márquez, C | 1 |
| Romero Gómez, M | 2 |
| Edson, RS | 1 |
| Litin, SC | 1 |
| Bundrick, JB | 1 |
| Tanabe, H | 1 |
| Ando, K | 1 |
| Sato, K | 5 |
| Ito, T | 1 |
| Goto, M | 1 |
| Fujinaga, A | 1 |
| Kawamoto, T | 1 |
| Utsumi, T | 1 |
| Yanagawa, N | 1 |
| Ichiishi, E | 1 |
| Otake, T | 1 |
| Kohgo, Y | 1 |
| Nomura, Y | 2 |
| Ueno, N | 2 |
| Sugano, H | 3 |
| Kashima, S | 2 |
| Moriichi, K | 2 |
| Fujiya, M | 2 |
| Okumura, T | 2 |
| Alba, C | 1 |
| Blanco, A | 1 |
| Alarcón, T | 8 |
| Khoury, J | 1 |
| Geffen, Y | 1 |
| Shaul, R | 1 |
| Sholy, H | 1 |
| Chowers, Y | 1 |
| Saadi, T | 1 |
| Lee, SM | 5 |
| Kim, JM | 10 |
| Lee, YS | 1 |
| Pittayanon, R | 1 |
| Rojborwonwitaya, J | 1 |
| Leelakusolvong, S | 1 |
| Maneerattanaporn, M | 1 |
| Chotivitayatarakorn, P | 1 |
| Treeprasertsuk, S | 1 |
| Kositchaiwat, C | 1 |
| Pisespongsa, P | 1 |
| Mairiang, P | 1 |
| Rani, A | 1 |
| Leow, A | 1 |
| Mya, SM | 1 |
| Rasachak, B | 1 |
| Chakravuth, O | 1 |
| Aung, MM | 1 |
| Trong Quach, D | 1 |
| Sansak, I | 1 |
| Wiwattanachang, O | 1 |
| Harnsomburana, P | 1 |
| Syam, AF | 2 |
| Fock, KM | 6 |
| Goh, KL | 8 |
| Sugano, K | 6 |
| Kuo, YT | 1 |
| Leow, AHR | 1 |
| Das, R | 1 |
| Tanaka, K | 1 |
| Sakatani, A | 1 |
| Fujibayashi, S | 1 |
| Goto, T | 1 |
| Sasajima, J | 1 |
| Yu, HC | 2 |
| Lin, KH | 1 |
| Cheng, JS | 3 |
| Sun, WC | 1 |
| Kwon, S | 1 |
| Kang, JB | 1 |
| Choi, YJ | 3 |
| González-Santiago, JM | 1 |
| Herranz, MT | 1 |
| Algaba, A | 2 |
| Costa, S | 1 |
| Soares, JB | 1 |
| Gonçalves, R | 1 |
| Bellesia, A | 1 |
| Vassallo, R | 1 |
| D'Angelo, A | 1 |
| Scaccianoce, G | 1 |
| Sacco, R | 1 |
| Bresci, G | 1 |
| Eramo, A | 1 |
| Tanzilli, A | 1 |
| Ridola, L | 2 |
| Alvaro, D | 1 |
| Londoni, C | 1 |
| Brambilla, G | 1 |
| Di Ciaula, A | 1 |
| Portincasa, P | 1 |
| Pastukh, N | 1 |
| Brodsky, D | 2 |
| Isakovich, N | 1 |
| Nakagawa, S | 4 |
| Shimoyama, T | 5 |
| Nakamura, M | 1 |
| Chiba, D | 1 |
| Kikuchi, H | 1 |
| Sawaya, M | 1 |
| Chinda, D | 1 |
| Mikami, T | 2 |
| Fukuda, S | 3 |
| Pérez-Arellano, E | 1 |
| Rodriguez-Garcia, MI | 1 |
| Galera Rodenas, AB | 1 |
| de la Morena-Madrigal, E | 1 |
| Kahramanoğlu Aksoy, E | 1 |
| Pirinçci Sapmaz, F | 1 |
| Göktaş, Z | 1 |
| Uzman, M | 4 |
| Nazlıgül, Y | 4 |
| Liu, DS | 1 |
| Wang, YH | 2 |
| Zeng, ZR | 1 |
| Zhang, ZY | 1 |
| Xu, JM | 2 |
| Du, YQ | 1 |
| Wang, JB | 1 |
| Xu, SP | 1 |
| Lan, CH | 1 |
| Jiang, MD | 1 |
| Zhang, LX | 1 |
| Huo, LJ | 1 |
| Chen, SY | 2 |
| Zhang, GX | 1 |
| Wu, KC | 1 |
| Chen, YX | 1 |
| Suzuki, H | 12 |
| Mori, H | 2 |
| Jung, JH | 2 |
| Cho, IK | 1 |
| Song, GG | 1 |
| Lim, JH | 3 |
| Ruiter, R | 1 |
| Wunderink, HF | 2 |
| Visser, LG | 1 |
| Adachi, T | 1 |
| Matsui, S | 1 |
| Watanabe, T | 1 |
| Okamoto, A | 1 |
| Kono, M | 1 |
| Yamada, M | 3 |
| Nagai, T | 1 |
| Komeda, Y | 1 |
| Minaga, K | 1 |
| Kamata, K | 1 |
| Yamao, K | 1 |
| Takenaka, M | 1 |
| Asakuma, Y | 1 |
| Sakurai, T | 1 |
| Nishida, N | 1 |
| Kashida, H | 1 |
| Kudo, M | 4 |
| Younes, R | 1 |
| Morgando, A | 3 |
| Choe, JW | 1 |
| Jung, SW | 4 |
| Hyun, JJ | 3 |
| Jung, YK | 2 |
| Koo, JS | 3 |
| Yim, HJ | 3 |
| Lee, SW | 4 |
| Pourakbari, B | 1 |
| Mahmoudi, S | 1 |
| Parhiz, J | 1 |
| Sadeghi, RH | 1 |
| Monajemzadeh, M | 1 |
| Mamishi, S | 1 |
| Scarpignato, C | 1 |
| Belsey, J | 1 |
| Ricci, C | 7 |
| Pan, X | 1 |
| Du, Y | 1 |
| Zeng, Z | 1 |
| Zhang, G | 1 |
| Wu, K | 1 |
| Lv, N | 1 |
| Mabe, K | 3 |
| Okuda, M | 3 |
| Kikuchi, S | 3 |
| Amagai, K | 1 |
| Yoshimura, R | 1 |
| Sakamoto, N | 2 |
| Asaka, M | 10 |
| Tursi, A | 4 |
| Franceschi, M | 7 |
| Allegretta, L | 1 |
| Savarino, E | 2 |
| De Bastiani, R | 2 |
| Elisei, W | 2 |
| Baldassarre, G | 2 |
| Ferronato, A | 2 |
| Scida, S | 1 |
| Miraglia, C | 1 |
| Penna, A | 1 |
| Licci, C | 1 |
| Rizzo, GL | 1 |
| Pranzo, G | 1 |
| Cassieri, C | 1 |
| Brandimarte, G | 1 |
| Picchio, M | 2 |
| Di Mario, F | 10 |
| Pintar, T | 1 |
| Kaliterna, N | 1 |
| Carli, T | 1 |
| Long, X | 2 |
| Liu, W | 7 |
| Salmanroghani, H | 1 |
| Mirvakili, M | 1 |
| Baghbanian, M | 1 |
| Salmanroghani, R | 1 |
| Sanati, G | 1 |
| Yazdian, P | 1 |
| Wan, L | 1 |
| Bie, M | 1 |
| Tang, C | 1 |
| Robotis, J | 2 |
| Tsiodras, S | 1 |
| Pan, CY | 1 |
| Chen, CL | 3 |
| Zagari, RM | 4 |
| Romiti, A | 1 |
| Panarese, A | 1 |
| Grande, G | 1 |
| Maconi, G | 5 |
| Stasi, E | 1 |
| Eusebi, LH | 1 |
| Farinati, F | 2 |
| Conigliaro, R | 1 |
| Bazzoli, F | 7 |
| Gonzalez-Hormazabal, P | 1 |
| Musleh, M | 1 |
| Escandar, S | 1 |
| Valladares, H | 1 |
| Lanzarini, E | 1 |
| Castro, VG | 1 |
| Jara, L | 1 |
| Berger, Z | 1 |
| Chang, CC | 5 |
| Agudo-Fernández, S | 1 |
| González Blanco, A | 1 |
| Silva, GM | 1 |
| Silva, HM | 1 |
| Nascimento, J | 1 |
| Gonçalves, JP | 1 |
| Pereira, F | 1 |
| Jones, L | 1 |
| Ta, J | 1 |
| Kelsburg, G | 1 |
| Safranek, S | 1 |
| Tang, D | 1 |
| Yuan, L | 1 |
| Yue, C | 1 |
| Cai, T | 1 |
| Wang, F | 1 |
| McNicholl, AG | 9 |
| Calleja, JL | 1 |
| Aldeguer, X | 1 |
| Calafat, M | 1 |
| Comino, L | 1 |
| Ramas, M | 1 |
| Callejo, Á | 1 |
| Badiola, C | 1 |
| Serra, J | 1 |
| Kabakambira, JD | 1 |
| Hategeka, C | 1 |
| Page, C | 1 |
| Ntirenganya, C | 1 |
| Dusabejambo, V | 1 |
| Ndoli, J | 1 |
| Ngabonziza, F | 1 |
| Hale, D | 1 |
| Bayingana, C | 1 |
| Walker, T | 1 |
| Muñoz, N | 4 |
| Sánchez-Delgado, J | 6 |
| Baylina, M | 3 |
| López-Góngora, S | 3 |
| Ennkaa, A | 1 |
| Shaath, N | 1 |
| Salam, A | 1 |
| Mohammad, RM | 1 |
| Dekhnich, N | 1 |
| Ivanchik, N | 1 |
| Kozlov, R | 1 |
| Alimov, A | 1 |
| Steshits, A | 1 |
| Kirsov, P | 1 |
| Pandav, K | 1 |
| Manfredi, M | 1 |
| Gaiani, F | 1 |
| Kayali, S | 1 |
| Bizzarri, B | 1 |
| Iuliano, S | 1 |
| Minelli, R | 1 |
| Leandro, G | 7 |
| De' Angelis, GL | 1 |
| Roh, JH | 1 |
| Park, SJ | 2 |
| Moon, W | 2 |
| Heo, JJ | 1 |
| Seddik, H | 1 |
| Boutallaka, H | 1 |
| Elkoti, I | 1 |
| Nejjari, F | 1 |
| Berraida, R | 1 |
| Berrag, S | 1 |
| Loubaris, K | 1 |
| Sentissi, S | 1 |
| Benkirane, A | 1 |
| Yurenev, GL | 1 |
| Partzvania-Vinogradova, EV | 1 |
| Andreev, DN | 1 |
| Dicheva, DT | 1 |
| Maiev, IV | 1 |
| Kusunoki, M | 2 |
| Yuki, M | 1 |
| Ishitobi, H | 2 |
| Kobayashi, Y | 2 |
| Nagaoka, M | 1 |
| Takahashi, Y | 1 |
| Fukuba, N | 1 |
| Komazawa, Y | 1 |
| Shizuku, T | 1 |
| Kinoshita, Y | 1 |
| Soo In, C | 1 |
| Liou, TC | 3 |
| Liao, PH | 1 |
| Lin, YC | 1 |
| Chu, CH | 1 |
| Shih, SC | 1 |
| Wang, C | 1 |
| Cruz, M | 1 |
| Doohan, D | 1 |
| Subsomwong, P | 3 |
| Abreu, JAJ | 1 |
| Hosking, C | 1 |
| Waskito, LA | 2 |
| Tseng, DS | 1 |
| Li, D | 2 |
| Cholleti, SM | 1 |
| Wei, JC | 1 |
| Jodesty, Y | 1 |
| Pham, HV | 1 |
| Lee, HS | 2 |
| Nabeta, H | 1 |
| Shinozaki, S | 1 |
| Abe, Y | 1 |
| Koyanagi, R | 1 |
| Nakamichi, T | 1 |
| Lefor, AK | 1 |
| Hirashima, H | 1 |
| Fallone, CA | 9 |
| Xu, B | 1 |
| Liu, M | 1 |
| Sun, Y | 1 |
| Zhao, Y | 1 |
| Xu, G | 1 |
| Song, Y | 1 |
| Eed, EM | 1 |
| Hawash, YA | 1 |
| Khalifa, AS | 1 |
| Alsharif, KF | 1 |
| Alghamdi, SA | 1 |
| Saber, T | 1 |
| Ismail, KA | 1 |
| Shehab-Eldeen, SA | 1 |
| Guiard, E | 1 |
| Lelievre, B | 1 |
| Rouyer, M | 1 |
| Zerbib, F | 1 |
| Diquet, B | 1 |
| Tison, F | 1 |
| Bignon, E | 1 |
| Lassalle, R | 1 |
| Droz-Perroteau, C | 1 |
| Moore, N | 1 |
| Blin, P | 1 |
| Kim, BW | 7 |
| Park, JC | 1 |
| Jung, HK | 3 |
| Lee, SH | 8 |
| Lee, WS | 1 |
| Chung, JW | 7 |
| Cheung, DY | 3 |
| Min, YW | 1 |
| Castro Fernández, M | 2 |
| Romero García, T | 1 |
| Keco Huerga, A | 1 |
| Pabón Jaén, M | 1 |
| Lamas Rojas, E | 1 |
| Llorca Fernández, R | 1 |
| Grande Santamaría, L | 1 |
| Rojas Feria, M | 1 |
| Vecchio, EC | 1 |
| Shawwa, K | 1 |
| Acosta-Gonzales, G | 1 |
| Resnick, MB | 1 |
| Lu, HH | 1 |
| Lai, FP | 1 |
| Lo, HY | 1 |
| Sheu, BS | 12 |
| Morilla, AM | 1 |
| Álvarez-Argüelles, ME | 1 |
| Duque, JM | 1 |
| Armesto, E | 1 |
| Villar, H | 1 |
| Melón, S | 1 |
| Valle Muñoz, J | 1 |
| Muñoz Gómez, P | 1 |
| Sierra Bernal, C | 1 |
| de Andrés, E | 1 |
| Gómez Hernando, C | 1 |
| Gómez Rodríguez, R | 1 |
| Attia, TZ | 1 |
| Yamashita, T | 1 |
| Tsujino, H | 1 |
| Derayea, SM | 1 |
| Tsutsumi, Y | 1 |
| Uno, T | 1 |
| Ogata, SK | 1 |
| Godoy, AP | 1 |
| da Silva Patricio, FR | 1 |
| Kawakami, E | 1 |
| Morgan, DR | 2 |
| Torres, J | 3 |
| Sexton, R | 1 |
| Herrero, R | 2 |
| Salazar-Martínez, E | 2 |
| Greenberg, ER | 2 |
| Bravo, LE | 7 |
| Dominguez, RL | 2 |
| Ferreccio, C | 2 |
| Lazcano-Ponce, EC | 2 |
| Meza-Montenegro, MM | 2 |
| Peña, EM | 2 |
| Peña, R | 2 |
| Correa, P | 10 |
| Martínez, ME | 2 |
| Valdivieso, M | 2 |
| Anderson, GL | 2 |
| Goodman, GE | 2 |
| Crowley, JJ | 2 |
| Baker, LH | 2 |
| Alfizah, H | 2 |
| Rukman, AH | 1 |
| Norazah, A | 2 |
| Hamizah, R | 1 |
| Ramelah, M | 2 |
| Marin, AC | 5 |
| Vinagre, G | 2 |
| Benajah, DA | 2 |
| Lahbabi, M | 2 |
| Alaoui, S | 2 |
| El Rhazi, K | 2 |
| El Abkari, M | 2 |
| Nejjari, C | 2 |
| Amarti, A | 2 |
| Bennani, B | 2 |
| Mahmoud, M | 2 |
| Ibrahimi, SA | 1 |
| Ilieva, J | 2 |
| Evstatiev, I | 2 |
| Nikolov, R | 1 |
| Mitov, I | 6 |
| Seyedmajidi, S | 1 |
| Mirsattari, D | 2 |
| Zojaji, H | 2 |
| Zanganeh, E | 1 |
| Seyyedmajidi, M | 1 |
| Almasi, S | 1 |
| Zali, M | 1 |
| Sierra, F | 1 |
| Forero, JD | 1 |
| Rey, M | 1 |
| Botero, ML | 1 |
| Cárdenas, A | 1 |
| Ducons, J | 5 |
| Montoro, M | 4 |
| Bory, F | 5 |
| Forné, M | 1 |
| Nishizawa, T | 7 |
| Takahashi, M | 4 |
| Suzuki, M | 3 |
| Hibi, T | 6 |
| Xirouchakis, E | 3 |
| Martinez-Gonzalez, B | 1 |
| Sgouras, DN | 1 |
| Spiliadi, C | 4 |
| Mentis, AF | 1 |
| Laoudi, F | 3 |
| Asaoka, D | 3 |
| Nagahara, A | 9 |
| Matsuhisa, T | 2 |
| Takahashi, S | 8 |
| Kawai, T | 4 |
| Kawakami, K | 2 |
| Kurihara, N | 1 |
| Ito, M | 3 |
| Sasaki, H | 2 |
| Omata, F | 1 |
| Mizuno, S | 1 |
| Torii, A | 1 |
| Ohkusa, T | 4 |
| Mine, T | 5 |
| Sakaki, N | 2 |
| Onal, IK | 1 |
| Gokcan, H | 1 |
| Benzer, E | 1 |
| Bilir, G | 1 |
| Oztas, E | 1 |
| Lee, HJ | 2 |
| Kim, TH | 2 |
| Jun, EJ | 2 |
| Oh, JH | 2 |
| Chung, WC | 2 |
| Kim, SS | 2 |
| Park, SH | 2 |
| Kim, JK | 1 |
| Cecchini, MP | 1 |
| Pellegrini, C | 1 |
| Bassetto, MA | 1 |
| Osculati, F | 1 |
| Sbarbati, A | 1 |
| Marcolini, L | 1 |
| Pegoraro, M | 1 |
| Fontana, R | 1 |
| De Franceschi, L | 1 |
| Krieger, T | 1 |
| Ecker, T | 1 |
| Zendedel, A | 1 |
| Moradimoghadam, F | 1 |
| Almasi, V | 1 |
| Zivarifar, H | 1 |
| Makobongo, MO | 1 |
| Einck, L | 1 |
| Peek, RM | 1 |
| Chakraborti, S | 1 |
| Bhattacharya, S | 1 |
| Chowdhury, R | 1 |
| Chakrabarti, P | 1 |
| Lee, HL | 1 |
| Shin, ES | 1 |
| Adriani, A | 1 |
| Smedile, A | 2 |
| Rizzetto, M | 4 |
| Kim, MS | 1 |
| Jo, HJ | 3 |
| Panov, V | 1 |
| Huang, J | 4 |
| Geng, L | 1 |
| Yang, M | 1 |
| Xu, XW | 1 |
| Ding, ZL | 1 |
| Mao, M | 1 |
| Wang, ZL | 1 |
| Li, ZL | 1 |
| Li, DY | 1 |
| Gong, ST | 2 |
| Kang, KK | 2 |
| Oh, DH | 2 |
| Jang, DK | 1 |
| Furuta, T | 9 |
| Sugimoto, M | 10 |
| Yamade, M | 4 |
| Uotani, T | 5 |
| Sahara, S | 6 |
| Ichikawa, H | 6 |
| Osawa, S | 3 |
| Sugimoto, K | 4 |
| Watanabe, H | 3 |
| Umemura, K | 3 |
| Bermejo, F | 8 |
| Antón, R | 1 |
| Sacristán, B | 1 |
| Cosme, A | 5 |
| Harb, Y | 1 |
| Gonzalez-Barcenas, M | 1 |
| Kodaira, C | 2 |
| Nishino, M | 2 |
| Sapmaz, F | 3 |
| Kalkan, IH | 2 |
| Güliter, S | 2 |
| Atasoy, P | 2 |
| Liu, KS | 1 |
| Hung, IF | 1 |
| Tong, T | 1 |
| Hsu, AS | 1 |
| Lam, FY | 1 |
| But, DY | 1 |
| Wong, SY | 1 |
| Laving, A | 1 |
| Kamenwa, R | 1 |
| Sayed, S | 2 |
| Kimang'a, AN | 2 |
| Revathi, G | 2 |
| Morse, AL | 1 |
| Goodman, KJ | 3 |
| Munday, R | 1 |
| Chang, HJ | 1 |
| Morse, JW | 1 |
| Keelan, M | 1 |
| Geary, J | 1 |
| Sander, Vv | 1 |
| Hojo, M | 4 |
| Matsumoto, K | 2 |
| Osada, T | 1 |
| Watanabe, S | 3 |
| Nashaat, EH | 3 |
| Mansour, GM | 3 |
| Hao, S | 1 |
| Zou, Q | 1 |
| Zeng, H | 1 |
| Yu, S | 1 |
| Romãozinho, JM | 1 |
| Donato, MM | 2 |
| Luxo, C | 1 |
| Cardoso, O | 1 |
| Cipriano, MA | 1 |
| Marinho, C | 1 |
| Sofia, C | 1 |
| Song, M | 2 |
| Wang, WM | 7 |
| Kagami, T | 3 |
| Paritsky, M | 1 |
| Nasser, O | 1 |
| Glyatman, T | 1 |
| Segal, S | 1 |
| Rasheed, F | 1 |
| Campbell, BJ | 1 |
| Varro, A | 1 |
| Zahra, R | 1 |
| Pritchard, DM | 1 |
| Tu, IF | 1 |
| Liao, JH | 1 |
| Yang, FL | 1 |
| Lin, NT | 2 |
| Chan, HL | 3 |
| Wu, SH | 1 |
| Jeon, HK | 1 |
| Yun, SC | 4 |
| Choi, KS | 1 |
| Delchier, JC | 10 |
| Thieroff-Ekerdt, R | 1 |
| Hosseini, SM | 1 |
| Sharifipoor, F | 1 |
| Nazemian, F | 1 |
| Ghanei, H | 1 |
| Zivarifar, HR | 1 |
| Fakharian, T | 1 |
| Maekawa, T | 1 |
| Watanabe, N | 1 |
| Harada, N | 1 |
| Hosoda, Y | 1 |
| Yoshinaga, M | 1 |
| Yoshio, T | 1 |
| Ohta, H | 1 |
| Inoue, S | 2 |
| Toyokawa, T | 1 |
| Yamashita, H | 2 |
| Saito, H | 1 |
| Kuwai, T | 1 |
| Katayama, S | 1 |
| Masuda, E | 1 |
| Miyabayashi, H | 2 |
| Kimura, T | 3 |
| Nishizawa, Y | 1 |
| Hwang, JH | 8 |
| Jeoung, SH | 2 |
| Kim, JW | 8 |
| Jang, ES | 3 |
| Jung, HC | 14 |
| Rakici, H | 1 |
| Akdoğan, RA | 1 |
| Bedir, R | 1 |
| Copur, A | 1 |
| Yilmaz, A | 1 |
| Teh, X | 1 |
| Khosravi, Y | 1 |
| Lee, WC | 1 |
| Leow, AH | 1 |
| Loke, MF | 1 |
| Vadivelu, J | 1 |
| Lee, ST | 2 |
| Song, IS | 13 |
| Heo, J | 2 |
| Jung, JT | 3 |
| Kwon, JG | 3 |
| Kim, EY | 2 |
| Seo, HE | 2 |
| Ha, CY | 1 |
| Kim, HJ | 4 |
| Kim, ES | 2 |
| Park, KS | 3 |
| Cho, KB | 3 |
| Jang, BI | 2 |
| de Boer, EM | 1 |
| Schneeberger, PM | 10 |
| de Boer, WA | 26 |
| Kutluk, G | 1 |
| Tutar, E | 1 |
| Bayrak, A | 1 |
| Volkan, B | 1 |
| Celikel, C | 1 |
| Ertem, D | 1 |
| Sakallioglu, O | 1 |
| Aisa, AP | 1 |
| Gisbert, JL | 6 |
| Marcos, S | 6 |
| Selgrad, M | 3 |
| Tu, S | 1 |
| Yang, H | 2 |
| Chung, KH | 1 |
| Jin, E | 1 |
| Cho, Y | 1 |
| Seo, JY | 2 |
| Jeong, SH | 5 |
| Lv, ZF | 1 |
| Xiong, HF | 1 |
| Yang, Y | 1 |
| Villalon, FN | 1 |
| Eizaguirre, FJ | 1 |
| Delgado, M | 1 |
| Muñoz-Seca, IM | 1 |
| Fernández-Reyes, M | 1 |
| Pérez-Trallero, E | 1 |
| Park, DK | 1 |
| Kwon, KA | 2 |
| Kim, KO | 3 |
| Kim, YJ | 3 |
| Boltin, D | 2 |
| Ben-Zvi, H | 2 |
| Perets, TT | 2 |
| Kamenetsky, Z | 1 |
| Samra, Z | 4 |
| Dickman, R | 2 |
| Tsugawa, H | 4 |
| Hong, SN | 1 |
| Min, BH | 1 |
| Rhee, PL | 1 |
| Mourad-Baars, PE | 1 |
| Mearin, ML | 1 |
| Wit, JM | 1 |
| Veldkamp, KE | 1 |
| Lai, KH | 4 |
| Chan, HH | 1 |
| Tsai, WL | 1 |
| Tseng, HH | 4 |
| Phan, TN | 1 |
| Santona, A | 1 |
| Tran, VH | 1 |
| Tran, TN | 1 |
| Le, VA | 1 |
| Cappuccinelli, P | 1 |
| Rubino, S | 1 |
| Paglietti, B | 1 |
| Laszewicz, W | 1 |
| Iwanczak, F | 2 |
| Dzierzanowska-Fangrat, K | 3 |
| Rozynek, M | 1 |
| Dzierzanowska, D | 4 |
| Dlugosz, J | 1 |
| Lee, JS | 1 |
| Berry, AC | 1 |
| Nakshabendi, R | 1 |
| Baltz, AC | 1 |
| Kwek, AB | 1 |
| Ong, J | 1 |
| Tan, J | 1 |
| Teo, EK | 2 |
| Dhamodaran, S | 1 |
| Scherübl, H | 1 |
| Fischbach, W | 3 |
| Glocker, E | 2 |
| Ben Chaabane, N | 2 |
| Al-Adhba, HS | 1 |
| Angueira, T | 1 |
| Rodriguez-Tellez, M | 1 |
| Balboa, A | 1 |
| Martin-Noguerol, E | 1 |
| Botargues-Bote, JM | 1 |
| Huerta, A | 1 |
| Herranz-Bachiller, MT | 1 |
| Koval', VIu | 1 |
| Kotsiubniak, LA | 1 |
| Moskal', OM | 1 |
| Andrianov, M | 1 |
| Rivera, E | 1 |
| Azzam, R | 1 |
| Abou Youssef, NA | 1 |
| Kassem, AA | 1 |
| El-Massik, MA | 1 |
| Boraie, NA | 1 |
| Lee, DS | 1 |
| Morrissey, R | 1 |
| Aponte-Pieras, JR | 1 |
| Rogers, AB | 1 |
| Rahmani, A | 1 |
| Abangah, G | 1 |
| Moradkhani, A | 1 |
| Hafezi Ahmadi, MR | 1 |
| Asadollahi, K | 1 |
| Yang, CH | 2 |
| Park, JB | 1 |
| Kim, JS | 11 |
| Park, SM | 3 |
| Liao, J | 1 |
| Xiao, S | 5 |
| Başyiğit, S | 3 |
| Kefeli, A | 2 |
| Yeniova, AÖ | 2 |
| Aktaş, B | 2 |
| Yüksel, O | 1 |
| Akkan, T | 1 |
| Atbaşı, ST | 1 |
| Yılmaz, B | 1 |
| Şimşek, G | 1 |
| Hauser, G | 1 |
| Salkic, N | 1 |
| Vukelic, K | 1 |
| JajacKnez, A | 1 |
| Stimac, D | 2 |
| Chang, WH | 4 |
| Wu, CY | 1 |
| Wang, HP | 3 |
| Hwang, JJ | 3 |
| Lee, AR | 2 |
| Matsuzaki, J | 3 |
| Masaoka, T | 4 |
| Hirayama, T | 1 |
| Nagasawa, H | 1 |
| Sakakibara, Y | 1 |
| Suematsu, M | 1 |
| Pan, KF | 2 |
| Gerhard, M | 1 |
| Ma, JL | 2 |
| Liu, WD | 2 |
| Ulm, K | 1 |
| Wang, JX | 1 |
| Bajbouj, M | 1 |
| Zhang, LF | 1 |
| Li, M | 1 |
| Vieth, M | 5 |
| Liu, RY | 1 |
| Quante, M | 1 |
| Wang, LH | 1 |
| Suchanek, S | 1 |
| Zhou, T | 2 |
| Guan, WX | 1 |
| Schmid, R | 1 |
| Classen, M | 3 |
| You, WC | 2 |
| Srivastava, AK | 1 |
| Tewari, M | 1 |
| Shukla, HS | 1 |
| Roy, BK | 1 |
| Altun, B | 1 |
| Ozturk, K | 1 |
| Jheng, GH | 1 |
| Wu, IC | 3 |
| Shih, HY | 1 |
| Wu, MC | 2 |
| Kuo, FC | 4 |
| Hu, HM | 3 |
| Liu, CJ | 2 |
| Hsu, WH | 1 |
| Hu, CT | 2 |
| Chiu, CH | 1 |
| Hu, ML | 4 |
| Lu, LS | 3 |
| Yen, YH | 2 |
| Chiou, SS | 3 |
| Chiu, YC | 3 |
| Hu, TH | 4 |
| He, L | 2 |
| Qian, J | 1 |
| Bai, P | 3 |
| Lin, S | 1 |
| Xiao, XM | 1 |
| Luo, Y | 1 |
| Ding, Y | 1 |
| Suslu, I | 1 |
| Demirci, H | 2 |
| Tongtawee, T | 1 |
| Dechsukhum, C | 1 |
| Leeanansaksiri, W | 1 |
| Kaewpitoon, S | 1 |
| Kaewpitoon, N | 1 |
| Loyd, RA | 1 |
| Matrakool, L | 1 |
| Panpimanmas, S | 1 |
| Grgov, S | 1 |
| Katić, V | 1 |
| Nagorni, A | 1 |
| Radovanović-Dinić, B | 1 |
| Tasić, T | 1 |
| Gungor, G | 1 |
| Baglıcakoglu, M | 1 |
| Kayacetin, E | 1 |
| Biyik, M | 1 |
| Ucar, R | 1 |
| Goktepe, H | 1 |
| Ataseven, H | 3 |
| Demir, A | 1 |
| Diós, P | 1 |
| Nagy, S | 1 |
| Pál, S | 1 |
| Pernecker, T | 1 |
| Kocsis, B | 1 |
| Budán, F | 1 |
| Horváth, I | 1 |
| Szigeti, K | 1 |
| Bölcskei, K | 1 |
| Máthé, D | 1 |
| Dévay, A | 1 |
| Ojetti, V | 2 |
| Stockbrugger, R | 1 |
| Gullini, S | 1 |
| Annibale, B | 5 |
| Rugge, M | 2 |
| Calabrese, C | 1 |
| Luzza, F | 1 |
| Pretolani, S | 1 |
| Savio, A | 1 |
| Gasbarrini, G | 5 |
| Caselli, M | 2 |
| Haider, RB | 1 |
| Brennan, DE | 1 |
| Omorogbe, J | 1 |
| Holleran, G | 1 |
| Hall, B | 1 |
| Breslin, N | 2 |
| O'Connor, HJ | 6 |
| Smith, SM | 1 |
| McNamara, D | 2 |
| Li, BZ | 1 |
| Threapleton, DE | 1 |
| Wang, JY | 2 |
| Yuan, JQ | 1 |
| Li, P | 1 |
| Ye, QL | 1 |
| Guo, B | 1 |
| Mao, C | 1 |
| Ye, DQ | 1 |
| Braden, B | 1 |
| Asif, HM | 1 |
| Zaidi, SF | 2 |
| Akhtar, N | 1 |
| Usmanghani, K | 2 |
| Dingemanse, C | 1 |
| Belzer, C | 1 |
| van Hijum, SA | 1 |
| Günthel, M | 1 |
| Salvatori, D | 1 |
| den Dunnen, JT | 1 |
| Devilee, P | 1 |
| de Vos, WM | 1 |
| van Ommen, GB | 1 |
| Robanus-Maandag, EC | 1 |
| Prapitpaiboon, H | 1 |
| Gamnarai, P | 2 |
| Namtanee, J | 1 |
| Wongcha-um, A | 1 |
| Chaithongrat, S | 2 |
| Karatapanis, S | 3 |
| Liu, TY | 1 |
| Hsieh, CF | 1 |
| Tsao, FY | 1 |
| Chen, KY | 1 |
| Lin, TJ | 1 |
| Lin, CL | 1 |
| Lee, HC | 1 |
| Wang, CK | 1 |
| Koumoutsos, I | 1 |
| Dogantzis, P | 1 |
| Suh, JH | 1 |
| Yaneva, P | 1 |
| Chien, CC | 1 |
| Chiang, YS | 1 |
| Cerqueira, RM | 1 |
| Correia, MR | 1 |
| Vilar, H | 1 |
| Manso, MC | 1 |
| Mel-Hennawi, D | 1 |
| Ahmed, MR | 2 |
| John, A | 1 |
| Al Kaabi, S | 1 |
| Doiphode, S | 1 |
| Chandra, P | 1 |
| Sharma, M | 1 |
| Babu, R | 1 |
| Yacoub, R | 1 |
| Derbala, M | 1 |
| Karpiński, TM | 1 |
| Andrzejewska, E | 1 |
| Eder, P | 1 |
| Linke, K | 1 |
| Szkaradkiewicz, A | 1 |
| Di Giulio, M | 1 |
| Di Campli, E | 2 |
| Di Bartolomeo, S | 1 |
| Cataldi, V | 1 |
| Marzio, L | 2 |
| Grossi, L | 2 |
| Ciccaglione, AF | 1 |
| Nostro, A | 1 |
| Cellini, L | 2 |
| Asilturk, Z | 1 |
| Hokkaomeroglu, M | 1 |
| Chen, A | 4 |
| El-Mahrouk, GM | 1 |
| Aboul-Einien, MH | 1 |
| Makhlouf, AI | 1 |
| Thung, I | 2 |
| Aramin, H | 1 |
| Vavinskaya, V | 1 |
| Gupta, S | 1 |
| Crowe, SE | 1 |
| Valasek, MA | 2 |
| Hassan, ST | 1 |
| Berchová, K | 1 |
| Majerová, M | 1 |
| Pokorná, M | 1 |
| Švajdlenka, E | 1 |
| Hung, HW | 1 |
| Muller, N | 1 |
| Amiot, A | 1 |
| Le Thuaut, A | 1 |
| Bastuji-Garin, S | 1 |
| Deforges, L | 1 |
| Šeruga, M | 1 |
| Stefanovič, M | 1 |
| Forte, A | 1 |
| Jeverica, S | 1 |
| Bakshi, SS | 1 |
| Meng, X | 1 |
| Liu, G | 1 |
| Kong, C | 1 |
| Zhao, L | 1 |
| Ji, C | 1 |
| Yang, L | 2 |
| Dunbar, KB | 1 |
| Mitui, M | 1 |
| Arnold, CA | 1 |
| Lam-Himlin, DM | 1 |
| Okwara, C | 1 |
| Coss, E | 1 |
| Cryer, B | 1 |
| Doern, CD | 1 |
| Amiri, M | 1 |
| Sakurai, Y | 2 |
| Shiino, M | 2 |
| Funao, N | 1 |
| Nishimura, A | 2 |
| Shichijo, S | 2 |
| Hirata, Y | 3 |
| Niikura, R | 1 |
| Hayakawa, Y | 2 |
| Yamada, A | 2 |
| Ushiku, T | 1 |
| Fukayama, M | 1 |
| Koike, K | 2 |
| Hu, B | 1 |
| Zhao, F | 1 |
| Wang, S | 1 |
| Olszewski, MA | 1 |
| Bian, H | 1 |
| Wu, Y | 1 |
| Kong, M | 1 |
| Xu, L | 1 |
| Miao, Y | 1 |
| Fang, Y | 1 |
| Yang, C | 1 |
| Soro, S | 1 |
| Rocchi, C | 1 |
| Loria, MF | 1 |
| Campillo, A | 2 |
| Amorena, E | 2 |
| Ostiz, M | 2 |
| Kutz, M | 2 |
| LaIglesia, M | 1 |
| Chiba, N | 8 |
| van Zanten, SV | 2 |
| Fischbach, L | 4 |
| Hunt, RH | 5 |
| Jones, NL | 1 |
| Render, C | 1 |
| Leontiadis, GI | 2 |
| Moayyedi, P | 8 |
| Marshall, JK | 1 |
| Hong, SJ | 2 |
| Shim, KN | 2 |
| Martinez-Gonzales, B | 1 |
| Zampeli, E | 1 |
| Grivas, E | 1 |
| Sotiropoulou, M | 1 |
| Petraki, K | 3 |
| Zografos, K | 1 |
| Sgouras, D | 1 |
| Mentis, A | 3 |
| Kasapidis, P | 1 |
| Michopoulos, S | 2 |
| Wong, AY | 1 |
| Wong, IC | 1 |
| Chui, CS | 1 |
| Lee, EH | 1 |
| Chang, WC | 2 |
| Chen, EY | 1 |
| Chan, EW | 1 |
| Serrano, CA | 1 |
| Leon, MA | 1 |
| Palma, C | 1 |
| Vera, M | 1 |
| Hernandez, C | 1 |
| Harris, PR | 1 |
| Chang, KC | 2 |
| Legendre, T | 1 |
| Boudebesse, C | 1 |
| Henry, C | 1 |
| Etain, B | 1 |
| Ban, H | 1 |
| Otsuka, T | 2 |
| Andoh, A | 1 |
| Phiphatpatthamaamphan, K | 1 |
| Siramolpiwat, S | 1 |
| Tangaroonsanti, A | 1 |
| Chonprasertsuk, S | 1 |
| Bhanthumkomol, P | 1 |
| Pornthisarn, B | 2 |
| Fukuda, Y | 4 |
| Han, JP | 1 |
| Kim, CW | 1 |
| Bang, BW | 1 |
| Kim, HG | 1 |
| Pena, AS | 1 |
| Miyaki, A | 1 |
| Yamaguchi, K | 1 |
| Ida, A | 1 |
| Miyauchi, T | 1 |
| Siddiqui, TR | 1 |
| Ahmed, W | 3 |
| Arif, A | 1 |
| Bibi, S | 1 |
| Khan, A | 1 |
| Lin, LC | 1 |
| Hsu, TH | 1 |
| Huang, KW | 1 |
| Tam, KW | 1 |
| Suarez, D | 1 |
| García-Iglesias, P | 2 |
| Dacoll, C | 1 |
| Cohen, H | 1 |
| Gingold-Belfer, R | 1 |
| La Iglesia, M | 1 |
| Regnath, T | 1 |
| Raecke, O | 1 |
| Enninger, A | 1 |
| Ignatius, R | 1 |
| Okamoto, H | 1 |
| Nakamura, K | 1 |
| Hasegawa, S | 1 |
| Shaikh, T | 1 |
| Ji, JS | 1 |
| Choi, H | 1 |
| Serizawa, T | 1 |
| Sakitani, K | 1 |
| Abuhammour, A | 1 |
| Dajani, A | 1 |
| Nounou, M | 1 |
| Zakaria, M | 1 |
| Fu, Q | 1 |
| Agah, E | 1 |
| Habibi, A | 1 |
| Naderi, H | 1 |
| Tafakhori, A | 1 |
| Giorgio, F | 1 |
| Principi, M | 1 |
| Barone, M | 1 |
| Kajihara, Y | 1 |
| Mizuki, I | 1 |
| Shrestha, PK | 1 |
| Sharma, RP | 1 |
| Warrington, E | 1 |
| López-Román, O | 1 |
| Tirado Montijo, R | 1 |
| Urbina, R | 1 |
| Cruz-Correa, M | 1 |
| Toro, DH | 1 |
| Nusi, IA | 1 |
| Makmun, D | 1 |
| Zein, LH | 1 |
| Akil, F | 1 |
| Uwan, WB | 1 |
| Simanjuntak, D | 1 |
| Wibawa, ID | 1 |
| Waleleng, JB | 1 |
| Saudale, AM | 1 |
| Yusuf, F | 1 |
| Mustika, S | 1 |
| Adi, P | 1 |
| Maimunah, U | 1 |
| Maulahela, H | 1 |
| Rezkitha, YA | 1 |
| Rahardjo, D | 1 |
| Suzuki, R | 1 |
| Akada, J | 1 |
| Marušić, M | 2 |
| Dominković, L | 1 |
| Majstorović Barać, K | 1 |
| Gulić, S | 1 |
| Bago, J | 3 |
| Pezerović, D | 1 |
| Ramzy, I | 1 |
| Elgarem, H | 1 |
| Hamza, I | 1 |
| Ghaith, D | 1 |
| Elbaz, T | 1 |
| Elhosary, W | 1 |
| Mostafa, G | 1 |
| Elzahry, MA | 1 |
| Deguchi, R | 3 |
| Shiraishi, K | 1 |
| Arase, Y | 1 |
| Dekiden, M | 1 |
| Shimada, H | 1 |
| Miyakita, H | 1 |
| Ogimi, T | 1 |
| Myojin, K | 1 |
| Çekin, AH | 1 |
| Şahintürk, Y | 1 |
| Akbay Harmandar, F | 1 |
| Uyar, S | 1 |
| Yolcular, BO | 1 |
| Çekin, Y | 1 |
| Tsujimae, M | 1 |
| Hashimura, H | 1 |
| Kano, C | 1 |
| Shimoyama, K | 1 |
| Kanamori, A | 1 |
| Koizumi, A | 1 |
| Momose, K | 1 |
| Eguchi, T | 1 |
| Fukuchi, T | 1 |
| Fujita, M | 1 |
| Okada, A | 1 |
| Fagoonee, S | 3 |
| Ono, S | 1 |
| Chang, JY | 1 |
| Tae, CH | 1 |
| Lee, KE | 1 |
| Lee, KH | 3 |
| Moon, CM | 1 |
| Jung, SA | 1 |
| Grillo, S | 1 |
| Landi, S | 1 |
| Zamparella, M | 1 |
| De Polo, M | 1 |
| Boscariolo, L | 1 |
| Gregório, C | 1 |
| Cabral, JE | 1 |
| Casela, A | 1 |
| Tomé, L | 1 |
| Sakurai, K | 2 |
| Suda, H | 1 |
| Ido, Y | 1 |
| Takeichi, T | 1 |
| Okuda, A | 1 |
| Hasuda, K | 1 |
| Hattori, M | 1 |
| Kim, HK | 1 |
| Lee, YD | 1 |
| Wu, CT | 1 |
| Ou, HY | 1 |
| Lin, CH | 1 |
| Cheng, HC | 2 |
| Chang, WL | 2 |
| Chen, WY | 1 |
| Yang, HB | 8 |
| Lu, CC | 1 |
| Attaran, B | 1 |
| Falsafi, T | 1 |
| Ghorbanmehr, N | 1 |
| Choi, WH | 1 |
| Park, DI | 1 |
| Oh, SJ | 1 |
| Baek, YH | 1 |
| Hong, CH | 1 |
| Hong, EJ | 1 |
| Song, MJ | 1 |
| Park, SK | 1 |
| Cho, YK | 1 |
| Sohn, CI | 1 |
| Jeon, WK | 1 |
| Kim, BI | 1 |
| Geva, A | 1 |
| Sabo, E | 1 |
| Levy, J | 1 |
| Blumenthal, M | 1 |
| Ophir, E | 1 |
| Geva, H | 1 |
| Bornstein, J | 1 |
| Seppälä, K | 8 |
| Kosunen, TU | 7 |
| Veijola, L | 1 |
| Sipponen, P | 11 |
| Arkkila, PE | 1 |
| Rautelin, H | 8 |
| Tilvis, R | 1 |
| Ching, SS | 1 |
| Sabanathan, S | 1 |
| Jenkinson, LR | 1 |
| Egan, BJ | 1 |
| O'Morain, CA | 11 |
| Vakil, N | 6 |
| Iovene, MR | 2 |
| Russo, MI | 1 |
| Rocco, A | 1 |
| Salerno, R | 1 |
| Cozzolino, D | 1 |
| Pilloni, AP | 1 |
| Tufano, MA | 2 |
| Nardone, G | 2 |
| De Leest, HT | 1 |
| Steen, KS | 1 |
| Bloemena, E | 1 |
| Lems, WF | 1 |
| Kuipers, EJ | 6 |
| Van de Laar, MA | 1 |
| Bijlsma, JW | 1 |
| Janssen, M | 1 |
| Houben, HH | 1 |
| Kostense, PJ | 1 |
| Boers, M | 1 |
| Dijkmans, BA | 1 |
| Hagymási, K | 1 |
| Tulassay, Z | 2 |
| Dehghani, SM | 1 |
| Erjaee, A | 1 |
| Imanieh, MH | 1 |
| Haghighat, M | 1 |
| Berrutti, M | 2 |
| De Angelis, C | 2 |
| Repici, A | 1 |
| Leone, N | 1 |
| Ngom, G | 1 |
| Diouf, ML | 1 |
| Fall, M | 1 |
| Konaté, I | 1 |
| Sankalé, AA | 1 |
| Diop, M | 1 |
| Fall, I | 1 |
| Ndoye, M | 1 |
| Nakagawa, I | 1 |
| Iwasaki, E | 2 |
| Yamagishi, T | 1 |
| Yagi, K | 1 |
| Kataoka, M | 1 |
| Sofuni, A | 1 |
| Itoi, T | 1 |
| Sakai, Y | 1 |
| Moriyasu, F | 1 |
| Osaka, Y | 1 |
| Takagi, Y | 1 |
| Aoki, T | 1 |
| Sasatsu, M | 2 |
| Aladag, I | 1 |
| Eyibilen, A | 1 |
| Guven, M | 1 |
| Erkokmaz, U | 1 |
| El-Nakeeb, A | 1 |
| Fikry, A | 1 |
| Abd El-Hamed, TM | 1 |
| Fouda, el Y | 1 |
| El Awady, S | 1 |
| Youssef, T | 1 |
| Sherief, D | 1 |
| Farid, M | 1 |
| Nguyen, TV | 2 |
| Bengtsson, C | 1 |
| Nguyen, GK | 1 |
| Hoang, TT | 2 |
| Phung, DC | 1 |
| Sörberg, M | 3 |
| Granström, M | 2 |
| Severi, C | 1 |
| Abdullahi, M | 1 |
| Tari, R | 1 |
| Vannella, L | 1 |
| Marcheggiano, A | 3 |
| Capoccia, D | 1 |
| Leonetti, F | 1 |
| Osborn, J | 1 |
| Filipec Kanizaj, T | 1 |
| Katicic, M | 1 |
| Skurla, B | 1 |
| Ticak, M | 1 |
| Plecko, V | 1 |
| Kalenic, S | 1 |
| Yu, FJ | 1 |
| Tsai, PY | 1 |
| Wang, SW | 2 |
| Li, CJ | 2 |
| Weng, BC | 1 |
| Chang, LL | 2 |
| Jan, CM | 5 |
| Pevec, B | 1 |
| Tomić, M | 2 |
| Bakula, V | 1 |
| Bago, P | 1 |
| Ueki, N | 1 |
| Miyake, K | 1 |
| Shindo, T | 1 |
| Kawagoe, T | 1 |
| Futagami, S | 1 |
| Tsukui, T | 1 |
| Inagaki, H | 1 |
| Sakamoto, C | 1 |
| Fischbach, LA | 6 |
| Zarama, GR | 1 |
| Bravo, JC | 4 |
| Ojha, RP | 1 |
| Ojha, PR | 1 |
| Priest, EL | 1 |
| Collazos, T | 2 |
| Casabon, AL | 2 |
| Casabon, LA | 1 |
| Guerrero, LZ | 1 |
| Singh, KP | 1 |
| Singh, PK | 1 |
| Yoshida, I | 1 |
| Butt, F | 1 |
| Yusuf, MA | 1 |
| Kadowaki, M | 1 |
| Oyedeji, KS | 1 |
| Smith, SI | 1 |
| Coker, AO | 1 |
| Arigbabu, AO | 1 |
| Abdou, AG | 1 |
| Elshayeb, EI | 1 |
| Farag, AG | 1 |
| Elnaidany, NF | 1 |
| Matsushima, M | 2 |
| Suzuki, T | 4 |
| Fukuda, R | 1 |
| Nishina, M | 1 |
| Ozawa, H | 1 |
| Takagi, A | 3 |
| Songür, Y | 1 |
| Senol, A | 1 |
| Balkarli, A | 1 |
| Baştürk, A | 1 |
| Cerçi, S | 1 |
| Wu, JJ | 5 |
| Talaie, R | 1 |
| Haghazali, M | 1 |
| Molaei, M | 1 |
| Mohsenian, N | 1 |
| Derakhshan, F | 1 |
| Zali, MR | 1 |
| Agudo, S | 1 |
| Cibrelus, L | 1 |
| Martínez, MJ | 5 |
| López-Brea, M | 7 |
| Alvarez, A | 2 |
| Moncayo, JI | 2 |
| Santacruz, JJ | 2 |
| Santacoloma, M | 1 |
| Corredor, LF | 2 |
| Reinosa, E | 2 |
| Soto, A | 1 |
| García, A | 1 |
| González, CL | 1 |
| Taneike, I | 3 |
| Nami, A | 2 |
| O'Connor, A | 2 |
| Fitzgerald, N | 2 |
| Murphy, P | 2 |
| Qasim, A | 3 |
| O'Connor, H | 2 |
| Moreno-Otero, R | 2 |
| Katelaris, PH | 4 |
| Rasinah, WZ | 1 |
| Zaili, Z | 1 |
| Aminuddin, A | 1 |
| Kandulski, A | 1 |
| Saleem, A | 1 |
| Singh, V | 1 |
| Mishra, S | 1 |
| Maurya, P | 1 |
| Rao, G | 1 |
| Jain, AK | 1 |
| Dixit, VK | 1 |
| Gulati, AK | 1 |
| Nath, G | 1 |
| Seck, A | 2 |
| Mbengue, M | 2 |
| Gassama-Sow, A | 1 |
| Diouf, L | 1 |
| Ka, MM | 1 |
| Boye, CS | 1 |
| Luther, J | 1 |
| Higgins, PD | 1 |
| Schoenfeld, PS | 1 |
| Tajik, A | 1 |
| Choe, YH | 3 |
| Chung, IS | 1 |
| Ma, J | 1 |
| Pan, K | 1 |
| Winawer, S | 1 |
| Zauber, A | 1 |
| You, W | 1 |
| Wenzhen, Y | 1 |
| Kehu, Y | 1 |
| Bin, M | 1 |
| Yumin, L | 1 |
| Quanlin, G | 1 |
| Donghai, W | 1 |
| Lijuan, Y | 1 |
| Sirimontaporn, N | 1 |
| Thong-Ngam, D | 2 |
| Tumwasorn, S | 2 |
| Martínez, JW | 1 |
| Beltrán, L | 1 |
| Pontone, S | 1 |
| Standoli, M | 1 |
| Angelini, R | 1 |
| Pontone, P | 1 |
| Gen, R | 2 |
| Demir, M | 3 |
| Perez-Gallardo, B | 2 |
| Hernandez-Alonso, M | 2 |
| Dueñas, C | 1 |
| Mateos-Rodriguez, JM | 2 |
| Gonzalez-Garcia, G | 2 |
| Abadia, EG | 1 |
| Zevit, N | 1 |
| Levy, I | 1 |
| Lee, BH | 2 |
| Hwang, TJ | 1 |
| Kivistö, R | 1 |
| Linros, J | 1 |
| Rossi, M | 1 |
| Hänninen, ML | 2 |
| Hassan, C | 4 |
| Ryan, B | 1 |
| Gawrońska-Szklarz, B | 1 |
| Siuda, A | 1 |
| Kurzawski, M | 1 |
| Bielicki, D | 1 |
| Marlicz, W | 1 |
| Droździk, M | 1 |
| Cetinkaya, ZA | 1 |
| Sezikli, M | 1 |
| Güzelbulut, F | 1 |
| Coşgun, S | 1 |
| Düzgün, S | 1 |
| Kurdaş, OO | 1 |
| Kwon, JH | 1 |
| Song, BJ | 1 |
| Göktürk, S | 1 |
| Oztürk, NA | 1 |
| Serin, E | 2 |
| Yilmaz, U | 2 |
| Tanih, NF | 2 |
| Okeleye, BI | 2 |
| Naidoo, N | 1 |
| Clarke, AM | 2 |
| Mkwetshana, N | 1 |
| Green, E | 1 |
| Ndip, LM | 3 |
| Ndip, RN | 4 |
| Kariuki, S | 2 |
| Devani, S | 1 |
| Siavoshi, F | 3 |
| Saniee, P | 1 |
| Latifi-Navid, S | 1 |
| Massarrat, S | 10 |
| Sheykholeslami, A | 1 |
| Koosirirat, C | 1 |
| Linpisarn, S | 1 |
| Changsom, D | 1 |
| Chawansuntati, K | 1 |
| Wipasa, J | 1 |
| Perna, F | 4 |
| D'Ercole, C | 1 |
| Del Carmen Martino-Cardona, M | 1 |
| Beck, SE | 1 |
| Brayton, C | 1 |
| Watson, J | 1 |
| Lee, PI | 2 |
| Hsueh, PR | 1 |
| Ben Mansour, K | 1 |
| Zribi, M | 1 |
| Masmoudi, A | 1 |
| Karoui, S | 1 |
| Kallel, L | 1 |
| Chouaib, S | 1 |
| Matri, S | 1 |
| Fekih, M | 1 |
| Zarrouk, S | 1 |
| Labbene, M | 1 |
| Boubaker, J | 1 |
| Cheikh, I | 1 |
| Hriz, MB | 1 |
| Siala, N | 1 |
| Ayadi, A | 1 |
| Filali, A | 1 |
| Mami, NB | 1 |
| Najjar, T | 1 |
| Maherzi, A | 1 |
| Sfar, MT | 1 |
| Fendri, C | 2 |
| Koizumi, W | 2 |
| Tanabe, S | 2 |
| Nakatani, K | 1 |
| Ishido, K | 1 |
| Nishimura, K | 1 |
| Azuma, M | 1 |
| Ae, T | 1 |
| Sasaki, T | 1 |
| Higuchi, K | 1 |
| Katada, C | 1 |
| Nakayama, N | 1 |
| Saigenji, K | 2 |
| Zheng, Q | 4 |
| Chen, WJ | 1 |
| Sun, QJ | 2 |
| Xiao, SD | 7 |
| Yakut, M | 1 |
| Çinar, K | 1 |
| Seven, G | 1 |
| Bahar, K | 1 |
| Özden, A | 2 |
| Kupčinskas, J | 2 |
| Kiudelis, G | 2 |
| Gu, WQ | 1 |
| Liu, WZ | 3 |
| Tanaka, A | 3 |
| Takahashi, Si | 1 |
| Riahizadeh, S | 1 |
| Malekzadeh, R | 6 |
| Agah, S | 3 |
| Zendehdel, N | 2 |
| Sotoudehmanesh, R | 3 |
| Ebrahimi-Dariani, N | 3 |
| Pourshams, A | 2 |
| Vahedi, H | 5 |
| Mikaeli, J | 2 |
| Khatibian, M | 3 |
| Mobarez, AM | 1 |
| Taghvaei, T | 1 |
| Wolfram, L | 1 |
| Smith, PT | 1 |
| Berning, M | 1 |
| Krasz, S | 1 |
| Labenz, J | 14 |
| Miehlke, S | 6 |
| Khoshnegah, J | 1 |
| Jamshidi, S | 1 |
| Mohammadi, M | 1 |
| Sasani, F | 1 |
| Strona, S | 1 |
| Nadir, I | 1 |
| Yonem, O | 1 |
| Ozin, Y | 1 |
| Kilic, ZM | 1 |
| Sezgin, O | 4 |
| Lochmannová, J | 1 |
| Allam, MA | 1 |
| El-Shafie, AM | 1 |
| Elwan, AM | 1 |
| Soliman, GM | 1 |
| Abu-Alfotuh, A | 1 |
| Al Shabrawi, H | 1 |
| Wang, G | 2 |
| Lo, LF | 1 |
| Maier, RJ | 2 |
| Ayala, G | 1 |
| Galván-Portillo, M | 1 |
| Chihu, L | 1 |
| Fierros, G | 1 |
| Sánchez, A | 1 |
| Carrillo, B | 1 |
| Román, A | 1 |
| López-Carrillo, L | 1 |
| Silva-Sánchez, J | 1 |
| Celiñski, K | 1 |
| Giguère, M | 1 |
| Rivière, M | 1 |
| Kamoshida, T | 1 |
| Furukawa, K | 1 |
| Inaba, T | 1 |
| Tomita, T | 1 |
| Shirai, T | 3 |
| Ishii, N | 1 |
| Nomura, H | 1 |
| Konda, Y | 1 |
| Mehrabadi, JF | 1 |
| Sirous, M | 1 |
| Daryani, NE | 1 |
| Eshraghi, S | 1 |
| Akbari, B | 1 |
| Shirazi, MH | 1 |
| Buonavolontà, R | 1 |
| Russo, D | 1 |
| Vecchione, R | 1 |
| Staiano, A | 1 |
| Schwarzer, A | 1 |
| Martínez-Gómez, MZ | 1 |
| Roma-Giannikou, E | 2 |
| Liptay, S | 1 |
| Bontem, P | 1 |
| Buderus, S | 2 |
| Wenzl, TG | 1 |
| Bugdaci, MS | 1 |
| Zuhur, SS | 1 |
| Sokmen, M | 1 |
| Toksoy, B | 1 |
| Bayraktar, B | 1 |
| Albayrak, B | 1 |
| Altuntas, Y | 1 |
| Mahacahai, V | 1 |
| Kachintorn, U | 2 |
| Anacleto, TP | 1 |
| Lopes, LR | 1 |
| Andreollo, NA | 1 |
| Bernis Filho, WO | 1 |
| Resck, MC | 1 |
| Macedo, A | 1 |
| Dahlerup, JF | 1 |
| Eriksen, JR | 1 |
| Jarbøl, DE | 1 |
| Rosenstock, S | 1 |
| Wildt, S | 1 |
| Shcherbakov, PL | 2 |
| Belousova, NL | 2 |
| Shcherbakova, MIu | 2 |
| Kashnikov, VS | 2 |
| Kim, NY | 2 |
| Kim, HB | 1 |
| Toros, AB | 1 |
| Ince, AT | 1 |
| Kesici, B | 1 |
| Saglam, M | 1 |
| Polat, Z | 2 |
| Uygun, A | 7 |
| Hori, K | 1 |
| Miwa, H | 8 |
| Matsumoto, T | 2 |
| Navaratnam, P | 2 |
| Sato, R | 9 |
| Watanabe, K | 6 |
| Fujioka, T | 13 |
| Tamura, T | 2 |
| Kurata, M | 1 |
| Kondo, T | 1 |
| Goto, Y | 1 |
| Kamiya, Y | 1 |
| Kawai, S | 1 |
| Hamajima, N | 1 |
| Oderda, G | 2 |
| Muyshont, L | 1 |
| Miendje, DY | 1 |
| Raymond, J | 9 |
| Scaillon, M | 2 |
| Misselwitz, B | 1 |
| Kaiser, P | 1 |
| Bauerfeind, P | 3 |
| Vavricka, SR | 1 |
| Oh, TH | 1 |
| Farina, V | 1 |
| Cuccu, M | 1 |
| Mameli, L | 1 |
| Massarelli, G | 2 |
| Ramalho, PM | 1 |
| Lemos, PS | 1 |
| Paixão, E | 1 |
| Benoliel, J | 1 |
| Santos, A | 2 |
| Mazzoleni, LE | 1 |
| Francesconi, CF | 1 |
| Sander, GB | 1 |
| Bessong, PO | 1 |
| Jeong, JY | 3 |
| Karczewska, E | 2 |
| Wojtas-Bonior, I | 1 |
| Sito, E | 2 |
| Zwolińska-Wcisło, M | 2 |
| Budak, A | 1 |
| Davidkov, L | 1 |
| Spassova, Z | 2 |
| Kamburov, V | 1 |
| Katsarov, N | 1 |
| Bornschein, J | 1 |
| Oh, HS | 2 |
| Cho, YR | 1 |
| Cho, HJ | 1 |
| Lee, SK | 1 |
| Kwon, BS | 1 |
| Kim, YS | 2 |
| Yoon, JH | 1 |
| Kim, JB | 1 |
| Kim, DY | 1 |
| Min, HJ | 1 |
| Kim, KH | 1 |
| Ugajin, T | 1 |
| Miyatani, H | 1 |
| Matsumoto, S | 2 |
| Takamatsu, T | 1 |
| Fukunishi, M | 1 |
| Yoshida, Y | 7 |
| Dobashi, Y | 1 |
| Maev, IV | 1 |
| Samsonov, AA | 1 |
| Golubev, NN | 1 |
| Xia, W | 1 |
| Sun, C | 1 |
| Wu, L | 1 |
| Zhang, JZ | 1 |
| Geng, QM | 1 |
| Han, YJ | 1 |
| Park, HG | 1 |
| Jung, MK | 1 |
| Prechtl, J | 1 |
| Deutschmann, A | 1 |
| Savic, T | 1 |
| Jahnel, J | 1 |
| Bogiatzis, A | 1 |
| Muntean, W | 1 |
| Hauer, AC | 1 |
| Hoffmann, KM | 1 |
| Hirata, K | 2 |
| Saito, Y | 1 |
| Okada, S | 1 |
| Fukuhara, S | 1 |
| Korownyk, C | 1 |
| Kolber, MR | 1 |
| Slater, CM | 1 |
| Ford, AC | 1 |
| Loghmari, H | 1 |
| Bdioui, F | 1 |
| Bouhlel, W | 1 |
| Melki, W | 1 |
| Hellara, O | 1 |
| Safer, L | 1 |
| Zakhama, A | 1 |
| Saffar, H | 1 |
| Ianova, OB | 1 |
| Masharova, AA | 1 |
| Goncharenko, LS | 1 |
| Firsova, LD | 1 |
| Kim, VA | 1 |
| Govorun, VM | 1 |
| Kadayifci, A | 6 |
| Kilciler, G | 2 |
| Kantarcioglu, M | 2 |
| Kara, M | 1 |
| Ozcan, A | 2 |
| Emer, O | 2 |
| Hojsak, I | 1 |
| Kos, T | 1 |
| Dumančić, J | 1 |
| Jadrešin, O | 1 |
| Jaklin Kekez, A | 1 |
| Lukić Grlić, A | 1 |
| Kolaček, S | 2 |
| Huang, YK | 1 |
| Wang, SS | 2 |
| Wang, TH | 3 |
| McNulty, CA | 3 |
| Lasseter, G | 1 |
| Shaw, I | 1 |
| Nichols, T | 1 |
| D'Arcy, S | 1 |
| Lawson, AJ | 1 |
| Başer, O | 1 |
| Milani, M | 1 |
| Ghotaslou, R | 1 |
| Akhi, MT | 1 |
| Nahaei, MR | 1 |
| Hasani, A | 1 |
| Somi, MH | 1 |
| Rafeey, M | 1 |
| Sharifi, Y | 1 |
| Barenys, M | 1 |
| Lisozain, J | 1 |
| Calvo, MM | 1 |
| Torra, S | 1 |
| Park, JJ | 1 |
| Chun, HJ | 2 |
| Goswami, S | 1 |
| Bhakuni, RS | 1 |
| Chinniah, A | 1 |
| Pal, A | 1 |
| Kar, SK | 1 |
| Das, PK | 1 |
| Pazos-Pacheco, C | 1 |
| Vinagre-Rodriguez, G | 1 |
| Dueñas-Sadornil, C | 1 |
| Kudo, T | 2 |
| Fujinami, H | 1 |
| Nishikawa, J | 1 |
| Ogawa, K | 2 |
| Hosokawa, A | 1 |
| Orihara, T | 1 |
| Murakami, J | 1 |
| Takahara, T | 1 |
| Kongchayanun, C | 1 |
| Amornsawadwattana, S | 1 |
| Obonyo, M | 1 |
| Thamphiwatana, S | 1 |
| Pornpattananangkul, D | 1 |
| Fu, V | 1 |
| Moretti, E | 1 |
| Vaglio, L | 1 |
| Langone, F | 1 |
| Vernillo, R | 1 |
| Vindigni, C | 1 |
| Giordano, N | 1 |
| Hahm, KB | 1 |
| Shidfar, F | 1 |
| Ekhlasi, G | 1 |
| Salehpour, A | 1 |
| Ghourchian, S | 1 |
| Lisgos, P | 1 |
| Papantoniou, N | 1 |
| Salazar, CO | 1 |
| Cardenas, VM | 1 |
| Reddy, RK | 1 |
| Dominguez, DC | 1 |
| Snyder, LK | 1 |
| Hsieh, MC | 1 |
| Higashida, A | 1 |
| Mamori, S | 1 |
| Kuwada, T | 1 |
| Mitsuoka, T | 1 |
| Taki, M | 1 |
| Suga, Y | 1 |
| Senda, E | 1 |
| Ashida, C | 1 |
| Yamada, H | 1 |
| Rasmussen, L | 1 |
| Jørgensen, M | 1 |
| Urbonaviciene, N | 1 |
| Tamosiunas, V | 1 |
| Miciuleviciene, J | 1 |
| Kadusevicius, E | 1 |
| Berg, D | 2 |
| Andersen, LP | 6 |
| Larsen, AL | 1 |
| Ragnhildstveit, E | 5 |
| Eliassen, L | 1 |
| Sugizaki, K | 1 |
| Sakata, Y | 1 |
| Arai, T | 1 |
| Furuhata, Y | 1 |
| Iinuma, N | 1 |
| Ou, WJ | 1 |
| Pan, RF | 1 |
| Geng, LL | 1 |
| He, WE | 1 |
| Liu, LY | 1 |
| Hsu, SJ | 1 |
| Tseng, PH | 1 |
| Yang, UC | 1 |
| Ibrahimi, A | 1 |
| Shah, A | 1 |
| Javid, G | 1 |
| Zargar, SA | 1 |
| Teli, F | 1 |
| Khan, BA | 1 |
| Yattoo, GN | 1 |
| Gulzar, GM | 1 |
| Sodhi, JS | 1 |
| Khan, MA | 1 |
| Shoukat, A | 1 |
| Saif, R | 1 |
| Holton, J | 2 |
| Castelli, V | 2 |
| Zaccaro, C | 2 |
| Secka, O | 1 |
| Berg, DE | 13 |
| Antonio, M | 1 |
| Corrah, T | 1 |
| Tapgun, M | 1 |
| Walton, R | 1 |
| Thomas, V | 1 |
| Galano, JJ | 1 |
| Sancho, J | 1 |
| Adegbola, RA | 1 |
| Thomas, JE | 2 |
| Dia, D | 1 |
| Onambele, M | 1 |
| Breurec, S | 1 |
| Choi, C | 1 |
| Sun, Q | 1 |
| Guardiola, J | 3 |
| Andreu, V | 1 |
| Guirao, R | 2 |
| Isakov, V | 1 |
| Domareva, I | 1 |
| Koudryavtseva, L | 1 |
| Maev, I | 1 |
| Ganskaya, Z | 1 |
| Picot, S | 1 |
| Sapin, G | 1 |
| Michault, A | 1 |
| Faulques, B | 1 |
| Becquart, JP | 1 |
| Simac, C | 1 |
| Amat, C | 1 |
| Ancelin-Malbreil, E | 1 |
| Wallace, MR | 1 |
| Treiber, G | 5 |
| Ammon, S | 4 |
| Klotz, U | 4 |
| Glupczynski, Y | 2 |
| Broutet, N | 2 |
| Cantagrel, A | 1 |
| Boixeda, D | 17 |
| Martín-De-Argila, C | 1 |
| López-Sanromán, A | 1 |
| Defarges, V | 1 |
| Hernández-Ranz, F | 1 |
| Milicua, JM | 1 |
| García-Plaza, A | 1 |
| Kopański, Z | 1 |
| Piekoszewski, W | 1 |
| Schlegel-Zawadzka, M | 1 |
| Witkowska, B | 1 |
| Tabak, J | 1 |
| Puto, T | 1 |
| Trebacz, P | 1 |
| Szuszko, R | 1 |
| Koskenpato, J | 2 |
| Färkkilä, M | 5 |
| Bégué, RE | 1 |
| Gómez, R | 1 |
| Compton, T | 1 |
| Vargas, A | 1 |
| Sherwood, PV | 1 |
| Wibawa, JI | 1 |
| Atherton, JC | 2 |
| Jordan, N | 1 |
| Jenkins, D | 2 |
| Barrett, DA | 2 |
| Shaw, PN | 2 |
| Spiller, RC | 5 |
| Goebeler-Kolve, M | 1 |
| Starostik, P | 1 |
| Greiner, A | 3 |
| Müller-Hermelink, HK | 1 |
| Vasil'ev, IuV | 3 |
| Zvenigorodskaia, LA | 2 |
| Kolomiets, EV | 1 |
| Firsanova, VIu | 1 |
| Ivashkin, VT | 1 |
| Lapina, TL | 1 |
| Bondarenko, OY | 1 |
| Sklanskaya, OA | 1 |
| Grigoriev, PY | 1 |
| Vasiliev, YV | 1 |
| Yakovenko, EP | 1 |
| Gulyaev, PV | 1 |
| Fedchenko, VI | 1 |
| Rosandić, M | 2 |
| Pilas, V | 1 |
| Bevanda, M | 2 |
| Falisevac, V | 1 |
| Korać, B | 1 |
| Perez Aldana, L | 1 |
| Kawarasaki, M | 1 |
| Nagasako, T | 1 |
| Mizushima, T | 1 |
| Oda, H | 1 |
| Kodaira, J | 1 |
| Shimizu, Y | 2 |
| Komatsu, Y | 2 |
| Zheng, R | 1 |
| Takeda, H | 2 |
| Chuang, CH | 2 |
| Huang, AH | 3 |
| Buckley, M | 2 |
| Gilvarry, J | 3 |
| Ling, TK | 11 |
| Lee, CC | 2 |
| Ng, EK | 4 |
| Yung, MY | 6 |
| Chung, SS | 2 |
| Sung, JJ | 14 |
| Cheng, AF | 9 |
| Garza-González, E | 1 |
| Pérez-Pérez, GI | 1 |
| Alanís-Aguilar, O | 1 |
| Tijerina-Menchaca, R | 1 |
| Maldonado-Garza, HJ | 1 |
| Bosques-Padilla, FJ | 1 |
| Halle, ZB | 1 |
| Strinić, D | 1 |
| Kućisec, N | 1 |
| Jandrić, D | 1 |
| Bilić, A | 1 |
| Cui, M | 1 |
| Hu, F | 1 |
| Jiang, H | 1 |
| Mantzaris, GJ | 2 |
| Archavlis, E | 1 |
| Amberiadis, P | 1 |
| Christoforidis, P | 1 |
| Kourtessas, D | 1 |
| Chiotakakou, E | 1 |
| Triantafyllou, G | 1 |
| Hung, WK | 1 |
| Wong, WM | 10 |
| Wong, GS | 1 |
| Yip, AW | 1 |
| Szeto, ML | 1 |
| Lai, KC | 14 |
| Chan, CK | 8 |
| Xia, HH | 6 |
| Yuen, MF | 4 |
| Fung, FM | 7 |
| Tong, TS | 3 |
| Ho, VY | 2 |
| Lam, SK | 16 |
| Wong, BC | 17 |
| Rai, R | 1 |
| Rai, S | 1 |
| Nasu, M | 6 |
| Kagawa, J | 2 |
| Vakhrushev, IaM | 1 |
| Kniazeva, BG | 1 |
| Schuster, MJ | 1 |
| Farup, PG | 2 |
| Tholfsen, J | 1 |
| Wetternus, S | 1 |
| Torp, R | 2 |
| Høie, O | 2 |
| Lange, OJ | 1 |
| Olafsson, S | 3 |
| Hatlebakk, JG | 5 |
| Berstad, A | 12 |
| Borody, T | 1 |
| Farley, A | 3 |
| Dallaire, C | 2 |
| Schuman, R | 1 |
| Piotrowski, J | 1 |
| Tytgat, G | 2 |
| Spénard, J | 4 |
| Loughlin, MF | 1 |
| Ala'Aldeen, DA | 1 |
| Jenks, PJ | 7 |
| Toro, C | 2 |
| García-Samaniego, J | 2 |
| Baquero, M | 2 |
| Rozynek, E | 3 |
| Celińska-Cedro, D | 4 |
| Jóźwiak, P | 2 |
| Madaliński, K | 1 |
| Crone, J | 2 |
| Granditsch, G | 1 |
| Huber, WD | 1 |
| Binder, C | 1 |
| Innerhofer, A | 1 |
| Amann, G | 1 |
| Urakami, Y | 3 |
| Sano, T | 3 |
| Lau, CS | 1 |
| Ip, WY | 1 |
| Hui, WM | 4 |
| Wong, RW | 1 |
| Marais, A | 1 |
| Bilardi, C | 4 |
| Cantet, F | 1 |
| Laine, L | 8 |
| Hunt, R | 2 |
| El-Zimaity, H | 1 |
| Nguyen, B | 3 |
| Osato, M | 3 |
| Chisholm, SA | 2 |
| Owen, RJ | 6 |
| Dupas, JL | 1 |
| Bruley des Varannes, S | 1 |
| Bereswill, S | 1 |
| Krainick, C | 1 |
| Stähler, F | 1 |
| Herrmann, L | 1 |
| Kist, M | 3 |
| Wada, S | 1 |
| Matsuda, M | 1 |
| Shingaki, M | 2 |
| Kai, A | 1 |
| Itoh, T | 2 |
| Kirchner, T | 3 |
| Leodolter, A | 2 |
| Peitz, U | 7 |
| Strobel, S | 2 |
| Bohuschke, M | 1 |
| Gatz, G | 2 |
| Azagra, R | 1 |
| Sato, N | 9 |
| Abbas, SZ | 1 |
| Abbas, AB | 1 |
| Crawshaw, A | 1 |
| Shaw, S | 1 |
| English, J | 1 |
| McGovern, D | 1 |
| Vivian, G | 1 |
| Dalton, HR | 1 |
| Veldhuyzen Van Zanten, S | 7 |
| Machado, S | 1 |
| Unge, P | 6 |
| Kimura, K | 8 |
| Ekström, P | 1 |
| Satoh, K | 7 |
| Hellblom, M | 3 |
| Ohlin, B | 1 |
| Stubberöd, A | 2 |
| Kihira, K | 6 |
| Yube, T | 1 |
| van Zanten, SJ | 3 |
| Kolesnikow, T | 1 |
| Leung, V | 1 |
| O'Rourke, JL | 1 |
| Nash, C | 1 |
| Isomoto, H | 2 |
| Inoue, K | 7 |
| Furusu, H | 1 |
| Enjoji, A | 1 |
| Fujimoto, C | 1 |
| Yamakawa, M | 1 |
| Hirakata, Y | 1 |
| Omagari, K | 1 |
| Mizuta, Y | 1 |
| Murase, K | 1 |
| Shimada, S | 1 |
| Murata, I | 1 |
| Kohno, S | 2 |
| Orziev, ZM | 2 |
| Nurbaev, FE | 2 |
| Rakhimova, GSh | 2 |
| Rerksuppaphol, S | 1 |
| Hardikar, W | 1 |
| Midolo, PD | 2 |
| Ward, P | 1 |
| Prónai, L | 2 |
| Feldman, M | 2 |
| Fontham, E | 3 |
| Priest, E | 1 |
| Jain, R | 1 |
| Loffeld, RJ | 1 |
| Fijen, CA | 1 |
| Mirmomen, S | 1 |
| Mansour-Ghanaei, F | 1 |
| Noormohammadpoor, P | 1 |
| Sotodehmanesh, R | 1 |
| Haghpanah, B | 1 |
| Bahrami, H | 1 |
| Rukhliada, NV | 1 |
| Nazarov, VE | 1 |
| Ermolaev, IA | 1 |
| Bakumov, PA | 1 |
| Shchepotkin, IV | 1 |
| Dugina, YL | 1 |
| Epstein, OI | 1 |
| Sergeeva, SA | 1 |
| Marras, L | 2 |
| Maragkoudakis, E | 2 |
| Nieddu, S | 2 |
| Realdi, G | 4 |
| Kirsch, C | 4 |
| Schneider-Brachert, W | 5 |
| Haferland, C | 4 |
| Neumeyer, M | 2 |
| Bästlein, E | 5 |
| Papke, J | 1 |
| Jacobs, E | 2 |
| Stolte, M | 15 |
| Lehn, N | 6 |
| Bayerdörffer, E | 14 |
| de Boer, SY | 2 |
| v d Meeberg, PC | 1 |
| Siem, H | 1 |
| Hiyama, T | 1 |
| Tanaka, S | 1 |
| Masuda, H | 1 |
| Shima, H | 1 |
| Kose, K | 1 |
| Tuncel, H | 1 |
| Kitadai, Y | 1 |
| Sumii, M | 1 |
| Uemura, N | 3 |
| Yoshihara, M | 1 |
| Shimamoto, F | 1 |
| Haruma, K | 5 |
| Chayama, K | 1 |
| Gu, Q | 4 |
| Chan, AO | 4 |
| Hui, CK | 2 |
| McMahon, BJ | 2 |
| Hennessy, TW | 2 |
| Bensler, JM | 1 |
| Bruden, DL | 2 |
| Parkinson, AJ | 3 |
| Morris, JM | 1 |
| Reasonover, AL | 1 |
| Hurlburt, DA | 2 |
| Bruce, MG | 3 |
| Sacco, F | 2 |
| Butler, JC | 1 |
| Sjölund, M | 1 |
| Wreiber, K | 2 |
| Andersson, DI | 1 |
| Blaser, MJ | 2 |
| Engstrand, L | 5 |
| Lara, LF | 1 |
| Cisneros, G | 1 |
| Gurney, M | 1 |
| Van Ness, M | 1 |
| Jarjoura, D | 1 |
| Moauro, B | 1 |
| Polen, A | 1 |
| Rutecki, G | 1 |
| Whittier, F | 1 |
| Malaty, W | 1 |
| Stigleman, S | 1 |
| Hansen, LB | 1 |
| Lamouliatte, H | 1 |
| Bretagne, JF | 1 |
| Courillon-Mallet, A | 1 |
| De Korwin, JD | 1 |
| Fauchère, JL | 1 |
| Labigne, A | 6 |
| Fléjou, JF | 3 |
| Barthelemy, P | 2 |
| Ebert, S | 1 |
| Buchner, M | 2 |
| Perri, F | 2 |
| Festa, V | 2 |
| Merla, A | 1 |
| Barberani, F | 1 |
| Pilotto, A | 5 |
| Andriulli, A | 2 |
| Parente, F | 1 |
| Cucino, C | 1 |
| Bianchi Porro, G | 6 |
| Tampieri, A | 2 |
| Miglioli, M | 1 |
| Lui, SY | 1 |
| Yeoh, KG | 3 |
| Ho, B | 4 |
| Neuhann, HF | 1 |
| Swai, B | 1 |
| Carpenter, CF | 1 |
| Shao, O | 1 |
| Herszényi, L | 1 |
| Bochenek, WJ | 1 |
| Peters, S | 1 |
| Fraga, PD | 1 |
| Wang, W | 2 |
| Mack, ME | 1 |
| Osato, MS | 12 |
| El-Zimaity, HM | 11 |
| Davis, KD | 1 |
| Gambaro, C | 1 |
| Dulbecco, P | 2 |
| Iiritano, E | 1 |
| Zentilin, P | 3 |
| Mansia, C | 1 |
| Usai, P | 1 |
| Vigneri, S | 8 |
| Savarino, V | 10 |
| Thyagarajan, SP | 1 |
| Ray, P | 3 |
| Das, BK | 1 |
| Ayyagari, A | 1 |
| Khan, AA | 1 |
| Dharmalingam, S | 1 |
| Rao, UA | 1 |
| Rajasambandam, P | 1 |
| Ramathilagam, B | 1 |
| Bhasin, D | 1 |
| Sharma, MP | 4 |
| Naik, SR | 1 |
| Habibullah, CM | 1 |
| Goebeler-Kolve, ME | 1 |
| Dragosics, B | 4 |
| Vithayasai, N | 1 |
| Chen, JS | 2 |
| Zheng, TT | 1 |
| Feng, RE | 1 |
| Yuen, ST | 3 |
| Leung, SY | 2 |
| Fong, DY | 1 |
| Ho, J | 3 |
| Ching, CK | 5 |
| Vallejos, C | 2 |
| Cerda, O | 1 |
| Valenzuela, M | 1 |
| Toledo, H | 2 |
| Kamilova, AT | 1 |
| Pazylova, SA | 1 |
| Abdullaeva, DA | 1 |
| Abduzhbarova, ZM | 1 |
| Veldhuyzen Van Zanten, SJ | 6 |
| Escobedo, S | 2 |
| Grace, E | 2 |
| Sinclair, P | 3 |
| Barkun, A | 1 |
| Armstrong, D | 2 |
| Thomson, AB | 2 |
| Gumurdulu, Y | 1 |
| Ozer, B | 1 |
| Kayaselcuk, F | 1 |
| Ozsahin, K | 1 |
| Cosar, AM | 1 |
| Gursoy, M | 1 |
| Gur, G | 1 |
| Boyacioglu, S | 1 |
| Marmo, R | 1 |
| Cuomo, A | 1 |
| De Simone, T | 1 |
| Mucherino, C | 1 |
| Montella, F | 1 |
| Del Vecchio Blanco, C | 1 |
| Henriksen, TH | 1 |
| Lia, A | 1 |
| Schøyen, R | 1 |
| Thoresen, T | 1 |
| Berge, T | 5 |
| Tveten, Y | 1 |
| Sharma, VK | 3 |
| Kirika, NV | 1 |
| Bodrug, NI | 1 |
| Butorov, IV | 3 |
| Butorov, SI | 3 |
| Koivisto, TT | 2 |
| Rautelin, HI | 2 |
| Voutilainen, ME | 2 |
| Niemelä, SE | 1 |
| Heikkinen, M | 1 |
| Sipponen, PI | 1 |
| Färkkilä, MA | 2 |
| Sarna, S | 2 |
| Valtonen, V | 1 |
| Cameron, EAB | 1 |
| Powell, KU | 6 |
| Baldwin, L | 1 |
| Jones, P | 1 |
| Bell, GD | 14 |
| Williams, SGJ | 1 |
| Bhatia, V | 1 |
| Ahuja, V | 2 |
| Bal, C | 2 |
| Iijima, K | 3 |
| Sekine, H | 3 |
| Koike, T | 1 |
| Imatani, A | 1 |
| Ohara, S | 4 |
| Shimosegawa, T | 3 |
| Fraser, A | 1 |
| Kusters, JG | 5 |
| Wheeldon, TU | 1 |
| Phuncarg, DC | 1 |
| Nilsson, LE | 1 |
| Lane, E | 1 |
| Lobetti, R | 1 |
| Burroughs, R | 1 |
| Przondo-Mordarska, A | 1 |
| Grabińska, J | 1 |
| Shigeto, N | 1 |
| Shimizu, S | 1 |
| Belson, G | 2 |
| Abudayyeh, S | 1 |
| Wollner, T | 1 |
| Chen, XX | 1 |
| Ou, BY | 1 |
| Wu, XY | 1 |
| Zhou, XL | 1 |
| Tang, HF | 1 |
| Qü, YP | 1 |
| Shang, SQ | 1 |
| Farrell, S | 1 |
| Milliken, I | 1 |
| Doherty, GM | 1 |
| Murphy, JL | 1 |
| Wootton, SA | 1 |
| McCallion, WA | 1 |
| Nada, T | 1 |
| Nobata, K | 1 |
| Tsuzuki, T | 1 |
| Minami, M | 1 |
| Ina, K | 1 |
| Iinuma, Y | 1 |
| Ichiyama, S | 1 |
| Ohta, M | 1 |
| El-Omar, E | 5 |
| Kusugami, K | 1 |
| Goto, H | 1 |
| Ozturk, Y | 1 |
| Buyukgebiz, B | 1 |
| Ozer, E | 1 |
| Arslan, N | 1 |
| Bekem, O | 1 |
| Hizli, S | 1 |
| Altintaş, E | 3 |
| Ulu, O | 1 |
| Aydin, O | 1 |
| Camdeviren, H | 1 |
| Wang, JD | 1 |
| Cheung, HK | 1 |
| Liu, XG | 1 |
| Wallace, RA | 1 |
| Schluter, PJ | 1 |
| Webb, PM | 1 |
| Ito, H | 1 |
| Maruyama, M | 1 |
| Ogura, N | 1 |
| Iwasaki, Y | 1 |
| Aikawa, A | 1 |
| Hasegawa, A | 1 |
| Guslandi, M | 1 |
| Montserrat, A | 1 |
| Güell, M | 1 |
| Vergara, M | 2 |
| Park, SC | 1 |
| Keum, B | 1 |
| Han, WS | 1 |
| Choung, RS | 1 |
| Jeen, YT | 1 |
| Um, SH | 1 |
| Kim, CD | 1 |
| Ryu, HS | 1 |
| Hyun, JH | 1 |
| Janssen, MJ | 1 |
| Laheij, RJ | 1 |
| Jansen, JB | 3 |
| Sherif, M | 1 |
| Mohran, Z | 1 |
| Fathy, H | 1 |
| Rockabrand, DM | 1 |
| Rozmajzl, PJ | 1 |
| Frenck, RW | 1 |
| Nahar, S | 1 |
| Mukhopadhyay, AK | 4 |
| Khan, R | 1 |
| Ahmad, MM | 2 |
| Datta, S | 3 |
| Chattopadhyay, S | 2 |
| Dhar, SC | 1 |
| Sarker, SA | 1 |
| Nair, GB | 3 |
| Rahman, M | 1 |
| Ahmed, D | 1 |
| Brooks, H | 1 |
| McConnell, M | 1 |
| Barbezat, G | 1 |
| Sherman, PM | 2 |
| Manes, G | 1 |
| Balzano, A | 1 |
| Gerrits, MM | 1 |
| van der Wouden, EJ | 5 |
| Bax, DA | 1 |
| van Zwet, AA | 9 |
| van Vliet, AH | 1 |
| de Jong, A | 2 |
| Thijs, JC | 10 |
| Maciorkowska, E | 1 |
| Kaczmarski, M | 1 |
| Kowalczuk, J | 1 |
| Kondej-Muszyńska, K | 1 |
| Roszko, I | 1 |
| Cieśla, J | 1 |
| Zielińska, A | 1 |
| Musaibili, S | 1 |
| Gomollón, F | 7 |
| Santolaria, S | 1 |
| Sicilia, B | 3 |
| Ferrero, M | 3 |
| Revillo, MJ | 2 |
| Villar, M | 2 |
| Celaya, MC | 1 |
| Branca, G | 1 |
| Spanu, T | 1 |
| Cammarota, G | 3 |
| Schito, AM | 1 |
| Gasbarrini, GB | 1 |
| Fadda, G | 1 |
| Fukushi, M | 2 |
| Munakata, A | 2 |
| Konno, M | 3 |
| Maisawa, S | 2 |
| Tajiri, H | 1 |
| Yoshimura, N | 1 |
| Shimizu, T | 5 |
| Toyoda, S | 1 |
| Nakayama, Y | 2 |
| Iinuma, K | 2 |
| van Zanten, S | 1 |
| Dickason, J | 1 |
| Kato, A | 1 |
| Kato, H | 1 |
| Hirashima, N | 1 |
| Sakamoto, T | 1 |
| Nukaya, H | 1 |
| Ito, K | 2 |
| Matsunaga, S | 1 |
| Kondo, H | 1 |
| Tanaka, Y | 1 |
| Sakakibara, K | 1 |
| Kawabe, M | 1 |
| Kurosawa, A | 3 |
| Terai, T | 1 |
| Miyazaki, A | 2 |
| De Paoli, P | 1 |
| Tomasini, ML | 1 |
| Basaglia, G | 1 |
| Elizalde, JI | 1 |
| Pérez-Pujol, S | 1 |
| Heras, M | 1 |
| Sionis, A | 1 |
| Casanovas, N | 1 |
| Martorell, T | 1 |
| Lozano, M | 1 |
| González, J | 1 |
| Escolar, G | 1 |
| Sanz, G | 1 |
| Piqué, JM | 2 |
| Gunaid, AA | 1 |
| Hassan, NA | 1 |
| Murray-Lyon, IM | 1 |
| Hu, PJ | 2 |
| Huang, JQ | 1 |
| Wu, SM | 1 |
| Chen, MH | 1 |
| Cui, Y | 1 |
| Malfatti, F | 3 |
| Giannini, E | 2 |
| Emanuela, T | 1 |
| Polegato, S | 2 |
| Podestà, E | 1 |
| Fumagalli, A | 2 |
| Cotelessa, T | 1 |
| Chiarbonello, B | 2 |
| Bellotti, M | 1 |
| Botta, F | 3 |
| Milazzo, S | 1 |
| Testa, R | 3 |
| Schuster, M | 1 |
| Opekun, AR | 3 |
| Carlson, MR | 1 |
| Marko, D | 1 |
| Nørgaard, M | 1 |
| Ratanajamit, C | 1 |
| Jacobsen, J | 1 |
| Skriver, MV | 1 |
| Pedersen, L | 1 |
| Sørensen, HT | 1 |
| Johansen, JK | 1 |
| Sehested, A | 1 |
| Myrhøj, T | 1 |
| Ladefoged, K | 1 |
| Krogfelt, KA | 2 |
| Chang, FY | 3 |
| Lu, CL | 1 |
| Lu, RH | 1 |
| Lee, SD | 4 |
| Oona, M | 1 |
| Rägo, T | 1 |
| Maaroos, HI | 1 |
| Saad, R | 1 |
| Tanabe, M | 1 |
| Hu, YY | 1 |
| Zhou, ZF | 1 |
| Nan, Q | 1 |
| Jiang, HY | 1 |
| Li, XY | 1 |
| Duan, LP | 1 |
| Chen, YR | 1 |
| Heikkinen, MT | 1 |
| Koskenpato, JP | 1 |
| Khedmat, H | 1 |
| Yari, F | 1 |
| Lee, MG | 1 |
| Arthurs, M | 1 |
| Smikle, MF | 1 |
| Dowe, G | 1 |
| Levy, V | 1 |
| Barton, EN | 1 |
| Yuen, B | 1 |
| Zbinden, R | 1 |
| Fried, M | 1 |
| Bernardi, M | 1 |
| Sun, WH | 1 |
| Ou, XL | 1 |
| Cao, DZ | 1 |
| Yu, Q | 1 |
| Yu, T | 1 |
| Hu, JM | 1 |
| Zhu, F | 1 |
| Sun, YL | 1 |
| Fu, XL | 1 |
| Su, H | 1 |
| Köksal, AS | 1 |
| Parlak, E | 1 |
| Filik, L | 1 |
| Yolcu, OF | 1 |
| Odemiş, B | 1 |
| Ulker, A | 1 |
| Saşmaz, N | 1 |
| Sahin, B | 1 |
| Rodríguez-Torres, M | 1 |
| Salgado-Mercado, R | 1 |
| Ríos-Bedoya, CF | 1 |
| Aponte-Rivera, E | 1 |
| Marxuach-Cuétara, AM | 1 |
| Rodríguez-Orengo, JF | 1 |
| Fernández-Carbia, A | 1 |
| Tonkić, M | 2 |
| Barisić, IG | 1 |
| Jukić, I | 2 |
| Mise, S | 1 |
| Zhang, ST | 2 |
| Yu, ZL | 2 |
| Wang, YS | 1 |
| Faber, J | 1 |
| Bar-Meir, M | 1 |
| Rudensky, B | 1 |
| Schlesinger, Y | 1 |
| Rachman, E | 1 |
| Benenson, S | 1 |
| Sirota, G | 1 |
| Stankiewic, H | 1 |
| Halle, D | 1 |
| Wilschanski, M | 1 |
| Fuentes, J | 3 |
| Carpio, D | 2 |
| Tomas, A | 1 |
| Olivares, D | 3 |
| Elviss, NC | 2 |
| Breathnach, A | 1 |
| Palmer, C | 1 |
| Shetty, N | 1 |
| Pyo, JH | 1 |
| Kwon, DH | 7 |
| Rhee, JC | 1 |
| Lengyel, G | 1 |
| Zsolt, T | 1 |
| Cheung, KL | 1 |
| Bernabucci, V | 1 |
| Cavina, M | 1 |
| Morini, S | 3 |
| Patra, R | 1 |
| De, R | 1 |
| Hembram, J | 1 |
| Chowdhury, A | 2 |
| Bhattacharya, SK | 2 |
| Van den Bulck, K | 1 |
| Decostere, A | 1 |
| Gruntar, I | 1 |
| Baele, M | 1 |
| Krt, B | 1 |
| Ducatelle, R | 1 |
| Haesebrouck, F | 1 |
| Khurana, R | 1 |
| Miki, I | 1 |
| Aoyama, N | 2 |
| Shirasaka, D | 1 |
| Watanabe, Y | 1 |
| Morita, Y | 1 |
| Toyoda, M | 1 |
| Mitani, T | 1 |
| Miyachi, H | 1 |
| Kasuga, M | 2 |
| Giannini, EG | 1 |
| Testa, E | 1 |
| Mamone, M | 1 |
| Dai, G | 1 |
| Cheng, N | 1 |
| Muramatsu, M | 1 |
| Wang, MW | 1 |
| Zhu, DX | 1 |
| Jury, J | 1 |
| Gee, LC | 1 |
| Delaney, KH | 1 |
| Perdue, MH | 1 |
| Bonner, RA | 1 |
| Pellegrini, M | 1 |
| Urso, R | 1 |
| Giorgi, G | 1 |
| Bayeli, PF | 1 |
| Marzocca, G | 1 |
| Cerretani, D | 1 |
| Salih, BA | 1 |
| Abasiyanik, MF | 1 |
| Saribasak, H | 1 |
| Huten, O | 1 |
| Sander, E | 1 |
| Horvat, D | 2 |
| Vcev, A | 4 |
| Soldo, I | 1 |
| Timarac, J | 1 |
| Dmitrović, B | 4 |
| Misević, T | 1 |
| Ivezić, Z | 1 |
| Kraljik, N | 1 |
| Cheon, JH | 4 |
| Park, MJ | 1 |
| Jarosz, M | 2 |
| Pawłowska, J | 1 |
| Szadkowski, A | 1 |
| Budzyńska, A | 1 |
| Nowak, J | 1 |
| Romańczuk, W | 1 |
| Prosiecki, R | 1 |
| Bergeret, M | 7 |
| Dupont, C | 7 |
| Chen, LT | 4 |
| Tai, JJ | 1 |
| Chen, GH | 3 |
| Yang, SS | 1 |
| Kuo, SH | 1 |
| Wang, TE | 1 |
| Wu, CW | 1 |
| Su, IJ | 3 |
| Whang-Peng, J | 1 |
| Cheng, AL | 2 |
| Aumais, C | 1 |
| Massicotte, J | 1 |
| Brunet, JS | 1 |
| Tremblay, C | 1 |
| Grace, M | 1 |
| Lefebvre, M | 1 |
| Gessner, BD | 1 |
| Gold, BD | 1 |
| Muth, PT | 1 |
| Dunaway, E | 1 |
| Baggett, HC | 1 |
| Pan, Y | 1 |
| Borody, TJ | 7 |
| Tan, S | 1 |
| Fraley, CD | 1 |
| Zhang, M | 1 |
| Dailidiene, D | 2 |
| Kornberg, A | 1 |
| Francavilla, R | 1 |
| Lionetti, E | 1 |
| Castellaneta, SP | 1 |
| Magistà, AM | 1 |
| Boscarelli, G | 1 |
| Piscitelli, D | 1 |
| Amoruso, A | 1 |
| Miniello, VL | 1 |
| Francavilla, A | 1 |
| Cavallo, L | 1 |
| Olczak, AA | 1 |
| Albert, TJ | 1 |
| Dailide, G | 1 |
| Norton, JE | 1 |
| Kalia, A | 1 |
| Richmond, TA | 1 |
| Molla, M | 1 |
| Singh, J | 1 |
| Green, RD | 1 |
| Hu, FL | 2 |
| Imase, K | 1 |
| Yamamoto, T | 1 |
| Shirai, N | 2 |
| Nakamura, A | 1 |
| Sakagami, T | 2 |
| Kobayashi, K | 2 |
| Fujishiro, M | 1 |
| Omata, M | 2 |
| Oka, M | 1 |
| Hiratsuka, T | 1 |
| Tamura, K | 1 |
| Hiratsuka, H | 1 |
| Bray, R | 1 |
| Nakagawa, M | 1 |
| Tsukada, K | 1 |
| Katoh, H | 1 |
| Miyazaki, T | 2 |
| Kuwano, H | 1 |
| Hikichi, T | 1 |
| Irisawa, A | 1 |
| Abe, C | 1 |
| Obara, K | 1 |
| Sato, Y | 1 |
| Mrad, SM | 1 |
| Boukthir, S | 1 |
| Fdhila, F | 1 |
| Barsaoui, S | 1 |
| Chu, KM | 3 |
| Yee, YK | 1 |
| Antos, D | 2 |
| Hänel, C | 1 |
| Meier, E | 1 |
| Trump, F | 1 |
| Pironti, A | 1 |
| Tadeu, V | 1 |
| Tedde, R | 1 |
| Delitala, G | 1 |
| Matteo, MJ | 1 |
| Pérez, CV | 1 |
| Domingo, MR | 1 |
| Olmos, M | 1 |
| Sanchez, C | 1 |
| Catalano, M | 1 |
| Pang, G | 1 |
| Wettstein, AR | 1 |
| Clancy, R | 1 |
| Herdman, K | 1 |
| Surace, R | 1 |
| Llorente, R | 1 |
| Ng, C | 1 |
| Benito, LM | 1 |
| López-Rivas, L | 1 |
| Lamas, E | 1 |
| Pabón, M | 1 |
| Kurumada, T | 2 |
| Masui, A | 1 |
| Muraoka, H | 2 |
| Kobayashi, I | 3 |
| Abe, T | 1 |
| Sato, S | 1 |
| Arita, T | 1 |
| Onoda, N | 1 |
| Katsuragi, K | 1 |
| Sawada, T | 1 |
| Maeda, K | 4 |
| Mino, A | 1 |
| Ohira, M | 1 |
| Ishikawa, T | 1 |
| Wakasa, K | 1 |
| Hirakawa, K | 1 |
| Postavnyĭ, VE | 1 |
| Osoianu, IuP | 2 |
| Maksimov, VV | 2 |
| Saad, RJ | 1 |
| Schoenfeld, P | 1 |
| Kim, HM | 1 |
| Luna, M | 1 |
| Herrerías, JM | 1 |
| Monés, J | 1 |
| Sánchez-Pobre, P | 1 |
| Pajares, JM | 10 |
| Kerton, A | 1 |
| Warden, P | 1 |
| Richy, F | 1 |
| Monteiro, ML | 1 |
| Gottrand, F | 2 |
| Orderda, G | 1 |
| Martínez-Gómez, MJ | 1 |
| Ashorn, M | 2 |
| Bodanszky, H | 1 |
| Bahremand, S | 1 |
| Nematollahi, LR | 1 |
| Fourutan, H | 1 |
| Tirgari, F | 1 |
| Nouripour, S | 1 |
| Mir, E | 1 |
| Aghakhani, S | 1 |
| Lwai-Lume, L | 1 |
| Ogutu, EO | 1 |
| Amayo, EO | 1 |
| Kawamura, Y | 1 |
| Petersen, AM | 1 |
| Gjøde, P | 1 |
| Vinge, OD | 1 |
| Jensen, S | 1 |
| Díaz-Reganon, J | 1 |
| Domingo, D | 3 |
| Tran, TT | 1 |
| Quandalle, P | 1 |
| Díte, P | 3 |
| Kunovská, M | 1 |
| Pulgretová, D | 1 |
| Woznica, V | 1 |
| Petrtýl, J | 1 |
| Hůlek, P | 1 |
| Pásková, J | 1 |
| Dostalík, Z | 1 |
| Novotný, I | 1 |
| Procházka, V | 1 |
| Hegyi, P | 1 |
| Zelenková, J | 1 |
| Samek, M | 1 |
| Králová, Z | 1 |
| Vyhnálek, P | 1 |
| Matejovic, F | 1 |
| Weinberg, J | 1 |
| Kyzeková, J | 1 |
| Takahashi, T | 1 |
| Hatao, K | 1 |
| Yamada, K | 1 |
| Shen, L | 1 |
| Lin, SR | 3 |
| Uçbilek, E | 2 |
| Tataroğlu, C | 1 |
| Hansky, K | 1 |
| Morgner, A | 2 |
| Madisch, A | 2 |
| Kuhlisch, E | 2 |
| Mousavi, S | 1 |
| Toussy, J | 1 |
| Yaghmaie, S | 1 |
| Zahmatkesh, M | 1 |
| Arenz, T | 1 |
| Rüssmann, H | 1 |
| Alberer, M | 1 |
| Kappler, M | 1 |
| Sechopoulos, P | 1 |
| Pistiolas, D | 1 |
| Mirbagheri, SA | 1 |
| Hasibi, M | 1 |
| Abouzari, M | 1 |
| Rashidi, A | 1 |
| Miyajima, H | 1 |
| Ono, M | 1 |
| Otsu, S | 1 |
| Nista, EC | 1 |
| Candelli, M | 1 |
| Zocco, MA | 1 |
| Cremonini, F | 1 |
| Finizio, R | 1 |
| Spada, C | 1 |
| Goić-Barisić, I | 1 |
| Simunić, M | 1 |
| Punda-Polić, V | 1 |
| Wu, CJ | 1 |
| Lo, GH | 1 |
| Ziemniak, W | 1 |
| Dzieniszewski, J | 1 |
| Khayat, O | 1 |
| Kilani, A | 1 |
| Chedly-Debbiche, A | 1 |
| Zeddini, A | 1 |
| Gargouri, D | 1 |
| Kharrat, J | 1 |
| Souissi, A | 1 |
| Ghorbel, AJ | 1 |
| Ben Ayed, M | 1 |
| Ben Khelifa, H | 1 |
| Choi, YS | 1 |
| John Albert, M | 1 |
| Al-Mekhaizeem, K | 1 |
| Neil, L | 1 |
| Dhar, R | 1 |
| Dhar, PM | 1 |
| Al-Ali, M | 1 |
| Al-Abkal, HM | 1 |
| Haridas, S | 1 |
| Safari, F | 1 |
| Doratotaj, D | 1 |
| Khatami, GR | 1 |
| Fallahi, GH | 2 |
| Mirnaseri, MM | 1 |
| Sancar, M | 1 |
| Izzettin, FV | 1 |
| Apikoglu-Rabus, S | 1 |
| Besisik, F | 1 |
| Tozun, N | 1 |
| Dulger, G | 1 |
| Emami, MH | 1 |
| Saberfiroozi, MM | 1 |
| Arj, A | 1 |
| Taghavi, AR | 1 |
| Bagheri-Lankarani, K | 1 |
| Dehbashi, N | 2 |
| Fattahi, MR | 1 |
| Alizadeh, M | 1 |
| Kaviani, MJ | 2 |
| Bahri-Najafi, R | 1 |
| Geramizadeh, B | 1 |
| Esmaeili, A | 1 |
| Evans, CT | 1 |
| Passaro, DJ | 2 |
| Dinari, G | 2 |
| Paoluzi, P | 1 |
| Iacopini, F | 1 |
| Crispino, P | 1 |
| Nardi, F | 1 |
| Bella, A | 1 |
| Rivera, M | 1 |
| Rossi, P | 1 |
| Gurnari, M | 1 |
| Caracciolo, F | 1 |
| Zippi, M | 1 |
| Pica, R | 1 |
| Reasonover, A | 1 |
| Morris, J | 1 |
| Peters, H | 1 |
| Martinez, P | 1 |
| Swenson, M | 1 |
| Parks, D | 1 |
| Kast, RE | 1 |
| Park, HY | 1 |
| Kim, KM | 1 |
| Tanaka, M | 1 |
| Nakasato, F | 1 |
| Tsai, SH | 1 |
| Chu, SJ | 1 |
| Wu, CP | 1 |
| Maleknejad, S | 1 |
| Khan, S | 1 |
| Sharrack, B | 1 |
| Sewell, WA | 1 |
| Khalil, T | 1 |
| Dorchy, H | 1 |
| Melot, C | 1 |
| Ajvadi, Y | 1 |
| Nasseri-Moghaddam, S | 1 |
| Ali-Asgari, A | 1 |
| Ishak, RA | 1 |
| Awad, GA | 1 |
| Mortada, ND | 1 |
| Nour, SA | 1 |
| Wu, CC | 1 |
| Lin, CY | 2 |
| Cheng, CC | 1 |
| Su, SC | 1 |
| Tseng, YH | 1 |
| Li, AQ | 1 |
| Dai, N | 1 |
| Zhu, YL | 1 |
| Garrido, L | 1 |
| Cáceres, D | 1 |
| Madrid, AM | 1 |
| Defilippi, C | 2 |
| Saracino, I | 1 |
| Ozel, AM | 1 |
| Yildiz, O | 1 |
| Aslan, M | 1 |
| Yesilova, Z | 2 |
| Erdil, A | 2 |
| Bagci, S | 2 |
| Gunhan, O | 1 |
| Ikuma, M | 1 |
| Kajimura, M | 1 |
| Ohashi, K | 1 |
| Ishizaki, T | 1 |
| Hishida, A | 1 |
| Ersoy, O | 1 |
| Ersoy, R | 1 |
| Yayar, O | 1 |
| Tatlican, S | 1 |
| Jung, SH | 1 |
| Navarro-Jarabo, JM | 1 |
| Sousa, FL | 1 |
| Cabrera, E | 1 |
| Ramírez, LM | 1 |
| Rivera, R | 1 |
| Ubiña, E | 1 |
| Vera, F | 1 |
| Méndez, I | 1 |
| Rivas-Ruiz, F | 1 |
| Moreno, JL | 1 |
| Perea-Milla, E | 1 |
| Li, XB | 1 |
| Ge, ZZ | 1 |
| Chen, XY | 1 |
| Serhal, L | 2 |
| Asmar, E | 1 |
| Campeotto, F | 1 |
| Dehecq, E | 1 |
| Spyckerelle, C | 2 |
| Charkaluk, ML | 1 |
| Decoster, A | 1 |
| Jakobsson, H | 1 |
| Fall, K | 1 |
| Fjelstad, B | 1 |
| Nyrén, O | 1 |
| Kubben, FJ | 1 |
| Sier, CF | 1 |
| Schram, MT | 1 |
| Witte, AM | 1 |
| van Duijn, W | 1 |
| Verheijen, JH | 1 |
| Hanemaaijer, R | 1 |
| Lamers, CB | 3 |
| Verspaget, HW | 2 |
| Chen, LH | 1 |
| Luo, HS | 1 |
| Fuccio, L | 1 |
| Minardi, ME | 1 |
| Grilli, D | 1 |
| Magrini, N | 1 |
| Azuma, T | 3 |
| Katsuyama, T | 4 |
| Safali, M | 2 |
| Ilgan, S | 2 |
| Fariña, N | 1 |
| Kasamatsu, E | 1 |
| Samudio, M | 1 |
| Morán, M | 1 |
| Sanabria, R | 1 |
| Laspina, F | 1 |
| Jimenez-Alonso, I | 1 |
| Kang, JM | 1 |
| Kim, YR | 1 |
| Nayir, E | 1 |
| Yan, WH | 2 |
| Hu, HJ | 2 |
| Yu, JD | 1 |
| Huang, XL | 1 |
| Gigliotti, F | 1 |
| Lee, VW | 1 |
| Chan, FK | 6 |
| Bang, SY | 1 |
| Han, DS | 1 |
| Eun, CS | 1 |
| Kim, JE | 1 |
| Ahn, SB | 1 |
| Sohn, JH | 1 |
| Jeon, YC | 1 |
| Kang, JO | 1 |
| Jebens, C | 1 |
| Zekorn, C | 1 |
| Knoth, H | 1 |
| Zhang, XP | 1 |
| Ogura, K | 1 |
| Yanai, A | 1 |
| Shibata, W | 1 |
| Ohmae, T | 1 |
| Mitsuno, Y | 1 |
| Watabe, H | 1 |
| Yamaji, Y | 1 |
| Okamoto, M | 1 |
| Yoshida, H | 1 |
| Kawabe, T | 1 |
| Camargo, MC | 1 |
| Piazuelo, MB | 1 |
| Mera, RM | 1 |
| Fontham, ET | 2 |
| Delgado, AG | 1 |
| Yepez, MC | 1 |
| Ceron, C | 1 |
| Buzás, GM | 1 |
| Széles, I | 2 |
| Malange Takang, AE | 1 |
| Ojongokpoko, JE | 1 |
| Luma, HN | 1 |
| Malongue, A | 1 |
| Akoachere, JF | 1 |
| MacMillan, M | 1 |
| Weaver, LT | 1 |
| Karaeren, N | 2 |
| Hansen, JM | 1 |
| Wildner-Christensen, M | 1 |
| Hallas, J | 1 |
| Schaffalitzky de Muckadell, OB | 1 |
| Yadav, MK | 1 |
| Rishi, JP | 1 |
| Nijawan, S | 1 |
| Baker, DE | 1 |
| Russell, RJ | 1 |
| Haines, DC | 1 |
| Anver, MR | 1 |
| Battles, JK | 1 |
| Gorelick, PL | 1 |
| Blumenauer, LL | 1 |
| Gonda, MA | 1 |
| Ward, JM | 1 |
| Andrews, P | 5 |
| Fracchia, G | 1 |
| Brandl, S | 4 |
| Shortis, NP | 1 |
| Bae, H | 1 |
| Xia, HY | 1 |
| Keane, CT | 7 |
| Vila, T | 2 |
| de Rafael, L | 6 |
| Alvarez Baleriola, I | 5 |
| Martín de Argila, C | 13 |
| García Plaza, A | 8 |
| Tillenburg, B | 7 |
| Köhl, H | 2 |
| Becker, T | 6 |
| Börsch, G | 12 |
| Domschke, W | 2 |
| Dettmer, A | 1 |
| Fenner, T | 1 |
| Gregor, M | 1 |
| Hesse, P | 1 |
| Holtmann, G | 2 |
| van Husen, N | 1 |
| Miederer, SE | 1 |
| Schentke, KU | 1 |
| Schütz, E | 1 |
| Schepp, W | 1 |
| Wilson, WH | 1 |
| Moore, RA | 1 |
| Beckthold, B | 1 |
| Bryan, LE | 1 |
| Hoffenberg, P | 1 |
| Reyes, V | 1 |
| Contreras, L | 1 |
| Giglio, M | 1 |
| Ossa, P | 1 |
| Weitz, JC | 1 |
| Folwaczny, C | 1 |
| Foltz, CJ | 2 |
| Fox, JG | 5 |
| Yan, L | 4 |
| Shames, B | 4 |
| Berstad, K | 8 |
| Wilhelmsen, I | 5 |
| Nesje, LB | 3 |
| Hausken, T | 4 |
| Yousfi, MM | 3 |
| al-Assi, MT | 1 |
| Cole, RA | 3 |
| Genta, RM | 8 |
| Blum, AL | 2 |
| Kreiss, C | 1 |
| Elta, GH | 4 |
| Scheiman, JM | 4 |
| Barnett, JL | 2 |
| Nostrant, TT | 1 |
| Behler, EM | 2 |
| Crause, I | 2 |
| Appelman, HD | 1 |
| Pikkarainen, P | 1 |
| Kivilaakso, E | 1 |
| Gormsen, MH | 1 |
| Moshkowitz, M | 4 |
| Konikoff, FM | 2 |
| Peled, Y | 4 |
| Santo, M | 3 |
| Hallak, A | 3 |
| Bujanover, Y | 2 |
| Tiomny, E | 4 |
| Gilat, T | 4 |
| Chong, SK | 1 |
| Lou, Q | 1 |
| Asnicar, MA | 1 |
| Zimmerman, SE | 1 |
| Croffie, JM | 1 |
| Fitzgerald, JF | 1 |
| Tytgat, GN | 17 |
| Fennerty, MB | 5 |
| Xia, HX | 5 |
| Beattie, S | 8 |
| Hamilton, H | 3 |
| Sweeney, EC | 1 |
| Penman, ID | 1 |
| Ardill, JE | 4 |
| Chittajallu, RS | 3 |
| Howie, C | 1 |
| McColl, KE | 9 |
| Blecker, U | 1 |
| McKeithan, TW | 1 |
| Hart, J | 1 |
| Kirschner, BS | 1 |
| Saberi-Firoozi, M | 1 |
| Zare, S | 1 |
| Fattahi, M | 1 |
| Javan, A | 1 |
| Etaati, H | 1 |
| Leung, VK | 6 |
| Chung, SC | 11 |
| Suen, R | 5 |
| Li, AK | 6 |
| Ozmen, MM | 1 |
| Johnson, CD | 1 |
| Windle, HJ | 1 |
| Marshall, DG | 1 |
| Smyth, CJ | 1 |
| de Graaf, B | 1 |
| Lynch, DA | 3 |
| Mapstone, NP | 2 |
| Sobala, GM | 3 |
| Jackson, P | 1 |
| Morrison, L | 1 |
| Dixon, MF | 5 |
| Quirke, P | 1 |
| Axon, AT | 10 |
| Lazzaroni, M | 5 |
| Bargiggia, S | 4 |
| Minguzzi, M | 1 |
| Kanduru, C | 1 |
| Bhutta, AS | 2 |
| Meehan, JM | 1 |
| Feeley, KM | 1 |
| Cunnane, K | 3 |
| Wewer, V | 2 |
| Christiansen, KM | 1 |
| Henriksen, FW | 1 |
| Hansen, JP | 2 |
| Tvede, M | 1 |
| Krasilnikoff, PA | 2 |
| Park, KN | 1 |
| Hahm, JS | 1 |
| Cohen, MH | 1 |
| Gormally, SM | 1 |
| Prakash, N | 1 |
| Durnin, MT | 1 |
| Daly, LE | 2 |
| Clyne, M | 2 |
| Kierce, BM | 1 |
| Drumm, B | 5 |
| Hudson, N | 1 |
| Brydon, WG | 1 |
| Eastwood, MA | 1 |
| Ferguson, A | 1 |
| Palmer, KR | 1 |
| Burridge, SM | 5 |
| Bowden, AF | 1 |
| Atoyebi, W | 1 |
| Bolton, GH | 1 |
| Jones, PH | 6 |
| Brown, C | 2 |
| Klotz, O | 1 |
| Taylor, NS | 1 |
| Akopyants, NS | 2 |
| Thompson, N | 1 |
| Janney, F | 1 |
| Hunter, FM | 3 |
| Li, MK | 1 |
| Adamek, RJ | 7 |
| Opferkuch, W | 3 |
| Wegener, M | 2 |
| Ido, K | 2 |
| Saifuku, K | 3 |
| Taniguchi, Y | 5 |
| Takimoto, T | 4 |
| McCarthy, C | 1 |
| Patchett, S | 3 |
| Collins, RM | 1 |
| Keane, C | 3 |
| Banatvala, N | 1 |
| Davies, GR | 1 |
| Abdi, Y | 1 |
| Clements, L | 1 |
| Rampton, DS | 1 |
| Hardie, JM | 1 |
| Feldman, RA | 1 |
| Driessen, WM | 7 |
| Xia, H | 1 |
| Awad, RW | 1 |
| Ward, KL | 1 |
| Hawker, PC | 1 |
| Rune, SJ | 1 |
| Jung, MH | 1 |
| Wee, SH | 1 |
| Goddard, A | 1 |
| Logan, R | 1 |
| Rühl, GH | 4 |
| Sollböhmer, M | 1 |
| Vetvik, K | 1 |
| Schrumpf, E | 1 |
| Mowinckel, P | 1 |
| Aase, S | 1 |
| Andersen, KJ | 1 |
| tho Pesch, S | 1 |
| Müller, W | 1 |
| Borchard, F | 1 |
| Peters, U | 1 |
| Archimandritis, A | 4 |
| Balatsos, V | 2 |
| Delis, V | 2 |
| Kastanas, K | 1 |
| Scandalis, N | 1 |
| Szymanski, C | 3 |
| Pfaffenbach, B | 4 |
| Ricken, D | 1 |
| Montalban, C | 1 |
| Manzanal, A | 1 |
| Redondo, C | 5 |
| Bellas, C | 1 |
| Papatheodorou, G | 1 |
| Karameris, A | 1 |
| Mavrogeorgis, A | 1 |
| Kalogeropoulos, N | 1 |
| Giannikos, N | 1 |
| Harris, A | 3 |
| Misiewicz, JJ | 9 |
| de Boer, W | 1 |
| Driessen, W | 1 |
| Jansz, A | 1 |
| Perng, DS | 2 |
| Liu, CS | 2 |
| Iser, JH | 1 |
| Buttigieg, RJ | 1 |
| Iseli, A | 1 |
| Hosking, SW | 3 |
| Queiroz, DM | 4 |
| Moura, SB | 2 |
| Mendes, EN | 4 |
| Rocha, GA | 4 |
| Barbosa, AJ | 2 |
| de Carvalho, AS | 1 |
| Fraser, AG | 3 |
| Sim, R | 1 |
| Sankey, EA | 1 |
| Dhillon, AP | 1 |
| Pounder, RE | 2 |
| Bertrams, J | 1 |
| Wang, JT | 2 |
| Lee, WY | 1 |
| Ohtaki, T | 1 |
| Meguro, T | 2 |
| Horita, S | 1 |
| Neeman, A | 1 |
| Kadish, U | 1 |
| Noach, LA | 1 |
| Langenberg, WL | 1 |
| Bertola, MA | 1 |
| Dankert, J | 4 |
| Nysaeter, G | 2 |
| Bang, CJ | 2 |
| Hjartholm, AS | 1 |
| Hundal, O | 4 |
| Peh, SC | 2 |
| Parasakthi, N | 4 |
| Wong, NW | 1 |
| Tan, KK | 1 |
| Lo, YL | 2 |
| Potters, VP | 1 |
| Stölzle, L | 1 |
| Layer, P | 1 |
| Weston, AP | 1 |
| Campbell, DR | 1 |
| McGregor, DH | 1 |
| Cherian, R | 1 |
| Karita, M | 4 |
| Morshed, MG | 1 |
| Ouchi, K | 1 |
| Okita, K | 3 |
| Tee, W | 1 |
| Sjödahl, R | 1 |
| Lobo, AJ | 2 |
| Uff, JS | 1 |
| Dent, J | 1 |
| Eyre-Brook, IA | 1 |
| Wilkinson, SP | 1 |
| Learned-Coughlin, S | 1 |
| Solcia, E | 2 |
| Villani, L | 2 |
| Fiocca, R | 2 |
| Luinetti, O | 2 |
| Boldorini, R | 1 |
| Trespi, E | 2 |
| Perego, M | 2 |
| Alvisi, C | 2 |
| Peura, DA | 1 |
| Wagner, S | 2 |
| Gladziwa, U | 1 |
| Soudah, B | 2 |
| Gebel, M | 2 |
| Bleck, J | 1 |
| Schmidt, H | 1 |
| Manns, M | 1 |
| Gallacher, B | 2 |
| Tucci, A | 4 |
| Poli, L | 2 |
| Gasperoni, S | 2 |
| Varoli, O | 3 |
| Paparo, GF | 4 |
| De Giorgio, R | 1 |
| Stanghellini, V | 3 |
| Corinaldesi, R | 2 |
| Reilly, TG | 1 |
| Walt, RP | 1 |
| Moum, B | 5 |
| Boyd, HK | 1 |
| Zaterka, S | 1 |
| Eisig, JN | 1 |
| Chinzon, D | 1 |
| Iriya, K | 1 |
| Laudanna, AA | 1 |
| Boyd, EJ | 1 |
| Chen, TS | 1 |
| Tsay, SH | 1 |
| Groisman, GM | 1 |
| George, J | 1 |
| Berman, D | 1 |
| Harpaz, N | 1 |
| Rebora, A | 3 |
| Drago, F | 3 |
| Picciotto, A | 1 |
| Sieber, CC | 1 |
| Frei, R | 1 |
| Beglinger, C | 2 |
| Mossi, S | 1 |
| Binek, J | 1 |
| Schaufelberger, H | 1 |
| Fried, R | 1 |
| Stalder, GA | 1 |
| Zala, G | 1 |
| Wirth, HP | 1 |
| Bauer, S | 1 |
| Wüst, J | 1 |
| Flury, R | 1 |
| Meyenberger, C | 1 |
| Ammann, R | 1 |
| Resende, LM | 2 |
| Coelho, LG | 4 |
| Passos, MC | 4 |
| Castro, LP | 2 |
| Oliveira, CA | 3 |
| Lima Júnior, GF | 3 |
| Ruiz, B | 4 |
| Rood, JC | 1 |
| Malcom, GT | 1 |
| Sobhan, M | 2 |
| Johnson, WD | 1 |
| Witteman, EM | 1 |
| Hopman, WP | 1 |
| Becx, MC | 1 |
| De Koning, RW | 1 |
| Janssen, AJ | 1 |
| Arber, N | 2 |
| Gorea, A | 1 |
| Schorah, CJ | 1 |
| Shires, S | 1 |
| Penman, I | 1 |
| Dorrian, CA | 1 |
| Weberg, R | 2 |
| Moolenaar, W | 2 |
| Oom, JA | 1 |
| De Korte, H | 1 |
| Runhaar, EA | 1 |
| Maniatis, AG | 1 |
| Brazer, SR | 1 |
| Go, MF | 1 |
| Lew, GM | 6 |
| Rehfeld, JF | 1 |
| Safe, AF | 1 |
| Warren, B | 1 |
| Corfield, A | 1 |
| Watson, B | 1 |
| Mountford, RA | 1 |
| Read, A | 1 |
| McCarthy, CJ | 1 |
| Collins, R | 1 |
| Samloff, IM | 1 |
| Jaspersen, D | 1 |
| Hammar, CH | 1 |
| Lacey, SL | 1 |
| Taylor, GW | 1 |
| Bowden, AN | 1 |
| Rameh, B | 1 |
| Bolton, G | 2 |
| Purser, K | 2 |
| Harrison, G | 5 |
| Gant, PW | 6 |
| Ferch, N | 2 |
| Jankiewicz, E | 3 |
| Hyland, L | 1 |
| Oey, HB | 1 |
| Hepps, KS | 1 |
| Ramirez, FC | 2 |
| Saeed, ZA | 2 |
| Logan, RP | 5 |
| Gummett, PA | 3 |
| Karim, QN | 4 |
| Walker, MM | 4 |
| Baron, JH | 5 |
| Gyenes, E | 2 |
| Cunha-Melo, JR | 1 |
| Carroll, M | 1 |
| Calam, J | 3 |
| Termini, R | 3 |
| Mela, GS | 2 |
| Brandstätter, G | 3 |
| Hentschel, E | 5 |
| Rotter, ML | 3 |
| Schütze, K | 4 |
| Taufer, M | 3 |
| Biasco, G | 3 |
| Ricci-Maccarini, M | 1 |
| Barbara, L | 1 |
| Cutler, AF | 2 |
| Schubert, TT | 2 |
| Li, Q | 2 |
| Huang, CK | 1 |
| Frazzoni, M | 1 |
| Lonardo, A | 1 |
| Grisendi, A | 1 |
| Della Casa, G | 1 |
| Pulvirenti, M | 1 |
| Ferrari, AM | 1 |
| Di Gregorio, C | 1 |
| Melini, L | 1 |
| Desai, M | 1 |
| Moreno, M | 1 |
| Linton, D | 1 |
| Nemec, H | 1 |
| Wurzer, H | 4 |
| Coimbra, RS | 1 |
| Alves, VM | 1 |
| Nakanishi, T | 1 |
| Shinomura, Y | 1 |
| Kanayama, S | 1 |
| Matsuzawa, Y | 1 |
| Klein, PD | 4 |
| Malaty, HM | 4 |
| Daw, MA | 1 |
| Jaskiewicz, K | 1 |
| Louw, JA | 1 |
| Marks, IN | 1 |
| Hatzis, A | 1 |
| Tamvakologos, G | 1 |
| Spiliades, C | 1 |
| Triadaphyllou, G | 1 |
| Pavicić, MJ | 1 |
| Namavar, F | 1 |
| Verboom, T | 1 |
| van Winkelhoff, AJ | 1 |
| De Graaff, J | 1 |
| Born, P | 1 |
| Sandro Mela, G | 1 |
| Celle, G | 3 |
| Wolfhagen, MJ | 1 |
| ten Bokkel Huinink, J | 1 |
| Hernández Ranz, F | 1 |
| Khulusi, S | 1 |
| Badve, S | 1 |
| Patel, P | 1 |
| Lloyd, R | 1 |
| Marrero, JM | 2 |
| Finlayson, C | 1 |
| Mendall, MA | 1 |
| Northfield, TC | 2 |
| Tsuda, M | 1 |
| Nakazawa, T | 1 |
| Diehl, HG | 1 |
| Götz, JM | 2 |
| Veselic, M | 1 |
| Bernards, S | 1 |
| Bate, CM | 2 |
| Tildesley, G | 3 |
| Kerr, GD | 3 |
| Green, JR | 1 |
| Emmas, CE | 1 |
| Taylor, MD | 2 |
| Parodi, A | 1 |
| Soll, AH | 1 |
| Dal Bó, N | 1 |
| Grassi, SA | 1 |
| Cassaro, M | 1 |
| Donisi, PM | 1 |
| Vianello, F | 1 |
| Kusstatscher, S | 1 |
| Salandin, S | 1 |
| Grasso, GA | 1 |
| Ferrana, M | 1 |
| Battaglia, G | 1 |
| Davis, S | 1 |
| Lau, JY | 4 |
| Lin, XZ | 5 |
| Shiesh, SC | 2 |
| Tefera, S | 3 |
| García, M | 1 |
| Blomgren, K | 1 |
| Alván, G | 1 |
| Cantón, R | 1 |
| Artan, R | 1 |
| Gelen, T | 1 |
| Cesana, B | 1 |
| Figueroa, G | 1 |
| Acuña, R | 1 |
| Troncoso, M | 1 |
| Portell, DP | 1 |
| Toledo, MS | 1 |
| Albornoz, V | 1 |
| Vigneaux, J | 1 |
| Taha, AS | 2 |
| Curry, GW | 1 |
| Morton, R | 2 |
| Park, RH | 2 |
| Beattie, AD | 2 |
| Shirotani, T | 2 |
| Okada, M | 3 |
| Murayama, H | 1 |
| Seo, M | 3 |
| Okabe, N | 3 |
| Nakahara, T | 1 |
| Hoshiko, K | 1 |
| Oda, K | 2 |
| Okumura, M | 1 |
| Alkan, S | 1 |
| Karcher, DS | 1 |
| Newman, MA | 1 |
| Cohen, P | 1 |
| Jurgos, L | 1 |
| Duris, I | 1 |
| Bátovský, M | 1 |
| Simkovicová, M | 1 |
| Pauer, M | 1 |
| Dorociak, F | 1 |
| Majercík, M | 1 |
| Kratochvílová, H | 1 |
| Valko, L | 1 |
| Paulen, P | 1 |
| Lambert, JR | 2 |
| Leung, KP | 1 |
| Yung, RW | 1 |
| Lai, CL | 3 |
| Goddard, AF | 4 |
| Perkins, SE | 1 |
| Yan, LL | 1 |
| Shen, Z | 1 |
| Hayward, A | 2 |
| Murphy, JC | 2 |
| Vasquez, A | 1 |
| Valdez, Y | 4 |
| Gilman, RH | 4 |
| McDonald, JJ | 1 |
| Westblom, TU | 1 |
| Mayta, H | 1 |
| Gutierrez, V | 2 |
| Stupnicki, T | 1 |
| Denk, H | 1 |
| Ratschek, M | 1 |
| Spath, P | 1 |
| Graf, K | 1 |
| Rosengren, H | 1 |
| Polson, RJ | 1 |
| Turnidge, J | 1 |
| Santander, C | 1 |
| Grávalos, RG | 2 |
| Gómez-Cedenilla, A | 1 |
| Cantero, J | 1 |
| Papa, A | 1 |
| Montalto, M | 1 |
| Fedeli, G | 1 |
| Sangaletti, O | 1 |
| Boldorini, M | 1 |
| Jorgensen, M | 1 |
| Daskalopoulos, G | 1 |
| Warburton, V | 1 |
| Mitchell, HM | 1 |
| Hazell, SL | 1 |
| Moore, L | 2 |
| Ali, MR | 1 |
| Chua, LE | 1 |
| Hollis, B | 2 |
| Little, SV | 1 |
| Konturek, PC | 1 |
| Bielański, W | 4 |
| Kwiecień, N | 1 |
| Konturek, SJ | 3 |
| Baniukiewicz, A | 1 |
| Jedynak, M | 1 |
| Gabryelewicz, A | 2 |
| Hahn, EG | 2 |
| Bergseth, M | 1 |
| Wolf, R | 1 |
| Jansz, AR | 2 |
| Stein, C | 1 |
| Garcia, F | 1 |
| Trujillo, M | 3 |
| Estrada, R | 3 |
| Jaup, BH | 2 |
| Norrby, A | 2 |
| van Etten, RJ | 7 |
| Schade, RW | 2 |
| Ouwehand, ME | 2 |
| Pollak, PT | 2 |
| Kapoor, H | 1 |
| Yeung, PK | 1 |
| Urruzuno Tellería, P | 1 |
| Román Riechman, E | 1 |
| Medina Benítez, E | 1 |
| Manzanares López-Manzanares, J | 1 |
| Echávarri Olavarría, F | 1 |
| Molina Arias, M | 1 |
| Griffiths, AE | 1 |
| Halliday, D | 1 |
| Jacyna, MR | 1 |
| Goenka, MK | 1 |
| Das, K | 1 |
| Vaiphei, K | 2 |
| Nijhawan, R | 1 |
| Kocbhar, R | 1 |
| Dammann, HG | 2 |
| Martin, JL | 1 |
| Richardson, PD | 1 |
| Lai, JY | 3 |
| Geuskens, LM | 1 |
| Weel, JF | 2 |
| van der Hulst, RW | 6 |
| Gerrits, Y | 1 |
| van der Ende, A | 5 |
| Thor, P | 1 |
| Lorens, K | 1 |
| Tabor, S | 1 |
| Herman, R | 1 |
| Konturek, JW | 1 |
| Beastall, G | 1 |
| Park, J | 1 |
| Chang, SK | 1 |
| Yoo, BC | 1 |
| Vivas, J | 1 |
| Buiatti, E | 1 |
| Kato, I | 1 |
| Oliver, W | 1 |
| Kalas, D | 1 |
| Ferenczi, K | 1 |
| Pálos, G | 1 |
| Daróczy, J | 1 |
| ten Kate, FJ | 1 |
| Alder, JD | 1 |
| Ewing, PJ | 1 |
| Mitten, MJ | 1 |
| Oleksijew, A | 1 |
| Tanaka, SK | 1 |
| Qureshi, H | 2 |
| Zuberi, SJ | 1 |
| Kawano, S | 2 |
| Murakami, M | 1 |
| Saita, H | 1 |
| Tsuji, S | 1 |
| Ishino, Y | 1 |
| Yamamoto, H | 1 |
| Gimeno, L | 2 |
| Valdepérez, J | 2 |
| Yus, C | 1 |
| Marzo, J | 1 |
| Pérez-Caballero, MC | 1 |
| Harris, AW | 3 |
| Pryce, DI | 1 |
| Gabe, SM | 1 |
| Langworthy, H | 4 |
| Brill, S | 1 |
| Soffiati, G | 2 |
| Scagnelli, M | 2 |
| Bozzola, L | 3 |
| Valerio, G | 2 |
| Chi, CH | 1 |
| Patchin, GM | 1 |
| Wieland, KA | 1 |
| Carmichael, JM | 1 |
| Taylor, JL | 1 |
| Zagari, M | 2 |
| Murphy, K | 1 |
| Freston, JW | 1 |
| Weel, J | 1 |
| Jiménez, I | 1 |
| Pérez García, JI | 1 |
| Bock, H | 2 |
| Mares, A | 1 |
| Bruno, M | 1 |
| Peyre, S | 1 |
| Grosso, S | 1 |
| Rizzi, R | 1 |
| Sategna-Guidetti, C | 1 |
| Paar, D | 1 |
| Terjung, B | 1 |
| Sauerbruch, T | 1 |
| Wang, XM | 1 |
| Nishifuku, K | 1 |
| Kidaira, K | 1 |
| Sohara, H | 1 |
| Kawada, H | 2 |
| Kajiwara, M | 1 |
| Trevisani, L | 1 |
| Sartori, S | 1 |
| Ruina, M | 1 |
| Luzzi, I | 2 |
| Gaudenzi, P | 1 |
| Alvisi, V | 1 |
| Cilleruelo, ML | 1 |
| Madruga, D | 1 |
| Sebastián, M | 1 |
| Román, E | 1 |
| Barrio, A | 1 |
| Manzanares, J | 1 |
| Medina, E | 1 |
| Sarría, J | 1 |
| Sanz, JC | 1 |
| Dohil, R | 1 |
| Israel, DM | 1 |
| Hassall, E | 1 |
| Haug, JB | 4 |
| Tolås, P | 4 |
| Breder, O | 1 |
| Aubert, E | 2 |
| Søberg, T | 2 |
| Flaaten, B | 1 |
| Farup, P | 2 |
| Idström, JP | 2 |
| Vautier, G | 1 |
| Scott, BB | 1 |
| van Unnik, AJ | 1 |
| Erah, PO | 1 |
| Seifrit, B | 1 |
| Kung, NN | 2 |
| Yuen, NW | 2 |
| Ng, PW | 2 |
| Wong, KC | 1 |
| Chung, EC | 1 |
| Lim, BH | 1 |
| Choi, CH | 2 |
| Li, TH | 2 |
| Ma, HC | 1 |
| Kwok, SP | 1 |
| Miederer, S | 1 |
| Sumazaki, R | 1 |
| Adachi, H | 1 |
| Ahmed, T | 1 |
| Matsubara, T | 1 |
| Hori, T | 1 |
| Nakahara, A | 1 |
| Takita, H | 1 |
| Gotoh, A | 3 |
| Kawakami, Y | 3 |
| Akahane, T | 1 |
| Akamatsu, T | 4 |
| Kiyosawa, K | 2 |
| Dayal, VM | 1 |
| Kumar, P | 1 |
| Kamal, J | 1 |
| Shahi, SK | 1 |
| Agrawal, BK | 1 |
| Martin, J | 1 |
| Boyle, S | 1 |
| Jacyna, M | 1 |
| Hauge, T | 1 |
| Henriksen, M | 2 |
| Efskind, PS | 1 |
| Nicolaysen, K | 1 |
| Odegaard, A | 1 |
| Jarczyk, G | 1 |
| Jarczyk, J | 1 |
| Raczyńska, A | 1 |
| Jedrzejczyk, W | 1 |
| Ström, M | 1 |
| Jönsson, KA | 1 |
| Peterson, WL | 2 |
| D'Ambra, G | 2 |
| Iannoni, C | 1 |
| Paoletti, M | 2 |
| Anania, MC | 1 |
| Marignani, M | 2 |
| Delle Fave, G | 3 |
| Adams, RM | 1 |
| Walsh, D | 2 |
| Goggin, N | 2 |
| Rowland, M | 4 |
| Durnin, M | 2 |
| Moriarty, S | 1 |
| Siehoff, S | 1 |
| Nakao, K | 1 |
| Imoto, I | 1 |
| Ikemura, N | 1 |
| Shibata, T | 1 |
| Takaji, S | 1 |
| Taguchi, Y | 1 |
| Misaki, M | 1 |
| Yamauchi, K | 1 |
| Yamazaki, N | 1 |
| MacConnachie, AM | 1 |
| Damianos, AJ | 1 |
| McGarrity, TJ | 1 |
| Forbes, GM | 2 |
| Lo, WC | 1 |
| Perng, CL | 2 |
| Buckley, MJ | 3 |
| Angeletti, S | 1 |
| Bordi, C | 1 |
| Malagnino, F | 1 |
| Mancino, C | 1 |
| Thio, JL | 1 |
| Offerhaus, GJ | 1 |
| Biemond, I | 1 |
| Vuković, D | 2 |
| Ivandić, A | 2 |
| Vceva, A | 3 |
| Kovacić, D | 1 |
| Volaric, M | 1 |
| Paulini, D | 1 |
| Mićunović, N | 2 |
| Mihaljević, S | 2 |
| Popiela, T | 1 |
| Kulig, J | 1 |
| Karcz, D | 1 |
| Tabor, J | 1 |
| Márquez, M | 1 |
| Fillat, O | 1 |
| Herrero, E | 1 |
| Ortiz, JA | 1 |
| Kim, MJ | 1 |
| Michener, R | 1 |
| Triadafilopoulos, G | 1 |
| Baffone, W | 2 |
| Belbusti, F | 1 |
| Barbieri, E | 1 |
| Pianetti, A | 2 |
| Bruscolini, F | 2 |
| Fabi, MT | 1 |
| Salvaggio, L | 1 |
| Albano, A | 1 |
| Breuer, T | 1 |
| Gurer, IE | 1 |
| Graham, DP | 2 |
| Myers, D | 1 |
| Abraira, V | 2 |
| Mukai, T | 1 |
| Okamoto, S | 1 |
| Yamaguchi, S | 1 |
| Mashiba, H | 1 |
| Taniyama, K | 1 |
| Sasaki, N | 1 |
| Sumii, K | 1 |
| Kajiyama, G | 1 |
| Ong, L | 1 |
| Rudnicka, L | 1 |
| Bobrzyński, A | 3 |
| Stachura, J | 3 |
| Tan, WC | 1 |
| Hogan, J | 1 |
| Purkayastha, SK | 1 |
| Lombard, M | 1 |
| Krasner, N | 1 |
| Kobler, E | 1 |
| Werth, B | 1 |
| Wüst, W | 1 |
| Reinhart, WH | 1 |
| Mansi, C | 4 |
| Mele, MR | 2 |
| Bisso, G | 3 |
| Saggioro, A | 1 |
| Caroli, M | 1 |
| Olivieri, A | 1 |
| Tosatto, R | 1 |
| Bateson, MC | 4 |
| Winn, G | 1 |
| Ahmad, F | 1 |
| Fisher, L | 1 |
| Nostrant, T | 1 |
| DelValle, J | 1 |
| Hasler, WL | 1 |
| To, KF | 1 |
| Lee, YT | 5 |
| Chan, CS | 1 |
| Li, EK | 1 |
| Woo, J | 1 |
| Scheynius, A | 1 |
| El-Zaatari, F | 1 |
| Frantz, JE | 1 |
| Baker, A | 1 |
| Neil, GA | 1 |
| Cottrill, MR | 1 |
| McKinnon, C | 1 |
| Mason, I | 1 |
| Chesters, SA | 1 |
| Slatcher, G | 1 |
| Copeman, MB | 1 |
| Turbitt, ML | 1 |
| Rinaldi, V | 1 |
| Pugliano, F | 1 |
| Valente, C | 1 |
| Diana, F | 1 |
| Attili, AF | 1 |
| Hoffman, J | 4 |
| Stamler, D | 1 |
| Archambault, A | 2 |
| Skandalis, N | 2 |
| Fedorak, R | 1 |
| Mora, P | 1 |
| Hyde, DM | 1 |
| Dobrucali, A | 1 |
| Tuncer, M | 1 |
| Eralp, YT | 1 |
| Goksel, S | 1 |
| Altin, M | 1 |
| Dinc, I | 1 |
| Wack, RF | 1 |
| Eaton, KA | 1 |
| Kramer, LW | 1 |
| Kawasaki, M | 1 |
| Hizawa, K | 1 |
| Aoyagi, K | 1 |
| Nakamura, S | 4 |
| Fujishima, M | 1 |
| Harford, W | 1 |
| Lanza, F | 1 |
| Arora, A | 1 |
| Haber, M | 2 |
| Rose, P | 2 |
| Siepman, N | 2 |
| Schwartz, H | 1 |
| Krause, R | 1 |
| Kidd, S | 1 |
| Sahba, B | 1 |
| Lind, T | 5 |
| Spiller, R | 3 |
| Bardhan, KD | 9 |
| Bradette, M | 2 |
| Wrangstadh, M | 4 |
| Cederberg, C | 2 |
| Suriani, R | 1 |
| Ravizza, M | 1 |
| Pallante, C | 1 |
| Mazzucco, D | 1 |
| Cardesi, E | 1 |
| Colozza, M | 1 |
| Malandrino, M | 1 |
| Oneglio, R | 1 |
| Orso Giacone, G | 1 |
| Dusio, P | 1 |
| Vajo, M | 1 |
| van de Wouw, BA | 2 |
| Keller, JJ | 1 |
| Rauws, EA | 2 |
| Batchelder, M | 1 |
| Palley, L | 1 |
| Czinn, SJ | 1 |
| Bierman, JC | 1 |
| Diters, RW | 1 |
| Blanchard, TG | 1 |
| Leunk, RD | 1 |
| Yiu, PY | 1 |
| Emami, S | 1 |
| Lelwala-Guruge, J | 1 |
| Srivastava, K | 1 |
| Watanabe, J | 2 |
| Miyagi, J | 1 |
| Ramirez-Ramos, A | 2 |
| Yoshiwara, TH | 1 |
| Recavarren, S | 1 |
| Leon-Barua, R | 2 |
| Recavarren-Arce, S | 1 |
| Salazar, G | 1 |
| Checkley, W | 1 |
| McDonald, J | 1 |
| Cordero, L | 1 |
| Carrazco, J | 1 |
| Carpintero, P | 1 |
| Blanco, M | 1 |
| Washizuka, Y | 1 |
| Tawara, S | 1 |
| Ikeda, F | 1 |
| Yokota, Y | 1 |
| Loane, J | 1 |
| Bindel, H | 1 |
| Gedliczka, O | 2 |
| Konturek, S | 2 |
| Budzyński, A | 2 |
| Lambert, I | 1 |
| Gormally, S | 1 |
| Hetherington, C | 1 |
| Chuah, SY | 2 |
| Toetsch, M | 1 |
| Seki, M | 1 |
| Korman, MG | 2 |
| Bolin, TD | 2 |
| Engelman, JL | 2 |
| Pianko, S | 1 |
| Sandvei, PK | 2 |
| Cockeram, A | 1 |
| Schep, G | 1 |
| Malatjalian, D | 1 |
| Sidorov, J | 1 |
| Matisko, A | 1 |
| Jewell, D | 1 |
| Levi, S | 3 |
| Cooper, BT | 3 |
| Piper, D | 2 |
| Whist, JE | 1 |
| Angelucci, D | 1 |
| Diodoro, MG | 1 |
| Metz, DC | 1 |
| Brandberg, A | 1 |
| Stenquist, B | 1 |
| Tzivras, M | 2 |
| Souyioultzis, S | 2 |
| Kanellopoulou, E | 1 |
| Manika, Z | 1 |
| Davaris, P | 1 |
| Takac, B | 2 |
| Gardasanić, J | 1 |
| Horonitz, M | 1 |
| Karner, I | 1 |
| Price, J | 1 |
| Hamilton, W | 1 |
| Jeljaszewicz, J | 1 |
| Suerbaum, S | 1 |
| Marcelino, M | 1 |
| Jahnsen, J | 1 |
| Lotay, N | 1 |
| Roberts, PM | 2 |
| Berquist, WE | 1 |
| Moreno, L | 1 |
| Leri, O | 1 |
| Perinelli, P | 1 |
| Mastropasqua, M | 1 |
| Tubili, S | 1 |
| Losi, T | 1 |
| Homan, A | 1 |
| Roorda, P | 1 |
| el-Nujumi, A | 4 |
| Williams, C | 1 |
| Oien, K | 1 |
| Hazell, S | 1 |
| Collins, BJ | 1 |
| McCullough, CA | 1 |
| Coombs, GW | 1 |
| Robins, PD | 1 |
| Glaser, J | 1 |
| Hein, J | 1 |
| Daikeler, R | 1 |
| Weithofer, G | 1 |
| Schmidt, M | 1 |
| Schneider, E | 1 |
| Carnicer, J | 1 |
| Loo, VG | 1 |
| Barkun, AN | 2 |
| Hibi, K | 1 |
| Imaizumi, H | 1 |
| Ohida, M | 1 |
| Okabe, H | 1 |
| Okayasu, I | 1 |
| McLoughlin, R | 1 |
| Kelly, S | 1 |
| Laundon, J | 1 |
| Benhamou, PH | 4 |
| Barbet, JP | 1 |
| Gendrel, D | 2 |
| Katsorida, M | 1 |
| Ducóns, JA | 3 |
| García, S | 2 |
| Vera, J | 1 |
| Calvet Calvo, X | 1 |
| García, N | 4 |
| Campo, R | 4 |
| Brullet, E | 4 |
| Comet, R | 2 |
| Kubota, T | 1 |
| Tokushima, H | 1 |
| Tamura, H | 1 |
| Murakawa, M | 1 |
| Matsumura, O | 1 |
| Itakura, Y | 1 |
| Itoyama, S | 1 |
| Mitarai, T | 1 |
| Isoda, K | 1 |
| Brieva, L | 1 |
| Ara, JR | 1 |
| Bertol, V | 1 |
| Canellas, A | 1 |
| del Agua, C | 1 |
| Murray, LS | 1 |
| Dickson, A | 3 |
| Kelman, AW | 1 |
| Hilditch, TE | 2 |
| Happonen, I | 2 |
| Jalava, K | 1 |
| Kovac, D | 1 |
| Cheah, PL | 1 |
| Chin, SC | 1 |
| Siem, TH | 1 |
| Haeck, PW | 1 |
| Otten, MH | 1 |
| Mulder, CJ | 1 |
| Nawaz, A | 1 |
| Mohammed, I | 1 |
| Ahsan, K | 1 |
| Karakurum, A | 1 |
| Hadjiyane, C | 1 |
| Pellecchia, C | 1 |
| Jeffries, MA | 1 |
| Fendrick, AM | 1 |
| el-Zaatari, FA | 4 |
| Lahaie, R | 2 |
| Fedorak, RN | 1 |
| Bailey, R | 2 |
| Bernucci, B | 1 |
| Dhar, A | 1 |
| Senouci, L | 1 |
| Ihm, P | 1 |
| Koch, HK | 1 |
| David, FL | 1 |
| Da Silva, CM | 2 |
| Mendes, FD | 2 |
| Ferraz, JG | 2 |
| Muscara, MN | 1 |
| Moreno, H | 1 |
| De Nucci, G | 2 |
| Pedrazzoli, J | 2 |
| Lokhvitskiĭ, SV | 1 |
| Darvin, VV | 1 |
| Proshin, AV | 1 |
| Bashirova, ES | 1 |
| Butorov, IL | 1 |
| Coremans, A | 1 |
| Ellenrieder, V | 2 |
| Fensterer, H | 1 |
| Waurick, M | 1 |
| Adler, G | 2 |
| Glasbrenner, B | 2 |
| Pasching, E | 2 |
| Wimmer, M | 2 |
| Velapatiño, B | 1 |
| León, C | 1 |
| Kooy, A | 2 |
| Kleibeuker, JH | 3 |
| Nicholson, FB | 1 |
| Tosetti, C | 1 |
| Grigioni, W | 1 |
| Mazzoni, C | 1 |
| Caletti, G | 1 |
| Choi, HK | 1 |
| Tuen, HH | 1 |
| Law, SY | 1 |
| Branicki, FJ | 1 |
| Wong, J | 1 |
| Huang, WH | 1 |
| Ho, AS | 1 |
| Shyu, RY | 2 |
| Lee, SC | 2 |
| Lee, MM | 1 |
| Hsu, CT | 2 |
| Makino, M | 1 |
| Koga, T | 1 |
| Tabata, K | 1 |
| Doermann, HP | 1 |
| Bethke, TD | 1 |
| Stack, WA | 1 |
| Knifton, A | 1 |
| Thirlwell, D | 1 |
| Cockayne, A | 1 |
| Hawkey, CJ | 1 |
| Oki, K | 1 |
| Nishimura, H | 2 |
| Ohkuma, K | 2 |
| Casswall, TH | 1 |
| Alfvén, G | 1 |
| Drapinski, M | 1 |
| Bergström, M | 1 |
| Dahlström, KA | 1 |
| Hua, J | 3 |
| Ng, HC | 2 |
| Ho, KY | 1 |
| Occhialini, A | 1 |
| Rossignol, JF | 1 |
| Hynes, B | 1 |
| Cornetta, AM | 1 |
| Simpson, KW | 1 |
| Strauss-Ayali, D | 1 |
| McDonough, PL | 1 |
| Gleed, RD | 1 |
| Konorev, MR | 2 |
| Valsecchi, R | 1 |
| Pigatto, P | 1 |
| Kalantar, J | 1 |
| Talley, NJ | 2 |
| Hoie, O | 1 |
| Kristensen, ES | 1 |
| Schuetz, E | 1 |
| Kliebe-Frisch, C | 1 |
| Pipkin, GA | 1 |
| Duggan, AE | 1 |
| Robertson, GJ | 1 |
| Bradbury, R | 1 |
| Ngu, MC | 1 |
| Coudron, PE | 1 |
| Stratton, CW | 1 |
| Shuter, J | 1 |
| Fletcher, DD | 1 |
| Simone, VJ | 1 |
| Bellin, EY | 1 |
| McColl, K | 1 |
| Murray, L | 1 |
| Wirz, A | 1 |
| Kelman, A | 2 |
| Penny, C | 1 |
| Knill-Jones, R | 1 |
| Hilditch, T | 1 |
| Lee, CL | 1 |
| Tu, TC | 1 |
| Wu, CH | 1 |
| Chen, TK | 1 |
| Chan, CC | 1 |
| Huang, SH | 1 |
| Wu, JC | 3 |
| Lai, AC | 1 |
| Pohle, T | 1 |
| Stoll, R | 1 |
| Heep, M | 1 |
| Lygren, I | 1 |
| Kleveland, PM | 1 |
| Vatn, M | 1 |
| Aursnes, I | 1 |
| Huang, FC | 1 |
| Chang, MH | 1 |
| Hsu, HY | 1 |
| Pivari, M | 2 |
| Biagini, R | 1 |
| Eshraghi, J | 1 |
| Fassihi, R | 1 |
| Zeijlon, L | 5 |
| Klinkenberg-Knol, EC | 1 |
| Rué, M | 1 |
| Takahashi, H | 1 |
| Kirihara, K | 1 |
| Kojima, T | 1 |
| Fujita, R | 1 |
| Kimoto, M | 1 |
| Kato, K | 3 |
| Iwasaki, A | 2 |
| Kouda, K | 1 |
| Tada, U | 1 |
| Wada, T | 1 |
| Harasawa, S | 1 |
| Miwa, T | 1 |
| Kumakura, Y | 1 |
| Nilsson, F | 1 |
| Walder, M | 1 |
| Utaş, S | 1 |
| Ozbakir, O | 1 |
| Turasan, A | 1 |
| Utaş, C | 1 |
| Lai, WM | 1 |
| Lui, YH | 1 |
| Lam, KN | 1 |
| Leung, EM | 1 |
| Henry, A | 1 |
| Batey, RG | 1 |
| Navuluri, R | 1 |
| Yue, S | 1 |
| Petsch, B | 1 |
| Kabala, A | 1 |
| Pawłowski, W | 1 |
| Zanten, SJ | 1 |
| Leddin, D | 1 |
| Lau, GK | 2 |
| Zwet, AA | 1 |
| Knigge, K | 1 |
| Kelly, C | 2 |
| Ferrero, RL | 2 |
| Marshall, JB | 1 |
| Rosário, M | 1 |
| Caetano, JM | 1 |
| Pessanha, MA | 1 |
| Marote, G | 1 |
| da Silva, JA | 1 |
| Caetano, JA | 1 |
| Lee, CK | 1 |
| Soike, K | 1 |
| Hill, J | 1 |
| Georgakopoulos, K | 1 |
| Tibbitts, T | 1 |
| Ingrassia, J | 1 |
| Gray, H | 1 |
| Boden, J | 1 |
| Kleanthous, H | 1 |
| Giannasca, P | 1 |
| Ermak, T | 1 |
| Weltzin, R | 1 |
| Blanchard, J | 1 |
| Monath, TP | 1 |
| Smoot, DT | 2 |
| Hinds, T | 1 |
| Ashktorab, H | 1 |
| Jagtap, J | 1 |
| Kim, KS | 1 |
| Scott, VF | 2 |
| Cheybani, K | 1 |
| Yeramian, P | 1 |
| Smith, S | 1 |
| Neil, G | 1 |
| Chen, W | 1 |
| Shu, D | 1 |
| Wilson, IR | 1 |
| Tie, A | 1 |
| Chadwick, VS | 1 |
| Imrie, C | 2 |
| Lin, CW | 1 |
| Chang, YS | 1 |
| Wu, SC | 1 |
| Cheng, KS | 1 |
| Hoffman, JS | 1 |
| Katz, LM | 1 |
| Cave, DR | 1 |
| Neville, PM | 2 |
| Everett, S | 1 |
| Tompkins, D | 1 |
| Lee, JM | 1 |
| Breslin, NP | 1 |
| Hyde, DK | 1 |
| van 't Hoff, BW | 1 |
| Mönkemüller, KE | 1 |
| Hirschowitz, BI | 1 |
| Catalano, F | 1 |
| Branciforte, G | 1 |
| Brogna, A | 1 |
| Bentivegna, C | 1 |
| Luca, S | 1 |
| Terranova, R | 1 |
| Michalos, A | 1 |
| Dawson, BK | 1 |
| Chodash, HB | 1 |
| Debets-Ossenkopp, YJ | 1 |
| Herscheid, AJ | 1 |
| Pot, RG | 1 |
| Vandenbroucke-Grauls, CM | 1 |
| Fortunato, A | 1 |
| Rassu, M | 3 |
| Meli, S | 1 |
| Bhasin, DK | 2 |
| Sharma, BC | 2 |
| Sinha, SK | 1 |
| Singh, K | 1 |
| Sánchez, I | 1 |
| Piana, A | 1 |
| Atzei, A | 1 |
| Carta, M | 1 |
| Cugia, L | 1 |
| Are, BM | 1 |
| Mura, I | 1 |
| Maida, A | 1 |
| Kim, SK | 1 |
| Son, BK | 1 |
| Hong, YC | 1 |
| Pai, SH | 1 |
| Nie, Y | 1 |
| Wu, H | 1 |
| Sha, W | 1 |
| Du, H | 1 |
| Dai, S | 1 |
| Kawashima, M | 1 |
| Takata, T | 1 |
| Grimley, CE | 1 |
| Penny, A | 1 |
| O'sullivan, M | 1 |
| Shebani, M | 1 |
| Lismore, JR | 1 |
| Cross, R | 1 |
| Illing, RC | 1 |
| Loft, DE | 1 |
| Nwokolo, CU | 2 |
| Houben, MH | 1 |
| Hensen, EF | 1 |
| Hulst, RW | 1 |
| Hoff, BW | 1 |
| Ende, AV | 1 |
| Kate, FJ | 1 |
| Dhali, GK | 1 |
| Garg, PK | 1 |
| Kavcic, B | 1 |
| Zaletel, LK | 1 |
| Gubina, M | 1 |
| Ihan, A | 1 |
| Poljak, M | 1 |
| Krizman, I | 1 |
| Mera, R | 1 |
| Realpe, JL | 3 |
| DeLany, JP | 1 |
| Neiger, R | 1 |
| Seiler, G | 1 |
| Schmassmann, A | 1 |
| Farkas, H | 1 |
| Gyeney, L | 1 |
| Majthényi, P | 1 |
| Füst, G | 1 |
| Varga, L | 1 |
| Roghani, HS | 1 |
| Pahlewanzadeh, MR | 1 |
| Dashti, M | 1 |
| Chida-Sakata, N | 1 |
| Baba, M | 1 |
| Inagawa, H | 1 |
| Wada, A | 1 |
| Tanaka, T | 1 |
| Hoshihara, Y | 1 |
| Takemoto, T | 1 |
| Shah, S | 1 |
| Qaqish, R | 1 |
| Patel, V | 1 |
| Amiji, M | 1 |
| Bourke, B | 1 |
| Gschwantler, M | 1 |
| Klimpfinger, M | 1 |
| Oberhuber, G | 1 |
| Weiss, W | 1 |
| Zwimpfer, J | 1 |
| Reddy, R | 4 |
| Boeck, W | 1 |
| Richter, C | 1 |
| Marre, R | 1 |
| Berretti, D | 2 |
| De Luca, L | 2 |
| Nicolini, G | 2 |
| Pozzato, P | 2 |
| Fossi, S | 2 |
| Nieves Rincón, M | 1 |
| Jesús Higes, M | 1 |
| Angeles Arpa, M | 1 |
| García Arata, I | 1 |
| Ates, Y | 1 |
| Cetin, C | 1 |
| Gulsen, M | 1 |
| Dagalp, K | 1 |
| Menelaou, A | 1 |
| Somogyi, AA | 1 |
| Barclay, ML | 1 |
| Bochner, F | 1 |
| Furusyo, N | 1 |
| Kanamoto, K | 1 |
| Yao, T | 1 |
| Suekane, H | 1 |
| Yano, Y | 1 |
| Ariyama, I | 1 |
| Hayashi, J | 1 |
| Kashiwagi, S | 1 |
| Zhang, XD | 1 |
| Zhang, SS | 1 |
| de Grauw, WJ | 1 |
| Lee, M | 3 |
| Kemp, JA | 1 |
| Canning, A | 1 |
| Egan, C | 1 |
| Tataronis, G | 1 |
| Farraye, FA | 1 |
| Adamsson, I | 3 |
| Nord, CE | 2 |
| Lundquist, P | 1 |
| Sjöstedt, S | 1 |
| Edlund, C | 3 |
| Rebrova, EL | 1 |
| Adeyemi, EO | 2 |
| Danial, MF | 1 |
| Helal, T | 1 |
| Benedict, S | 1 |
| Abdulle, AM | 1 |
| Vasudeva, R | 1 |
| Mach, T | 1 |
| Zahradnik-Bilska, J | 1 |
| Tanigawara, Y | 1 |
| Kita, T | 1 |
| Shirakawa, K | 1 |
| Komada, F | 1 |
| Okumura, K | 1 |
| Lonovics, J | 1 |
| Díete, U | 1 |
| Domján, L | 1 |
| Kisfalvi, I | 1 |
| Pap, A | 1 |
| Burman, CF | 2 |
| Martino, G | 1 |
| García Cabezudo, J | 1 |
| Simón, MA | 2 |
| Raderer, M | 1 |
| Pfeffel, F | 1 |
| Pohl, G | 1 |
| Mannhalter, C | 1 |
| Valencak, J | 1 |
| Chott, A | 1 |
| Nishikawa, K | 1 |
| Ishizuka, J | 1 |
| Katagiri, M | 1 |
| Sukegawa, M | 1 |
| Kagaya, H | 1 |
| Toyota, J | 1 |
| García Pérez, A | 1 |
| Valverde de La Osa, J | 1 |
| Giménez Samper, M | 1 |
| Alonso García, I | 1 |
| Ng, WW | 1 |
| Lam, CP | 1 |
| Chau, WK | 1 |
| Fen-Yau Li, A | 1 |
| Huang, CC | 2 |
| Thiboutot, DM | 1 |
| Hoshiya, S | 1 |
| Ninomiya, H | 1 |
| Saito, S | 1 |
| Ishida, H | 1 |
| Dillon, J | 1 |
| Wyatt, JI | 1 |
| Braun, W | 1 |
| Van Oijen, AH | 1 |
| Rollan, A | 1 |
| Giancaspero, R | 1 |
| Fuster, F | 1 |
| Acevedo, C | 1 |
| Figueroa, C | 1 |
| Hola, K | 1 |
| Schulz, M | 1 |
| Duarte, I | 1 |
| Arain, GM | 1 |
| Hafiz, S | 1 |
| Anderson, SY | 2 |
| Qian, SC | 1 |
| Huang, NX | 1 |
| Manan, C | 1 |
| Lesmana, L | 1 |
| Carpio, RE | 1 |
| Perez, JY | 1 |
| Phornphutkul, K | 1 |
| Kullavanijaya, P | 2 |
| Chelvam, P | 1 |
| Marshall, CP | 1 |
| Hoshi, T | 1 |
| Sasano, H | 1 |
| Toyota, T | 1 |
| Nagura, H | 2 |
| Furihata, K | 1 |
| Ueno, I | 1 |
| Taskin, V | 1 |
| Gurer, I | 1 |
| Ozyilkan, E | 1 |
| Sare, M | 1 |
| Hilmioglu, F | 1 |
| Fölsch, UR | 1 |
| von Kleist, DH | 1 |
| Klör, HU | 1 |
| van Doorn, LJ | 3 |
| Nouhan, N | 1 |
| Plaisier, AP | 1 |
| Quint, WG | 1 |
| Tankovic, J | 3 |
| Lamarque, D | 2 |
| Soussy, CJ | 2 |
| Shalom, A | 1 |
| Wasserman, I | 1 |
| Segal, M | 1 |
| Orda, R | 1 |
| Grilli, R | 1 |
| Hirschmann, JV | 1 |
| Szlachcic, A | 1 |
| Sliwowski, Z | 1 |
| Pytko-Polonczyk, J | 1 |
| Shamaly, H | 1 |
| Berkowitz, D | 1 |
| Rosenthal, E | 1 |
| Naveh, Y | 1 |
| Schweeger, I | 1 |
| Fitscha, P | 1 |
| Sinzinger, H | 1 |
| Kearney, DJ | 1 |
| Brousal, A | 1 |
| Linden, J | 1 |
| Westermarck, E | 1 |
| Ansari, R | 1 |
| Alizadeh, BZ | 2 |
| Eshraghian, MR | 1 |
| Vakili, A | 1 |
| Saghari, M | 1 |
| Begum, S | 2 |
| Endo, H | 2 |
| Kawamata, H | 2 |
| Friedman, G | 1 |
| Mayrand, S | 1 |
| Loo, V | 1 |
| Beech, R | 1 |
| Best, L | 1 |
| Joseph, L | 1 |
| Bojarski, C | 1 |
| Epple, HJ | 1 |
| Kirstein, FW | 1 |
| Fromm, M | 1 |
| Bisson, S | 1 |
| Riecken, EO | 1 |
| Schulzke, JD | 1 |
| López, T | 1 |
| Roque, M | 1 |
| Stancheva, I | 1 |
| Katzarov, N | 1 |
| Koumanova, R | 1 |
| Ito, S | 1 |
| Suto, H | 1 |
| Ito, Y | 2 |
| Miyaji, H | 1 |
| Yamazaki, Y | 1 |
| Kato, T | 1 |
| Kuriyama, M | 1 |
| Kersulyte, D | 1 |
| Chowdhury, S | 1 |
| Santra, A | 1 |
| Rappuoli, R | 1 |
| Pizza, M | 1 |
| Covacci, A | 1 |
| Ng, TM | 1 |
| Khor, CJ | 1 |
| Tan, AL | 1 |
| Bouzakis, H | 1 |
| Balta, A | 1 |
| Vougadiotis, J | 1 |
| Kralios, N | 1 |
| Adamthwaite, D | 1 |
| Midolo, P | 1 |
| Yeomans, ND | 1 |
| Davidson, G | 1 |
| Lambert, J | 1 |
| Kees, F | 1 |
| Ohkura, R | 3 |
| Iida, N | 1 |
| Lawnik, M | 1 |
| Czkwianianc, E | 1 |
| Chmiela, M | 1 |
| Płaneta-Małecka, I | 1 |
| Rudnicka, W | 1 |
| Hackett, M | 1 |
| Vukobrat-Bijedić, Z | 1 |
| Lacević, N | 1 |
| Bratović, I | 1 |
| Gribajcević, M | 2 |
| Gogov, B | 1 |
| Radović, S | 1 |
| Raffaella Mele, M | 1 |
| Borro, P | 1 |
| Tessieri, L | 1 |
| Borgonovo, G | 1 |
| De Salvo, L | 1 |
| Cho, CH | 2 |
| Muraoka, S | 1 |
| Imai, T | 1 |
| Kashima, K | 1 |
| Mansurova, FKh | 1 |
| Kadyrov, DM | 1 |
| Odinaev, RI | 1 |
| Ishankulova, DM | 1 |
| Hurenkamp, GJ | 1 |
| Grundmeijer, HG | 1 |
| Vanis, N | 1 |
| Salaka, U | 1 |
| Pasalić, G | 1 |
| Garuz, R | 1 |
| Barrera, F | 1 |
| Malo, J | 1 |
| Tirado, M | 1 |
| Frevel, M | 1 |
| Daake, H | 1 |
| Janisch, HD | 1 |
| Kellner, HU | 1 |
| Krezdorn, HG | 1 |
| Tanneberger, D | 1 |
| Wack, R | 1 |
| Calafatti, SA | 1 |
| dos Santos, A | 1 |
| Deguer, M | 1 |
| Carvalho, AF | 1 |
| Bento, AP | 1 |
| Pereira, AA | 1 |
| Piovesana, H | 1 |
| Lerner, F | 1 |
| Nakajima, S | 1 |
| Hattori, T | 1 |
| Bamba, T | 1 |
| Buzás György, M | 1 |
| Székely, E | 1 |
| Illyés, G | 1 |
| Martínez Delgado, C | 1 |
| Grande, L | 1 |
| Otero Fernández, MA | 1 |
| Vargas, J | 1 |
| Thiberge, JM | 2 |
| Sierra, E | 2 |
| Goh, K | 1 |
| Cheah, P | 1 |
| Ranjeev, C | 1 |
| Rosmawati, M | 1 |
| Tan, Y | 1 |
| Chin, S | 1 |
| Romagnoli, P | 1 |
| Fasoli, A | 1 |
| Risso, D | 1 |
| Lantieri, PB | 1 |
| Miskovitz, P | 1 |
| Cooper, R | 1 |
| Nagler, J | 1 |
| Bezborodnyĭ, SD | 1 |
| Ling, KL | 1 |
| Ng, HS | 1 |
| Nuutinen, H | 2 |
| Hyvärinen, H | 1 |
| Miettinen, TA | 1 |
| Aalykke, C | 1 |
| Rune, S | 1 |
| Weywadt, L | 1 |
| Gjørup, T | 1 |
| Eriksen, J | 1 |
| Bonnevie, O | 1 |
| Bekker, C | 1 |
| Kromann-Andersen, H | 1 |
| Kjaergaard, J | 1 |
| Rask-Madsen, J | 1 |
| Vilien, M | 1 |
| Hansen, J | 1 |
| Justesen, T | 1 |
| Vyberg, M | 1 |
| Teglbjaerg, PS | 1 |
| Touati, E | 1 |
| Hofnung, M | 1 |
| Michel, V | 1 |
| Oki, Y | 1 |
| Smaill, FM | 1 |
| Aydin, A | 1 |
| Isler, M | 1 |
| Baena Díez, JM | 1 |
| López Mompó, C | 1 |
| Rams Rams, F | 1 |
| García Lareo, M | 1 |
| Rosario Hernández Ibáñez, M | 1 |
| Teruel Gila, J | 1 |
| Lago, A | 1 |
| Furlan, F | 1 |
| Maggi-Solcà, N | 1 |
| Valsangiacomo, C | 1 |
| Piffaretti, JC | 1 |
| Seensalu, R | 1 |
| Bardhan, K | 1 |
| Gromark, P | 1 |
| María Pajares, J | 1 |
| Lahaie, RG | 1 |
| Gaudreau, C | 1 |
| Mollison, LC | 1 |
| Stingemore, N | 1 |
| Wake, RA | 1 |
| Cullen, DJ | 1 |
| McGechie, DB | 1 |
| Clemente, R | 1 |
| Villani, MR | 1 |
| Quitadamo, M | 1 |
| Caruso, N | 1 |
| Bergoli, ML | 1 |
| Fakheri, H | 1 |
| Merat, S | 1 |
| Fazel, A | 1 |
| Muto, H | 1 |
| Satoh, R | 1 |
| Watanabe, M | 1 |
| Suen, BY | 1 |
| Hui, Y | 1 |
| Lai, MS | 1 |
| Al-Qurashi, AR | 1 |
| El-Morsy, F | 1 |
| Al-Quorain, AA | 1 |
| Wong, KW | 1 |
| Saeed, MA | 1 |
| Palka, M | 1 |
| Avidan, B | 1 |
| Keller, N | 2 |
| Bar-Meir, S | 1 |
| Shiotani, A | 1 |
| Okada, K | 1 |
| Yanaoka, K | 1 |
| Itoh, H | 1 |
| Nishioka, S | 1 |
| Sakurane, M | 1 |
| Matsunaka, M | 1 |
| Citterio, B | 1 |
| Lombardelli, G | 1 |
| Vittoria, E | 1 |
| Reddy, SG | 1 |
| Penland, RL | 1 |
| Barrowclough, S | 1 |
| Crocombe, W | 1 |
| Della Libera, E | 1 |
| Rohr, MR | 1 |
| Moraes, M | 1 |
| Siqueira, ES | 1 |
| Ferrari, AP | 1 |
| Ramirez, H | 1 |
| Schmidt, BA | 1 |
| Meier, R | 1 |
| Wettstein, A | 1 |
| Drewe, J | 1 |
| Geiser, HR | 1 |
| Nguyen, HN | 1 |
| Sanfeliu, I | 1 |
| Yakoob, J | 2 |
| Fan, XG | 1 |
| Hu, GL | 1 |
| Yang, HX | 1 |
| Liu, SH | 1 |
| Tan, DM | 1 |
| Li, TG | 1 |
| Zhang, Z | 2 |
| Ferrus, M | 1 |
| Gibson, J | 1 |
| Hopkins, RJ | 2 |
| Phillips, RH | 1 |
| Whitehead, MW | 1 |
| Doig, LA | 1 |
| Sieniawska, CE | 1 |
| Delves, HT | 1 |
| Thompson, RP | 1 |
| Powell, JJ | 1 |
| Murphy, B | 1 |
| Chan, KL | 1 |
| Zhou, H | 1 |
| Ng, DK | 1 |
| Tam, PK | 1 |
| Ell, C | 1 |
| Schoerner, C | 1 |
| Solbach, W | 1 |
| Ridl, W | 1 |
| Moser, W | 1 |
| Ruuska, T | 1 |
| Mäkipernaa, A | 1 |
| Hall, L | 1 |
| Eccles, M | 1 |
| Barton, R | 1 |
| Steen, N | 1 |
| Campbell, M | 1 |
| Morton, D | 1 |
| Perry, MJ | 1 |
| Sanders, DS | 2 |
| Morris, P | 1 |
| Rowland, A | 1 |
| Thompson, M | 1 |
| Mitchell, TR | 1 |
| Arents, NL | 1 |
| Smeets, LC | 1 |
| Degener, JE | 1 |
| Kate, V | 1 |
| Ananthakrishnan, N | 1 |
| Badrinath, S | 1 |
| Cicconi, V | 1 |
| Carloni, E | 1 |
| Franceschi, F | 1 |
| Nocente, R | 1 |
| Silveri, NG | 1 |
| Manna, R | 1 |
| Servidei, S | 1 |
| Bentivoglio, AR | 1 |
| Sotoudeh, M | 1 |
| Kamalian, N | 1 |
| Sazhin, VP | 1 |
| Fedorov, AV | 1 |
| Latham, SR | 1 |
| Wongkusoltham, P | 1 |
| Phaosawadi, K | 1 |
| Beales, IL | 1 |
| Magaret, N | 1 |
| Burm, M | 1 |
| Faigel, D | 1 |
| Peterson, W | 1 |
| Müller, H | 1 |
| Rappel, S | 1 |
| Wündisch, T | 2 |
| Bühling, A | 1 |
| Radun, D | 1 |
| Müller, WA | 1 |
| Kamberoglou, D | 1 |
| Polymeros, D | 1 |
| Sanidas, I | 1 |
| Doulgeroglou, V | 1 |
| Savva, S | 1 |
| Patra, E | 1 |
| Tzias, V | 1 |
| Yang, KC | 1 |
| Wang, CS | 1 |
| Kuo, CF | 1 |
| Ponich, T | 1 |
| Oravec, M | 1 |
| Whitsitt, P | 1 |
| Marcon, N | 1 |
| Dumont, A | 1 |
| Desrochers, S | 1 |
| Fan, X | 1 |
| Hu, G | 1 |
| Hildebrand, P | 1 |
| Bardhan, P | 1 |
| Rossi, L | 1 |
| Parvin, S | 1 |
| Rahman, A | 1 |
| Arefin, MS | 1 |
| Hasan, M | 1 |
| Glatz-Krieger, K | 1 |
| Terracciano, L | 1 |
| Gyr, N | 1 |
| Khan, AK | 1 |
| Lascols, C | 1 |
| Timm, S | 1 |
| Sailer, M | 1 |
| Fuchs, KH | 1 |
| McAtee, CP | 1 |
| Hoffman, PS | 1 |
| Laurent, J | 1 |
| Caekaert, A | 1 |
| Paerregaard, A | 1 |
| Gernow, A | 1 |
| Matzen, P | 1 |
| Mayr-Kanhäuser, S | 1 |
| Kränke, B | 1 |
| Kaddu, S | 1 |
| Müllegger, RR | 1 |
| Carbó, J | 1 |
| Iñiguez, A | 1 |
| Chiang, IP | 1 |
| Liu, SM | 1 |
| Kusano, Y | 1 |
| Esaki, M | 1 |
| Kurahara, K | 1 |
| Fukuda, T | 1 |
| Sahai, AV | 1 |
| Corder, FA | 1 |
| Alpen, B | 1 |
| Röbbecke, J | 1 |
| Neubauer, A | 1 |
| Meyer, JM | 1 |
| Silliman, NP | 1 |
| Siepman, NY | 1 |
| Sugg, JE | 1 |
| Morris, D | 1 |
| Bhattacharyya, H | 1 |
| King, EC | 1 |
| Wittig, J | 1 |
| Walker, S | 1 |
| Edwards, DI | 1 |
| Fujimura, S | 2 |
| Udagawa, H | 1 |
| Ozawa, K | 1 |
| Nakao, M | 1 |
| Miyagaw, K | 1 |
| Nakano, Y | 1 |
| Sakane, T | 1 |
| Tada, M | 1 |
| Nishimura, O | 1 |
| Fujino, M | 1 |
| Schilling, D | 1 |
| Messerer, P | 1 |
| Ott, MG | 1 |
| Schauwecker, P | 1 |
| Zober, A | 1 |
| Riemann, JF | 1 |
| Dariani, NE | 1 |
| Asgari, AA | 1 |
| Ricciardiello, L | 1 |
| Alampi, G | 1 |
| Di Pietro, C | 1 |
| Morelli, P | 1 |
| Roda, E | 1 |
| Poon, SK | 1 |
| Su, J | 1 |
| Yang, CC | 1 |
| Wang, WC | 1 |
| Kawamura, T | 1 |
| Watanabe, A | 1 |
| Levy, M | 1 |
| Copie-Bergman, C | 1 |
| Traulle, C | 1 |
| Lavergne-Slove, A | 1 |
| Brousse, N | 1 |
| de Mascarel, A | 1 |
| Hemery, F | 1 |
| Gaulard, P | 1 |
| Narayani, RI | 1 |
| Burton, MP | 1 |
| Young, GS | 1 |
| Kokkola, A | 1 |
| Härkönen, M | 1 |
| Haapiainen, R | 1 |
| Puolakkainen, P | 1 |
| Ladas, SD | 1 |
| Triantafyllou, K | 1 |
| Artikis, V | 1 |
| Raptis, SA | 1 |
| Parsons, HK | 1 |
| Carter, MJ | 1 |
| Aragaki, C | 1 |
| Husson, MO | 1 |
| Barbier, C | 1 |
| Sizemore, CF | 1 |
| Quispe, JD | 1 |
| Amsler, KM | 1 |
| Modzelewski, TC | 1 |
| Merrill, JJ | 1 |
| Stevenson, DA | 1 |
| Foster, LA | 1 |
| Slee, AM | 1 |
| Yeh, YC | 1 |
| Fang, CT | 1 |
| Ferguson, RA | 1 |
| Yamamoto, N | 1 |
| Fu, HY | 1 |
| Tanimura, H | 1 |
| Hiraishi, H | 1 |
| Kanke, K | 1 |
| Terano, A | 1 |
| Kuwayama, H | 1 |
| Suzuki, K | 1 |
| Suga, M | 1 |
| Takata, H | 1 |
| Ohara, T | 1 |
| Koizumi, K | 1 |
| Kiriyama, Y | 1 |
| Cuchí Burgos, E | 1 |
| Forné Bardera, M | 1 |
| Quintana Riera, S | 1 |
| Lite Lite, J | 1 |
| Garau Alemany, J | 1 |
| Mele, R | 1 |
| Wedi, B | 1 |
| Kapp, A | 1 |
| Prazeres Magalhães, P | 1 |
| De Magalhães Queiroz, DM | 1 |
| Campos Barbosa, DV | 1 |
| Aguiar Rocha, G | 1 |
| Nogueira Mendes, E | 1 |
| Valle Corrêa, PR | 1 |
| Camargos Rocha, AM | 1 |
| Martins Teixeira, L | 1 |
| Affonso de Oliveira, C | 1 |
| Vallve, M | 1 |
| Noguchi, K | 1 |
| Geler, A | 1 |
| Gal, E | 1 |
| Fishman, M | 1 |
| Bachor, J | 1 |
| Shimodaira, K | 1 |
| Kaneko, T | 1 |
| Ishida, K | 1 |
| Ikeno, T | 1 |
| Sugiyama, A | 1 |
| Ota, H | 1 |
| Harikrishnan, P | 1 |
| Bindayna, KM | 1 |
| Knippig, C | 1 |
| Arand, F | 1 |
| Nilius, M | 1 |
| Klein, U | 1 |
| Hasegawa, M | 1 |
| Saika, T | 1 |
| Nishida, M | 1 |
| Kawamura, M | 1 |
| Ando, R | 1 |
| Katelaris, P | 1 |
| Powell, K | 5 |
| Cheng, A | 1 |
| Leung, JW | 1 |
| George, LL | 2 |
| Ostapowicz, N | 1 |
| Pallecaros, A | 1 |
| Trowell, JE | 4 |
| Fadlalla, H | 1 |
| al-Homsi, M | 1 |
| Nnalue, NA | 1 |
| Goodwin, S | 1 |
| Boehme, D | 1 |
| Sim, AJ | 1 |
| Goggin, PM | 1 |
| Spychal, RT | 1 |
| Jackson, PA | 1 |
| Corbishley, CM | 1 |
| Diver-Haber, A | 1 |
| Jonas, A | 1 |
| Howie, CA | 1 |
| Hakala, K | 1 |
| Väänänen, H | 1 |
| Playford, RJ | 2 |
| Ayesu, K | 1 |
| Li, SK | 1 |
| Spencer, G | 1 |
| Brooks, S | 1 |
| Prosser, S | 1 |
| Neithercut, WD | 1 |
| Chausson, Y | 2 |
| Costa, EL | 1 |
| Maia, AF | 1 |
| Brandao, MJ | 1 |
| Rodrigues, DC | 1 |
| Goldie, J | 1 |
| Hollingsworth, J | 1 |
| Silletti, C | 1 |
| Richardson, H | 1 |
| Evans, DG | 3 |
| Evans, DJ | 3 |
| Dobrilla, G | 1 |
| Piazzi, L | 1 |
| Amplatz, S | 1 |
| Benvenuti, S | 1 |
| Di Fede, F | 1 |
| Lenne, J | 1 |
| Moore-Jones, D | 1 |
| Devine, M | 1 |
| Walton, M | 1 |
| Renkonen, OV | 1 |
| Vainio, U | 1 |
| Heatley, RV | 1 |
| Weil, J | 3 |
| Beardshall, K | 1 |
| Moss, S | 1 |
| Gill, J | 1 |
| Ghosh, P | 1 |
| Alpert, LC | 1 |
| Leen, E | 1 |
| Dorval, ED | 1 |
| Loulergue, J | 1 |
| Barbieux, JP | 1 |
| Metman, EH | 1 |
| de Muret, A | 1 |
| Lukash, NV | 1 |
| Kriuchkova, ON | 1 |
| Gofel'd, AM | 1 |
| Varrentrapp, M | 1 |
| Lange, P | 1 |
| Müller, MJ | 1 |
| Schorn, T | 1 |
| Bär, W | 1 |
| Khoo, SH | 1 |
| Blackwell, N | 1 |
| Hirschl, MM | 1 |
| Berger, J | 1 |
| Fullarton, GM | 1 |
| Chittajalu, R | 1 |
| el Nujumi, AM | 1 |
| MacDonald, AM | 1 |
| Dahill, SW | 1 |
| Castro, Lde P | 1 |
| Prewett, EJ | 1 |
| Smith, JT | 1 |
| Hudson, M | 1 |
| Sawyerr, AM | 1 |
| Lind, CD | 1 |
| Jobson, R | 1 |
| Gant, P | 1 |
| Ormand, JE | 1 |
| Carpenter, HA | 1 |
| Phillips, SF | 1 |
| Uppal, R | 1 |
| Lateef, SK | 1 |
| Korsten, MA | 1 |
| Paronetto, F | 1 |
| Lieber, CS | 1 |
| Morden, A | 1 |
| Xia, DH | 1 |
| Jiang, SJ | 1 |
| Wang, RN | 1 |
| Zhang, ZH | 1 |
| Xu, WW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Comparison of Helicobacter Pylori Treatment Between Modified Quadruple Therapy and Tailored Eradication Based on the Presence of Clarithromycin Resistance[NCT05002595] | 270 participants (Actual) | Observational | 2018-01-01 | Completed | |||
| Helicobacter Pylori Resistance. A Study of Morbidity, Immunological and Clinical Phenotypes[NCT05019586] | 185 participants (Actual) | Observational | 2010-04-15 | Completed | |||
| A Phase 3 Randomized Multicenter Study to Evaluate the Efficacy and Safety of Open-Label Dual Therapy With Oral Vonoprazan 20 mg or Double-Blind Triple Therapy With Oral Vonoprazan 20 mg Compared to Double-Blind Triple Therapy With Oral Lansoprazole 30 mg[NCT04167670] | Phase 3 | 1,046 participants (Actual) | Interventional | 2019-12-10 | Completed | ||
| Comparison of the Efficacy of Clarithromycin-based Triple Therapy Versus Quadruple Therapies in the First Line Therapy of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial[NCT01906879] | Phase 4 | 1,620 participants (Anticipated) | Interventional | 2013-06-30 | Recruiting | ||
| Comparative Recurrence Rate Investigation of Esomeprazole Versus Lansoprazole in Triple-Combination Therapy to Eradicate Helicobacter Pylori Infection Among Pediatrics: Multicentre, Randomized, and Controlled Trials[NCT05861687] | Phase 2/Phase 3 | 51 participants (Actual) | Interventional | 2021-08-01 | Completed | ||
| Efficacy of High Dose of Amoxicillin And Metronidazole Plus Bismuth For Helicobacter Pylori Treatment In Naive Patients : A Randomized Clinical Trial[NCT03557437] | Phase 4 | 216 participants (Actual) | Interventional | 2018-05-25 | Completed | ||
| The Effect of Different Time Intervals on Rescue Treatment of Helicobacter Pylori Infection: a Prospective, Multicenter Observational Study[NCT05620589] | 626 participants (Anticipated) | Observational | 2022-11-11 | Not yet recruiting | |||
| The Effect of Different Time Intervals on Rescue Treatment of Helicobacter Pylori Infection: a Prospective, Multicenter Observational Study[NCT05620602] | 628 participants (Anticipated) | Observational | 2022-11-11 | Not yet recruiting | |||
| Comparison of Empirical and Genotypic Resistance Guided Tailored Therapy for Helicobacter Pylori Infection[NCT04006340] | 62 participants (Anticipated) | Interventional | 2019-01-04 | Enrolling by invitation | |||
| European Registry on the Management of Helicobacter Pylori Infection[NCT02328131] | 10,000 participants (Anticipated) | Observational | 2013-06-30 | Recruiting | |||
| A Randomized Controlled Study: Concomitant Versus Hybrid Therapy in the Treatment of Helicobacter Pylori Infection[NCT03572777] | 159 participants (Actual) | Interventional | 2018-04-15 | Completed | |||
| An Open-Label, Randomized, Crossover Study to Evaluate the Pharmacokinetic Interaction After Multiple Oral Doses of Tegoprazan, Metronidazole, Tetracycline and Bismuth in Healthy Volunteers[NCT04066257] | Phase 1 | 32 participants (Actual) | Interventional | 2019-01-17 | Completed | ||
| Comparison of 7-day Proton Pump Inhibitor (PPI)-Clarithromycin Containing Triple Therapy and 10-day Bismuth Quadruple Therapy for Helicobacter Eradication as First-line Regimen: Randomized Controlled Trial[NCT02557932] | Phase 3 | 352 participants (Actual) | Interventional | 2015-09-30 | Completed | ||
| High Eradication Rate of Helicobacter Pylori Infection With Moxifloxacin-Based Triple Therapy in Comparison With Levofloxacin-Based Sequential Therapy: Randomized Controlled Trials[NCT05863858] | Phase 3 | 162 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Helicobacter Pylori Eradication Therapy in Portugal: Prospective, Randomized, Blind and Multicentre Trial on the Efficacy of Quadruple Therapies and Their Clinical Impact, and Immunological and Gut Microbiota Changes[NCT05449028] | 230 participants (Anticipated) | Interventional | 2022-05-01 | Recruiting | |||
| The Efficacy of Bismuth-containing Quadruple Therapy in the First-line Treatment of Helicobacter Pylori Infection in 10 Days and 14 Days: a Prospective, Randomized, Controlled Study[NCT05586113] | Phase 4 | 398 participants (Anticipated) | Interventional | 2023-02-06 | Not yet recruiting | ||
| Comparison of Hybrid and Bismuth Containing Quadruple Therapies for Helicobacter Pylori Eradication: a Randomized Controlled Trial[NCT02541864] | 330 participants (Actual) | Interventional | 2013-07-31 | Completed | |||
| Comparison of Vonoprazan and Amoxicillin Dual Therapy With Standard Triple Therapy With Proton Pump Inhibitor for Helicobacter Pylori Eradication; a Randomized Control Trial[NCT04901663] | Phase 4 | 179 participants (Actual) | Interventional | 2021-06-21 | Completed | ||
| Genotypic Resistance Guided Therapy in the Treatment of Helicobacter Pylori Infection[NCT01725906] | Phase 4 | 450 participants (Anticipated) | Interventional | 2012-11-30 | Recruiting | ||
| Intraluminal Therapy for Helicobacter Pylori Infection[NCT03124420] | Phase 4 | 100 participants (Actual) | Interventional | 2017-04-28 | Completed | ||
| A Phase III Randomized Trial of Three Antibiotic Regimens to Eradicate Helicobacter Pylori[NCT01061437] | Phase 3 | 1,859 participants (Actual) | Interventional | 2009-06-30 | Completed | ||
| A Prospective Randomized Trial of Levofloxacin-amoxicillin Triple Therapy vs. Levofloxacin-tetracycline Quadruple Therapy in Second-line Helicobacter Pylori Treatment[NCT02978157] | 102 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Comparison of Two Rescue Therapies for Helicobacter Pylori Infection - A Multicenter Randomized Controlled Trial[NCT02547012] | 51 participants (Actual) | Interventional | 2013-11-30 | Completed | |||
| Reinfection After Eradication of Helicobacter Pylori Infection in Adult :A National Multicentre Study[NCT02674802] | 3,500 participants (Anticipated) | Observational | 2015-12-31 | Recruiting | |||
| Phase 4, Prospective, Randomized and Comparative Study Comparing Sequential and Concomitant Therapy for Helicobacter Pylori Eradication in Routine Clinical Practice[NCT01273441] | Phase 4 | 338 participants (Actual) | Interventional | 2010-12-31 | Completed | ||
| [NCT01792700] | Phase 4 | 648 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| Ten Days Quadruple Versus Sequential Therapy as Empirical First and Second Line Treatment for Helicobacter Pylori Eradication: a Randomized Crossover Trial[NCT01760824] | 391 participants (Actual) | Interventional | 2011-05-31 | Completed | |||
| Does Eradication of H-pylori in Pregnant Patients With Iron Deficiency Anemia Have an Effect on Iron Replacement Therapy?[NCT03347513] | Phase 4 | 150 participants (Anticipated) | Interventional | 2017-11-25 | Recruiting | ||
| Comparing the Efficacy and Impact on Gastrointestinal Microbiome of Reverse Hybrid Therapy and Bismuth Quadruple Therapy in Helicobacter Pylori Eradication[NCT02547038] | 352 participants (Actual) | Interventional | 2015-02-28 | Completed | |||
| Evaluation of the Efficacy of Concomitant Therapy for Eradication of Helicobacter Pylori[NCT01922765] | Phase 4 | 540 participants (Anticipated) | Interventional | 2013-08-31 | Recruiting | ||
| A Randomized Controlled Trial of Triple Therapy Versus Sequential Therapy Versus Concomitant Therapy as First Line Treatment for Helicobacter Pylori Infection[NCT02092506] | Phase 4 | 462 participants (Actual) | Interventional | 2011-12-31 | Completed | ||
| Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial[NCT02635191] | Phase 4 | 200 participants (Anticipated) | Interventional | 2014-03-31 | Recruiting | ||
| Prospective, Randomized Controlled Trial Comparing Amoxicillin and Metronidazole Based Bismuth-containing Quadruple Therapy With Amoxicillin and Clarithromycin Based Quadruple Therapy for First-line Helicobacter Pylori Eradication[NCT02175901] | Phase 4 | 215 participants (Actual) | Interventional | 2014-07-31 | Completed | ||
| Comparison of the Efficacy of Clarithromycin-based Triple Therapy for 14 Days Versus Sequential Therapy for 10 Days in the First Line Therapy for Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial[NCT01607918] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| A Greek, Single Center, Randomized, Double Blind Controlled Clinical Study Comparing the 10-day Versus the 14-day Concomitant Proton Pump Inhibitor [PPI] + Amoxicillin + Metronidazole + Clarithromycin (PAMC) Therapeutic Scheme as First-line Treatment Stra[NCT02959255] | Phase 4 | 364 participants (Actual) | Interventional | 2017-01-30 | Completed | ||
| The Efficacy of the Culture Based Tailored Therapy for Helicobacter Pylori Eradication Comparing With the Traditional 2nd Line Rescue Therapy in Korean[NCT02349685] | 219 participants (Actual) | Interventional | 2010-01-31 | Completed | |||
| The Efficacy of 10-day Metronidazole and Levofloxacin Containing Sequential Therapy and 10-day Levofloxacin-containing Triple Therapy In Second Line Helicobacter Pylori Eradication Therapies[NCT02596620] | 164 participants (Actual) | Interventional | 2013-10-31 | Completed | |||
| Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Triple Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection- A Multi-center Randomized Trial[NCT01537055] | Phase 4 | 600 participants (Anticipated) | Interventional | 2012-02-29 | Recruiting | ||
| A Phase 3, Randomized, Double-Blind, Double Dummy, Multicenter, Parallel Group Comparison Study to Evaluate Efficacy and Safety of a Triple Therapy With TAK-438, Amoxicillin and Clarithromycin by Comparison With a Triple Therapy With AG-1749 (Lansoprazole[NCT01505127] | Phase 3 | 650 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Optimized Bismuth Quadruple Therapy vs Triple Standard Therapy for Helicobacter Pylori Eradication: Clinical Efficacy Randomized Trial[NCT05664685] | Phase 4 | 204 participants (Anticipated) | Interventional | 2022-10-17 | Recruiting | ||
| 10 Day Concomitant Versus 14 Day Hybrid Regimen as First Line H. Pylori Eradication Treatment in a High Clarithromycin Resistance Area. A Multicenter Randomized Equivalence Trial[NCT03592069] | Phase 4 | 345 participants (Actual) | Interventional | 2018-02-21 | Completed | ||
| Comparison Between Hybrid, Reverse Hybrid, and Non-Bismuth Levofloxacin Quadruple Regimens for Helicobacter Pylori Infection in Egypt: A Randomized Controlled Trial[NCT04039412] | Phase 4 | 330 participants (Actual) | Interventional | 2018-06-01 | Completed | ||
| Comparison of the Efficacy of 14-day Sequential Therapy and 10-day Bismuth Quadruple Therapy in the Second Line Therapy for Helicobacter Pylori Infection: A Multi-center Randomized Trial[NCT03208426] | Phase 4 | 240 participants (Anticipated) | Interventional | 2017-10-01 | Recruiting | ||
| HELicobacter Pylori Screening to Prevent Gastrointestinal Bleeding in Patients With Acute Myocardial Infarction Trial Based on the SWEDEHEART Registry (HELP-SWEDEHEART)[NCT05024864] | 22,000 participants (Anticipated) | Interventional | 2021-11-17 | Recruiting | |||
| Effects of Helicobacter Pylori Eradication Therapy in Children With Chronic Immune Thrombocytopenic Purpura[NCT03172676] | Phase 4 | 75 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | ||
| Strategy on the Increment of H. Pylori Eradication Rate and Investigating the Gastric Pathology and Antimicrobial Resistance in Diabetic Patients[NCT02466919] | Phase 4 | 114 participants (Actual) | Interventional | 2014-05-31 | Completed | ||
| Comparison of 12-day Reverse Hybrid Therapy and 12-day Standard Triple Therapy for Helicobacter Pylori Infection - a Randomized Controlled Trial (REHYTRI Study)[NCT02359435] | 440 participants (Actual) | Interventional | 2012-10-31 | Completed | |||
| "Phase 4, Prospective, Randomized Study Comparing 14-day Non-bismuth Quadruple Hybrid and Concomitant Therapies for Helicobacter Pylori Eradication in Settings With High Clarithromycin Resistance"[NCT01464060] | Phase 4 | 400 participants (Anticipated) | Interventional | 2011-09-30 | Recruiting | ||
| Comparison Between Ten Days Sequential Treatment (With Metronidazole or Tetracycline) and Ten Days Standard Triple Therapy of Helicobacter Pylori[NCT01573975] | Phase 4 | 345 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| Personalized Treatment for Refractory H Pylori Infection[NCT02547025] | 126 participants (Actual) | Interventional | 2012-08-01 | Completed | |||
| A Randomized Clinical Trial to Examine the Efficacy of a Clarithromycin-, Amoxicillin-, and Metronidazole-Based Regimen to Eradicate Helicobacter Pylori Infections in Pasto, Colombia[NCT00719420] | Phase 3 | 151 participants (Actual) | Interventional | 2006-04-30 | Completed | ||
| Efficacy and Safety of Quadruple Therapy by Bismuth Subcitrate Potassium, Metronidazole, and Tetracycline Given X 10 Days With Omeprazole in Eradication of Helicobacter Pylori: A Comparison to Omeprazole, Amoxicillin and Clarithromycin Given X 7 Days[NCT00669955] | Phase 3 | 440 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication.[NCT00841854] | Phase 4 | 199 participants (Actual) | Interventional | 2008-06-30 | Completed | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT05049902] | Phase 4 | 1,300 participants (Actual) | Interventional | 2021-09-21 | Completed | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Multicenter Randomized Clinical Trial of 10 and 14 Days[NCT04901117] | Phase 4 | 1,300 participants (Anticipated) | Interventional | 2021-06-30 | Not yet recruiting | ||
| Comparison of the Efficacy of Levofloxacin-based Sequential Therapy and Bismuth Quadruple Therapy in the Second Line and Third Line Therapy for Helicobacter Pylori Infection- A Multi-center Randomized Trial[NCT03148366] | Phase 3 | 560 participants (Actual) | Interventional | 2015-02-28 | Completed | ||
| Phase IV Study Comparing the Duration of Sequential Therapy[NCT01042184] | Phase 4 | 900 participants (Actual) | Interventional | 2009-12-31 | Completed | ||
| Comparison of the Eradications Rates of Sequential Therapy Versus Concomitant Therapy of Treatment of Helicobacter Pylori Infection in Korea[NCT02108184] | Phase 4 | 264 participants (Anticipated) | Interventional | 2014-02-28 | Recruiting | ||
| Helicobacter Pylori Treatment[NCT01668927] | Phase 4 | 424 participants (Actual) | Interventional | 2012-07-31 | Completed | ||
| The Phase 2 Study of FP-10, the Food Ingredient Derived From Milk Casein, on the Eradication Rates of Helicobacter Pylori by a Triple Therapy With Lansoprazole, Amoxicillin, and Clarithromycin[NCT00281047] | Phase 2/Phase 3 | 138 participants | Interventional | 2006-01-31 | Recruiting | ||
| Rifaximin Associated With Classic Triple Therapy (Inhibitor of Proton Pump, Amoxicillin and Clarithromycin) for the Eradication of Helicobacter Pylori Infection[NCT03124199] | Phase 3 | 40 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| Randomized, Controlled, Multicenter Phase III Study for the Efficacy and Tolerability of Triple Therapy With Esomeprazole, Moxifloxacin and Amoxicillin for Rescue Therapy of Helicobacter Pylori Infection[NCT00455806] | Phase 3 | 132 participants | Interventional | 2007-01-31 | Recruiting | ||
| Bismuth Quadruple Therapy in Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05802888] | Phase 4 | 260 participants (Anticipated) | Interventional | 2023-03-12 | Recruiting | ||
| Bismuth-containing Quadruple Therapy for Helicobacter Pylori First-line Treatment: A Multicenter Randomized Clinical Trial of Different Tetracycline Doses and Frequencies.[NCT05431075] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-07-31 | Not yet recruiting | ||
| Bismuth Quadruple Therapy for Helicobacter Pylori Rescue Therapy: A Multicenter Randomized Non-Inferiority Trial of Different Tetracycline Doses and Frequencies.[NCT05432115] | Phase 4 | 407 participants (Anticipated) | Interventional | 2022-06-25 | Recruiting | ||
| Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of Mucosa-associated Lymphoid Tissue Type of The Stomach[NCT00201422] | 70 participants (Actual) | Interventional | 1996-06-30 | Completed | |||
| Sequential Versus Concomitant Therapy for Helicobacter Pylori Infection[NCT00656968] | Phase 4 | 232 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| Effectiveness of Rifabutin Triple Therapy for First-line and Rescue Treatment of Helicobacter Pylori Infection[NCT04652284] | Phase 3 | 300 participants (Anticipated) | Interventional | 2021-05-01 | Not yet recruiting | ||
| Eradication of Helicobacter Pylori According to 23S rRNA Point Mutations Associated With Clarithromycin Resistance[NCT01453036] | Phase 4 | 924 participants (Actual) | Interventional | 2011-08-31 | Completed | ||
| Phase IV Study Comparing Helicobacter Pylori Empiric Eradication With Test-Guided Treatment in Patients With Peptic Ulcer Bleeding[NCT00687336] | Phase 4 | 178 participants (Anticipated) | Interventional | 2008-03-31 | Recruiting | ||
| Comparison of Clinical Outcomes in Bloodstream Infections With Carbapenem Hetero-resistant vs Carbapenem Resistant Klebsiella Pneumoniae (COMBAT)[NCT04229498] | 300 participants (Anticipated) | Observational | 2020-04-30 | Not yet recruiting | |||
| Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients[NCT03428568] | Phase 2 | 132 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | ||
| "Zinc Sulfate in the Treatment of Rosacea: A Randomized, Controlled Trial. Prospective, Double Blind, Randomized, Controlled Trial Comparing the Effects of Supplemental Zinc Sulfate and Placebo on the Severity of Rosacea."[NCT00395226] | 65 participants (Actual) | Interventional | 2006-07-31 | Terminated (stopped due to Difficulty recruiting subjects) | |||
| Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori[NCT05957432] | Phase 2 | 90 participants (Anticipated) | Interventional | 2023-07-15 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
H pylori eradication was determined by the ^13C-UBT test. (NCT04167670)
Timeframe: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Vonoprazan Dual Therapy | 77.2 |
| Vonoprazan Triple Therapy | 80.8 |
| Lansoprazole Triple Therapy | 68.5 |
H pylori eradication was determined by the ^13C-UBT test. (NCT04167670)
Timeframe: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Vonoprazan Dual Therapy | 69.6 |
| Vonoprazan Triple Therapy | 65.8 |
| Lansoprazole Triple Therapy | 31.9 |
H pylori eradication was determined by the ^13C-UBT test. (NCT04167670)
Timeframe: Baseline to 4 weeks after the last dose of study drugs (maximum duration of treatment was 2 weeks)
| Intervention | percentage of participants (Number) |
|---|---|
| Vonoprazan Dual Therapy | 78.5 |
| Vonoprazan Triple Therapy | 84.7 |
| Lansoprazole Triple Therapy | 78.8 |
Repeated endoscopy with rapid urease test, histological examination and culture or urea breath tests are conducted to assess H. pylori status. (NCT02541864)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 154 |
| Hybrid Therapy | 154 |
Number of participants with negative H pylori status in follow-up tests as a measure of successful eradication (NCT02978157)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo | 36 |
| Esomeprazole+Bismuth+Tetra+Levo | 49 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02547012)
Timeframe: six weeks after the end of anti-H pylori therapy.
| Intervention | participants (Number) |
|---|---|
| Esomeprazole+Amox+Levo+Tetra | 13 |
| Esomeprazole+Amox+Levo | 21 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (Number of Participants With Complete Eradication of Helicobacter Pylori) (NCT02547038)
Timeframe: sixth week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Pantoprazole+Bismuth+Tetra+Metro | 169 |
| (Panto+Amox+Clar+Metr)+(Panto+Amox) | 170 |
"the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens.~The eradication rate was evaluated by intention to treat (ITT)" (NCT02349685)
Timeframe: 6 weeks after completion of eradication
| Intervention | participants (Number) |
|---|---|
| 14 Day PBMT Group | 67 |
| 14 Day MEA Group | 63 |
| 14 Day Tailored Therapy Group | 36 |
"the efficacy of H. pylori eradication between a personalized therapy for H. pylori infection based on the results of antibiotics resistance by using H. pylori culture and minimal inhibitory concentration (MIC) and the traditional 2nd rescue regimens.~The eradication rate was evaluated by per-protocol analysis (PP)" (NCT02349685)
Timeframe: 6 weeks after completion of eradication
| Intervention | participants (Number) |
|---|---|
| 14 Day PBMT Group | 67 |
| 14 Day MEA Group | 63 |
| 14 Day Tailored Therapy Group | 37 |
Successful eradication of H. pylori is defined as (1) negative results of both rapid urease test and histology, or (2) a negative result of urea breath test at 4 weeks. (NCT02596620)
Timeframe: Negative results of H.pylori 4 weeks after eradication
| Intervention | percentage of eradication (Number) |
|---|---|
| Sequential Therapy | 91.4 |
| Triple Therapy | 81.5 |
Questionnaire to measure the number of Participants with Treatment-Emergent Adverse Events (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 49 |
| (2) Hybrid Regimen | 58 |
| (3) Levofloxacin Quadruple Regimen | 44 |
Measuring the curative rate of each regimen by a fecal antigen test (NCT04039412)
Timeframe: 40-44 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 102 |
| (2) Hybrid Regimen | 101 |
| (3) Levofloxacin Quadruple Regimen | 91 |
Questionnaire to evaluate the compliance with each treatment regimen (NCT04039412)
Timeframe: 10-14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| (1) Reverse Hybrid Regimen | 109 |
| (2) Hybrid Regimen | 107 |
| (3) Levofloxacin Quadruple Regimen | 108 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT02359435)
Timeframe: at the 6th week after the end of anti- H. pylori therapy
| Intervention | participants (Number) |
|---|---|
| Reverse Hybrid Therapy | 206 |
| Standard Triple Therapy | 191 |
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to clarithromycin at baseline. Resistance to clarithromycin defined as Minimum Inhibitory Concentration (MIC) of 1 ug/ml and above (NCT00669955)
Timeframe: Measured at baseline
| Intervention | participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 30 |
| Triple Therapy (OAC) 7 Days | 2 |
Eradication rates in the subset of patients with peptic ulcer (current or past history) at baseline are reported based on the per protocol population. Eradication must be confirmed at week 6 and week 10 by a negative Urea Breath Test conducted within the allocated windows. (NCT00669955)
Timeframe: Week 6 and week 10 follow-up visits
| Intervention | Participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 18 |
| Triple Therapy (OAC) 7 Days | 15 |
H. pylori Eradication defined as a negative C13-UBT (urea breath test) result at both Week 6 and Week 10 follow-up visits. (NCT00669955)
Timeframe: Week 6 and week 10 follow-up visits
| Intervention | Participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 166 |
| Triple Therapy (OAC) 7 Days | 112 |
Eradication rates in subset of patients infected with a bacterial strain confirmed as resistant to metronidazole at baseline. Resistance to metronidazole defined as Minimum Inhibitory Concentration (MIC) above 8 ug/ml (NCT00669955)
Timeframe: Measured at baseline
| Intervention | participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 38 |
| Triple Therapy (OAC) 7 Days | 28 |
"A treatment-emergent adverse event is defined as an event not present prior to exposure to the study medication or any event already present that worsens in either intensity or frequency following exposure to study medication up to 30 days after study discontinuation.~All safety analysis based on the safety population." (NCT00669955)
Timeframe: at the end of treatment (day 8-14), week 6 and wek 10 follow-up visits.
| Intervention | Participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 101 |
| Triple Therapy (OAC) 7 Days | 112 |
Tolerability of OBMT with respect to plasma bismuth concentrations: number of patients with bismuth concentrations above the toxic level (50 ug per liter) (NCT00669955)
Timeframe: Baseline (both arms), end of treatment (Day 11-14) and end of study (Day 70) OBMT arm only
| Intervention | participants (Number) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 0 |
Overall compliance: number of capsules dispensed - number of capsules returned/Number of prescribed capsules X 100. Percentages based on safety population (NCT00669955)
Timeframe: At the end of the treatment phase (days 8-14)
| Intervention | participants (Mean) |
|---|---|
| Quadruple Therapy (OBMT) 10 Days | 97.58 |
| Triple Therapy (OAC) 7 Days | 97.47 |
Percentage of patients that has comply with treatment, considered as intake of more than 90% of study drugs in patients who attended the post-treatment visit. (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 100 |
Percentage of Participants with H.Pylori Infection Eradication confirmed with urea breath test at least 4 weeks after the end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | percentage of participants (Number) |
|---|---|
| Rifaximin | 61 |
Patients with side effects present during treatment and in the 4 weeks after end of treatment (NCT03124199)
Timeframe: 1 month
| Intervention | participants (Number) | ||||
|---|---|---|---|---|---|
| with diarrhea | with metallic taste | headache | nausea | abdominal pain | |
| Rifaximin | 13 | 9 | 5 | 5 | 1 |
Evaluate eradication outcome by endoscopy urease test and histology or urea breath test (NCT00656968)
Timeframe: one month after finishing study drugs
| Intervention | participants (Number) |
|---|---|
| Concomitant Therapy (A) | 92 |
| Sequential Therapy (B) | 95 |
Good drug compliance is defined as taking equal to or more than 80% of eradication medicines (NCT00656968)
Timeframe: one month after finishing test therapy
| Intervention | participants (Number) |
|---|---|
| Concomitant Therapy (A) | 106 |
| Sequential Therapy (B) | 104 |
Eradication was determined by the C13-urea breath test 6 to 8 weeks after the eradication therapy when PPIs had not been used for at least 2 weeks. (NCT01453036)
Timeframe: 8 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| Convential AOC Group | 75.9 |
| Mutation Test Group | 91.2 |
| Convential AOM Group | 79.1 |
Modified Rosacea Severity Scoring System evaluating four signs of rosacea, flushing (transient erythema or redness), erythema (redness), papules and pustules and telangiectasia (spider-veins) ranges from 0 (best, absent) to 12 (worst, severe on all items) (NCT00395226)
Timeframe: 90 days
| Intervention | units on scale 0 to 12 (Mean) |
|---|---|
| Placebo (Lactose) | 4.9 |
| Zinc Sulfate | 5.1 |
213 reviews available for metronidazole and Infections, Helicobacter
| Article | Year |
|---|---|
V Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2021 |
V Spanish Consensus Conference on Helicobacter pylori infection treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2022 |
Treatment of
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Hypersensitivity; Drug Therapy, Combination; Helic | 2021 |
The influence of pretreatment with PPI on Helicobacter pylori eradication: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2021 |
Diagnosis and Treatment of
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobac | 2022 |
Helicobacter pylori Antibiotic Resistance in the United States Between 2011 and 2021: A Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2022 |
Heteroresistance to clarithromycin and metronidazole in patients with a Helicobacter pylori infection: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2022 |
Clinical relevance of the cagA and vacA s1m1 status and antibiotic resistance in Helicobacter pylori: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Clarithromycin; Drug Re | 2022 |
Host Cell Antimicrobial Responses against
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacteria | 2022 |
Third-line and rescue therapy for refractory
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter | 2023 |
Antibiotic Resistance of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2023 |
Antibiotic resistance in Helicobacter pylori: From potential biomolecular mechanisms to clinical practice.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicoba | 2023 |
Primary antibiotic resistance in Helicobacter pylori in China: a systematic review and meta-analysis.
Topics: Adult; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infect | 2023 |
Efficacy of genotypic susceptibility-guided tailored therapy for Helicobacter pylori infection: A systematic review and single arm meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Genotype; Helicobacter Infec | 2023 |
Recent progress in Helicobacter pylori treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 2020 |
Helicobacter pylori: A Review of Current Diagnostic and Management Strategies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Biopsy; Bismuth; Breath | 2020 |
Gastrointestinal: Rapid emergence of double-expressor lymphoma after Helicobacter pylori eradication therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Digestive System; Follow-Up Studies; Gastric Mu | 2021 |
Efficacy of second-line regimens for
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Multiple; Drug The | 2020 |
An update on current and advancing pharmacotherapy options for the treatment of H. pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2021 |
Antibiotic resistance of Helicobacter pylori in Australia and New Zealand: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Australia; Clarithromycin; Drug Resistance, Bacterial; Fluoroqui | 2021 |
Reverse hybrid therapy for Helicobacter pylori eradication: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2021 |
Helicobacter pylori eradication following first-line treatment failure in Europe: What, how and when chose among different standard regimens? A systematic review.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 2021 |
Treatment of Refractory
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2022 |
Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2021 |
Helicobacter pylori antimicrobial resistance in Melbourne, Australia. Time to review therapeutic guidelines?
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Australia; Clarithromycin; Drug Resistance, Bacterial; He | 2021 |
Novel and Effective Therapeutic Regimens for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2017 |
Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Antibiotic resistance in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2017 |
Helicobacter pylori management in ASEAN: The Bangkok consensus report.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Consensus; Drug Resistance, Bacterial; | 2018 |
Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Asia; Clarithromycin; Disease Eradication; Drug Resistance, Bact | 2017 |
World trends for H. pylori eradication therapy and gastric cancer prevention strategy by H. pylori test-and-treat.
Topics: Anti-Bacterial Agents; Clarithromycin; Consensus; Disease Eradication; Drug Resistance, Bacterial; G | 2018 |
Meta-analysis: High-dose vs. low-dose metronidazole-containing therapies for Helicobacter pylori eradication treatment.
Topics: Anti-Infective Agents; Dose-Response Relationship, Drug; Helicobacter Infections; Helicobacter pylor | 2018 |
Understanding treatment guidelines with bismuth and non-bismuth quadruple Helicobacter pylori eradication therapies.
Topics: Anti-Bacterial Agents; Antimicrobial Stewardship; Bismuth; Drug Resistance, Bacterial; Drug Therapy, | 2018 |
Clinical Inquiries: What's the best secondary treatment for patients who fail initial triple therapy for H pylori?
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Co | 2018 |
Systematic Review with Meta-Analysis: Concomitant Therapy vs. Triple Therapy for the First-Line Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedul | 2018 |
Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Drug Substitution; Heli | 2018 |
[New
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Resistance, Bacterial; Helico | 2018 |
Meta-analysis of three-in-one single capsule bismuth-containing quadruple therapy for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Drug Resistance, Bacterial; Drug Therapy, Combina | 2019 |
Metronidazole for Helicobacter pylori eradication therapy among children and adolescents in Japan: Overcoming controversies and concerns.
Topics: Adolescent; Anti-Bacterial Agents; Child; Disease Eradication; Helicobacter Infections; Helicobacter | 2019 |
Systematic review: Would susceptibility-guided treatment achieve acceptable cure rates for second-line Helicobacter pylori therapy as currently practiced?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Endoscopy; Helicobacter Infections; Helicobacter | 2019 |
Reconciliation of Recent Helicobacter pylori Treatment Guidelines in a Time of Increasing Resistance to Antibiotics.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Canada; Clarithromycin; Drug Resistance, Bact | 2019 |
A review of rescue regimens after clarithromycin-containing triple therapy failure (for Helicobacter pylori eradication).
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Dose-Response Relationship, Drug; Drug | 2013 |
Meta-analysis of bismuth quadruple therapy versus clarithromycin triple therapy for empiric primary treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; | 2013 |
Meta-analysis: is sequential therapy superior to standard triple therapy for Helicobacter pylori infection in Asian adults?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2013 |
Second and third line treatment options for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroquinolo | 2014 |
Meta-analysis of first-line triple therapy for helicobacter pylori eradication in Korea: is it time to change?
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Communicab | 2014 |
[Expanded indication of National Health Insurance for H. pylori associated gastritis].
Topics: Amoxicillin; Anti-Bacterial Agents; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Gast | 2014 |
Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combinatio | 2014 |
Review: efficacy and safety of hybrid therapy for Helicobacter pylori infection: a systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2015 |
[Study of infection strategies of Helicobacter pylori and host cell response against CagA oncoprotein].
Topics: Amino Acids; Antigens, Bacterial; Autophagy; Bacterial Proteins; Biomarkers, Pharmacological; Citric | 2014 |
[What is new in treating Helicobacter pylori infection?].
Topics: Adult; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combi | 2015 |
Sequential or concomitant therapy for eradication of Helicobacter pylori infection: A systematic review and meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Databases, Bibliographic; Drug Therapy, Combinat | 2015 |
Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2015 |
How to Effectively Use Bismuth Quadruple Therapy: The Good, the Bad, and the Ugly.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Hypersensitivity; Drug | 2015 |
Treatment of Helicobacter Pylori infection: optimization strategies in a high resistance era.
Topics: Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 CYP2C19; Drug Resistance, Bacterial; Drug Th | 2015 |
Review article: the global emergence of Helicobacter pylori antibiotic resistance.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; China; Clarithromycin; Drug Resistance, Microbial; Fem | 2016 |
Doxycycline in Eradication Therapy of Helicobacter pylori--a Systematic Review and Meta-Analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Therapy, Combination | 2016 |
Helicobacter pylori therapy: a paradigm shift.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2016 |
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Sche | 2016 |
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Sche | 2016 |
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Sche | 2016 |
The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Canada; Clarithromycin; Drug Administration Sche | 2016 |
[Antibiomania: Think of the manic syndrome secondary to antibiotic therapy].
Topics: Amoxicillin; Anti-Bacterial Agents; Bipolar Disorder; Clarithromycin; Drug Therapy, Combination; Fem | 2017 |
Nonbismuth concomitant quadruple therapy for Helicobacter pylori eradication in Chinese regions: A meta-analysis of randomized controlled trials.
Topics: Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Disease Eradication; Drug Therapy, Combin | 2016 |
Systematic review and meta-analysis: triple therapy combining a proton-pump inhibitor, amoxicillin and metronidazole for Helicobacter pylori first-line treatment.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacte | 2016 |
What is new in the management of Helicobacter pylori?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2008 |
Helicobacter pylori treatment: is sequential or quadruple therapy the answer?
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helico | 2008 |
[The new aspects of the eradication of Helicobacter pylori and the importance of bacterial resistance].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Administration Schedule; Drug Res | 2008 |
Helicobacter pylori: diagnosis and treatment.
Topics: Amoxicillin; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Fluoroq | 2009 |
Pylera for the eradication of Helicobacter pylori infection.
Topics: Administration, Oral; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Ad | 2009 |
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2010 |
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2010 |
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2010 |
Empiric quadruple vs. triple therapy for primary treatment of Helicobacter pylori infection: Systematic review and meta-analysis of efficacy and tolerability.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2010 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Sequential therapy or triple therapy for Helicobacter pylori infection: systematic review and meta-analysis of randomized controlled trials in adults and children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
[Helicobacter pylori eradication therapy in children].
Topics: Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; | 2009 |
Moxifloxacin-based triple therapy versus clarithromycin-based triple therapy for first-line treatment of Helicobacter pylori infection: a meta-analysis of randomized controlled trials.
Topics: Aza Compounds; Clarithromycin; Drug Therapy, Combination; Female; Fluoroquinolones; Helicobacter Inf | 2009 |
Helicobacter pylori eradication therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bac | 2010 |
[Modern Helicobacter pylori therapies in times of increasing anti biotic resistance].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2010 |
[Current perspective of the resistance of Helicobacter pylori strains to antimicrobial drugs].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Helico | 2010 |
Optimal therapy for Helicobacter pylori infections.
Topics: Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2011 |
Diagnosis and treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Clarithromycin; Denmark; Drug Therapy, | 2011 |
[New options for helicobacter pylori antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Administr | 2011 |
[Helicobacter pylori: an infection with local complications and systemic effects].
Topics: Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Asthma; Clarithromycin; Cross-Sectional | 2011 |
[Helicobacter pylori: what schemes of eradication are essential today?].
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Drug Resistance, Multiple, Bacterial; Drug Therapy, Co | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
A new look at anti-Helicobacter pylori therapy.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2011 |
[Helicobacter pylori. Update 2002].
Topics: Adenocarcinoma; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2002 |
[First line therapy for Helicobacter pylori eradication in France].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance; D | 2003 |
[How to treat after Helicobacter pylori eradication failure?].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combin | 2003 |
Triple vs. quadruple therapy for treating Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Ditiocarb; Drug Resistance, B | 2003 |
What are the global response rates to Helicobacter pylori eradication therapy?
Topics: Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2003 |
Is it time for quadruple therapy to be first line?
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Dru | 2003 |
Clinical inquiries. What regimens eradicate Helicobacter pylori?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug | 2003 |
Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromyci | 2003 |
[Eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enzym | 2003 |
[Antimicrobial resistance of Helicobacter pylori: clinical and molecular aspects].
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacte | 2003 |
[Guidelines for the diagnosis and treatment of H. pylori infection].
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Drug Therapy, Combination; Duodenal Ulcer; Dysp | 2003 |
[Second-line eradication therapy for H. pylori infection].
Topics: Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metron | 2004 |
Sequential therapy; a new treatment for Helicobacter pylori infection. But is it ready for general use?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromyci | 2004 |
[Eradication of Helicobacter pylori for idiopathic thrombocytopenic purpura].
Topics: Aged; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infecti | 2004 |
Eradicate H. pylori with effective treatment regimens.
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori | 2004 |
Appropriate strategies for testing and treating Helicobacter pylori in children: when and how?
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Breath Tests; Carrier State; Child; Ch | 2004 |
Tinidazole: from protozoa to Helicobacter pylori--the past, present and future of a nitroimidazole with peculiarities.
Topics: Amebiasis; Animals; Anti-Bacterial Agents; Antibiotic Prophylaxis; Antitrichomonal Agents; Clinical | 2004 |
Meta-analysis: the efficacy, adverse events, and adherence related to first-line anti-Helicobacter pylori quadruple therapies.
Topics: Antacids; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Guideline Adherence; Helic | 2004 |
[Evaluation of the efficacy of an Helicobacter pylori eradication treatment for idiopathic thrombocytopenic purpura patients].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; D | 2004 |
[Helicobacter pylori: reasons for eradication].
Topics: Adenocarcinoma; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis | 2004 |
A clinician's guide to managing Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diagnosis, Differential; Endoscopy; Gastrointestinal | 2005 |
[Failure in the eradication of Helicobacter pylori: the role of antibiotic resistance].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicoba | 2005 |
An update on anti-Helicobacter pylori treatment in children.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Clarithromycin; Helicobacter Infec | 2005 |
[Guidelines in the management of H. pylori infection in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2005 |
[Establishment of 2nd line treatment regimen for H. pylori infection--future prospect for the application for national health insurance system in Japan].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Therapy, Combination; Hel | 2005 |
[Drug sensitivity test for Helicobacter pylori].
Topics: Amoxicillin; Bacteriological Techniques; Clarithromycin; Drug Resistance, Bacterial; Helicobacter In | 2005 |
[Is antimicrobial susceptibility testing necessary before second-line treatment for Helicobacter pylori infection?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Re | 2005 |
[Second-line eradication therapy for H. pylori infection--PPI+AMPC+MNZ triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Drug Resistance, Bacterial; Dr | 2005 |
[High dose dual PPI/AMPC therapy for the treatment of Helicobacter pylori infection after failure of usual standard triple PPI/AMPC/CAM therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydrox | 2005 |
[Anti-Helicobacter pylori quadruple therapy].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter | 2005 |
[Comparison between one-week and two-week regimens of new triple therapy in H. pylori eradication].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Enzyme | 2005 |
[Investigation about 3rd line eradication of H. pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ampicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxy | 2005 |
[Helicobacter pylori eradication therapy for children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents | 2005 |
[Eradication of Helicobacter pylori in patients with end-stage renal disease undergoing dialysis treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dialysi | 2005 |
[Influence of cytochrome P450 2C19 genetic polymorphism on H. pylori eradication therapy].
Topics: Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cytochrome P-450 | 2005 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Levofloxacin-based triple therapy versus bismuth-based quadruple therapy for persistent Helicobacter pylori infection: a meta-analysis.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Gast | 2006 |
Role of Helicobacter pylori in functional dyspepsia.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Clarithromycin; Dose-Response Relationsh | 2006 |
Meta-analysis: duration of first-line proton-pump inhibitor based triple therapy for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspeps | 2007 |
[Treatment for Helicobacter pylori: current criteria].
Topics: Alkylating Agents; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug A | 2007 |
Pylera plus omeprazole: quadruple treatment for Helicobacter pylori.
Topics: Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Capsules; Drug Therapy, Combination; He | 2008 |
[Functional dyspepsia: approaches to Helicobacter pylori eradication therapy].
Topics: Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyspepsia; Gastritis | 1995 |
The best therapy for Helicobacter pylori infection: should efficacy or side-effect profile determine our choice?
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Resistan | 1995 |
Treating peptic ulcer: an ongoing challenge.
Topics: Antacids; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combina | 1995 |
Treatment strategies for symptom resolution, healing, and Helicobacter pylori eradication in duodenal ulcer patients.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; | 1994 |
[Management of the peptic ulcer patient in the Helicobacter pylori age].
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Breath Tests; Child; Drug Therapy, Com | 1994 |
Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 1994 |
Endoscopic and histologic resolution of gastric pseudolymphoma (reactive lymphoid hyperplasia) following treatment with bismuth and oral antibiotics.
Topics: Aged; Amoxicillin; Biopsy; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Helicobacter Infectio | 1994 |
The role of acid inhibition in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Depression, Chemical; Drug Administration Schedule; Drug Therapy, Combination; Gastric | 1994 |
Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobac | 1994 |
[Treatment of Helicobacter pylori infection in adults].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Gas | 1994 |
[Treatment of Helicobacter pylori infection in children].
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; Helicobacter I | 1994 |
Duodenal ulcer treatment: progress from pH to HP.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobacter Infect | 1994 |
[Alternatives of drug therapy in Helicobacter pylori infections].
Topics: Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metronidaz | 1994 |
Helicobacter pylori infection.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Hu | 1993 |
May Helicobacter pylori be important for dermatologists?
Topics: Bacterial Toxins; Case-Control Studies; Chronic Disease; Gastric Mucosa; Helicobacter Infections; He | 1995 |
Consensus conference. Medical treatment of peptic ulcer disease. Practice guidelines. Practice Parameters Committee of the American College of Gastroenterology.
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Biopsy; | 1996 |
Triple therapy and Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; | 1996 |
Bismuth therapy for Helicobacter pylori infection. A review of five years experience at a university hospital in Norway.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Follow-Up St | 1996 |
Critical evaluation of the treatment of peptic ulcer diseases associated with Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1996 |
[Helicobacter pylori eradication: triple therapy versus dual therapy].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Com | 1996 |
Pharmacoeconomic comparison of treatments for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Trials as Topic; Cost-Benefit Analysis; Dru | 1997 |
Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
The role of antisecretory drugs in the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Syner | 1997 |
Treatment strategies for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combin | 1997 |
Review: Helicobacter pylori. Current issues and new directions.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Therapy, Combination; | 1997 |
Peptic ulcer disease in the 1990s: an Asian perspective.
Topics: Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Asia; Bismu | 1997 |
Current European concepts in the management of Helicobacter pylori infection. The Maastricht Consensus Report. European Helicobacter Pylori Study Group.
Topics: Amoxicillin; Antitrichomonal Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Com | 1997 |
Treatment of Helicobacter pylori infection: a review of the world literature.
Topics: Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Resistance, Micro | 1996 |
Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Clinical Trials as Topic; Dru | 1997 |
[Helicobacter pylori infection and ulcer].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori | 1998 |
[Treatment of Helicobacter pylori infections].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Thera | 1998 |
[Problems following antibiotic therapy for eradication of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Clarithromycin; Drug Resistance, Microbi | 1998 |
Helicobacter pylori and peptic ulcer disease. Current evidence for management strategies.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Evidence-Based Medicine; Family | 1998 |
Clinical relevance of resistant strains of Helicobacter pylori: a review of current data.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combinatio | 1998 |
[Role of pantoprazole in the eradicating treatment of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
Helicobacter pylori, acid, and omeprazole revisited: bacterial eradication and rebound hypersecretion.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Gastric Acid; Gastroesophagea | 1999 |
[Importance of drug selection and the use of sensitivity tests for the eradication therapy for Helicobacter pylori].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; | 1999 |
[Antibiotic-resistant H. pylori strains in the last ten years in Japan].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infecti | 1999 |
[Eradication rate and side effect from a point of view of Helicobacter pylori eradication of peptic ulcer disease in dual therapy or new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
[Antibiotic resistance of Helicobacter pylori in Malmö. Therapeutic success in spite of antibiotic resistance].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, | 1999 |
Antibiotic treatment of Helicobacter pylori infection.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastrointestinal Di | 1999 |
[Treatment of Helicobacter pylori infections].
Topics: Clarithromycin; Clinical Protocols; Drug Resistance; Drug Therapy, Combination; Duodenal Ulcer; Fema | 1999 |
The importance of clarithromycin dose in the management of Helicobacter pylori infection: a meta-analysis of triple therapies with a proton pump inhibitor, clarithromycin and amoxycillin or metronidazole.
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Helicobacter Infec | 1999 |
Bismuth triple therapy: still a very important drug regimen for curing Helicobacter pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helico | 1999 |
How should Helicobacter pylori infected children be managed?
Topics: Anti-Bacterial Agents; Child; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; | 1999 |
[Resistance of Helivobacter pylori to antibacterial agents and possible ways of its treatment].
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Hum | 1999 |
Acne and rosacea. New and emerging therapies.
Topics: Acne Vulgaris; Aged; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Is | 2000 |
Microbial ecology and treatment of Helicobacter pylori infections: review.
Topics: Adenocarcinoma; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; | 2000 |
A meta-analysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2000 |
[How to eradicate Helicobacter pylori?].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Hu | 1999 |
Strategy for treatment of Helicobacter pylori infection in adults. II. Practical policy in 2000.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 2000 |
Implications of antibiotic resistance in the management of Helicobacter pylori infection: Canadian Helicobacter Study Group.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Gastrointestinal Diseases; Helico | 2000 |
Epidemiology of the antibiotic resistance of Helicobacter pylori in Canada.
Topics: Anti-Bacterial Agents; Canada; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; | 2000 |
[Helicobacter pylori resistance to metronidazole and to clarithromycin in Spain. A systematic review].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infections; Helicoba | 2001 |
Helicobacter pylori antibiotic resistance: trends over time.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter I | 2000 |
[Antimicrobial resistant test of H. pylori].
Topics: Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infections; Heli | 2001 |
[Selection of antibiotics and planning of eradication for H. pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Drug Administr | 2001 |
[A strategy for second-line anti-Helicobacter pylori therapy in patients with previously failed treatment].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Aryl Hydrocarbon Hydroxylases; Clarithromycin; | 2001 |
Helicobacter pylori: a clinical update.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Clinical Trials as Topic; Drug Therapy, Combinat | 2001 |
Antibiotic resistance of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infecti | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection.
Topics: Abietanes; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diterpenes; Drug T | 2001 |
Treatment of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Co | 2001 |
Current management of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 2001 |
Helicobacter pylori therapy: first-line options and rescue regimen.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combin | 2001 |
Helicobacter pylori eradication is superior to ulcer healing with or without maintenance therapy to prevent further ulcer haemorrhage.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infection | 2001 |
A novel therapeutic approach for Helicobacter pylori infection: the bismuth-based triple therapy monocapsule.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clinical Trials as Topic; Drug Combinations; Helicobacter | 2001 |
Risk factors for Helicobacter pylori resistance in the United States: the surveillance of H. pylori antimicrobial resistance partnership (SHARP) study, 1993-1999.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarith | 2002 |
Metronidazole resistance in Helicobacter pylori.
Topics: Animals; Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Bacterial; Forecasting; Helicob | 2002 |
Sources of variation of Helicobacter pylori treatment success in adults worldwide: a meta-analysis.
Topics: Adult; Anti-Bacterial Agents; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylo | 2002 |
[Development of Helicobacter pylori eradication therapy].
Topics: Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobact | 2002 |
[Drug sensitivity test for Helicobacter pylori].
Topics: Amoxicillin; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylor | 2002 |
[Guidelines of Helicobacter pylori eradication in children].
Topics: Amoxicillin; Breath Tests; Child; Clarithromycin; Drug Therapy, Combination; Europe; Gastroscopy; He | 2002 |
[New triple therapy for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Clinical Trials as Topic; Drug | 2002 |
[Classic triple therapy for Helicobacter pylori infection].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 2002 |
[Dual therapy for Helicobacter pylori resistance to anti microbial agents].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Proton pump inhibitor-based quadruple therapy regimen for Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Bismuth; Clarithromycin; Drug | 2002 |
[Effect of PPI/AM re-treatment regimen for the patients with Helicobacter pylori infection after failure of first line eradication therapy by PPI/AC regimens].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Enz | 2002 |
[Second line treatment regimen of PPI + AMPC + MNZ for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Benzimidazoles; Clarithromycin; Clinical Trial | 2002 |
[Minocycline-containing eradication therapy for patients with clarithromycin-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Benzimidazoles; Clarithromycin; Drug Administration Schedul | 2002 |
[Eradication therapy for clarithromycin-resistant and metronidazole-resistant Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; | 2002 |
[Role of proton pump inhibitors in the eradication therapy for Helicobacter pylori (overviews)].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Gastri | 2002 |
[Proton pump inhibitors: Omeprazole].
Topics: Amoxicillin; Clarithromycin; Clinical Trials as Topic; Depression, Chemical; Drug Therapy, Combinati | 2002 |
[Metronidazol (MNZ)].
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infection | 2002 |
[Sucralfate].
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; Gastric Ac | 2002 |
[Polaprezinc].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Anti-Ulcer Agents; Carnosine; Clarith | 2002 |
[Helicobacter heilmannii-associated gastritis].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Animals; Clarithromycin; Drug Therapy, Combina | 2002 |
Helicobacter pylori infection in skin diseases: a critical appraisal.
Topics: Amoxicillin; Clarithromycin; Clinical Trials as Topic; Comorbidity; Drug Therapy, Combination; Femal | 2002 |
Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Resistance, | 2002 |
Single vs. double dose of a proton pump inhibitor in triple therapy for Helicobacter pylori eradication: a meta-analysis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
[Should Helicobacter infection be treated?].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Female; Gastrointestinal Diseases; Helicobacter Infe | 1991 |
Helicobacter pylori and gastric ulcer therapy: reflections and uncertainties.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Cefixime; Cefotaxime; Cimetidine; Drug Therapy, Combinatio | 1992 |
Review article: the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Hel | 1992 |
Helicobacter pylori and duodenal ulceration.
Topics: Cimetidine; Duodenal Ulcer; Gastrins; Gastritis; Helicobacter Infections; Helicobacter pylori; Human | 1991 |
652 trials available for metronidazole and Infections, Helicobacter
| Article | Year |
|---|---|
Comparison of tailored
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2022 |
Bismuth-Based Quadruple Therapy versus Metronidazole-Intensified Triple Therapy as a First-Line Treatment for Clarithromycin-Resistant
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2022 |
Nitazoxanide-based therapeutic regimen as a novel treatment for Helicobacter pylori infection in children and adolescents: a randomized trial.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Therapy, Combination; He | 2022 |
Metagenomic Changes of Gut Microbiota following Treatment of
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter | 2022 |
A randomized controlled trial to compare Helicobacter pylori eradication rates between the empirical concomitant therapy and tailored therapy based on 23S rRNA point mutations.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2022 |
Bismuth, esomeprazole, metronidazole and amoxicillin or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter I | 2023 |
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2023 |
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2023 |
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2023 |
Prevalence and trends of multiple antimicrobial resistance of Helicobacter pylori in one tertiary hospital for 20 years in Korea.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2023 |
Second-line levofloxacin-based quadruple therapy versus bismuth-based quadruple therapy for Helicobacter pylori eradication and long-term changes to the gut microbiota and antibiotic resistome: a multicentre, open-label, randomised controlled trial.
Topics: Adult; Anti-Bacterial Agents; Australia; Bismuth; Clarithromycin; Drug Therapy, Combination; Esomepr | 2023 |
Ten-day concomitant and sequential therapy for Helicobacter pylori effective in region with high antibiotic resistance rates.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combin | 2022 |
Intravenous metronidazole-, levofloxacin-containing triple therapy for treating patients with Helicobacter pylori-related active peptic ulcer complications: A pilot study.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Esomeprazole; Helicobacter Infections | 2023 |
Tailored triple plus bismuth therapy based on previous antibiotic medication history for first-line Helicobacter pylori eradication: A randomized trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2023 |
A randomized superiority clinical trial: metronidazole improved the efficacy of high-dose dual therapy in Helicobacter pylori rescue treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; Helicob | 2023 |
New regimens as first-line eradication therapy for Helicobacter pylori infection in patients allergic to penicillin: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Cefuroxime; Drug Therapy, Combination; Helicobacter Inf | 2023 |
A "new" option in Helicobacter pylori eradication: High-dose amoxicillin dual therapy outperforms bismuth quadruple therapy in a high dual resistance setting.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicob | 2023 |
Bismuth, esomeprazole, metronidazole, and minocycline or tetracycline as a first-line regimen for Helicobacter pylori eradication: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter I | 2023 |
Minocycline vs. tetracycline in bismuth-containing quadruple therapy for Helicobacter pylori rescue treatment: a multicentre, randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 2023 |
Rifabutin-Containing Triple Therapy Versus Bismuth Quadruple Therapy for Helicobacter pylori Rescue Treatment: A Multicenter, Randomized Controlled Trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Esomeprazole; Helicobacter I | 2023 |
Comparison of the efficacies of triple, quadruple and sequential antibiotic therapy in eradicating Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 2023 |
Susceptibility-guided sequential strategy versus empirical therapy for Helicobacter pylori infection: study protocol for a randomised controlled trial.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; H | 2023 |
Twice-a-day PPI, tetracycline, metronidazole quadruple therapy with Pylera® or Lactobacillus reuteri for treatment naïve or for retreatment of Helicobacter pylori. Two randomized pilot studies.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 2019 |
Ten-Day Concomitant, 10-Day Sequential, and 7-Day Triple Therapy as First-Line Treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Administration Schedul | 2019 |
Comparison of concomitant therapy versus standard triple-drug therapy for eradication of Helicobacter pylori infection: A prospective open-label randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therap | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Long-term changes of gut microbiota, antibiotic resistance, and metabolic parameters after Helicobacter pylori eradication: a multicentre, open-label, randomised trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Disease Eradicatio | 2019 |
Efficacy and Cost-effectiveness Comparison of 10-Day, 14-Day Sequential Versus 14-Day Triple Therapies for Treating Helicobacter pylori Infection in Egyptian Patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Combination | 2020 |
Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resist | 2020 |
14-Day High-Dose Amoxicillin- and Metronidazole-Containing Triple Therapy With or Without Bismuth as First-Line Helicobacter pylori Treatment.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Monitoring; Drug Resistance; Drug Th | 2020 |
10-Day Versus 14-Day Quadruple Concomitant Nonbismuth Therapy for the Treatment of Helicobacter pylori Infection: Results From a Randomized Prospective Study in a High Clarithromycin Resistance Country.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2020 |
Equivalent efficacies of reverse hybrid and concomitant therapies in first-line treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dexlansoprazole; Drug Administratio | 2020 |
Amoxicillin or tetracycline in bismuth-containing quadruple therapy as first-line treatment for
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therapy, Com | 2020 |
Addition of bismuth to standard triple therapy for Helicobacter pylori eradication: a randomised controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Heli | 2020 |
Susceptibility-guided quadruple therapy is not superior to medication history-guided therapy for the rescue treatment of Helicobacter pylori infection: A randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Co | 2020 |
Empiric Versus Clarithromycin Resistance-Guided Therapy for Helicobacter pylori Based on Polymerase Chain Reaction Results in Patients With Gastric Neoplasms or Gastric Mucosa-Associated Lymphoid Tissue Lymphoma: A Randomized Controlled Trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Clarithromycin; DNA, Bacterial; Drug Resi | 2020 |
Randomised clinical trial comparing concomitant and hybrid therapy for eradication of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Croatia; Drug Administration Schedule; Dru | 2020 |
Ten-day bismuth-containing quadruple therapy versus 7-day proton pump inhibitor-clarithromycin containing triple therapy as first-line empirical therapy for the Helicobacter pylori infection in Korea: a randomized open-label trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2021 |
Randomized, double-blind, placebo-controlled clinical trial on the usefulness of probiotic Lactobacillus reuteri in bismuth-containing quadruple eradication therapy for infection with Helicobacter pylori.
Topics: Abdominal Pain; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; | 2022 |
Efficacy and safety of bismuth-based quadruple therapy for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Drug Therapy, Combination; Helicobac | 2021 |
Tetracycline-levofloxacin versus amoxicillin-levofloxacin quadruple therapies in the second-line treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 2021 |
Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administration Sc | 2017 |
Randomized Controlled Trial for Helicobacter pylori Eradication in a Naive Portuguese Population: Is Sequential Treatment Superior to Triple Therapy in Real World Clinical Setting?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Clarithromycin; Disease | 2017 |
Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; | 2017 |
A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Clarithromycin; Drug Administration Schedule; | 2017 |
Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Administrati | 2017 |
Comparison of Helicobacter pylori Eradication Rates of 2-Week Levofloxacin-Containing Triple Therapy, Levofloxacin-Containing Bismuth Quadruple Therapy, and Standard Bismuth Quadruple Therapy as a First-Line Regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; | 2017 |
Concomitant, sequential, and 7-day triple therapy in first-line treatment of Helicobacter pylori infection in Korea: study protocol for a randomized controlled trial.
Topics: Amoxicillin; Clarithromycin; Clinical Protocols; Drug Administration Schedule; Drug Therapy, Combina | 2017 |
Comparative Study of Clarithromycin- versus Metronidazole-Based Triple Therapy as First-Line Eradication for Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; F | 2017 |
Comparative study of Helicobacter pylori eradication rates of concomitant therapy vs modified quadruple therapy comprising proton-pump inhibitor, bismuth, amoxicillin, and metronidazole in Korea.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pyl | 2018 |
New single capsule of bismuth, metronidazole and tetracycline given with omeprazole versus quadruple therapy consisting of bismuth, omeprazole, amoxicillin and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a Chinese pro
Topics: Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; China; Cla | 2018 |
Randomized controlled trial: PPI-based triple therapy containing metronidazole versus clarithromycin as first-line treatment for Helicobacter pylori in adolescents and young adults in Japan.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infectio | 2018 |
Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; China; Clarithromycin; Drug Resistance, B | 2018 |
Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; He | 2018 |
The "three-in-one" formulation of bismuth quadruple therapy for Helicobacter pylori eradication with or without probiotics supplementation: Efficacy and safety in daily clinical practice.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infecti | 2018 |
Efficacies of Genotypic Resistance-Guided vs Empirical Therapy for Refractory Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacteriological Techniques; Breath Tests; Clarithro | 2018 |
Probiotic supplementation with Lactobacillus plantarum and Pediococcus acidilactici for Helicobacter pylori therapy: A randomized, double-blind, placebo-controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combin | 2018 |
Efficacy of Helicobacter pylori eradication regimens in Rwanda: a randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Disease Eradication; Doxyc | 2018 |
Comparison of 10 and 14 days of triple therapy versus 10 days of sequential therapy for Helicobacter pylori eradication: A prospective randomized study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Sc | 2018 |
Saccharomyces boulardii CNCM I-745 plus sequential therapy for Helicobacter pylori infections: a randomized, open-label trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicoba | 2019 |
Evaluation of the efficacy and safety of the hybrid scheme for eradication therapy of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dru | 2018 |
Intraluminal therapy for Helicobacter pylori infection.
Topics: Acetylcysteine; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration | 2019 |
Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Resistance, Bact | 2019 |
Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Administr | 2019 |
Risk of recurrent Helicobacter pylori infection 1 year after initial eradication therapy in 7 Latin American communities.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Breath | 2013 |
[Is sequential eradication of Helicobacter pylori effective? Sequential treatment more effective than triple therapy in patients with clarithromycin resistance].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2013 |
Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter | 2013 |
Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter | 2013 |
Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter | 2013 |
Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter | 2013 |
Penbactam for Helicobacter pylori eradication: a randomised comparison of quadruple and triple treatment schedules in an Iranian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Analysis of Variance; Anti-Bact | 2013 |
Randomised clinical trial comparing sequential and concomitant therapies for Helicobacter pylori eradication in routine clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 2014 |
Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, | 2013 |
Eradication of Helicobacter pylori according to 23S ribosomal RNA point mutations associated with clarithromycin resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2013 |
Long-term follow up Helicobacter Pylori reinfection rate after second-line treatment: bismuth-containing quadruple therapy versus moxifloxacin-based triple therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Disease-Fr | 2013 |
Randomised controlled trial: sequential vs. standard triple therapy for Helicobacter pylori infection in Chinese children-a multicentre, open-labelled study.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Asian People; Child; Child, Preschool; China; Clarit | 2013 |
Effect of dosing schemes of amoxicillin on eradication rates of Helicobacter pylori with amoxicillin-based triple therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Dr | 2014 |
Third-line rescue therapy with bismuth-containing quadruple regimen after failure of two treatments (with clarithromycin and levofloxacin) for H. pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helico | 2014 |
Sitafloxacin-based third-line rescue regimens for Helicobacter pylori infection in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cyto | 2014 |
Comparison of Helicobacter pylori eradication rates of standard 14-day quadruple treatment and novel modified 10-day, 12-day and 14-day sequential treatments.
Topics: Adult; Anti-Infective Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Helic | 2014 |
Ten day sequential versus 10 day modified bismuth quadruple therapy as empirical firstline and secondline treatment for Helicobacter pylori in Chinese patients: an open label, randomised, crossover trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Breath T | 2014 |
Effectiveness of sequential v. standard triple therapy for treatment of Helicobacter pylori infection in children in Nairobi, Kenya.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Cla | 2013 |
A randomized controlled trial comparing sequential with triple therapy for Helicobacter pylori in an Aboriginal community in the Canadian North.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; | 2013 |
Feasibility of shortening 14-day hybrid therapy while maintaining an excellent Helicobacter pylori eradication rate.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2014 |
Use of a combination formulation of bismuth, metronidazole and tetracycline with omeprazole as a rescue therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Combinations; Drug Resista | 2014 |
Helicobacter pylori eradication in renal recipient: triple or quadruple therapy?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Drug Therapy, Combination; | 2014 |
Clarithromycin Versus Metronidazole as First-line Helicobacter pylori Eradication: A Multicenter, Prospective, Randomized Controlled Study in Japan.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Resi | 2015 |
Efficacy of hybrid therapy as first-line regimen for Helicobacter pylori infection compared with sequential therapy.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; | 2014 |
Comparison of standard triple therapy, sequential therapy and moxifloxacin-based triple therapy for Helicobacter pylori infection: Patients' compliance and bacterial eradication rates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; | 2014 |
A comparison between 15-day sequential, 10-day sequential and proton pump inhibitor-based triple therapy for Helicobacter pylori infection in Korea.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Clarithromycin | 2014 |
A randomised clinical trial of 10-day concomitant therapy and standard triple therapy for Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Clarithromycin | 2014 |
Sequential therapy versus standard triple therapy for Helicobacter pylori eradication in children: any advantage in clarithromycin-resistant strains?
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Child; Child, Preschool; Clarithromyci | 2014 |
Comparison of efficacy and safety of levofloxacin-containing versus standard sequential therapy in eradication of Helicobacter pylori infection in Korea.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; | 2015 |
Reverse sequential therapy achieves a similar eradication rate as standard sequential therapy for Helicobacter pylori eradication: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combinati | 2015 |
Concomitant therapy achieved the best eradication rate for Helicobacter pylori among various treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 2015 |
Ten-day triple therapy versus sequential therapy versus concomitant therapy as first-line treatment for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Gastr | 2015 |
Ciprofloxacin-containing versus clarithromycin-containing sequential therapy for Helicobacter pylori eradication: A randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Ciprofloxacin; Clarithromycin; Drug Therapy, Combination; Fema | 2015 |
Optimised empiric triple and concomitant therapy for Helicobacter pylori eradication in clinical practice: the OPTRICON study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2015 |
[Estimation of efficiency of anti-helicobacter therapy in patients with a chronic pancreatitis combined with an erosive gastropathy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 2014 |
Coenzyme Q10 in combination with triple therapy regimens ameliorates oxidative stress and lipid peroxidation in chronic gastritis associated with H. pylori infection.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Double-Blind Method; Drug Therapy, Com | 2015 |
Concomitant and hybrid therapy for Helicobacter pylori infection: A randomized clinical trial.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Esomeprazole; F | 2015 |
Fourteen-day optimized levofloxacin-based therapy versus classical quadruple therapy for Helicobacter pylori treatment failures: a randomized clinical trial.
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Biopsy, Needle; Bismuth; Dose-Response Relationship, | 2015 |
Different treatment choice for first-line treatment of Helicobacter pylori in an area with a high antibiotic resistance.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacteri | 2014 |
The impact of amalgam dental fillings on the frequency of Helicobacter pylori infection and H. pylori eradication rates in patients treated with concomitant, quadruple, and levofloxacin-based therapies.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dental A | 2015 |
Probiotics for standard triple Helicobacter pylori eradication: a randomized, double-blind, placebo-controlled trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2015 |
Efficacy of moxifloxacin-based sequential therapy for first-line eradication of Helicobacter pylori infection in gastrointestinal disease.
Topics: Aged; Anti-Bacterial Agents; Biopsy; Breath Tests; Clarithromycin; Drug Administration Schedule; Dru | 2015 |
A large randomised controlled intervention trial to prevent gastric cancer by eradication of Helicobacter pylori in Linqu County, China: baseline results and factors affecting the eradication.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; China; Double-Blind Method; Drug Therapy, Combinati | 2016 |
Comparison of Second-Line Quadruple Therapies with or without Bismuth for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Female; Helicobacter Infections; Helicobacter pylori; Humans; Mal | 2015 |
Seven-Day Nonbismuth Containing Quadruple Therapy Could Achieve a Grade "A" Success Rate for First-Line Helicobacter pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Combinations; Esomeprazole; Fe | 2015 |
Tailored versus Triple plus Bismuth or Concomitant Therapy as Initial Helicobacter pylori Treatment: A Randomized Trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; China; Clarithromycin; Cytochrome P-450 CYP | 2016 |
Effect of Pretreatment with Lactobacillus delbrueckii and Streptococcus thermophillus on Tailored Triple Therapy for Helicobacter pylori Eradication: A Prospective Randomized Controlled Clinical Trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combinati | 2015 |
Current Status of Five Different Regimens for Empiric First-Line Helicobacter pylori Eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Bismuth; Breath Tests; Clinic | 2015 |
A randomized-controlled study to compare the efficacy of sequential therapy with standard triple therapy for Helicobacter pylori eradication in an Irish population.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Breath Tests; Clarithromycin | 2015 |
Phytomedicine-based and Quadruple Therapies in Helicobacter pylori Infection: A Comparative, Randomized Trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Com | 2015 |
Bismuth, lansoprazole, amoxicillin and metronidazole or clarithromycin as first-line Helicobacter pylori therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, | 2015 |
Sequential therapy for 10 days versus triple therapy for 14 days in the eradication of
Topics: Adult; Ambulatory Care; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Admin | 2016 |
Effects of N-acetylcysteine on First-Line Sequential Therapy for Helicobacter pylori Infection: A Randomized Controlled Pilot Trial.
Topics: Acetylcysteine; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedu | 2016 |
Efficacy of moxifloxacin-based sequential and hybrid therapy for first-line Helicobacter pylori eradication.
Topics: Aged; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, Bacteria | 2015 |
Hybrid vs sequential therapy for eradication of Helicobacter pylori in Taiwan: A prospective randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; | 2015 |
Concomitant versus sequential therapy for the treatment of Helicobacter pylori infection: a Greek randomized prospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2016 |
Comparison of the efficacy of culture-based tailored therapy for Helicobacter pylori eradication with that of the traditional second-line rescue therapy in Korean patients: a prospective single tertiary center study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combin | 2016 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Case-Control Studies; Child; Child, Prescho | 2015 |
A Randomized Controlled Study Comparing Reverse Hybrid Therapy and Standard Triple Therapy for Helicobacter pylori Infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2015 |
Levofloxacin Sequential Therapy vs Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori: A Randomized Trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Monitoring; Drug | 2016 |
Randomized clinical trial comparing 10-day sequential, 7-day concomitant and 7-day standard triple therapies for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Sch | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Drug A | 2016 |
Sequential Therapy versus Triple Therapy for the First Line Treatment of Helicobacter pylori in Korea: A Nationwide Randomized Trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2016 |
Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; Carbon Isotopes; Clarithromyc | 2016 |
Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country.
Topics: Adolescent; Amplified Fragment Length Polymorphism Analysis; Anti-Bacterial Agents; Bacterial Protei | 2017 |
A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Drug Administration Schedule; Drug Therapy, Combina | 2016 |
Effect of IL-1 Polymorphisms, CYP2C19 Genotype and Antibiotic Resistance on Helicobacter pylori Eradication Comparing Between 10-day Sequential Therapy and 14-day Standard Triple Therapy with Four-Times-Daily-Dosing of Amoxicillin in Thailand: a Prospecti
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cytochrome P-450 CYP2C1 | 2016 |
Ten-day empirical sequential or concomitant therapy is more effective than triple therapy for Helicobacter pylori eradication: A multicenter, prospective study.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Resistance, Bacterial; Drug T | 2016 |
Pharmacokinetics and Safety of Triple Therapy with Vonoprazan, Amoxicillin, and Clarithromycin or Metronidazole: A Phase 1, Open-Label, Randomized, Crossover Study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Healthy Volunt | 2016 |
Randomized clinical trial comparing 10- or 14-day sequential therapy and 10- or 14-day concomitant therapy for the first line empirical treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Clarithromycin; Drug Administration Sche | 2017 |
Standard triple therapy versus sequential therapy for eradication of Helicobacter pylori in treatment naïve and retreat patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Child; Clarithromycin; Dr | 2016 |
Rescue Therapy for Helicobacter pylori Eradication: A Randomized Non-Inferiority Trial of Amoxicillin or Tetracycline in Bismuth Quadruple Therapy.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration Sche | 2016 |
Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Co | 2016 |
Use of probiotics as an adjuvant to sequential H. pylori eradication therapy: impact on eradication rates, treatment resistance, treatment-related side effects, and patient compliance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Amoxicillin; Anorexia; Anti-Bacteria | 2017 |
Ten days of levofloxacin-containing concomitant therapy can achieve effective Helicobacter pylori eradication in patients with type 2 diabetes.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Diabetes Mellitus, Type 2; Drug Res | 2017 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
[Effectiveness of 10 day-sequential therapy for Helicobacter pylori eradication in Korea].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Data Interpretation, Statistical; Drug | 2008 |
Treatment of Helicobacter pylori in surgical practice: a randomised trial of triple versus quadruple therapy in a rural district general hospital.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2008 |
Helicobacter pylori eradication in patients on long-term treatment with NSAIDs reduces the severity of gastritis: a randomized controlled trial.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents | 2009 |
Efficacy of the standard quadruple therapy versus triple therapies containing proton pump inhibitor plus amoxicillin and clarithromycin or amoxicillin-clavulanic acid and metronidazole for Helicobacter pylori eradication in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Child; Child, Preschool; Clarithromyci | 2009 |
Helicobacter pylori eradication: metronidazole or tinidazole? Data from Turin, Italy.
Topics: Anti-Infective Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Male; Me | 2008 |
Gatifloxacin-based triple therapy as a third-line regimen for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; D | 2008 |
Tailored eradication therapy based on fecal Helicobacter pylori clarithromycin sensitivities.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Clarithromycin; Cyto | 2008 |
Effect of Helicobacter pylori eradication on ulcer recurrence after simple closure of perforated duodenal ulcer.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 2009 |
Evaluation of two triple-therapy regimens with metronidazole or clarithromycin for the eradication of H. pylori infection in Vietnamese children: a randomized, double-blind clinical trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2008 |
High efficacy of bismuth subcitrate for Helicobacter pylori eradication in pangastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2009 |
Helicobacter pylori eradication therapy success regarding different treatment period based on clarithromycin or metronidazole triple-therapy regimens.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Efficacy of levofloxacin-based rescue therapy for Helicobacter pylori infection after standard triple therapy: a randomized controlled trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Endoscopy, Gastrointestinal; Esomeprazo | 2009 |
Second-line treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Aza Compounds; Breath Tests; Drug Administration Sc | 2009 |
Impact of quadruple regimen of clarithromycin added to metronidazole-containing triple therapy against Helicobacter pylori infection following clarithromycin-containing triple-therapy failure.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections | 2009 |
A randomized clinical trial to determine the efficacy of regimens containing clarithromycin, metronidazole, and amoxicillin among histologic subgroups for Helicobacter pylori eradication in a developing country.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Colombia; Developin | 2009 |
Helicobacter pylori and hyperemesis gravidarum.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Helicobacter Infections; Helicobacter pylor | 2009 |
Comparison of a monoclonal with a polyclonal antibody-based enzyme immunoassay stool test in diagnosing Helicobacter pylori infection after eradication therapy.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal | 2009 |
Triple or quadruple tetracycline-based therapies versus standard triple treatment for Helicobacter pylori treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2009 |
The efficacy of Helicobacter pylori eradication regimen with and without vitamin C supplementation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2009 |
A placebo-controlled trial of 10-day bismuth-based quadruple therapy to eradicate Helicobacter pylori infection; a pilot study for the large Linqu County trial.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Te | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Clinical trial: clarithromycin vs. levofloxacin in first-line triple and sequential regimens for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 2010 |
Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Resistance, Bacterial; Drug The | 2010 |
Comparison of the efficacy of the two tetracycline-containing sequential therapy regimens for the eradication of Helicobacter pylori: 5 days versus 14 days amoxicillin.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Animals; Anti-Bacterial Agents; Female; | 2010 |
Bismuth-based first-line therapy for Helicobacter pylori eradication in type 2 diabetes mellitus patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infectiv | 2010 |
Investigation of the anti-inflammatory effect of Curcuma longa in Helicobacter pylori-infected patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bacterial Load; | 2010 |
Eradication of Helicobacter spp. by using medicated diet in mice deficient in functional natural killer cells and complement factor D.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Antigens, CD1; Clarithromycin; Complement Factor D; Dru | 2010 |
Effect of sequential treatment as a first-line therapy for Helicobacter pylori eradication in patients with diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Diab | 2010 |
Comparison of the efficacy of triple versus quadruple therapy on the eradication of Helicobacter pylori and antibiotic resistance.
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Comb | 2010 |
Sequential metronidazole-furazolidone or clarithromycin-furazolidone compared to clarithromycin-based quadruple regimens for the eradication of Helicobacter pylori in peptic ulcer disease: a double-blind randomized controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Double-Blind Meth | 2010 |
Comparison of two different treatment protocols in Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromyc | 2011 |
Triple therapy with ecabet sodium, amoxicillin and lansoprazole for 2 weeks as the rescue regimen for H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abietanes; Amoxicillin; Anti-Bacterial Agents; Clarithromyc | 2011 |
Helicobacter pylori chronic gastritis in children: to eradicate or not to eradicate?
Topics: Adolescent; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Bacterial Agents; Breath Tests; Child; C | 2011 |
New effective treatment regimen for children infected with a double-resistant Helicobacter pylori strain.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; Drug Res | 2011 |
The role of Helicobacter pylori in patients with hypothyroidism in whom could not be achieved normal thyrotropin levels despite treatment with high doses of thyroxine.
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infec | 2011 |
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy | 2011 |
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy | 2011 |
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy | 2011 |
Is there a benefit to extending the duration of Helicobacter pylori sequential therapy to 14 days?
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Modified sequential Helicobacter pylori therapy: proton pump inhibitor and amoxicillin for 14 days with clarithromycin and metronidazole added as a quadruple (hybrid) therapy for the final 7 days.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2011 |
Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2011 |
Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2011 |
Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2011 |
Helicobacter pylori infection: a randomized, controlled study comparing 2 rescue therapies after failure of standard triple therapies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP | 2011 |
A new modified concomitant therapy for Helicobacter pylori eradication in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2011 |
Efficacy of 2-week, second-line Helicobacter pylori eradication therapy using rabeprazole, amoxicillin, and metronidazole for the Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Sequential therapy versus tailored triple therapies for Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2011 |
Second-line Helicobacter pylori eradication: a randomized comparison of 1-week or 2-week bismuth-containing quadruple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Bism | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
Twice-a-day bismuth-containing quadruple therapy for Helicobacter pylori eradication: a randomized trial of 10 and 14 days.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2011 |
Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, C | 2011 |
Ten-day sequential therapy is more effective than proton pump inhibitor-based therapy in Korea: a prospective, randomized study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Ag | 2012 |
Randomised clinical trial: the efficacy of a 10-day sequential therapy vs. a 14-day standard proton pump inhibitor-based triple therapy for Helicobacter pylori in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Cl | 2011 |
Survey of anaemia and Helicobacter pylori infection in adolescent girls in Suihua, China and enhancement of iron intervention effects by H. pylori eradication.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodi | 2012 |
Randomised clinical trial: a comparative study of 10-day sequential therapy with 7-day standard triple therapy for Helicobacter pylori infection in naïve patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
Clarithromycin versus metronidazole in first-line Helicobacter pylori eradication. Prospective randomized study of 85 Tunisian adults.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Female; Helico | 2012 |
[Enterofuril eradication therapy in chronic inflammatory diseases of the upper digestive tract].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Chronic Disease; Clarithromyc | 2011 |
Low efficacy of clarithromycin including sequential regimens for Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Comb | 2012 |
Lansoprazole-based sequential and concomitant therapy for the first-line Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2012 |
Comparison of bismuth-containing quadruple and concomitant therapies as a first-line treatment option for Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2012 |
Doxycycline-based quadruple regimen versus routine quadruple regimen for rescue eradication of Helicobacter pylori: an open-label control study in Chinese patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Doxycy | 2012 |
Comparative study of Helicobacter pylori eradication rates with 5-day quadruple "concomitant" therapy and 7-day standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Algorithms; Amoxicillin; Anti-Bacterial Agents; Clar | 2013 |
Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2012 |
Comparison of lafutidine and rabeprazole in 7-day second-line amoxicillin- and metronidazole-containing triple therapy for Helicobacter pylori: a pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetamides; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2012 |
Pilot studies to identify the optimum duration of concomitant Helicobacter pylori eradication therapy in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2012 |
Ten-day sequential versus triple therapy for Helicobacter pylori eradication: a prospective, open-label, randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2012 |
Lycopene an adjunctive therapy for Helicobacter pylori eradication: a quasi-control trial.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antioxidants; Bismuth; | 2012 |
Nonbismuth quadruple "concomitant" therapy versus standard triple therapy, both of the duration of 10 days, for first-line H. pylori eradication: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Therapy, Combination; | 2013 |
Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; | 2013 |
A multicenter prospective observational study of triple therapy with rabeprazole, amoxicillin and metronidazole for Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2012 |
[A 10-day sequential therapy for eradication of Helicobacter pylori infection in children].
Topics: Administration, Oral; Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Test | 2012 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential versus triple therapy for the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2013 |
Sequential therapy versus standard triple-drug therapy for Helicobacter pylori eradication: result of the HPFEZ randomised study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2013 |
Safety and efficacy of 1-week levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori-related peptic ulcer disease in Kashmir, India.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dru | 2013 |
Clinical outcomes of two-week sequential and concomitant therapies for Helicobacter pylori eradication: a randomized pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents | 2013 |
Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Resistan | 2013 |
One-week triple vs. quadruple therapy for Helicobacter pylori infection - a randomized trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2002 |
Furazolidone-based triple 'rescue therapy' vs. quadruple 'rescue therapy' for the eradication of Helicobacter pylori resistant to metronidazole.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Bacterial; Drug Therap | 2002 |
Impact of furazolidone-based quadruple therapy for eradication of Helicobacter pylori after previous treatment failures.
Topics: Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Furazolidone; | 2002 |
Efficacy of quadruple therapy with pantoprazole, bismuth, tetracycline and metronidazole as rescue treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2002 |
Helicobacter pylori and different topographic types of gastritis: treatment response after successful eradication therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Chronic Disease; Drug T | 2002 |
Effect of Helicobacter pylori eradication in the glycemia of children with type 1 diabetes: a preliminary study.
Topics: Adolescent; Anti-Bacterial Agents; Child; Clarithromycin; Diabetes Mellitus, Type 1; Female; Follow- | 2002 |
[Fromilid (clarithromycin) in eradication patients in patients with duodenal ulcer associated with Helicobacter pylori (comparison of two treatment variations)].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Duodenal | 2002 |
[Fromilide (clarithromycin) in eradication of Helicobacter pylori in patients with duodenal ulcer].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Com | 2002 |
Azithromycin in a triple therapy for H.pylori eradication in active duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug T | 2002 |
Vitamin C and E supplements to lansoprazole-amoxicillin-metronidazole triple therapy may reduce the eradication rate of metronidazole-susceptible Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; D | 2002 |
Does Helicobacter pylori eradication affect symptoms in nonulcer dyspepsia: a 5-year follow-up study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Dyspep | 2002 |
The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate- vs. omeprazole-based one-week triple therapies in H. pylori eradication--a randomised controlled trial.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance; Drug Therapy, Combi | 2002 |
[Comparison of pantoprazole and omeprazole-based triple therapy regimens in the treatment of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti | 2002 |
Omeprazole triple therapy versus omeprazole quadruple therapy for healing duodenal ulcer and eradication of Helicobacter pylori infection: a 24-month follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 2002 |
One-week ranitidine bismuth citrate, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combinati | 2002 |
Efficacy of triple therapy comprising rabeprazole, amoxicillin and metronidazole for second-line Helicobacter pylori eradication in Japan, and the influence of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
[Conservative treatment of patients with stomach polyps].
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Drug Therapy, Combination; Female; Gastric Acid; He | 2002 |
Comparison of three triple regimens with omeprazole or ranitidine bismuth citrate for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female | 2002 |
Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenitis; Female; Fo | 2002 |
Efficacy and safety of single-triple capsules of bismuth biskalcitrate, metronidazole and tetracycline, given with omeprazole, for the eradication of Helicobacter pylori: an international multicentre study.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Fema | 2003 |
Effect of treatment of Helicobacter pylori on the prevention of gastroduodenal ulcers in patients receiving long-term NSAIDs: a double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Inflammatory Agents, Non-Steroidal; Cl | 2003 |
Characterization of the genes rdxA and frxA involved in metronidazole resistance in Helicobacter pylori.
Topics: Anti-Bacterial Agents; Escherichia coli; FMN Reductase; Helicobacter Infections; Helicobacter pylori | 2003 |
Bismuth-based quadruple therapy using a single capsule of bismuth biskalcitrate, metronidazole, and tetracycline given with omeprazole versus omeprazole, amoxicillin, and clarithromycin for eradication of Helicobacter pylori in duodenal ulcer patients: a
Topics: Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Capsules; | 2003 |
Helicobacter pylori eradication and gastric ulcer healing--comparison of three pantoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Be | 2003 |
Diagnosis and eradication of Helicobacter pylori in patients with duodenal ulceration in the community.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Duodenal Ulcer; Female; | 2003 |
One-week triple therapy with esomeprazole, clarithromycin and metronidazole provides effective eradication of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 2003 |
Do Japanese and Swedish peptic ulcer patients respond differently to Helicobacter pylori eradication therapies and what are their histological features?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asian People; Clarithromycin; Dr | 2003 |
High-dose rabeprazole-amoxicillin versus rabeprazole-amoxicillin-metronidazole as second-line treatment after failure of the Japanese standard regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2003 |
Increased reflux symptoms after calcium carbonate supplementation and successful anti-Helicobacter pylori treatment.
Topics: Adult; Amoxicillin; Antacids; Bismuth; Calcium Carbonate; Drug Therapy, Combination; Dyspepsia; Fema | 2003 |
The efficacy of furazolidone-based quadruple therapy for eradication of Helicobacter pylori infection in Iranian patients resistant to metronidazole-based quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents, Local; Breath Tests; Drug Resistance, Bacterial | 2003 |
Clinical efficiency of Epigam in patients with exacerbation of peptic ulcer disease of the stomach and duodenum.
Topics: Adolescent; Adult; Amoxicillin; Anti-Ulcer Agents; Antibodies; Dose-Response Relationship, Drug; Dru | 2003 |
Salvage therapy after two or more prior Helicobacter pylori treatment failures: the super salvage regimen.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Te | 2003 |
A prospective, randomized study of quadruple therapy and high-dose dual therapy for treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Re | 2003 |
Comparison of four-day and seven-day pantoprazole-based quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Ag | 2003 |
One-day quadruple therapy compared with 7-day triple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; B | 2003 |
Second-line treatment for failure to eradicate Helicobacter pylori: a randomized trial comparing four treatment strategies.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2003 |
Esomeprazole-based one-week triple therapy with clarithromycin and metronidazole is effective in eradicating Helicobacter pylori in the absence of antimicrobial resistance.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance; Drug Therapy | 2003 |
Randomized study of different 'second-line' therapies for Helicobacter pylori infection after failure of the standard 'Maastricht triple therapy'.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2003 |
Efficacy of different antibiotic regimens for eradication treatment of Helicobacter pylori infection in peptic ulcer disease in Tanzanian patients.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Sc | 2003 |
Eradication of Helicobacter pylori by 7-day triple-therapy regimens combining pantoprazole with clarithromycin, metronidazole, or amoxicillin in patients with peptic ulcer disease: results of two double-blind, randomized studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2003 |
Comparable Helicobacter pylori eradication rates obtained with 4- and 7-day rabeprazole-based triple therapy: a preliminary study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2003 |
Long term outcome of patients with gastric marginal zone B cell lymphoma of mucosa associated lymphoid tissue (MALT) following exclusive Helicobacter pylori eradication therapy: experience from a large prospective series.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Therapy, Co | 2004 |
[Treatment of Helicobacter pylori infection--results and experiences with an Internet-based collaboration trial].
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Fe | 2003 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial.
Topics: Adult; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Anti-Ulcer Agents; Chin | 2004 |
[Efficacy of omeprazole in the treatment of Helicobacter pylori-associated duodenal ulcers... in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Child; Dru | 2003 |
Economic evaluation of Helicobacter pylori eradication in the CADET-Hp randomized controlled trial of H. pylori-positive primary care patients with uninvestigated dyspepsia.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithrom | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Low eradication rate of Helicobacter pylori with triple 7-14 days and quadriple therapy in Turkey.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agent | 2004 |
Pretreatment antimicrobial susceptibility testing is cost saving in the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost Savings; Cost-Ben | 2003 |
Laboratory handling of Helicobacter pylori critically influences the results of in-vitro metronidazole resistance determination.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Bismuth; Drug Resistance, Bacterial; Drug The | 2004 |
[Efficacy of different schemes of anti-helicobacter therapy in duodenal ulcer].
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Drug | 2004 |
Does the 'test-and-treat' strategy work in primary health care for management of uninvestigated dyspepsia? A prospective two-year follow-up study of 1552 patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Endoscopy, Gastrointestinal | 2004 |
Use of imidazole-based eradication regimens for Helicobacter pylori should be abandoned in North India regardless of in vitro antibiotic sensitivity.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 2004 |
Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Ant | 2004 |
[Long-term therapeutic effect of triple therapy consisted of omeperazole, clarithromycin and amoxycillin in children with Helicobacter pylori infection and approach to re-treatment after failure of the treatment].
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Clarithromycin; Drug Therapy, C | 2004 |
Total family unit Helicobacter pylori eradication and pediatric re-infection rates.
Topics: Adolescent; Amoxicillin; Breath Tests; Child; Child, Preschool; Clarithromycin; Community-Acquired I | 2004 |
Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
Topics: Adult; Anti-Infective Agents; Anti-Ulcer Agents; Azithromycin; Bismuth; Drug Resistance, Bacterial; | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
Ranitidine-bismuth citrate, tetracycline and metronidazole followed by triple therapy as alternative strategy for Helicobacter pylori treatment: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Administration Schedu | 2004 |
[Effects of different triple therapies on duodenal ulcer-associated Helicobacter pylori infection and a one-year follow-up study].
Topics: Amoxicillin; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; H | 2004 |
The influence of pretreatment on cure rates of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth | 2004 |
Effects of Helicobacter pylori eradication on platelet activation and disease recurrence in patients with acute coronary syndromes.
Topics: Acute Disease; Amoxicillin; Antigens, CD; Coronary Disease; Female; Helicobacter Infections; Helicob | 2004 |
Effects of the association of lansoprazole, clarithromycin and metronidazole for helicobacter Pylori eradication therapy, measured by the 13C Aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Aminopyrine; Breath Tests; Carbon | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clari | 2005 |
Response of blood endothelin-1 and nitric oxide activity in duodenal ulcer patients undergoing Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2005 |
First-line eradication therapy for Helicobacter pylori in primary health care based on antibiotic resistance: results of three eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Cl | 2005 |
Eradication rate of Helicobacter pylori in dyspeptic patients.
Topics: Analysis of Variance; Anti-Bacterial Agents; Breath Tests; Ciprofloxacin; Drug Therapy, Combination; | 2005 |
Efficacy of omeprazole and amoxicillin with either clarithromycin or metronidazole on eradication of Helicobacter pylori in Chinese peptic ulcer patients.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Asian People; Clarithromycin | 2005 |
Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Chi-Square Dist | 2005 |
High eradication rates of Helicobacter pylori infection with first- and second-line combination of esomeprazole, tetracycline, and metronidazole in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Hypersensitivity; Drug Therapy | 2005 |
Treatment regimens for Helicobacter pylori infection in children: is in vitro susceptibility testing helpful?
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2005 |
7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Combinations; Drug Therapy | 2005 |
Low-dose rabeprazole, amoxicillin and metronidazole triple therapy for the treatment of Helicobacter pylori infection in Chinese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2005 |
Levofloxacin- versus metronidazole-based rescue therapy for H. pylori infection in Japan.
Topics: Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 2005 |
Influence of 1-week Helicobacter pylori eradication therapy with rabeprazole, clarithromycin, and metronidazole on 13C-aminopyrine breath test.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aminopyrine; Anti-Bacterial Agents; Anti-Infective Ag | 2005 |
Is a long-term ranitidine-based triple therapy against Helicobacter pylori only a heritage of the past? A prospective, randomized clinicopharmacological study.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Chromatogr | 2005 |
A follow-up study on the effect of Helicobacter pylori eradication on the severity of gastric histology.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2005 |
The results of Helicobacter pylori eradication on repeated bleeding in patients with stomach ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Administration Sc | 2005 |
Effects of food and formulation on the relative bioavailability of bismuth biskalcitrate, metronidazole, and tetracycline given for Helicobacter pylori eradication.
Topics: Administration, Oral; Adolescent; Adult; Antacids; Anti-Bacterial Agents; Biological Availability; B | 2005 |
A randomized trial of triple therapy for pediatric Helicobacter pylori infection and risk factors for treatment failure in a population with a high prevalence of infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2005 |
Comparison of the efficacy of 1-day high-dose quadruple therapy versus 7-day triple therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
Improved efficacy of 10-Day sequential treatment for Helicobacter pylori eradication in children: a randomized trial.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Antitrichomonal | 2005 |
[PPI plus bismuth-based quintuple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Drug | 2005 |
[Children Helicobacter pylori infection: antibiogram results].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Biopsy; Child; Child, Prescho | 2005 |
Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infec | 2006 |
7-day triple therapy of Helicobacter pylori infection with levofloxacin, amoxicillin, and high-dose esomeprazole in patients with known antimicrobial sensitivity.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dose-Response Relationship, Drug; D | 2006 |
Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Esomeprazole; Female; Fluoroquinolones; He | 2006 |
Twice-a-day quadruple therapy for eradication of Helicobacter pylori in the elderly.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Dyspepsia; Esomeprazole; Female; Helic | 2006 |
Third-line rescue therapy with levofloxacin after two H. pylori treatment failures.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, C | 2006 |
Effectiveness of minocycline-based triple therapy for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Benz | 2006 |
[Lipid peroxidation and antioxidant system in treatment dynamics of patients with chronic gastritis].
Topics: Adult; Aged; alpha-Tocopherol; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antioxidants; | 2005 |
[Comparison of the effectiveness of tri- and quadricomponent eradication therapy in patients with peptic ulcer].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administrat | 2005 |
Evaluation of triple and quadruple Helicobacter pylori eradication therapies in Iranian children: a randomized clinical trial.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Child, Preschool; Clar | 2006 |
Efficacy of metronidazole as second-line drug for the treatment of Helicobacter pylori Infection in the Japanese population: a multicenter study in the Tokyo Metropolitan Area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Dr | 2006 |
[Double blind randomized multicentre study of a seven-day eradication regime of Helicobacter pylori by omeprazole, clarithromycin and ornidazole vs. omeprazole, clarithromycin and metronidazole].
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Meth | 2002 |
Eradication of H pylori infection in a rural population: one-day quadruple therapy versus 7-day triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective A | 2006 |
Bismuth-based therapies for the first step eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Antacids; Anti-Infect | 2006 |
Randomized trial of rifabutin-based triple therapy and high-dose dual therapy for rescue treatment of Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cros | 2006 |
Azithromycin in one week quadruple therapy for H pylori eradication in Iran.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agent | 2006 |
Combinations containing amoxicillin-clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacteri | 2006 |
Triple, standard quadruple and ampicillin-sulbactam-based quadruple therapies for H. pylori eradication: a comparative three-armed randomized clinical trial.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 2006 |
Comparison of amoxicillin-metronidazole plus famotidine or lansoprazole for amoxicillin-clarithromycin-proton pump inhibitor treatment failures for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2006 |
Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Therapy, Combination; E | 2006 |
Randomized comparison of two rescue therapies for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 2006 |
Efficacy of Helicobacter pylori eradication taking into account its resistance to antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2006 |
Pharmacoeconomic comparison of Helicobacter pylori eradication regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Clar | 2006 |
Does delayed gastric emptying shorten the H pylori eradication period? A double blind clinical trial.
Topics: Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Dopamine Agents; | 2006 |
Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure.
Topics: Anti-Bacterial Agents; Biopsy; Cells, Cultured; Clarithromycin; Cohort Studies; Disease Susceptibili | 2006 |
2-week triple therapy for Helicobacter pylori infection is better than 1-week in clinical practice: a large prospective single-center randomized study.
Topics: Administration, Oral; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Administration Schedu | 2006 |
Duration of the metronidazole-containing regimen for eradication of Helicobacter pylori infection in northern Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2006 |
Furazolidone-based, metronidazole-based, or a combination regimen for eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Drug Therapy, Combination; | 2007 |
Comparison of three different second-line quadruple therapies including bismuth subcitrate in Turkish patients with non-ulcer dyspepsia who failed to eradicate Helicobacter pylori with a 14-day standard first-line therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Dyspepsia; Femal | 2008 |
Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug | 2007 |
H pylori infection in patients with Behcet's disease.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Behcet Syndrome; Biopsy; Case-Control S | 2007 |
Efficacy of rifabutin-based triple therapy as second-line treatment to eradicate helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Drug Therapy, Combinat | 2007 |
Eradication of Helicobacter pylori infection favourably affects altered gastric mucosal MMP-9 levels.
Topics: Adult; Aged; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 2007 |
Effects of H pylori therapy on erythrocytic and iron parameters in iron deficiency anemia patients with H pylori-positive chronic gastristis.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anemia, Iron-Deficiency; Anti-Infective Agents; Chronic Diseas | 2007 |
The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2007 |
Empirical rescue therapy after Helicobacter pylori treatment failure: a 10-year single-centre study of 500 patients.
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combina | 2008 |
Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Drug Administrati | 2007 |
A pilot study evaluating sequential administration of a PPI-amoxicillin followed by a PPI-metronidazole-tetracycline in Turkey.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Administration Sch | 2007 |
One-week once-daily triple therapy with esomeprazole, moxifloxacin, and rifabutin for eradication of persistent Helicobacter pylori resistant to both metronidazole and clarithromycin.
Topics: Adult; Aged; Anti-Bacterial Agents; Aryl Hydrocarbon Hydroxylases; Aza Compounds; Clarithromycin; Cy | 2008 |
Evaluation of three different proton pump inhibitors with amoxicillin and metronidazole in retreatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Infective Agents; Drug Therapy, Co | 2008 |
Interpretation of the 13C-urea breath test in the choice of second- and third-line eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Infective Agents; Bismuth; Breath Tests; Clarit | 2008 |
Comparison of sequential and standard triple-drug regimen for Helicobacter pylori eradication: a 14-day, open-label, randomized, prospective, parallel-arm study in adult patients with nonulcer dyspepsia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2008 |
Effect of a community screening for Helicobacter pylori: a 5-Yr follow-up study.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Community Health Services; Cost-Benefit Analy | 2008 |
Omeprazole enhances efficacy of triple therapy in eradicating Helicobacter pylori.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsia; Famotidine; F | 1995 |
Omeprazole/amoxicillin versus triple therapy for Helicobacter pylori in duodenal ulcer disease: two-year follow-up of a prospective randomized study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Female; | 1995 |
[Comparison of 2 treatment schemes to eradicate Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Dyspepsia; Endosco | 1995 |
[Antibacterial treatment of gastric ulcers associated with Helicobacter pylori without acid suppression].
Topics: Aluminum Hydroxide; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; | 1995 |
Spiramycin in triple therapy of Helicobacter pylori-associated peptic ulcer disease. An open pilot study with 12-month follow-up.
Topics: Adult; Aged; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobact | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole in eradication of Helicobacter pylori].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Benzimid | 1995 |
Long-term follow-up of Helicobacter pylori treatment in non-ulcer dyspepsia patients.
Topics: Adult; Bismuth; Drug Therapy, Combination; Dyspepsia; Female; Follow-Up Studies; Helicobacter Infect | 1995 |
Cure of peptic gastric ulcer associated with eradication of Helicobacter pylori. Finnish Gastric Ulcer Study Group.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therap | 1995 |
Recrudescence of Helicobacter pylori infection in patients with healed duodenal ulcer after treatment with different regimens.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Comb | 1995 |
Effect of triple therapy or amoxycillin plus omeprazole or amoxycillin plus tinidazole plus omeprazole on duodenal ulcer healing, eradication of Helicobacter pylori, and prevention of ulcer relapse over a 1-year follow-up period: a prospective, randomized
Topics: Adult; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1995 |
Triple therapy with sucralfate, tetracycline, and metronidazole for Helicobacter pylori-associated duodenal ulcers.
Topics: Adult; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; Female; Hel | 1995 |
Is short-term triple therapy with lansoprazole, clarithromycin, and metronidazole a definitive answer for Helicobacter pylori eradication?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinatio | 1995 |
Efficacy of omeprazole combined with antibiotics for Helicobacter pylori eradication and duodenal ulcer recurrence.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Female; Fo | 1995 |
Pharmacological effects of metronidazole+tetracycline+bismuth subcitrate versus omeprazole+amoxycillin+bismuth subcitrate in Helicobacter pylori-related gastritis and peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1994 |
Association of symptoms with Helicobacter pylori infection in children.
Topics: Adolescent; Biopsy; Bismuth; Child; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; Duod | 1995 |
Successful Helicobacter pylori eradication incorporating a one-week antibiotic regimen.
Topics: Adult; Amoxicillin; Drug Synergism; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 1995 |
Rapid eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Chi-Square Distribution; Cost-Benefit Analysis; Drug Interactions; Drug Sy | 1995 |
Long-term colonization with single and multiple strains of Helicobacter pylori assessed by DNA fingerprinting.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Base Sequence; DNA Fingerprinting; DNA Primers; DNA, B | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Antibacterial treatment of gastric ulcers associated with Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Confidence Intervals; Female; Follow-Up Studi | 1995 |
Modified short-term triple therapy--ranitidine, clarithromycin, and metronidazole--for cure of Helicobacter pylori infection.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Duodenitis; Female; Gastritis; Helicobacter | 1995 |
A 1-h topical therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infecti | 1995 |
Long-term prospective study of Helicobacter pylori in nonulcer dyspepsia.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combina | 1995 |
Quality of life and relapse of duodenal ulcer before and after eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Antacids; Bismuth; Cognitive Behavioral Therapy; Combined Modality Therapy; Drug | 1994 |
Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Diffusion; Female; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 1994 |
The effect of eradication of Helicobacter pylori upon the duodenal ulcer recurrence--a 24 month follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; | 1994 |
One-week low-dose triple therapy for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combinat | 1995 |
Effects of omeprazole and eradication of Helicobacter pylori on gastric and duodenal mucosal enzyme activities and DNA in duodenal ulcer patients.
Topics: Antacids; Biopsy; Bismuth; DNA; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Female; Gastric | 1994 |
Triple therapy eradicated H. pylori equally in patients pretreated with omeprazole or ranitidine. A 12-month follow-up.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chi-Square Distribution; Confidence Intervals; Drug Ther | 1995 |
[Short-term triple therapy with pantoprazole, clarithromycin and metronidazole for the healing of Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Benzimidazoles; Biopsy; Clarithrom | 1995 |
Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Female; Hel | 1995 |
Eradication of Helicobacter pylori infection and the recurrence of duodenal ulcers.
Topics: Adolescent; Adult; Aged; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helic | 1993 |
Duodenal ulcer healing by eradication of Helicobacter pylori without anti-acid treatment: randomised controlled trial.
Topics: Adult; Aged; Antacids; Biopsy; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer | 1994 |
Prospective, randomized study of H2-blocker and triple therapy for duodenal ulcer treatment and the eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Famotidine; Female; Helicoba | 1994 |
Causal role of Helicobacter pylori in peptic ulcer relapse.
Topics: Aged; Amoxicillin; Bismuth; Chi-Square Distribution; Drug Therapy, Combination; Gastric Mucosa; Heli | 1994 |
Selection of patients for treatment of duodenal ulcer infected with Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Cimetidine; Drug Therapy, Combination; Duodenal Ulcer; Fe | 1994 |
Omeprazole 40 mg o.m. combined with amoxycillin alone or with amoxycillin and metronidazole in the eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Female; Follow-Up Studies; | 1994 |
Randomized study comparing 1 with 2 weeks of quadruple therapy for eradicating Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; Hel | 1994 |
[H. pylori and chronic duodenal ulcer: eradication therapy with ranitidine-antibiotic combination and follow-up of ulcer disease].
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Heli | 1994 |
Bismuth-free triple therapy for eradicating Helicobacter pylori and reducing the gastric ulcer recurrence rate.
Topics: Amoxicillin; Anti-Ulcer Agents; Diterpenes; Drug Therapy, Combination; Fatty Alcohols; Female; Gastr | 1994 |
Effects of eradication of Helicobacter pylori on gastritis in duodenal ulcer patients.
Topics: Amoxicillin; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Gastrit | 1994 |
Effectiveness of a five times daily triple therapy regimen against Helicobacter pylori.
Topics: Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therapy, Combination; Duodenal Ulcer; Gastroscop | 1994 |
Evaluation of two therapeutic regimens for the treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combinat | 1994 |
Helicobacter pylori and refractory duodenal ulcers: cross-over comparison of continued cimetidine with cimetidine plus antimicrobials.
Topics: Adult; Amoxicillin; Cimetidine; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ul | 1994 |
[Eradication of metronidazole-resistant Helicobacter pylori: is omeprazole/amoxicillin a therapeutic alternative?].
Topics: Adult; Aged; Amoxicillin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Co | 1994 |
Effect of eradication of Helicobacter pylori on gastric juice ascorbic acid concentrations.
Topics: Aged; Ampicillin; Anti-Ulcer Agents; Ascorbic Acid; Drug Therapy, Combination; Duodenal Ulcer; Fasti | 1993 |
Eradicating Helicobacter pylori infection lowers gastrin mediated acid secretion by two thirds in patients with duodenal ulcer.
Topics: Amoxicillin; Anti-Bacterial Agents; Basal Metabolism; Breath Tests; Carbon Radioisotopes; Duodenal U | 1993 |
Helicobacter pylori eradication with bismuth subnitrate, oxytetracycline and metronidazole in patients with peptic ulcer disease.
Topics: Adult; Aged; Antacids; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicoba | 1994 |
Short report: clarithromycin, an alternative to metronidazole in the triple therapy of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female | 1994 |
Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens.
Topics: Aged; Amoxicillin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combinati | 1993 |
Use of high efficacy, lower dose triple therapy to reduce side effects of eradicating Helicobacter pylori.
Topics: Abdominal Pain; Anti-Bacterial Agents; Constipation; Diarrhea; Drug Administration Schedule; Drug Th | 1994 |
[The effect of the eradication of H. pylori on the intractable ulcer].
Topics: Ampicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacte | 1993 |
Efficacy and side effects of a triple drug regimen for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, C | 1993 |
Treatment of Helicobacter pylori reduces the rate of rebleeding in peptic ulcer disease.
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Gastrointestinal Hemorrhage; Hel | 1993 |
One-year follow-up of duodenal ulcers after 1-wk triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studi | 1994 |
Kinetics of specific IgG antibodies for monitoring the effect of anti-Helicobacter pylori chemotherapy.
Topics: Amoxicillin; Antibodies, Bacterial; Double-Blind Method; Drug Therapy, Combination; Duodenal Ulcer; | 1993 |
Colloidal bismuth subcitrate, ranitidine, and ranitidine plus metronidazole in the treatment of duodenal ulcer and Helicobacter pylori infection: a controlled and prospective study.
Topics: Adult; Anti-Ulcer Agents; Colloids; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infectio | 1993 |
Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Female; | 1993 |
Are routine duodenal and antral biopsies useful in the management of "functional" dyspepsia? A diagnostic and therapeutic study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Cisapride; Double-Blind Method; Du | 1993 |
Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer.
Topics: Adult; Aged; Amoxicillin; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer; F | 1993 |
Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection--tetracycline, amoxicillin, bismuth.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infection | 1993 |
Patient factors affecting Helicobacter pylori eradication with triple therapy.
Topics: Adult; Age Factors; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ulcer | 1993 |
Prospective, randomized, investigator-blind trial of Helicobacter pylori infection treatment in patients with refractory duodenal ulcers. Healing and long-term relapse rates.
Topics: Adolescent; Adult; Aged; Anti-Ulcer Agents; Chi-Square Distribution; Colloids; Drug Therapy, Combina | 1993 |
Triple therapy vs. amoxicillin plus omeprazole for treatment of Helicobacter pylori infection: a multicenter, prospective, randomized, controlled study of efficacy and side effects.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Colloids; Drug Therapy, Combination; Female; Helico | 1996 |
[Ulcer healing through the elimination of Helicobacter pylori: is a week of therapy enough?].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug The | 1996 |
Pathogenesis of gastric metaplasia of the human duodenum: role of Helicobacter pylori, gastric acid, and ulceration.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Du | 1996 |
Triple therapy with ranitidine, clarithromycin, and metronidazole in the treatment of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Interactions; Drug Thera | 1995 |
Addition of metronidazole to omeprazole/amoxycillin dual therapy increases the rate of Helicobacter pylori eradication: a double-blind, randomized trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; An | 1995 |
Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribut | 1996 |
Long-term outcome of triple therapy in Helicobacter pylori-related nonulcer dyspepsia: a prospective controlled assessment.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Chronic Disease; Drug Th | 1996 |
Bismuth-based combination therapy for Helicobacter pylori-associated peptic ulcer disease (metronidazole for eradication, ranitidine for pain).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bism | 1996 |
Omeprazole coupled with two antibiotics for Helicobacter pylori eradication and prevention of ulcer recurrence.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Com | 1996 |
Low H. pylori reinfection rate after triple therapy in Chilean duodenal ulcer patients.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Chile; Drug Therapy, Combination; | 1996 |
Effect of the eradication of Helicobacter pylori on duodenal ulcer healing and ulcer relapse: randomized controlled study in Japan.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cimetidine; Drug Administration Schedu | 1996 |
Antimicrobial therapy for Helicobacter pylori infection versus long-term maintenance antisecretion treatment in the prevention of recurrent hemorrhage from peptic ulcer: prospective nonrandomized trial on 125 patients.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Du | 1996 |
Eradication of Helicobacter pylori and long-term outcome of functional dyspepsia. A clinical endoscopic study.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; | 1996 |
One week treatment with omeprazole, clarithromycin and tinidazole or lansoprazole, amoxicillin and metronidazole for cure of Helicobacter pylori infection in duodenal ulcer patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1996 |
Quadruple therapy compared with dual therapy for eradication of Helicobacter pylori in ulcer patients: results of a randomized prospective single-centre study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Ant | 1995 |
Prospective evaluation of the macrolide antibiotic dirithromycin for the treatment of Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Combinations; Eryth | 1996 |
Comparison of two low-dose one-week triple therapy regimens with and without metronidazole for cure of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1996 |
4-day lansoprazole quadruple therapy: a highly effective cure for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1996 |
One week treatment for Helicobacter pylori infection: a randomised study of quadruple therapy versus triple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, C | 1995 |
Only four days of quadruple therapy can effectively cure Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Th | 1995 |
Helicobacter pylori eradication--evaluation of triple therapy containing omeprazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ul | 1996 |
Symptomatic and endoscopic duodenal ulcer relapse rates 12 months following Helicobacter pylori eradication treatment with omeprazole and amoxycillin with or without metronidazole.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastroscopy; Helic | 1996 |
Long-term follow-up after cure of Helicobacter pylori infection with 4 days of quadruple therapy.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Dyspepsia; Heli | 1996 |
Omeprazole and clarithromycin with and without metronidazole for the eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cohort Studies; Drug Administration Schedu | 1996 |
Helicobacter pylori infection and serum pepsinogen I concentration in peptic ulcer patients: effect of bacterial eradication.
Topics: Adult; Antacids; Anti-Ulcer Agents; Antitrichomonal Agents; Duodenal Ulcer; Female; Helicobacter Inf | 1996 |
One-week therapy for Helicobacter pylori. A randomized trial of two treatment regimens.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Fe | 1996 |
Chemoprevention trial on precancerous lesions of the stomach in Venezuela: summary of study design and baseline data.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anticarcinogenic Agents; Antioxidants; Clarithromyc | 1996 |
Therapeutic options after failed Helicobacter pylori eradication therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1996 |
A liquid chromatography assay for the study of serum and gastric juice metronidazole concentrations in the treatment of Helicobacter pylori.
Topics: Antitrichomonal Agents; Chromatography, High Pressure Liquid; Drug Interactions; Gastric Juice; Heli | 1996 |
Lansoprazole, clarithromycin and metronidazole for seven days in Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clar | 1996 |
One week triple therapy with omeprazole, clarithromycin and tinidazole for Helicobacter pylori: differing efficacy in previously treated and untreated patients.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Admin | 1996 |
Cure of Helicobacter pylori infection in the elderly: effects of eradication on gastritis and serological markers.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer | 1996 |
Reinfection and duodenal ulcer relapse in south-east Asian patients following successful Helicobacter pylori eradication: results of a 2-year follow-up.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1996 |
A twelve-month follow-up after Helicobacter pylori eradication. A clinical and histological evaluation.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Duodenal Ulcer; Fema | 1996 |
Short-term low-dose triple therapy with azithromycin, metronidazole and lansoprazole appears highly effective for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Anti-Bacterial Agents; A | 1997 |
Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance?
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromyci | 1997 |
One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Therapy, Combina | 1997 |
One-day intensified lansoprazole-quadruple therapy for cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1997 |
Anti-Helicobacter pylori treatment in bleeding ulcers: randomized controlled trial comparing 2-day versus 7-day bismuth quadruple therapy.
Topics: Activities of Daily Living; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Adm | 1997 |
Triple therapy with ranitidine or lansoprazole in the treatment of Helicobacter pylori-associated duodenal ulcer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
A comparison between omeprazole-based triple therapy and bismuth-based triple therapy for the treatment of Helicobacter pylori infection: a prospective randomized 1-yr follow-up study.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 1997 |
Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 1997 |
Does pretreatment with omeprazole decrease the chance of eradication of Helicobacter pylori in peptic ulcer patients?
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fe | 1997 |
One week treatment for Helicobacter pylori infection.
Topics: Adolescent; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Breath Tests; Child; Child, Pres | 1997 |
Clarithromycin in the combination therapy for the eradication of Helicobacter pylori in peptic ulcer disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; | 1997 |
Eradication of Helicobacter pylori affects symptoms in non-ulcer dyspepsia.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Double-Blind Method; Drug Therapy, Combination; Dyspepsia; Fe | 1997 |
Another therapeutic schedule in eradication of Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Bacterial Agents; Anti | 1997 |
Efficacy of ebrotidine and ranitidine combined with amoxicillin and metronidazole in the eradication of Helicobacter pylori in patients with duodenal ulcer.
Topics: Adult; Amoxicillin; Benzenesulfonates; Double-Blind Method; Duodenal Ulcer; Female; Gastritis; Helic | 1997 |
Comparison of colloidal bismuth subcitrate and metronidazole, both in combination with an H2-antagonist as therapy for Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1997 |
Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Double-Blind Method; Drug Administration Schedule; Drug Th | 1997 |
Helicobacter pylori eradication--comparison of three drug regimens and symptomatic assessment in duodenitis and antral gastritis.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; | 1997 |
A new 1-week therapy for Helicobacter pylori eradication: ranitidine bismuth citrate plus two antibiotics.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infe | 1997 |
Bismuth subsalicylate instead of metronidazole with lansoprazole and clarithromycin for Helicobacter pylori infection: a randomized trial.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1997 |
Randomised trial of eradication of Helicobacter pylori before non-steroidal anti-inflammatory drug therapy to prevent peptic ulcers.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Drug Administration Schedul | 1997 |
A United States multicentre trial of dual and proton pump inhibitor-based triple therapies for Helicobacter pylori.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibit | 1997 |
Two omeprazole-based Helicobacter pylori eradication regimens for the treatment of duodenal ulcer disease in general practice.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Double-Blind Method; Drug Therapy, Combination; Duodenal | 1997 |
The management of failed dual or triple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; Fe | 1997 |
Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; | 1997 |
Short-course therapy with amoxycillin-clarithromycin triple therapy for 10 days (ACT-10) eradicates Helicobacter pylori and heals duodenal ulcer. ACT-10 Study Group.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Canada; Clarithromycin; Double-Blind Method; Drug Resista | 1997 |
Pantoprazole versus omeprazole in one-week low-dose triple therapy for curve of H. pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidazoles; C | 1997 |
Double-blind, multicenter evaluation of lansoprazole and amoxicillin dual therapy for the cure of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Diar | 1996 |
Seven-day triple therapy with lansoprazole, clarithromycin, and metronidazole for the cure of Helicobacter pylori infection: a short report.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Clarithromycin; Diarrhea; Drug Administration | 1996 |
Quadruple therapy: the golden bullet or a drug too far?
Topics: Antacids; Drug Therapy, Combination; Enzyme Inhibitors; Famotidine; Helicobacter Infections; Helicob | 1996 |
Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I Study.
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Administration Schedule; D | 1996 |
Helicobacter pylori-positive duodenal ulcer: a long-term double-blind randomized study in patients healed with H2-receptor antagonists.
Topics: Adult; Aged; Antacids; Anti-Ulcer Agents; Disease-Free Survival; Double-Blind Method; Doxycycline; D | 1996 |
Effectiveness of quadruple therapy using lansoprazole, instead of omeprazole, in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Antacids; Anti-Ulcer Agents; Bacterial Protein | 1996 |
Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Bismuth; Breath Test | 1997 |
Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Follow- | 1997 |
Ranitidine versus colloidal bismuth subcitrate in combination with amoxicillin and metronidazole for eradicating Helicobacter pylori in patients with duodenal ulcer.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 1997 |
One week triple therapy for Helicobacter pylori: does high-dose clarithromycin confer additional benefit?
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Cl | 1997 |
[Hormonal changes and secretion and stomach mucosal microstructure in the course of H. pylori in patients with duodenal ulcer].
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Epidermal Growth Factor; Gastric Juice; Gas | 1997 |
[Endocrine and exocrine gastric mucosal secretion in the course of H. pylori eradication in patients with non-ulcer dyspepsia].
Topics: Amoxicillin; Bismuth; Dyspepsia; Epidermal Growth Factor; Gastric Juice; Gastric Mucosa; Gastrins; H | 1997 |
Carbon 13-labeled urea breath test for the diagnosis of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Breath Tests; Carbon Radioisotopes; Child; C | 1997 |
Combination amoxycillin and metronidazole with famotidine in the eradication of Helicobacter pylori--a randomized, double-blind comparison of a three times daily and twice daily regimen.
Topics: Adolescent; Adult; Aged; Amoxicillin; Antitrichomonal Agents; Double-Blind Method; Drug Resistance, | 1997 |
The efficacy and safety of one-week triple therapy with lansoprazole, clarithromycin, and metronidazole for the treatment of Helicobacter pylori infection in Japanese patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1997 |
Sucralfate as an alternative to bismuth in quadruple therapy for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Female; Gastritis; Helicobacter Infe | 1997 |
Highly effective second-line anti-Helicobacter pylori therapy in patients with previously failed metronidazole-based therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithr | 1997 |
One-week antibiotics versus maintenance acid suppression therapy for Helicobacter pylori-associated peptic ulcer bleeding.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicob | 1997 |
Should we abandon metronidazole containing Helicobacter pylori treatment regimens? The clinical relevance of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Ag | 1998 |
Adding once-daily omeprazole 20 mg to metronidazole/amoxicillin treatment for Helicobacter pylori gastritis: a randomized, double-blind trial showing the importance of metronidazole resistance.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Chronic Disease; C | 1998 |
One week triple therapy for Helicobacter pylori: a multicentre comparative study. Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Age | 1997 |
Eradicate the bug before you start the drug?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Drug Therapy, Combination; | 1998 |
One-week therapy with omeprazole, clarithromycin and metronidazole or ornidazole, followed by 3 weeks' treatment with omeprazole, eradicates Helicobacter pylori equally and heals duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomona | 1997 |
[Omeprazole and azithromycin with and without metronidazole in the eradication of Helicobacter pylori in duodenal ulcer disease].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combination; Duodenal U | 1997 |
Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; | 1998 |
[new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 1998 |
[Effects of the triple therapy in the eradication of Helicobacter pylori: comparison of 3 different antibiotics].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Clarithromycin; Da | 1997 |
Eradicating Helicobacter pylori reduces hypergastrinaemia during long-term omeprazole treatment.
Topics: Adult; Alginates; Aluminum Hydroxide; Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Combinations; D | 1998 |
Short duration therapy for Helicobacter pylori in Western Australia: the impact of metronidazole resistance.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug The | 1998 |
Utility of serology in determining Helicobacter pylori eradication after therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Double-Blind Me | 1998 |
A prospective randomized study of amoxycillin and omeprazole with and without metronidazole in the eradication treatment of Helicobacter pylori.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1998 |
Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Four-day lansoprazole-quadruple therapy in the routine treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Administration Sch | 1998 |
One-week proton pump inhibitor-based triple therapy eradicates residual Helicobacter pylori after failed dual therapy.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microb | 1998 |
Two-day quadruple therapy for cure of Helicobacter pylori infection: a comparative, randomized trial.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Fema | 1998 |
Omeprazole, azithromycin and either amoxycillin or metronidazole in eradication of Helicobacter pylori in duodenal ulcer patients.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; | 1998 |
Comparison of two 1-week low-dose omeprazole triple therapies--optimal treatment for Helicobacter pylori infection?
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug | 1997 |
Optimal treatment of Helicobacter pylori with ranitidine bismuth citrate (RBC): a randomized comparison between two 7-day triple therapies and a 14-day dual therapy.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clar | 1998 |
Helicobacter pylori eradication: kill the bug and save the pill?
Topics: Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Bismuth; Follow-Up Studies | 1998 |
Lansoprazole and secnidazole with clarithromycin, amoxycillin or pefloxacin in the eradication of Helicobacter pylori in a developing country.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Spiramycin as an alternative to amoxicillin treatment associated with lansoprazole/metronidazole for Helicobacter pylori infection in children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool | 1998 |
Efficacy of tetracycline and metronidazole alone or with ranitidine on the healing of duodenal ulcer and eradication of Helicobacter pylori. A randomized controlled multicenter study. Tetra-Metro-Ran Study Group.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Combinations; Duodenal Ulcer; Female; Helicobacter In | 1998 |
Acid suppression by omeprazole does not affect orally administered metronidazole bioavailability and metabolism in healthy male volunteers.
Topics: Administration, Oral; Adult; Anti-Ulcer Agents; Antitrichomonal Agents; Biological Availability; Cro | 1998 |
Two-day 'weekend' lansoprazole-quadruple therapy for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Influence of clarithromycin dosage on pantoprazole combined triple therapy for eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
One-week triple therapy with ranitidine bismuth citrate, clarithromycin and metronidazole versus two-week dual therapy with ranitidine bismuth citrate and clarithromycin for Helicobacter pylori infection: a randomized, clinical trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clari | 1998 |
Incidence of duodenal ulcer healing after 1 week of proton pump inhibitor triple therapy for eradication of Helicobacter pylori. The Lansoprazole Helicobacter Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1998 |
Lansoprazole quadruple therapy is effective in curing Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1998 |
Cure of H. pylori infection using a 7-day triple therapy combining pantoprazole with two antibiotics.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1998 |
Reversal of fundic atrophy after eradication of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Atrophy; Female; Follow-Up Studies; Gastric A | 1998 |
A prospective randomized trial comparing the use of omeprazole-based dual and triple therapy for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1998 |
New one-week, low-dose triple therapy for the treatment of duodenal ulcer with Helicobacter pylori infection.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infecti | 1998 |
Cure of Helicobacter pylori infection and healing of duodenal ulcer: comparison of pantoprazole-based one-week modified triple therapy versus two-week dual therapy. The International Pantoprazole HP Study Group.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial | 1998 |
Safety and efficacy of rabeprazole in combination with four antibiotic regimens for the eradication of Helicobacter pylori in patients with chronic gastritis with or without peptic ulceration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; Clarithromy | 1998 |
A new quadruple therapy for the eradication of Helicobacter pylori. Effect of pretreatment with omeprazole on the cure rate.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Dyspe | 1998 |
Chronic urticaria and Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Blood Donors; Breath Tests; | 1998 |
High Helicobacter pylori eradication rate with a 1-week regimen containing ranitidine bismuth citrate.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Confidence Intervals; Double-Blin | 1998 |
Symptomatic benefit from eradicating Helicobacter pylori infection in patients with nonulcer dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 1998 |
Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Drug Therapy, Combination; | 1998 |
Eradication of Helicobacter pylori with lansoprazole, roxithromycin and metronidazole--an open pilot study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Drug Resistance, Microbial; Femal | 1998 |
[Previous treatment with omeprazole and H. pylori: does it diminish the eradication efficacy of the "new" triple therapies of one week's duration?].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 1998 |
Optimal duration of therapy combining ranitidine bismuth citrate with clarithromycin and metronidazole in the eradication of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Clarithromycin; Drug Therapy, Combi | 1999 |
The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Double-Blind Method; Drug Resistance, Microbial; | 1999 |
[Recurrence rate of H. pylori after successful eradication and second eradication therapy after initial failure of treatment].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Follow-Up Studies; Helico | 1999 |
[Four kinds of new triple therapy regiments for Helicobacter pylori eradication in patients with peptic ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin | 1999 |
[Triple therapy regimens involving H2 blockaders for therapy of Helicobacter pylori infections].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 1999 |
One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Sche | 1999 |
Enhancing compliance not a prerequisite for effective eradication of Helicobacter pylori: the HelP Study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, | 1999 |
[The treatment of chronic duodenal ulcer with accompanying Helicobacter pylori infection].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; C | 1998 |
The DU-MACH study: eradication of Helicobacter pylori and ulcer healing in patients with acute duodenal ulcer using omeprazole based triple therapy.
Topics: Acute Disease; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-B | 1999 |
Triple therapy for Helicobacter pylori eradication is more effective than long-term maintenance antisecretory treatment in the prevention of recurrence of duodenal ulcer: a prospective long-term follow-up study.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Drug Therapy, Combina | 1999 |
The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistan | 1999 |
Eradication of Helicobacter pylori infection after ranitidine bismuth citrate, metronidazole and tetracycline for 7 or 10 days.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Dru | 1999 |
Effectiveness of ranitidine bismuth citrate, clarithromycin, and metronidazole therapy for treating Helicobacter pylori.
Topics: Adult; Bismuth; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Female; Hel | 1999 |
Once-daily therapy for H. pylori infection: a randomized comparison of four regimens.
Topics: Adult; Amoxicillin; Azithromycin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combin | 1999 |
Rapid elimination of Helicobacter pylori and reduction of histocompatibility leucocyte antigen-DR expression 12 h after a single dose of omeprazole, amoxycillin and metronidazole triple therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Female; Ga | 1999 |
Efficacy of a 1-week regimen of ranitidine bismuth citrate in combination with metronidazole and clarithromycin for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Female | 1999 |
The optimal antibiotic combination in a 5-day Helicobacter pylori eradication regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 1999 |
Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; C | 1999 |
[Antral biopsy is sufficient to confirm Helicobacter pylori eradication with the "new" one-week long triple treatments].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Administration S | 1999 |
Helicobacter pylori-positive functional dyspepsia in elderly patients: comparison of two treatments.
Topics: Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; D | 1999 |
Efficacy of 7 day lansoprazole-based triple therapy for Helicobacter pylori infection in elderly patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial | 1999 |
Helicobacter pylori eradication: comparison of three treatment regimens in India.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Pretreatment antibiotic resistance in Helicobacter pylori infection: results of three randomized controlled studies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Doxycycline; Drug Resistance, | 1999 |
Randomized placebo-controlled trial of Helicobacter pylori eradication for iron-deficiency anemia in preadolescent children and adolescents.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; | 1999 |
Colloidal bismuth pectin: an alternative to bismuth subcitrate for the treatment of Helicobacter pylori--positive duodenal ulcer.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; B | 1999 |
Comparison of two 3-day Helicobacter pylori eradication regimens with a standard 1-week regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
Randomized trial of omeprazole and clarithromycin combined with either metronidazole or amoxycillin in patients with metronidazole-resistant or -susceptible Helicobacter pylori strains.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug | 1999 |
Role of anti-Helicobacter pylori treatment in H. pylori-positive and cytoprotective drugs in H. pylori-negative, non-ulcer dyspepsia: results of a randomized, double-blind, controlled trial in Asian Indians.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Double-Blind Method; Drug Therapy, Combinat | 1999 |
Eradication of Helicobacter pylori infection with proton pump-based triple therapy in patients in whom bismuth-based triple therapy failed.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; C | 1999 |
Effect of two different doses of metronidazole and tetracycline in bismuth triple therapy on eradication of Helicobacter pylori and its resistant strains.
Topics: Adult; Antacids; Anti-Bacterial Agents; Bismuth; Female; Helicobacter Infections; Helicobacter pylor | 1999 |
One-week ranitidine bismuth citrate in combinations with metronidazole, amoxycillin and clarithromycin in the treatment of Helicobacter pylori infection: the RBC-MACH study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromy | 1999 |
Famotidine versus omeprazole in combination with clarithromycin and metronidazole for eradication of Helicobacter pylori--a randomized, controlled trial.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Resis | 1999 |
Prevalence of resistance to clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 1999 |
The OAC and OMC options.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Double-Blind Method; Drug Res | 1999 |
Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithro | 1999 |
Assessment of decisions in the treatment of Helicobacter pylori-related duodenal ulcer: a cost-effectiveness study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; China; Cimetidine; Cost-Be | 1999 |
Helicobacter treatment with quadruple therapy in primary health care for patients with a history of ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Drug Therapy, Combinati | 1999 |
Seven-day 'rescue' therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Administ | 1999 |
A randomized controlled trial of an enhanced patient compliance program for Helicobacter pylori therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination | 1999 |
Comparative effects of omeprazole, amoxycillin plus metronidazole versus omeprazole, clarithromycin plus metronidazole on the oral, gastric and intestinal microflora in Helicobacter pylori-infected patients.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Co | 1999 |
The outcome of a 2-week treatment of Helicobacter pylori-positive duodenal ulcer with omeprazole-based antibiotic regimen in a region with high metronidazole resistance rate.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Contraindications; Dr | 1999 |
[Reinfection with Helicobacter pylori in patients with duodenal ulcer after successful eradication].
Topics: Adult; Amoxicillin; Bismuth; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duodenal Ul | 1999 |
Efficacy of two different dosage regimens of omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Drug Resistance; | 1999 |
Quadruple therapy is effective for eradicating Helicobacter pylori after failure of triple proton-pump inhibitor-based therapy: a detailed, prospective analysis of 21 consecutive cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Re | 1999 |
Eradication of Helicobacter pylori using 30 mg or 60 mg lansoprazole combined with amoxicillin and metronidazole: one and two weeks of a new triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 1999 |
Triple therapy for Helicobacter pylori eradication: a comparison of pantoprazole once versus twice daily.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2000 |
Bismuth-based quadruple therapy for Helicobacter pylori - a single triple capsule plus lansoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Antacids; Anti- | 2000 |
Furazolidone combination therapies for Helicobacter pylori infection in the United States.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Fu | 2000 |
Comparison of lansoprazole-based triple and dual therapy for treatment of Helicobacter pylori-related duodenal ulcer: an Asian multicentre double-blind randomized placebo controlled study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 2000 |
Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Asia, Southeastern; | 2000 |
Omeprazole once or twice daily with clarithromycin and metronidazole for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; Female; Heli | 2000 |
Influence of oral Helicobacter pylori on the success of eradication therapy against gastric Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromy | 2000 |
Effect of Helicobacter pylori eradication on peptic ulcer disease complicated with outlet obstruction.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, | 2000 |
Eradication of H. pylori with pantoprazole, clarithromycin, and metronidazole in duodenal ulcer patients: a head-to-head comparison between two regimens of different duration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Abdominal Pain; Adult; Aged; Anti-Bacterial Agents; Anti-Ul | 2000 |
Four-day, twice daily, quadruple therapy with amoxicillin, clarithromycin, tinidazole and omeprazole to cure Helicobacter pylori infection: a pilot study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Drug A | 2000 |
Importance of Helicobacter pylori cagA and vacA status for the efficacy of antibiotic treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti | 2000 |
[The MACH2 Study: value of inhibiting gastric acid secretion in eradication of Helicobacter pylori with a one week triple therapy protocol].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Double-Blind Metho | 2000 |
Helicobacter pylori and its eradication in rosacea.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dy | 1999 |
Efficacy of bismuth-based triple therapy in children with abdominal pain and Helicobacter pylori gastritis.
Topics: Abdominal Pain; Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool | 2000 |
Effect of triple therapy on eradication of canine gastric helicobacters and gastric disease.
Topics: Amoxicillin; Animals; Antacids; Anti-Bacterial Agents; Dog Diseases; Dogs; Drug Therapy, Combination | 2000 |
Furazolidone versus metronidazole in quadruple therapy for eradication of Helicobacter pylori in duodenal ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Drug Combinations; Duodenal Ulcer; Female; Furazolidone; Helicobacter | 2000 |
Is Helicobacter pylori eradication associated with gastroesophageal reflux disease?
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Double-Blind Method; Drug Therapy, | 2000 |
Patients with dyspepsia benefit from eradication of Helicobacter pylori if other organic causes for dyspepsia were carefully ruled out.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Clarithromycin; Diagnosis, Differential; Dose- | 2000 |
Pharmacokinetics of clarithromycin in Helicobacter pylori eradication therapy in patients with liver cirrhosis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromy | 2000 |
Randomized study comparing omeprazole with ranitidine as anti-secretory agents combined in quadruple second-line Helicobacter pylori eradication regimens.
Topics: Administration, Oral; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; | 2000 |
Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Drug Admi | 2000 |
Randomized trial of omeprazole and metronidazole with amoxycillin or clarithromycin for Helicobacter pylori eradication, in a region of high primary metronidazole resistance: the HERO study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; Drug T | 2000 |
Addition of metronidazole to rabeprazole-amoxicillin-clarithromycin regimen for Helicobacter pylori infection provides an excellent cure rate with five-day therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2000 |
[Effect of pantoprazole, amoxicillin and metronidazole treatment on the level of H. pylori eradication and the histological image of antral gastritis in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
The impact of antibiotic resistance on the efficacy of three 7-day regimens against Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Com | 2000 |
Equally high efficacy of 4, 7 and 10-day triple therapies to eradicate Helicobacter pylori infection in patients with ulcer disease.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 2000 |
[Cost-effectiveness analysis of 2 strategies of Helicobacter pylori eradication: results of a prospective and randomized study in primary care].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benef | 2000 |
Eradication of Helicobacter pylori with pantoprazole and two antibiotics: a comparison of two short-term regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2000 |
Transfer of metronidazole to gastric juice: impact of Helicobacter pylori infection and omeprazole.
Topics: Adult; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Cross-Over Studies; Gastric Juic | 2000 |
[Lansoprazole versus ranitidine bismuth citrate containing triple regimens for Helicobacter pylori eradication in patients with duodenal ulcer].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; C | 2000 |
Intravenous eradication therapy for bleeding gastroduodenal ulcer associated with Helicobacter pylori infection.
Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Schedule; Fem | 2000 |
Impact of Helicobacter pylori antimicrobial resistance on the outcome of 1-week lansoprazole-based triple therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Clarithromycin; Drug Resistance, Microb | 2000 |
Treatment of Helicobacter pylori in patients with duodenal ulcer hemorrhage--a long-term randomized, controlled study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; D | 2000 |
Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Double-Blind Method; Female; Follo | 2000 |
Influence of Helicobacter pylori eradication therapy on 13C aminopyrine breath test: comparison among omeprazole-, lansoprazole-, or pantoprazole-containing regimens.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aminopyrine; Anti-Ulcer Agents; Benzimidazoles | 2000 |
Eradication of Helicobacter pylori compared with long-term acid suppression in duodenal ulcer disease. A randomized trial with 2-year follow-up. The Danish Ulcer Study Group.
Topics: Amoxicillin; Anti-Ulcer Agents; Double-Blind Method; Duodenal Ulcer; Female; Follow-Up Studies; Gast | 2000 |
Incidence of secondary Helicobacter pylori resistance to antibiotics in treatment failures after 1-week proton pump inhibitor-based triple therapies: a prospective study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, | 2000 |
The HOMER Study: the effect of increasing the dose of metronidazole when given with omeprazole and amoxicillin to cure Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Presch | 2000 |
Randomized study of two "rescue" therapies for Helicobacter pylori-infected patients after failure of standard triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Benzimidaz | 2001 |
One-week ranitidine bismuth citrate-based triple therapy for the eradication of Helicobacter pylori in Hong Kong with high prevalence of metronidazole resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; | 2001 |
Five-day proton pump inhibitor-based quadruple therapy regimen is more effective than 7-day triple therapy regimen for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adolescent; Adult; Aged; Amoxicillin; | 2001 |
Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rate.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Anti-Ulcer Agents; Clarithr | 2001 |
Prevalence of Helicobacter pylori resistance to antibiotics in Northeast Italy: a multicentre study. GISU. Interdisciplinary Group for the Study of Ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy, Needle; Clarithromycin; Confidence Interval | 2000 |
Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Drug The | 2001 |
Nitrofurantoin quadruple therapy for Helicobacter pylori infection: effect of metronidazole resistance.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents, Urinary; Anti-Ulcer | 2001 |
The effect of culture results for Helicobacter pylori on the choice of treatment following failure of initial eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ul | 2001 |
Randomised study of the efficacy of omeprazole and clarithromycin with either amoxycillin or metronidazole in the eradication of Helicobacter pylori in screened primary care patients.
Topics: Adult; Amoxicillin; Clarithromycin; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2001 |
Ranitidine bismuth citrate or omeprazole-based triple therapy for Helicobacter pylori eradication in Helicobacter pylori-infected non-ulcer dyspepsia.
Topics: Adult; Amoxicillin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Co | 2001 |
Eradication of Helicobacter pylori infection in patients with duodenal ulcer and non-ulcer dyspepsia and analysis of one-year reinfection rates.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duoden | 2001 |
Anti-inflammatory and tissue-protectant drug effects: results from a randomized placebo-controlled trial of gastritis patients at high risk for gastric cancer.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Calcium Carbonate; Drug Therapy, | 2001 |
Fish oil (Eicosapen) is less effective than metronidazole, in combination with pantoprazole and clarithromycin, for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Benz | 2001 |
Modified seven-day, quadruple therapy as a first line Helicobacter pylori treatment.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Administration Sch | 2001 |
Is eradication of Helicobacter pylori with colloidal bismuth subcitrate quadruple therapy safe?
Topics: Adult; Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacte | 2001 |
High efficacy of ranitidine bismuth citrate, amoxicillin, clarithromycin and metronidazole twice daily for only five days in Helicobacter pylori Eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Therapy, | 2001 |
Quadruple therapy for symptomatic spontaneous duodenal ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Anti-Ulcer Agents; Clarithr | 2001 |
The AMOR study: a randomized, double-blinded trial of omeprazole versus ranitidine together with amoxycillin and metronidazole for eradication of Helicobacter pylori.
Topics: Adolescent; Aged; Aged, 80 and over; Amoxicillin; Dose-Response Relationship, Drug; Double-Blind Met | 2001 |
Helicobacter pylori and iron deficiency anaemia in children.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath T | 2001 |
Is untargeted outreach visiting in primary care effective? A pragmatic randomized controlled trial.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Community Pharmacy Services; Community-Instit | 2001 |
Ranitidine bismuth citrate with clarithromycin alone or with metronidazole for the eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Carbon Isotopes; Clari | 2001 |
Effect of Helicobacter pylori eradication on the ulcer recurrence rate after simple closure of perforated duodenal ulcer: retrospective and prospective randomized controlled studies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer | 2001 |
Various durations of a standard regimen (amoxycillin, metronidazole, colloidal bismuth sub-citrate for 2 weeks or with additional ranitidine for 1 or 2 weeks) on eradication of Helicobacter pylori in Iranian peptic ulcer patients. A randomized controlled
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Biopsy, Needle; Bismuth; Breath Tests; Drug Administratio | 2001 |
A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti | 2001 |
Comparison of 1-week vs. 2- or 4-week therapy regimens with ranitidine bismuth citrate plus two antibiotics for Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dose-Response Relati | 2001 |
A multicenter study on eradication of Helicobacter pylori infection in patients with duodenal ulcer by lansoprazole-antibiotics combined therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 1999 |
Bismuth-based quadruple therapy with bismuth subcitrate, metronidazole, tetracycline and omeprazole in the eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2001 |
A randomized comparison of four omeprazole-based triple therapy regimens for the eradication of Helicobacter pylori in patients with non-ulcer dyspepsia.
Topics: Administration, Oral; Adult; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Azit | 2001 |
Treatment of Helicobacter pylori in children with recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Coho | 2001 |
Helicobacter pylori eradication therapy is more effective in peptic ulcer than in non-ulcer dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Dyspepsia; Female; H | 2001 |
Helicobacter pylori eradication and standardized 3-month omeprazole therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Double-Blind Method; Drug Therapy, Combinatio | 2001 |
Helicobacter pylori eradication therapy in gastric high grade non Hodgkin's lymphoma (NHL).
Topics: Aged; Anti-Ulcer Agents; Clarithromycin; Combined Modality Therapy; Drug Therapy, Combination; Gastr | 2001 |
Clinical outcome and influencing factors of a new short-term quadruple therapy for Helicobacter pylori eradication: a randomized controlled trial (MACLOR study).
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2002 |
Low-dose lansoprazole and clarithromycin plus metronidazole vs. full-dose lansoprazole and clarithromycin plus amoxicillin for eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Adult; Aged; Amoxicillin; Anti-Bacter | 2002 |
Primary resistance to antibiotics and its clinical impact on the efficacy of Helicobacter pylori lansoprazole-based triple therapies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2002 |
Conservative treatment of primary gastric low-grade B-cell lymphoma of mucosa-associated lymphoid tissue: predictive factors of response and outcome.
Topics: Adult; Aged; Amoxicillin; Antineoplastic Agents, Alkylating; Biopsy, Needle; Chlorambucil; Clarithro | 2002 |
Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Interactions | 2002 |
Treating Helicobacter pylori infection in primary care patients with uninvestigated dyspepsia: the Canadian adult dyspepsia empiric treatment-Helicobacter pylori positive (CADET-Hp) randomised controlled trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Canada; Clarithromy | 2002 |
Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Enzyme Inhibitors; | 2002 |
Additive effect of pronase on the efficacy of eradication therapy against Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 2002 |
Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Duodenum; Helicobacter Infections; Helicobacter | 1992 |
Experience with 'triple' anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance.
Topics: Adult; Aged; Aged, 80 and over; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helic | 1992 |
Surface hydrophobicity of gastric mucosa in Helicobacter pylori infection: effect of clearance and eradication.
Topics: Adult; Aged; Amoxicillin; Analysis of Variance; Bismuth; Duodenal Ulcer; Endoscopy, Digestive System | 1992 |
Effect of Helicobacter pylori on parietal cell sensitivity to pentagastrin in duodenal ulcer subjects.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acidity De | 1992 |
Short report: omeprazole plus antibiotic combinations for the eradication of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Bismuth; Circadian Rhythm; Drug Administration Schedule; Drug Resistance, Microbial; Dr | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicoba | 1992 |
Helicobacter pylori and gastric ulcer therapy: reflections and uncertainties.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Cefixime; Cefotaxime; Cimetidine; Drug Therapy, Combinatio | 1992 |
Helicobacter pylori eradication with doxycycline-metronidazole-bismuth subcitrate triple therapy.
Topics: Adult; Aged; Antacids; Bismuth; Doxycycline; Drug Therapy, Combination; Female; Helicobacter Infecti | 1992 |
One week eradication regimen for Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Algorithms; Amoxicillin; Anti-Ulcer Agents; Drug Adminis | 1991 |
Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia.
Topics: Adult; Aged; Amoxicillin; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Dyspepsi | 1991 |
The role of omeprazole (40 mg) in the treatment of gastric Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Bismuth; Dose-Response Relationship, Drug; Drug Administration Schedule; F | 1991 |
Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing. A randomized controlled trial.
Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Bismuth; | 1991 |
Duodenal ulcer disease--to heal or to cure?
Topics: Amoxicillin; Antacids; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter In | 1991 |
Triple therapy for Helicobacter pylori in nonulcer dyspepsia.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Helicobacter Infections | 1991 |
Chronic alcoholic gastritis. Roles of alcohol and Helicobacter pylori.
Topics: Adult; Alcoholism; Aluminum Hydroxide; Amoxicillin; Bismuth; Gastritis; Helicobacter Infections; Hel | 1991 |
The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori--a randomized double-blind placebo-controlled clinical trial.
Topics: Adolescent; Adult; Aged; Chronic Disease; Double-Blind Method; Female; Furazolidone; Gastric Mucosa; | 1990 |
950 other studies available for metronidazole and Infections, Helicobacter
| Article | Year |
|---|---|
Anti-Helicobacter pylori agents. 1. 2-(Alkylguanidino)-4-furylthiazoles and related compounds.
Topics: Animals; Anti-Bacterial Agents; Gastric Acid; Helicobacter Infections; Helicobacter pylori; Histamin | 1997 |
A redox basis for metronidazole resistance in Helicobacter pylori.
Topics: Anti-Infective Agents; Bacterial Proteins; Drug Resistance, Bacterial; Electrophoresis, Gel, Two-Dim | 2009 |
Identification of 3',4',5'-trimethoxychalcone analogues as potent inhibitors of Helicobacter pylori-induced inflammation in human gastric epithelial cells.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents; Cell Line; Chalcones; Epithelial Cells; Gastritis; | 2010 |
Synthesis and bioevaluation of novel 3,4,5-trimethoxybenzylbenzimidazole derivatives that inhibit Helicobacter pylori-induced pathogenesis in human gastric epithelial cells.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Benzimidazoles; Cell Adhesion; Cell | 2012 |
Development of bacterial transglycosylase inhibitors as new antibiotics: moenomycin A treatment for drug-resistant Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bambermycins; Drug Design; Drug Resistance, Multiple, Bacterial; Duodenal Ulc | 2014 |
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
Topics: Anaerobiosis; DNA-Directed RNA Polymerases; Helicobacter Infections; Helicobacter pylori; Humans; Ni | 2022 |
Clinical audit of current
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Clinical Audit; Drug Therapy, Combinati | 2022 |
Mutations associated with Helicobacter pylori antimicrobial resistance in the Ecuadorian population.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Ecuador; Helicobacter Infections; He | 2022 |
Increasing Helicobacter pylori clarithromycin resistance in Australia over 20 years.
Topics: Amoxicillin; Anti-Bacterial Agents; Australia; Clarithromycin; Drug Resistance, Bacterial; Helicobac | 2022 |
Comparison of Drug Resistance of Helicobacter pylori Between Children and Adults in Jilin, China.
Topics: Adult; Amoxicillin; Amplified Fragment Length Polymorphism Analysis; Anti-Bacterial Agents; Child; C | 2021 |
Clinical Effect of Clarithromycin Combined with Tinidazole on Helicobacter pylori-Related Gastritis and Its Influence on COX-2 Expression.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cyclooxygenase 2; Drug Therapy, Combinati | 2021 |
RP-HPLC-DAD Method Development and Validation for Simultaneous Determination of Lansoprazole, Tinidazole, Amoxicillin, and Naproxen in Their Raw Materials and Combined Dosage Form: DOE Approach for Optimization of the Proposed Method.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chromatography, High Pressure Liquid; Drug Th | 2022 |
Antibiotic resistance patterns and therapeutic outcomes of pediatric Helicobacter pylori infection in a high-migrant Singaporean cohort.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; H | 2022 |
In Silico Screening and In Vitro Assessment of Natural Products with Anti-Virulence Activity against
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Biofilms; Biological Products; Catalytic Domain; Clarith | 2021 |
Genotypic detection of metronidazole and clarithromycin resistance in dyspeptic patients with helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistance, Bacterial; H | 2022 |
Establishment of a reference panel of Helicobacter pylori strains for antimicrobial susceptibility testing.
Topics: Agar; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter I | 2022 |
The efficacies of non-bismuth containing quadruple therapies in the treatment of first-line anti-Helicobacter pylori across 4-year time interval with changing antibiotics resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combin | 2021 |
Geospatial analysis of Helicobacter pylori infection in South Australia: Should location influence eradication therapy?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2022 |
Second-line Therapy for Helicobacter Pylori Eradication: State of the Art.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Helicobacter | 2022 |
Interplay between Amoxicillin Resistance and Osmotic Stress in Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacte | 2022 |
Biofilm Formation of
Topics: Anti-Bacterial Agents; Biofilms; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections | 2022 |
Age of eradication and failure rates of clarithromycin-containing triple therapy for Helicobacter pylori: A 15-year population-based study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Th | 2022 |
Helicobacter pylori resistance to antibiotics before and after treatment: Incidence of eradication failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2022 |
Direct Detection of Antibiotic Resistance in Chinese
Topics: Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Microbial; Helicobacter | 2022 |
Antibiotic resistance of Helicobacter pylori isolated from children in Chongqing, China.
Topics: Anti-Bacterial Agents; Child; China; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infect | 2022 |
Synergistic activity and molecular modelling of fosfomycin combinations with some antibiotics against multidrug resistant Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Fosfomycin; Helicobacter Infections | 2022 |
[Important rise in antibiotic resistance rates inHelicobacter pyloriin the Netherlands].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter | 2022 |
A Survey of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Genotype; Helicobact | 2022 |
The Activity of Liposomal Linolenic Acid Against
Topics: alpha-Linolenic Acid; Amoxicillin; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Hum | 2022 |
Comparative Effectiveness of Various Eradication Regimens for Helicobacter Pylori Infection in the Northeastern Region of Poland.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pyl | 2022 |
Antimicrobial evaluation of the Cynara cardunculus extract in Helicobacter pylori cells using mid-infrared spectroscopy and chemometric methods.
Topics: Anti-Bacterial Agents; Chemometrics; Clarithromycin; Helicobacter Infections; Helicobacter pylori; H | 2022 |
Increase in amoxicillin resistance in Helicobacter pylori from Bulgarian patients over 15 years.
Topics: Amoxicillin; Anti-Bacterial Agents; Bulgaria; Clarithromycin; Helicobacter Infections; Helicobacter | 2022 |
Antibiotic resistance status of helicobacter pylori strains isolated from initial eradication patients in Ningbo, China, from 2017 to 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Doxycycline; Drug Resistance, Bacterial; Fosfomy | 2022 |
Antibiotic resistance patterns of Helicobacter pylori strains isolated from the Tibet Autonomous Region, China.
Topics: Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacterial; Female; Furaz | 2022 |
Comparative Study of Helicobacter Pylori Resistance to Clarithromycin and Metronidazole and Its Association with Epidemiological Factors in A Moroccan Population.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2022 |
Region-specific genomic signatures of multidrug-resistant Helicobacter pylori isolated from East and South India.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacteria | 2022 |
Antibiotic resistance patterns of Helicobacter pylori in North Israel - A six-year study.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mic | 2022 |
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Genotype; Helicobacter Infections; H | 2022 |
Single-capsule bismuth-based quadruple therapy as a rescue therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Drug-Related Side Effects an | 2023 |
Rates of Antimicrobial Resistance in Helicobacter pylori Isolates From Clinical Trial Patients Across the US and Europe.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Europe; Helic | 2023 |
Effects of Quadruple Therapy Combined with Probiotics on
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Gastrins; Helicobacter Infec | 2022 |
Alarming antibiotics resistance of Helicobacter pylori from children in Southeast China over 6 years.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Furazolidone; | 2022 |
Effect of metronidazole resistance on Helicobacter pylori eradication regimens.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2022 |
Management of Helicobacter pylori infection in paediatric patients in Europe: results from the EuroPedHp Registry.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Therapy, Combination; Eu | 2023 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Two vonoprazan combinations (Voquezna) for H. pylori.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2022 |
Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mul | 2023 |
Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mul | 2023 |
Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mul | 2023 |
Primary Helicobacter pylori resistance to antimicrobials in the Brussels area in 2021.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mul | 2023 |
Antimicrobial Resistance of Helicobacter Pylori Among Low-resource Chinese Minorities.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Cross-Sectional Studies; Drug Resistance, Bacteria | 2023 |
Antimicrobial Resistance of Helicobacter Pylori Among Low-resource Chinese Minorities.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Cross-Sectional Studies; Drug Resistance, Bacteria | 2023 |
Antimicrobial Resistance of Helicobacter Pylori Among Low-resource Chinese Minorities.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Cross-Sectional Studies; Drug Resistance, Bacteria | 2023 |
Antimicrobial Resistance of Helicobacter Pylori Among Low-resource Chinese Minorities.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Cross-Sectional Studies; Drug Resistance, Bacteria | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
An eco-friendly multi-analyte high-performance thin layer chromatographic densitometric determination of amoxicillin, metronidazole, and famotidine in their ternary mixtures and simulated gastric juice: A promising protocol for eradicating Helicobacter py
Topics: Amoxicillin; Chromatography, Thin Layer; Famotidine; Gastric Juice; Helicobacter Infections; Helicob | 2023 |
The impact of Helicobacter pylori infection and eradication therapy containing minocycline and metronidazole on intestinal microbiota.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Gastrointestinal Microbiome; Helicobacter Infectio | 2022 |
Efficacy and Safety of 7-Day Non-Bismuth Concomitant Quadruple Therapy for First-Line Helicobacter pylori Eradication in the Elderly.
Topics: Aged; Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori | 2023 |
A Vonoprazan, Clarithromycin, and Metronidazole Regimen as Helicobacter pylori Eradication Therapy for Patients with Penicillin Allergy in Light of Clarithromycin Resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Importance of Metronidazole in Vonoprazan-based Helicobacter pylori Treatment in Japan.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Geographic distribution of antibiotic resistance of Helicobacter pylori: A study in Bulgaria.
Topics: Amoxicillin; Anti-Bacterial Agents; Bulgaria; Clarithromycin; COVID-19; Drug Resistance, Bacterial; | 2023 |
Clarithromycin-based Helicobacter pylori eradication therapy is not associated with higher treatment failure compared with non-clarithromycin-based regimens in a tertiary referral hospital in Switzerland.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Antibiotic Resistance of
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug | 2022 |
A true point-of-care molecular testing method for tailored therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2023 |
Molecular Characterization of Clarithromycin Resistance in Helicobacter pylori Strains.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2023 |
Time trend prevalence of helicobacter pylori infection and endoscopic findings in symptomatic children in Portugal: A retrospective study based on three time points in 2009, 2014, and 2019.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Clarithromycin; Gastroscopy; Helicobacter Infection | 2023 |
Editorial:
Topics: Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole | 2023 |
Characteristics of phenotypic antibiotic resistance of Helicobacter pylori and its correlation with genotypic antibiotic resistance: A retrospective study in Ningxia.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistanc | 2023 |
Long-Read- and Short-Read-Based Whole-Genome Sequencing Reveals the Antibiotic Resistance Pattern of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Microbial; Furaz | 2023 |
Antibiotic resistance characteristics and risk factors analysis of
Topics: Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacterial; Helicobacter | 2023 |
Current Trends in the Management of Helicobacter pylori Infection in Serbia: Preliminary Results from the European Registry on H. pylori Management.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy | 2023 |
Susceptibility patterns and virulence genotypes of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Egypt; Genotype; Heli | 2023 |
Twice-daily intake of bismuth-based quadruple therapy for first-line Helicobacter pylori eradication: A retrospective study on 10-day, 14-day, and half-dose antibiotic therapy.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infectio | 2023 |
Molecular detection of Helicobacter pylori and its genotypic antimicrobial resistance patterns in dyspeptic Mozambican patients.
Topics: Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistance, Bacterial; Fluoroqu | 2023 |
Diagnostic and Treatment Practices for Helicobacter Pylori Infection in an Academic Pediatric Hospital.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Therapy, Combination; He | 2023 |
Ten-day tegoprazan-based concomitant therapy as a first-line treatment for Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2023 |
Antibiotic resistance, heteroresistance, and eradication success of Helicobacter pylori infection in children.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, | 2023 |
Surveillance of Helicobacter pylori resistance over 22 Years (2000-2021) in Northern Spain.
Topics: Anti-Bacterial Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Humans; Levoflo | 2023 |
Antibiotic resistance profile of
Topics: Amoxicillin; Anti-Bacterial Agents; Cefixime; Clarithromycin; Doxycycline; Drug Resistance, Bacteria | 2023 |
Bismuth quadruple three-in-one single capsule three times a day increases effectiveness compared with the usual four times a day schedule: results from the European Registry on
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter | 2023 |
Antibiotic resistance and heteroresistance in Helicobacter pylori isolates from symptomatic Vietnamese children: A prospective multicenter study.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Helicobacter | 2023 |
Roles of Lipopolysaccharide Glycosyltransferases in Maintenance of
Topics: Amoxicillin; Anti-Bacterial Agents; Antimicrobial Cationic Peptides; Cell Wall; Clarithromycin; Glyc | 2023 |
Helicobacter pylori Antimicrobial Resistance Using Next-Generation Sequencing in Stool Samples in a Pediatric Population.
Topics: Agar; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Helicob | 2023 |
A comprehensive study of Helicobacter pylori infection: molecular analysis, antibacterial susceptibility, and histopathological examination.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistance, Bacterial; F | 2023 |
Urolithin B alleviates Helicobacter pylori-induced inflammation and oxidative stress in mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antioxidants; Clarithromycin; Drug Therapy | 2023 |
Real-world practice of Helicobacter pylori management: A survey among physicians in Southeast Asia.
Topics: Amoxicillin; Anti-Bacterial Agents; Asia, Southeastern; Bismuth; Clarithromycin; Drug Therapy, Combi | 2023 |
Antibiotic-Resistant Strains of Helicobacter pylori in 50 Antibiotic Treatment-Naive Children in Northeast Poland Diagnosed by Gastric or Duodenal Biopsy Between February 2019 and May 2022.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Clarithromycin; Hel | 2023 |
Refractory Helicobacter pylori infection in Australia: updated multicentre antimicrobial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Australia; Clarithromycin; Drug Resistance, Bacterial; Helicobac | 2023 |
Relationship between antibiotic resistance and the cagA and vacA genotypes among Helicobacter pylori strain isolates from patients in Xi'an.
Topics: Antigens, Bacterial; Bacterial Proteins; Drug Resistance, Microbial; Genotype; Helicobacter Infectio | 2023 |
High incidence of antibiotic resistance amongst isolates of
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Helicobacter Infecti | 2023 |
The epidemiology of Helicobacter pylori resistance in a university affiliated hospital: a comparison between two time periods-a cross-sectional design.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistan | 2023 |
Molecular characterization of Helicobacter pylori isolated from Nile Tilapia (Oreochromis niloticus) and fish handlers.
Topics: Animals; Anti-Bacterial Agents; Anti-Infective Agents; Cichlids; Clarithromycin; Drug Resistance, Ba | 2023 |
Management of Helicobacter pylori treatment failures: A large population-based study (HP treatment failures trial).
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter | 2023 |
Clostridium difficile infection associated with metronidazole-based treatment for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Enterocolitis, Pseudomembranous; Female; Helicobacter Infections; Helicobacte | 2019 |
Helicobacter pylori: Multiple resistance in patients from Bogotá, Colombia
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Colombia; DNA, Bacterial; D | 2019 |
Polysorbate 80 add-on therapy in the treatment of Helicobacter pylori infection: Polysorbate 80 and HP antibiotic resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Combinations; Drug Resistance, Bacterial; H | 2019 |
Helicobacter pylori eradication regimens in an antibiotic high-resistance European area: A cost-effectiveness analysis.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Ana | 2020 |
First Detection in
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Female; Helicobacter heilm | 2020 |
Which should be the first-line treatment for Helicobacter pylori in Colombia? A lesson from a recent study.
Topics: Anti-Bacterial Agents; Clarithromycin; Colombia; Drug Combinations; Drug Resistance, Multiple, Bacte | 2019 |
Molecular detection of H. pylori antibiotic-resistant genes and molecular docking analysis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacteria | 2020 |
[Helicobacter pylori infection in the HIV + population: a comorbidity to think about].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-HIV Agents; Anti-Ulcer Agents; Clarithromycin; Comor | 2020 |
Reverse hybrid therapy achieves a similar eradication rate as standard hybrid therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections | 2020 |
Comparison of four different regimens against Helicobacter pylori as a first-line treatment: A prospective, cross-sectional, comparative, open trial in Chinese children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Breath Tests; Child; China; Clarithromycin; | 2020 |
Efficacy and safety of twice a day, bismuth-containing quadruple therapy using high-dose tetracycline and metronidazole for second-line Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Female; Helicobac | 2020 |
Evaluation of Mutations in 23S rRNA, rdxA and frxA Genes of Helicobacter pylori in Paraffin-Embedded Gastric Biopsy Specimens from Iranian Gastric Cancer and Gastritis Patients.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; Biopsy; Clarithromycin; DNA Muta | 2021 |
Annual eradication rate of bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: A 15-year prospective study at a tertiary hospital in Korea.
Topics: Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Disease Eradication; Drug Administration Schedul | 2020 |
Helicobacter pylori Infection Facilitates the Expression of Resistin-like Molecule Beta in Gastric Carcinoma and Precursor Lesions.
Topics: Adenocarcinoma; Adult; Aged; Amoxicillin; Cell Line, Tumor; Female; Gene Expression Regulation, Neop | 2020 |
Helicobacter pylori first-line and rescue treatments in patients allergic to penicillin: Experience from the European Registry on H pylori management (Hp-EuReg).
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Hypersensitivity; Drug Therapy, Combination; He | 2020 |
Helicobacter pylori eradication therapy outcome according to clarithromycin susceptibility testing in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Th | 2020 |
Antibiotic resistance of Helicobacter pylori infection in a children's hospital in Vietnam: prevalence and associated factors.
Topics: Amoxicillin; Child; Child, Preschool; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Comb | 2020 |
Population-based study of Helicobacter pylori infection and antibiotic resistance in Bhutan.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bhutan; Clarithromycin; Drug Resistance, Bacterial; Femal | 2020 |
Helicobacter pylori Infection in Pediatric Patients Living in Europe: Results of the EuroPedHP Registry 2013 to 2016.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Therapy, Combination; Europe; Female | 2020 |
Apparent Intracellular Helicobacter pylori Detected by Immunohistochemistry: The Missing Link in Eradication Failure.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2021 |
Rifabutin-Based Triple Therapy Or Bismuth-Based Quadruple Regimen As Rescue Therapies For Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Hel | 2020 |
Long-term changes in the gut microbiota after 14-day bismuth quadruple therapy in penicillin-allergic children.
Topics: Adolescent; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Cross-Sectional Studies; Drug Hyp | 2020 |
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Combin | 2020 |
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Combin | 2020 |
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Combin | 2020 |
Bismuth quadruple regimen with tetracycline or doxycycline versus three-in-one single capsule as third-line rescue therapy for Helicobacter pylori infection: Spanish data of the European Helicobacter pylori Registry (Hp-EuReg).
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Doxycycline; Drug Combin | 2020 |
Mutations of Helicobacter pylori RdxA are mainly related to the phylogenetic origin of the strain and not to metronidazole resistance.
Topics: Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infections; H | 2020 |
Helicobacter pylori and antibiotic resistance in the pediatric population: an update from Vietnam.
Topics: Amoxicillin; Bismuth; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combination; | 2020 |
Lack of significant differences between gastrointestinal tract microbial population structure of Helicobacter pylori-infected subjects before and 2 years after a single eradication event.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastro | 2020 |
High prevalence and risk factors of multiple antibiotic resistance in patients who fail first-line Helicobacter pylori therapy in southern China: a municipality-wide, multicentre, prospective cohort study.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacte | 2020 |
Impact of previous metronidazole exposure on metronidazole-based second-line quadruple therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2020 |
Efficacy of a novel sequential treatment regimen containing bismuth for Helicobacter pylori eradication in Turkish children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Clarithromycin; Drug Therapy, Combin | 2020 |
Clinical factors associated with initial Helicobacter pylori eradication therapy: a retrospective study in China.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Dr | 2020 |
Antimicrobial resistance of Helicobacter pylori in an eastern German region.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Germany; Helicobacter Inf | 2021 |
High Metronidazole and Clarithromycin Resistance of Helicobacter Pylori Isolated from Previously Treated and Naïve Patients.
Topics: Academic Medical Centers; Adult; Chi-Square Distribution; Clarithromycin; Cohort Studies; Cross-Sect | 2020 |
Survey of the antimicrobial resistance of Helicobacter pylori in France in 2018 and evolution during the previous 5 years.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; | 2021 |
Helicobacter pylori Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on H. pylori Management.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Disease Eradication; Drug Therap | 2021 |
Modified bismuth quadruple therapy with low-dose metronidazole as first-line therapy for Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2021 |
European Registry on Helicobacter pylori management: Single-capsule bismuth quadruple therapy is effective in real-world clinical practice.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Resistance, Bac | 2021 |
Modified quadruple therapy or bismuth-containing quadruple therapy in the first-line treatment of Helicobacter pylori in Turkey.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pyl | 2021 |
Tailored Helicobacter pylori eradication therapy in obese patients undergoing bariatric surgery.
Topics: Amoxicillin; Anti-Bacterial Agents; Bariatric Surgery; Drug Therapy, Combination; Helicobacter Infec | 2021 |
Prospective comparative study of the treatment of Helicobacter pylori with antibiotic susceptibility testing-guided triple therapy compared to quadruple therapy with bismuth-metronidazole-tetracycline subcitrate.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pyl | 2021 |
Recent Developments Pertaining to H. pylori Infection.
Topics: Adenocarcinoma; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistan | 2021 |
Room for Improvement in the Treatment of Helicobacter pylori Infection: Lessons from the European Registry on H. pylori Management (Hp-EuReg).
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2022 |
Dual Clarithromycin and Metronidazole Resistance Is the Main Cause of Failure in Ultimate Helicobacter pylori Eradication.
Topics: Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combinatio | 2021 |
Impact of Antimicrobial Resistance Rates on Eradication of Helicobacter pylori in a US Population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Bismuth; Child; Child, Preschool; Clarithrom | 2021 |
Antimicrobial activity and additive effect of the modified Gingyo-san with antimicrobials against Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacteria | 2021 |
Detection of Helicobacter pylori by invasive tests in adult dyspeptic patients and antibacterial resistance to six antibiotics, including rifampicin in Turkey. Is clarithromycin resistance rate decreasing?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, | 2021 |
Pharmacokinetic Interactions between Tegoprazan and Metronidazole/Tetracycline/Bismuth and Safety Assessment in Healthy Korean Male Subjects.
Topics: Anti-Bacterial Agents; Benzene Derivatives; Bismuth; Cross-Over Studies; Drug Therapy, Combination; | 2021 |
Gastric mucosal changes, and sex differences therein, after Helicobacter pylori eradication: A long-term prospective follow-up study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Female; Follow-Up Studies; | 2021 |
Armeniaspirol A: a novel anti-Helicobacter pylori agent.
Topics: Animals; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Metronidazole; Mice; P | 2022 |
The effect of previous eradication failure on antibiotic resistance of Helicobacter pylori: A retrospective study over 8 years in Beijing.
Topics: Amoxicillin; Anti-Bacterial Agents; Beijing; Clarithromycin; Drug Resistance, Bacterial; Drug Resist | 2021 |
Construction of metronidazole capped in gold nanoparticles against
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Thera | 2021 |
Primary antibiotic resistance of Helicobacter pylori isolates is twofold more frequent in HIV-positive than HIV-negative individuals: A descriptive observational study.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter | 2021 |
Antimicrobial Resistance and the Successful Eradication of
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Asian People; Child; Child, Preschool; Clarithromyci | 2021 |
Early genetic diagnosis of clarithromycin resistance in
Topics: Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacterial; Early Diagnosis; Helicobac | 2021 |
Novel "High-dose Quad" Salvage Therapy Approach for
Topics: Aged, 80 and over; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections | 2023 |
Favorable outcomes of rescue second- or third-line culture-based Helicobacter pylori eradication treatment in areas of high antimicrobial resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacteria | 2021 |
Low Adherence to Society Guidelines for the Management of Helicobacter Pylori Among Pediatric Gastroenterologists.
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Therapy, Combination; Gastroenterolo | 2021 |
Moxifloxacin, but not Metronidazole can be used in therapeutic regimens against Helicobacter pylori.
Topics: Amoxicillin; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Moxifloxacin | 2017 |
Antibiotic susceptibility of Helicobacter pylori in Iceland.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, | 2017 |
Amoxycillin and Metronidazole Therapy for Helicobacter pylori Eradication: A 10-Year Trend in Turin, Italy.
Topics: Amoxicillin; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Humans; Italy; Met | 2017 |
A real life study of Helicobacter pylori eradication with bismuth quadruple therapy in naïve and previously treated patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cohort Studies; Drug Combinations; Drug Therapy, Combination; Fe | 2017 |
Clinical Pearls in Infectious Diseases 2017.
Topics: Administration, Intravaginal; Adult; Aged; Anti-Bacterial Agents; Body Piercing; Campylobacter Infec | 2017 |
Secondary antibiotic resistance of Helicobacter pylori isolates in Israeli children and adults.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Multiple, Bacteri | 2017 |
rdxA, frxA, and efflux pump in metronidazole-resistant Helicobacter pylori: Their relation to clinical outcomes.
Topics: Adult; Aged; Bacterial Proteins; Drug Resistance, Bacterial; Female; Gastritis; Helicobacter Infecti | 2018 |
Second-line therapy for Helicobacter pylori eradication causing antibiotic-associated hemorrhagic colitis.
Topics: Abdominal Pain; Aged; Amoxicillin; Biopsy; Colitis; Colon; Colonoscopy; Female; Gastrointestinal Hem | 2017 |
[The Efficacy of Moxifloxacin-containing Triple Therapy after Hybrid Therapy Failure in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Fluoroq | 2017 |
Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection.
Topics: Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Body Mass Index; Clarithromycin; Drug Resist | 2017 |
Bismuth-based quadruple therapy following H. pylori eradication failures: a multicenter study in clinical practice.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Capsules; Drug Administration Sch | 2017 |
Antimicrobial susceptibility of Helicobacter pylori strains isolated from children in Israel.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Clarithromycin; Dru | 2018 |
The Resolution of Helicobacter suis-associated Gastric Lesions after Eradication Therapy.
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Esomeprazo | 2018 |
Eradication of Helicobacter pylori infection with a new bismuth-based quadruple therapy in clinical practice.
Topics: Anti-Infective Agents; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylo | 2018 |
Primary antibiotic resistance of Helicobacter pylori in Chinese patients: a multiregion prospective 7-year study.
Topics: Adult; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacte | 2018 |
Clinical Outcomes of Standard Triple Therapy Plus Probiotics or Concomitant Therapy for
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dietary Supplements; Drug Therapy, | 2018 |
Inappropriate treatment in Helicobacter pylori eradication failure: a retrospective study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; China; Clarithromycin; Drug Therapy, Combination; Female; | 2018 |
Helicobacter pylori resistance in the Netherlands: a growing problem?
Topics: Adult; Aged; Ampicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; | 2017 |
Comment on Helicobacter pylori eradication using metronidazole.
Topics: Amoxicillin; Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Moxifloxa | 2018 |
High frequency of metronidazole and clarithromycin-resistant Helicobacter pylori in formalin-fixed, paraffin-embedded gastric biopsies.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Biopsy; Child; Child, Preschool; Clarithromycin; Drug Res | 2018 |
Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2018 |
Impact of primary antibiotic resistance on the effectiveness of sequential therapy for Helicobacter pylori infection: lessons from a 5-year study on a large number of strains.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Resistance, M | 2018 |
Effectiveness and Safety of Pylera® in Patients Infected by Helicobacter Pylori: A Multicenter, Retrospective, Real Life Study.
Topics: Anti-Bacterial Agents; Bismuth; Demography; Drug Therapy, Combination; Endoscopy; Female; Helicobact | 2018 |
Antibiotic resistance pattern of Helicobacter pylori strains isolated in Italy during 2010-2016.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Female; Helicoba | 2018 |
The need for a patient-tailored Helicobacter pylori eradication protocol prior to bariatric surgery.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bariatric Surgery; Body Mass Index; Cl | 2018 |
[Phylogenetic study of drug resistance genes from clinical isolates of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Clarithromycin; Drug Resistance, Bacterial; | 2018 |
Helicobacter pylori eradication may successfully treat primary cutaneous follicle center lymphoma.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Doxycycline; Female; Helicobacter Infec | 2018 |
Helicobacter pylori eradication with bismuth quadruple therapy leads to dysbiosis of gut microbiota with an increased relative abundance of Proteobacteria and decreased relative abundances of Bacteroidetes and Actinobacteria.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Actinobacteria; Adult; Anti-Bacterial Agents; Bacteroidetes | 2018 |
Prevalence of clarithromycin resistance in Helicobacter pylori in Santiago, Chile, estimated by real-time PCR directly from gastric mucosa.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Chile; Clarithromycin; Drug Resistance, Bacterial; Gastri | 2018 |
Retrospective analysis of the use of quadruple therapy with bismuth (Pylera
Topics: Adult; Aged; Breath Tests; Cross-Sectional Studies; Drug Evaluation; Drug Therapy, Combination; Fema | 2018 |
Helicobacter pylori antimicrobial resistance in a pediatric population.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resist | 2018 |
[Efficacy of bismuth containing quadruple therapies on Helicobacter pylori eradication in patients with history of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; Furazolidone | 2018 |
Dynamics of antimicrobial resistance of Helicobacter pylori isolates in the Smolensk region of Russian Federation.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2018 |
Modified quadruple therapy versus bismuth-containing quadruple therapy in first-line treatment of Helicobacter pylori infection in Korea; rationale and design of an open-label, multicenter, randomized controlled trial.
Topics: Adult; Amoxicillin; Anti-Infective Agents; Clinical Protocols; Drug Resistance, Bacterial; Drug Ther | 2018 |
Role of MIC levels of resistance to clarithromycin and metronidazole in Helicobacter pylori eradication.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2019 |
How and when investigating and treating Helicobacter pylori infection in children.
Topics: Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Clarithromycin; Drug Resistance | 2018 |
Effect of 7-day Bismuth Quadruple Therapy versus 14-day Moxifloxacin Triple Therapy for Second-line
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Administration Schedule; Drug Therapy | 2019 |
Effect of Age on Effectiveness of Vonoprazan in Triple Therapy for Helicobacter pylori Eradication.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Clarithromycin; Drug Therapy, | 2019 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug T | 2019 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug T | 2019 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug T | 2019 |
Risk factors of rescue bismuth quadruple therapy failure for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Bismuth; Dose-Response Relationship, Drug; Drug Resistance, Bacterial; Drug T | 2019 |
[Eradication Rates of 10-day Sequential Therapy for
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2019 |
A novel hybrid first-line therapy for H. pylori eradication: results of a pilot study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Load; Drug Administration Schedule; Drug Combina | 2019 |
Five alternative Helicobacter pylori antibiotics to counter high levofloxacin and metronidazole resistance in the Dominican Republic.
Topics: Adult; Anti-Bacterial Agents; Bacterial Proteins; DNA-Directed RNA Polymerases; Dominican Republic; | 2019 |
Effect of Helicobacter pylori Treatment on Unexplained Iron Deficiency Anemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Age | 2019 |
A Potassium-Competitive Acid Blocker-Based Regimen as Second-Line Therapy Improves Helicobacter pylori Eradication.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Drug Administration Schedule; Drug Therap | 2020 |
Molecular diagnosis of Helicobacter pylori antibiotic resistance in the Taif region, Saudi Arabia.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; Clarithromycin; Cohort Studies; DNA Gyrase; | 2019 |
Bismuth Concentrations in Patients Treated in Real-Life Practice with a Bismuth Subcitrate-Metronidazole-Tetracycline Preparation: The SAPHARY Study.
Topics: Aged; Bismuth; Cohort Studies; Drug Combinations; Female; Helicobacter Infections; Helicobacter pylo | 2019 |
Nationwide antibiotic resistance mapping of Helicobacter pylori in Korea: A prospective multicenter study.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, | 2019 |
Compliance, adverse effects and effectiveness of first line bismuth-containing quadruple treatment (Pylera®) to eradicate Helicobacter pylori infection in 200 patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Capsules; Drug Combinations; Fema | 2019 |
Retrospective Analysis Confirms Tetracycline Quadruple as Best Helicobacter pylori Regimen in the USA.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Electronic Health Records; Fema | 2019 |
Increasing antimicrobial resistance to clarithromycin and metronidazole in pediatric Helicobacter pylori infection in southern Taiwan: A comparison between two decades.
Topics: Adolescent; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resistance, Bacteri | 2019 |
Primary antimicrobial resistance rates and prevalence of Helicobacter pylori infection in the north of Spain. A 13-year retrospective study.
Topics: Age Factors; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Mul | 2019 |
Tailored Helicobacter pylori eradication based on prior intake of macrolide antibiotics allows the use of triple therapy with optimal results in an area with high clarithromycin resistance.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Re | 2019 |
Effect of Drug Combination on Omeprazole Metabolism by Cytochrome P450 2C19 in Helicobacter pylori Eradication Therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Chromatography, High Pressure Liquid; Clarithromycin; Cytochrome | 2019 |
High Helicobacter pylori resistance to metronidazole and clarithromycin in Brazilian children and adolescents.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Brazil; Child; Child, Preschool; Clarithromyc | 2013 |
Ethnicity association of Helicobacter pylori virulence genotype and metronidazole susceptibility.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asian People; Bacterial Proteins; | 2013 |
Prevalence of Helicobacter pylori and its recurrence after successful eradication in a developing nation (Morocco).
Topics: Adult; Amoxicillin; Anti-Infective Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Developing | 2013 |
Living in Sofia is associated with a risk for antibiotic resistance in Helicobacter pylori: a Bulgarian study.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bulgaria; Clarithromycin; Drug Resistance, Ba | 2013 |
Pilot study: miscellaneous therapy is highly successful for Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastri | 2013 |
Bismuth + metronidazole + tetracycline. Why risk adding bismuth?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Helicobact | 2013 |
Delay of second-line eradication therapy for Helicobacter pylori can increase eradication failure.
Topics: Aged; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Helicobacter Infect | 2013 |
Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug Therap | 2014 |
Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disease Eradication; Drug Therapy, | 2013 |
What is the impact of Helicobacter pylori density on the success of eradication therapy: a clinico-histopathological study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Breath Tests; Case-Control Studies; Cla | 2013 |
Follow-up of Helicobacter pylori infection in children over two decades (1988-2007): persistence, relapse and acquisition rates.
Topics: Adolescent; Anti-Bacterial Agents; Belgium; Biopsy; Chi-Square Distribution; Child; Child, Preschool | 2014 |
Might Helicobacter pylori infection be associated with distortion on taste perception?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Clarithromycin; Dysgeusia; Female; G | 2013 |
Antibiotic resistance of Helicobacter pylori in Mashhad, Iran.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Chi-Square Distribution; Clarithromycin; Cross-Sectiona | 2013 |
In vitro characterization of the anti-bacterial activity of SQ109 against Helicobacter pylori.
Topics: Adamantane; Amoxicillin; Antitubercular Agents; Cell Membrane; Chloramphenicol; Clarithromycin; Drug | 2013 |
The molecular basis of inactivation of metronidazole-resistant Helicobacter pylori using polyethyleneimine functionalized zinc oxide nanoparticles.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Hum | 2013 |
[Guidelines for the diagnosis and treatment of Helicobacter pylori infection in Korea, 2013 revised edition].
Topics: Amoxicillin; Anti-Bacterial Agents; Aspirin; Bismuth; Breath Tests; Clarithromycin; Gastroesophageal | 2013 |
Efficacy of cefixime plus metronidazole therapy for Helicobacter pylori eradication: a retrospective study.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Cefixime; Drug Therapy, Combination; Female; Helicobacter | 2013 |
Characterization of oral Helicobacter pylori strain by 4 methods.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacterial Typing Techniques; Clarithromycin; Genotype; He | 2013 |
Ten-year trend of the cumulative Helicobacter pylori eradication rate for the 'Japanese eradication strategy'.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Dise | 2013 |
Helicobacter pylori and anemia with pregnancy.
Topics: Adult; Ampicillin; Anemia, Iron-Deficiency; Anti-Infective Agents; Drug Therapy, Combination; Female | 2014 |
A novel gastroretentive porous microparticle for anti-Helicobacter pylori therapy: preparation, in vitro and in vivo evaluation.
Topics: Acrylic Resins; Animals; Anti-Infective Agents; Cell Line; Cell Survival; Colony Count, Microbial; D | 2014 |
Triple therapy with high-dose proton-pump inhibitor, amoxicillin, and doxycycline is useless for Helicobacter pylori eradication: a proof-of-concept study.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Disease Eradication; | 2014 |
Eradication of H. pylori infection in patients allergic to penicillin using triple therapy with a PPI, metronidazole and sitafloxacin.
Topics: Anti-Bacterial Agents; Breath Tests; Cytochrome P-450 CYP2C19; Drug Administration Schedule; Drug Hy | 2014 |
Efficacy of tailored Helicobacter pylori eradication treatment based on clarithromycin susceptibility and maintenance of acid secretion.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; He | 2014 |
Resistance of Helicobacter pylori to tetracycline, amoxicillin, clarithromycin and metronidazole in Israeli children and adults.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Female; Helicoba | 2014 |
Analysis of clinical isolates of Helicobacter pylori in Pakistan reveals high degrees of pathogenicity and high frequencies of antibiotic resistance.
Topics: Adult; Aged; Aged, 80 and over; Bacterial Proteins; Base Sequence; Clarithromycin; Cohort Studies; D | 2014 |
Lon protease affects the RdxA nitroreductase activity and metronidazole susceptibility in Helicobacter pylori.
Topics: Amino Acid Sequence; Anti-Infective Agents; Bacterial Proteins; Drug Resistance, Bacterial; Helicoba | 2014 |
Does standard triple therapy still have a role in first-line Helicobacter pylori eradication in Korea?
Topics: Amoxicillin; Clarithromycin; Communicable Disease Control; Disease Eradication; Drug Resistance, Bac | 2014 |
Functional and molecular surveillance of Helicobacter pylori antibiotic resistance in Kuala Lumpur.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Resistance, Multiple; Fluoro | 2014 |
Efficacy of 7-Day and 14-Day Bismuth-Containing Quadruple Therapy and 7-Day and 14-Day Moxifloxacin-Based Triple Therapy as Second-Line Eradication for Helicobacter pylori Infection.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Drug Administration Schedule; Dr | 2015 |
[Antibiotic resistance of Helicobacter pylori: prevalence in one region in the southern Netherlands and implications for treatment].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Dose-Response Rel | 2014 |
Black tongue due to lansoprazole plus metronidazole.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Drug Therapy, Combination; Female; Helicobacter Inf | 2014 |
Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Administration Schedule | 2015 |
[Progress in the treatment of Helicobacter pylori infection].
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Drugs, Chinese Herbal; Gastritis; | 2014 |
The efficacy of moxifloxacin-containing triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Cohort Studies; Drug Ther | 2014 |
Helicobacter pylori Infection in Children. Antimicrobial Resistance and Treatment Response.
Topics: Adolescent; Amoxicillin; Anti-Infective Agents; Breath Tests; Child; Child, Preschool; Clarithromyci | 2015 |
[Ten day concomitant therapy is superior to ten day sequential therapy for Helicobacter pylori eradication].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithromycin; Drug Administration S | 2014 |
Trends in secondary antibiotic resistance of Helicobacter pylori from 2007 to 2014: has the tide turned?
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; | 2015 |
Low antibiotic resistance of Helicobacter pylori in The Netherlands.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Child, Preschool; Clarithr | 2015 |
High rate of levofloxacin resistance in a background of clarithromycin- and metronidazole-resistant Helicobacter pylori in Vietnam.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Clarithromycin; DNA Gyrase; Drug Resistance, Bacteri | 2015 |
Genotypic and clinical differences of seropositive Helicobacter pylori children and adults in the Polish population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antibodies, Bacteria | 2014 |
Not All Helicobacter Are pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anti-Bacterial Agents; Biopsy; Clarithromycin; | 2015 |
A 15-year-old boy with abdominal pain, growth retardation, and anemia secondary to Helicobacter pylori-associated peptic ulcer.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Clarithromycin; Drug Therapy, Combination; Growth | 2015 |
Development of gastroretentive metronidazole floating raft system for targeting Helicobacter pylori.
Topics: Alginates; Anti-Infective Agents; Diglycerides; Drug Delivery Systems; Drug Liberation; Fatty Acids; | 2015 |
Early or late antibiotic intervention prevents Helicobacter pylori-induced gastric cancer in a mouse model.
Topics: Animals; Anti-Bacterial Agents; Chemokine CXCL10; Chemokine CXCL9; Clarithromycin; Gastric Mucosa; G | 2015 |
The Primary Resistance of Helicobacter pylori in Taiwan after the National Policy to Restrict Antibiotic Consumption and Its Relation to Virulence Factors-A Nationwide Study.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; Genotype; Helicobacter Infections; Helic | 2015 |
Nordihydroguaiaretic Acid Disrupts the Antioxidant Ability of Helicobacter pylori through the Repression of SodB Activity In Vitro.
Topics: Antioxidants; Bacterial Proteins; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Huma | 2015 |
In Silico Profiling of the Potentiality of Curcumin and Conventional Drugs for CagA Oncoprotein Inactivation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Ba | 2015 |
High Helicobacter pylori cure rate with sitafloxacin-based triple therapy.
Topics: Adult; Aged; Anti-Bacterial Agents; Breath Tests; Drug Therapy, Combination; Female; Fluoroquinolone | 2015 |
Efficiency of Moxifloxacin in the Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Fluoroquinolones; Helicobacter Infect | 2015 |
Susceptibility of Helicobacter pylori to antibiotics in Chinese patients.
Topics: Adult; Aged; Anti-Bacterial Agents; Cephalosporins; Clarithromycin; Drug Resistance, Bacterial; Drug | 2015 |
Lower plasma pantoprazole level predicts Helicobacter pylori treatment failure in patients with type 2 diabetes mellitus.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Diabetes M | 2015 |
Treatment of low-grade gastric MALT lymphoma using Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Disease-Free Survival; Female; Heli | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Fourteen- vs seven-day bismuth-based quadruple therapy for second-line Helicobacter pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Breath Tests; Drug Administration Schedule; D | 2015 |
Preformulation studies and optimization of sodium alginate based floating drug delivery system for eradication of Helicobacter pylori.
Topics: Adhesiveness; Alginates; Animals; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Drug Delivery Sy | 2015 |
Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antigens, Bac | 2015 |
The best and worst treatments for Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2015 |
Akkermansia muciniphila and Helicobacter typhlonius modulate intestinal tumor development in mice.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Carcinogenesis; Clarithromycin; Drug Therapy, Combinati | 2015 |
Seven-Day Bismuth-based Quadruple Therapy as an Initial Treatment for Helicobacter pylori Infection in a High Metronidazole Resistant Area.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Resistance, Bacterial; Drug Therapy, Combination; | 2015 |
Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm.
Topics: Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Rabeprazole | 2015 |
Letter: sitafloxacin for H. pylori infection in Japan: considerations on resistance rates, generalisability and its place in the therapeutic algorithm - author's reply.
Topics: Female; Fluoroquinolones; Helicobacter Infections; Humans; Male; Metronidazole; Rabeprazole | 2015 |
Linezolid susceptibility in Helicobacter pylori, including strains with multidrug resistance.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Helicobact | 2015 |
Five-year sequential changes in secondary antibiotic resistance of Helicobacter pylori in Taiwan.
Topics: Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Resistance, Bacterial; Drug Resista | 2015 |
How Effective Is the Quadruple Concomitant Helicobacter Pylori Eradication Therapy for Obese Patients Undergoing Gastric Bypass Surgery?
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Therapy, | 2016 |
Does emerging Clarithromycin resistance signal an obituary to empirical standard triple therapy for Helicobacter pylori infection?
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2015 |
Evaluation of antimicrobial resistance of Helicobacter pylori in the last 15 years in West Poland.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Helicobact | 2015 |
In vitro antimicrobial susceptibility of Helicobacter pylori to nine antibiotics currently used in Central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Ampicillin; Anti-Bacterial Agents; Child; C | 2016 |
The impact of bismuth addition to sequential treatment on Helicobacter pylori eradication: A pilot study.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Drug Res | 2015 |
Clarithromycin Resistance Mutations in Helicobacter pylori in Association with Virulence Factors and Antibiotic Susceptibility of the Strains.
Topics: Adult; Anti-Bacterial Agents; Bacterial Proteins; Child; Clarithromycin; DNA, Bacterial; Drug Resist | 2016 |
Design, Optimization, and Evaluation of a Novel Metronidazole-Loaded Gastro-Retentive pH-Sensitive Hydrogel.
Topics: Animals; Chemistry, Pharmaceutical; Chitosan; Dogs; Drug Carriers; Drug Delivery Systems; Drug Liber | 2016 |
In vitro synergistic effect of Hibiscus sabdariffa aqueous extract in combination with standard antibiotics against Helicobacter pylori clinical isolates.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Flowe | 2016 |
Levofloxacin, bismuth, amoxicillin and esomeprazole as second-line Helicobacter pylori therapy after failure of non-bismuth quadruple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Cytochrome P-450 CYP2C | 2016 |
Rescue therapy with bismuth-containing quadruple therapy in patients infected with metronidazole-resistant Helicobacter pylori strains.
Topics: Anti-Infective Agents; Drug Combinations; Drug Resistance, Multiple, Bacterial; Drug Therapy, Combin | 2016 |
Outcome evaluation of clarithromycin, metronidazole and lansoprazole regimens in Helicobacter pylori positive or negative children with resistant otitis media with effusion.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; | 2016 |
[Antibiotic resistance of Helicobacter pylori clinical isolates in Hebei Province].
Topics: Amoxicillin; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Resistance, Microbial; Furazolidone | 2016 |
Extremely High Prevalence of Metronidazole-Resistant Helicobacter pylori Strains in Mountain People (Karen and Hmong) in Thailand.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Drug Resistance, Bacterial | 2016 |
Helicobacter pylori Clarithromycin Resistance and Treatment Failure Are Common in the USA.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; C | 2016 |
Impact of Helicobacter pylori Eradication Therapy on Platelet Counts in Patients With Chronic Idiopathic Thrombocytopenic Purpura.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Therapy, Combination; Fema | 2015 |
Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after Helicobacter pylori eradication.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Atrophy; Breath Tests; Clarithromycin; Cohort Studies; Fem | 2016 |
A high-throughput multiplex genetic detection system for Helicobacter pylori identification, virulence and resistance analysis.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Base Sequence; Biopsy; China; DNA Mutational | 2016 |
Inclusion of Lactobacillus Reuteri in the Treatment of Helicobacter pylori in Sardinian Patients: A Case Report Series.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Drug Therapy, Combination; Female; H | 2016 |
[10-day triple therapy with esomeprazole 40 mg/12 h vs. quadruple concomitant non-bismuth therapy as first line treatment for Helicobacter pylori infection].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug | 2016 |
Association Between Acute Neuropsychiatric Events and Helicobacter pylori Therapy Containing Clarithromycin.
Topics: Adult; Affect; Anti-Bacterial Agents; Anti-Infective Agents; Case-Control Studies; Clarithromycin; D | 2016 |
Four-times-daily Dosing of Rabeprazole with Sitafloxacin, High-Dose Amoxicillin, or Both for Metronidazole-Resistant Infection with Helicobacter pylori in Japan.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Fluoroquinolone | 2017 |
Nationwide survey of Helicobacter pylori treatment for children and adolescents in Japan.
Topics: Adolescent; Amoxicillin; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Child; Clarithromycin; Drug | 2017 |
Ensuring the highest eradication rates in H. pylori: the case of non-bismuth quadruple concomitant therapy.
Topics: Anti-Bacterial Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2016 |
Authors' reply.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; | 2016 |
An assessment of the efficacy of first-line Helicobacter pylori-eradication therapy based on clarithromycin susceptibility.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2016 |
Emerging trends of antimicrobial resistance in Helicobacter pylori isolates obtained from Pakistani patients: The need for consideration of amoxicillin and clarithromycin.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cross-Sectional Studies; Drug Resistance, Bacter | 2016 |
Appropriateness of Repeating Helicobacter pylori Culture and Susceptibility Testing Following Failure of Individualized Antibiotic Therapy.
Topics: Adult; Anti-Bacterial Agents; Cell Culture Techniques; Drug Resistance, Multiple, Bacterial; Drug Th | 2015 |
[Cuadruple concomitant non-bismuth therapy vs. classical triple therapy as first line therapy for Helicobacter pylori infection].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therapy, Combinat | 2016 |
Increasing metronidazole and rifampicin resistance of Helicobacter pylori isolates obtained from children and adolescents between 2002 and 2015 in southwest Germany.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Female; Germ | 2017 |
Effectiveness of Second through Sixth Line Salvage Helicobacter pylori Treatment: Bismuth Quadruple Therapy is Almost Always a Reasonable Choice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bismuth; Canada; Drug Therapy, Combination; F | 2016 |
Efficacy of triple therapy with esomeprazole, amoxicillin, and sitafloxacin as a third-line Helicobacter pylori eradication regimen.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2016 |
Metronidazole-induced neurotoxicity presenting with sudden bilateral hearing loss, encephalopathy, and cerebellar dysfunction.
Topics: Adult; Anti-Bacterial Agents; Brain Diseases; Female; Hearing Loss, Bilateral; Helicobacter Infectio | 2017 |
Role of concomitant therapy for
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2016 |
Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Cost-Benefit Analysis; Drug Therapy, Comb | 2017 |
Emerging Helicobacter pylori levofloxacin resistance and novel genetic mutation in Nepal.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; Clar | 2016 |
Bismuth and Non-bismuth Quadruple Therapy for Helicobacter pylori Eradication: Time to Make the Switch in Clinical Practice?
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Antidiarrheals; Bismuth; Drug Therapy, Combination; He | 2017 |
Surveillance of Helicobacter pylori Antibiotic Susceptibility in Indonesia: Different Resistance Types among Regions and with Novel Genetic Mutations.
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Endoscopy; Female; | 2016 |
Bismuth-based quadruple therapy modified with moxifloxacin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; | 2017 |
GENETIC MUTATIONS AFFECTING THE FIRST LINE ERADICATION THERAPY OF Helicobacter pylori-INFECTED EGYPTIAN PATIENTS.
Topics: Adult; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Egypt; Female; Gene Deletion; Hel | 2016 |
Successful Eradication Therapy for Helicobacter pylori-positive Atrophic Gastritis at the Sixth Attempt: A Case Report.
Topics: Aged; Drug Therapy, Combination; Female; Fluoroquinolones; Gastritis, Atrophic; Helicobacter Infecti | 2016 |
A Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Clarithromycin; Disease E | 2016 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
ACG Clinical Guideline: Treatment of Helicobacter pylori Infection.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Bismuth; Clarithromycin; Drug T | 2017 |
Increasing role for modified bismuth-containing quadruple therapies for Helicobacter pylori eradication.
Topics: Anti-Infective Agents; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Huma | 2017 |
Vonoprazan improves the efficacy of Helicobacter pylori eradication therapy with a regimen consisting of clarithromycin and metronidazole in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Breath Tests; Carbon Isotopes; Clarithromycin; Female; Helicobacter Infection | 2017 |
Triple therapy versus sequential therapy for the first-line Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Administration Schedule; Drug Therapy, Comb | 2017 |
New bismuth-containing quadruple therapy in patients infected with Helicobacter pylori: A first Italian experience in clinical practice.
Topics: Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Female; Helicobacter Infect | 2017 |
Levofloxacin or Clarithromycin-based quadruple regimens: what is the best alternative as first-line treatment for Helicobacter pylori eradication in a country with high resistance rates for both antibiotics?
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2017 |
Comparative study: Vonoprazan and proton pump inhibitors in
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicob | 2017 |
Second-line bismuth-containing quadruple therapy for
Topics: Adult; Aged; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Diabetes Mellitus, Type 2; Dise | 2017 |
Effect of biofilm formation by clinical isolates of
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Biofilms; Child; Clarithromycin; Drug Resistance, Bacteri | 2017 |
A search for Helicobacter pyloriin localized vulvodynia.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Dysp | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Ten-day sequential treatment for Helicobacter pylori eradication in clinical practice.
Topics: Amoxicillin; Anti-Infective Agents; Breath Tests; Clarithromycin; Drug Administration Schedule; Drug | 2008 |
Cure of Helicobacter pylori infection in all compliant patients: report on 644 subjects.
Topics: Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Drug Therapy, Com | 2008 |
Failure of first-line eradication treatment significantly increases prevalence of antimicrobial-resistant Helicobacter pylori clinical isolates.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Case-Control Studies; Chi-Square Distribution; Clar | 2008 |
[Perforation and haemorrhage duodenal bulbar ulcers in a child: a case report].
Topics: Adrenergic Agonists; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Child; Drug Therapy, | 2008 |
Effects of helicobacter pylori eradication on chronic nonspecific pharyngeal symptoms.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chronic Disease; Cohort | 2008 |
[What is currently the Helicobacter pylori eradication therapy of choice? Triple therapy (PPI, amoxicillin and clarithromycin) or sequential therapy (PPI and amoxicillin for 5 days followed by PPI, clarithromycin and metronidazole for a further 5 days)?].
Topics: Amoxicillin; Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter I | 2009 |
Potent bactericidal constituents from Mallotus philippinensis against clarithromycin and metronidazole resistant strains of Japanese and Pakistani Helicobacter pylori.
Topics: Anti-Bacterial Agents; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Fruit; Helicobact | 2009 |
Antibiotic susceptibility patterns in Helicobacter pylori strains from patients with upper gastrointestinal pathology in western Nigeria.
Topics: Amoxicillin; Anti-Bacterial Agents; Biopsy; Ciprofloxacin; Clarithromycin; DNA, Bacterial; Drug Resi | 2009 |
Helicobacter pylori infection in patients with chronic urticaria: correlation with pathologic findings in gastric biopsies.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Biopsy; Case-Control Studies; Chronic Disease; Fema | 2009 |
Resistance to metronidazole, clarithromycin and levofloxacin of Helicobacter pylori before and after clarithromycin-based therapy in Taiwan.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Asian People; Child; | 2009 |
[High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children].
Topics: Adolescent; Amoxicillin; Child; Child, Preschool; Ciprofloxacin; Clarithromycin; Drug Resistance, Mi | 2009 |
Antimicrobial susceptibility and mutations involved in clarithromycin resistance in Helicobacter pylori isolates from patients in the western central region of Colombia.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colombia; Drug Resistance, Bacterial; Helicobact | 2009 |
In vitro antagonism of rabeprazole and metronidazole upon clinical isolates of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Drug Synergism; Drug Th | 2009 |
Analysis of drug resistance and virulence-factor genotype of Irish Helicobacter pylori strains: is there any relationship between resistance to metronidazole and cagA status?
Topics: Anti-Infective Agents; Antigens, Bacterial; Bacterial Proteins; Drug Resistance, Microbial; Female; | 2009 |
Helicobacter pylori first-line treatment and rescue option containing levofloxacin in patients allergic to penicillin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration | 2010 |
Helicobacter pylori: antibiotic resistance and treatment options.
Topics: Amoxicillin; Anti-Bacterial Agents; Asian People; Clarithromycin; Drug Resistance, Multiple, Bacteri | 2009 |
Analysis of PCR-RAPD DNA and antibiotic susceptibility profiles of antrum and corpus isolates of Helicobacter pylori from Malaysian patients.
Topics: Adult; Anti-Bacterial Agents; DNA, Bacterial; Drug Resistance, Bacterial; Female; Helicobacter Infec | 2009 |
Drug resistance pattern and clonality in H. pylori strains.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents, Local; beta-Lactamases; Clarithromycin; | 2009 |
Antibiotic susceptibility of Helicobacter pylori isolates in Dakar, Senegal.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Bacterial; Duodenal Ulcer | 2009 |
Oral and intravenous eradication of Helicobacter pylori.
Topics: Administration, Oral; Adult; Amoxicillin; Anti-Infective Agents; Bismuth; Female; Helicobacter Infec | 2009 |
[Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Bismuth; Breath Tests; Clarithromycin; Enzyme-Linked I | 2009 |
Editorial: Sequential therapy for eradication of Helicobacter pylori: a new guiding light or a false dawn?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug T | 2009 |
Ten-day sequential therapy of Helicobacter pylori infection in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Breath Tes | 2010 |
[Antimicrobial susceptibility of Helicobacter pylori strains isolated in Colombia].
Topics: Anti-Bacterial Agents; Colombia; DNA, Ribosomal; Drug Resistance, Bacterial; Helicobacter Infections | 2009 |
Effect of Helicobacter pylori eradication on insulin resistance, serum lipids and low-grade inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; C-Reactive Prote | 2010 |
Antibiotic resistance of Helicobacter pylori in Israeli children.
Topics: Adolescent; Amoxicillin; Analysis of Variance; Anti-Bacterial Agents; Biopsy; Chi-Square Distributio | 2010 |
Characterization of multiple Helicobacter bizzozeronii isolates from a Finnish patient with severe dyspeptic symptoms and chronic active gastritis.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Bacteriological Techniques; Catalase; Culture Media; DNA, | 2010 |
Sequential or concomitant therapy for Helicobacter pylori eradication?
Topics: Anti-Bacterial Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infecti | 2010 |
Helicobacter pylori resistance to metronidazole and clarithromycin in Ireland.
Topics: Adult; Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Resistance, Bacterial; Female; Gastritis; | 2010 |
Effects of CYP2C19, MDR1, and interleukin 1-B gene variants on the eradication rate of Helicobacter pylori infection by triple therapy with pantoprazole, amoxicillin, and metronidazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2010 |
Ten-day sequential therapy as first-line treatment for Helicobacter pylori infection in Korea: a retrospective study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Breath Tests; Clarithro | 2010 |
Marked susceptibility of South African Helicobacter pylori strains to ciprofloxacin and amoxicillin: clinical implications.
Topics: Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Drug Resistance, Multiple, Bacterial; Erythromyci | 2010 |
Helicobacter pylori: prevalence and antibiotic susceptibility among Kenyans.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Black People; Child; Clarithromycin; Cohort Studies; Drug | 2010 |
Increase in resistance rates of H. pylori isolates to metronidazole and tetracycline--comparison of three 3-year studies.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Amoxicillin; Chi-Square Distribution; Clari | 2010 |
A new 24 h ELISA culture based method for Helicobacter pylori chemosusceptibility.
Topics: Anti-Bacterial Agents; Clarithromycin; Culture Media; Enzyme-Linked Immunosorbent Assay; Helicobacte | 2010 |
Clarithromycin or levofloxacin in the sequential therapy for H. pylori eradication?
Topics: Adolescent; Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; | 2010 |
In vitro activity of nemonoxacin, tigecycline, and other antimicrobial agents against Helicobacter pylori isolates in Taiwan, 1998-2007.
Topics: Amino Acid Substitution; Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Ciprofloxacin; Clarithro | 2010 |
Primary resistance to clarithromycin, metronidazole and amoxicillin of Helicobacter pylori isolated from Tunisian patients with peptic ulcers and gastritis: a prospective multicentre study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Child; Child, Presch | 2010 |
Quadruple therapy with ecabet sodium, omeprazole, amoxicillin and metronidazole is effective for eradication of Helicobacter pylori after failure of first-line therapy (KDOG0201 Study).
Topics: Abietanes; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combina | 2010 |
Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infectio | 2010 |
Sequential therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents | 2010 |
De novo erosive esophagitis in duodenal ulcer patients related to pre-existing reflux symptoms, smoking, and patient age, but not to Helicobacter pylori eradication: a one-year follow-up study.
Topics: Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Cl | 2010 |
Resistance of Helicobacter pylori to antibiotics from 2000 to 2009 in Shanghai.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; China; Clarithromycin; Drug Resis | 2010 |
[Helicobacter pylori eradication therapy for gastric ulcer in elderly].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Adminis | 2010 |
Antibiotic resistance of Helicobacter pylori in Mazandaran, North of Iran.
Topics: Adolescent; Adult; Aged; Amoxicillin; Clarithromycin; Drug Resistance, Multiple, Bacterial; Female; | 2010 |
Role of Helicobacter pylori in the pathogenesis of hyperemesis gravidarum.
Topics: Adult; Ampicillin; Anti-Infective Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Enzyme-Linked Im | 2011 |
Case of the month. MALT lymphoma.
Topics: Anemia; Anti-Bacterial Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Drug Therapy, Co | 2010 |
The efficacy and safety of long-term Helicobacter species quadruple therapy in asymptomatic cats with naturally acquired infection.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Clarithromycin; DNA, Bacterial; Dru | 2011 |
Efficacy of clarithromycin plus metronidazole-based triple therapy for Helicobacter pylori eradication: a retrospective study.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter | 2010 |
Haematological side effect of Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Enzyme Inhibitors; Female; Helicobacter Infections; He | 2010 |
The RecRO pathway of DNA recombinational repair in Helicobacter pylori and its role in bacterial survival in the host.
Topics: Acids; Animals; Bacterial Proteins; Cross-Linking Reagents; DNA Repair; Gastric Mucosa; Gene Order; | 2011 |
Resistance to antibiotics and characterization of Helicobacter pylori strains isolated from antrum and body from adults in Mexico.
Topics: Adult; Age Factors; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Bacterial Typing | 2011 |
Quadruple or triple therapy to eradicate H pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Combinations; Drug Therapy, Combinati | 2011 |
Assessing the role of the RND efflux pump in metronidazole resistance of Helicobacter pylori by RT-PCR assay.
Topics: Anti-Bacterial Agents; Bacterial Outer Membrane Proteins; Drug Resistance, Bacterial; Helicobacter I | 2011 |
CagA genotype and metronidazole resistant strain of Helicobacter pylori in functional dyspepsia in Thailand.
Topics: Abdominal Pain; Anti-Infective Agents; Antigens, Bacterial; Bacterial Proteins; Biopsy; Drug Resista | 2011 |
Studies of distribution and recurrence of Helicobacter spp. gastric mucosa of dogs after triple therapy.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Dog Diseases; Dogs; Drug Therapy, Combination; Gastric | 2011 |
[Eradication therapy of antibiotic-resistant strains of Helicobacter pylori].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, | 2010 |
[Regional difference of antibiotic resistance of helicobacter pylori strains in Korea].
Topics: Amoxicillin; Anti-Bacterial Agents; Aza Compounds; Azithromycin; Ciprofloxacin; Clarithromycin; Drug | 2011 |
High Helicobacter pylori resistance to metronidazole but zero or low resistance to clarithromycin, levofloxacin, and other antibiotics in Malaysia.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Female; He | 2011 |
Development of corpus atrophic gastritis may be associated with Helicobacter pylori-related idiopathic thrombocytopenic purpura.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithrom | 2011 |
Improvements in Helicobacter pylori eradication rates through clinical CYP2C19 genotyping.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Aryl Hydrocarb | 2011 |
Helicobacter pylori eradication: A new, single-capsule bismuth-containing quadruple therapy.
Topics: Anti-Bacterial Agents; Bismuth; Capsules; Drug Combinations; Drug Therapy, Combination; Helicobacter | 2011 |
Ranitidine bismuth citrate in the first-line of Helicobacter pylori treatment.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Bismuth; Clarithromycin; Drug Therapy, Combination; | 2011 |
Primary antibiotic resistance of Helicobacter pylori strains isolated from Portuguese children: a prospective multicentre study over a 10 year period.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Ciprofloxacin; Clarithromyc | 2011 |
Mass eradication of Helicobacter pylori: feasible and advisable?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Ad | 2011 |
Preliminary phytochemical screening and in vitro anti-helicobacter pylori activity of extracts of the stem bark of Bridelia micrantha (Hochst., Baill., Euphorbiaceae).
Topics: Acetates; Acetone; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disk Diffusion Antimicrobial | 2011 |
Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance.
Topics: Adult; Aged; Amoxicillin; Ampicillin Resistance; Anti-Bacterial Agents; Ciprofloxacin; Clarithromyci | 2012 |
Characterisation of the genes encoding resistance to metronidazole (rdxA and frxA) and clarithromycin (the 23S-rRNA genes) in South African isolates of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacterial Proteins; Child; Child, | 2011 |
Primary and secondary clarithromycin, metronidazole, amoxicillin and levofloxacin resistance to Helicobacter pylori in southern Poland.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Hel | 2011 |
Numerous risk factors for Helicobacter pylori antibiotic resistance revealed by extended anamnesis: a Bulgarian study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bulgaria; Clarithromycin; Coinfec | 2012 |
Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: repeated quadruple therapy as a third-line therapy.
Topics: Adult; Anti-Bacterial Agents; Bismuth; Drug Resistance, Bacterial; Drug Therapy, Combination; Female | 2011 |
Regression of multiple duodenal hyperplastic polyps following Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biop | 2011 |
[The effects of pronase on drugs concentrations for treatment of Helicobacter pylori infection in gastric tissue].
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Gastric Mucosa; Gastritis; Helicobac | 2011 |
Monitoring of antibiotic resistance rates of Helicobacter pylori in Austrian children, 2002-2009.
Topics: Adolescent; Anti-Bacterial Agents; Austria; Child; Child, Preschool; Clarithromycin; Drug Resistance | 2012 |
Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies.
Topics: Adult; Aged; Anti-Bacterial Agents; Bacterial Proteins; Biomarkers, Pharmacological; Clarithromycin; | 2012 |
FecA1, a bacterial iron transporter, determines the survival of Helicobacter pylori in the stomach.
Topics: Animals; Anti-Infective Agents; Bacterial Proteins; Drug Resistance, Bacterial; Enzyme Activation; G | 2012 |
Is quadruple therapy the new triple therapy for H pylori?
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; He | 2012 |
Treatment of Helicobacter pylori in Latin America.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; | 2012 |
Treatment of Helicobacter pylori in Latin America.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; | 2012 |
Treatment of Helicobacter pylori in Latin America.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Female; | 2012 |
Antibiotic resistance of Helicobacter pylori in pediatric patients -- 10 years' experience.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Child; Child, Preschool; Clarithromycin; Cro | 2012 |
Is Helicobacter pylori antibiotic resistance surveillance needed and how can it be delivered?
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Dyspepsia; Endoscopy; England; Fe | 2012 |
The status of antimicrobial resistance of Helicobacter pylori in Eastern Azerbaijan, Iran: comparative study according to demographics.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resistance, | 2012 |
High-dose, ten-day esomeprazole, amoxicillin and metronidazole triple therapy achieves high Helicobacter pylori eradication rates.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Breath Tests; Dose-Response Relationshi | 2012 |
Anti-Helicobacter pylori potential of artemisinin and its derivatives.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Antimalarials; Artemisia annua; Artemisinins; Cell Line | 2012 |
Antibacterial activities of liposomal linolenic acids against antibiotic-resistant Helicobacter pylori.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Lin | 2012 |
Factors modulating the outcome of treatment for the eradication of Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Antibodies, Bacterial; Antigens, Bacterial; Bacterial P | 2012 |
Greater than 95% success with 14-day bismuth quadruple anti- Helicobacter pylori therapy: a pilot study in US Hispanics.
Topics: Administration, Oral; Adult; Aged; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combi | 2012 |
Effectiveness of esomeprazole-based triple therapy of H. pylori in young patients in Japan.
Topics: Adult; Age Factors; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Coh | 2013 |
Evolution of Helicobacter pylori susceptibility to antibiotics during a 10-year period in Lithuania.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ciprofloxacin; Clarithromycin; Clindamycin; Drug Resistan | 2013 |
Resistance rates of metronidazole and other antibacterials in Helicobacter pylori from previously untreated patients in Norway.
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Hum | 2013 |
High prevalence of primary antibiotic resistance in Helicobacter pylori isolates in Italy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; D | 2012 |
Antimicrobial susceptibility and resistance patterns among Helicobacter pylori strains from The Gambia, West Africa.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Bacterial Proteins; Child; Child, Presc | 2013 |
Culture-based selection therapy for patients who did not respond to previous treatment for Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Biopsy; Breath Tests; Clarithromycin; Drug Therapy, Combination; | 2013 |
Primary antibiotic resistance and associated mechanisms in Helicobacter pylori isolates from Senegalese patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Clarithromycin; DNA Gyrase; Drug Resistance | 2013 |
[Antibiotic resistance of Helicobacter pylori in Reunion Island: therapeutic consequences].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chi-Square Distribution; Ciprofloxacin; Clari | 2002 |
Risk factors for Helicobacter pylori resistance.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Female; | 2002 |
Comparison of the E test and agar dilution method for antimicrobial suceptibility testing of Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2002 |
[The efficacy of the Helicobacter pylori eradication in people of an advanced age].
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Female; Helicobacter Infections | 2002 |
Impact of acid secretion, gastritis, and mucus thickness on gastric transfer of antibiotics in rats.
Topics: Amoxicillin; Animals; Anti-Infective Agents, Local; Clarithromycin; Gastric Acid; Gastric Mucosa; Ga | 2002 |
Minimal residual low-grade gastric MALT-type lymphoma after eradication of Helicobacter pylori.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacte | 2002 |
[Zantac (ranitidine) in treating duodenal ulcers].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobact | 2002 |
Quantification of Helicobacter pylori resistance in functional and organic dyspepsia.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Cohort Studies; Drug | 2002 |
The relationship between consumption of antimicrobial agents and the prevalence of primary Helicobacter pylori resistance.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infections; | 2002 |
The antimicrobial susceptibility of Helicobacter pylori in Hong Kong (1997-2001).
Topics: Anti-Bacterial Agents; Clarithromycin; DNA, Ribosomal; Drug Resistance, Bacterial; Helicobacter Infe | 2002 |
Antibiotic susceptibility patterns of Helicobacter pylori strains isolated from northeastern Mexico.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2002 |
Pseudomembranous colitis requiring surgical intervention following triple therapy for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Clarithromycin; Drug Therapy, Combination; Enterocol | 2002 |
Bismuth subcitrate/metronidazole/ tetracycline--Axcan Pharma. Bismuth triple therapy--Axcan Pharma, Helicide.
Topics: Anti-Bacterial Agents; Bismuth; Drug Combinations; Helicobacter Infections; Helicobacter pylori; Hum | 2002 |
Monotherapy with mastic does not eradicate Helicobacter pylori infection from mice.
Topics: Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colony Count, Microbial; Helicoba | 2003 |
[Association among anti-CagA antibody detection, antibiotic susceptibility, and peptic ulcer in patients with Helicobacter pylori infection].
Topics: Adult; Aged; Antibodies, Bacterial; Antibody Specificity; Antigens, Bacterial; Bacterial Proteins; C | 2003 |
Primary resistance of Helicobacter pylori to antimicrobial agents in Polish children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; DNA, Bacterial; Drug Resistan | 2002 |
Helicobacter pylori in children and adolescents: increase of primary clarithromycin resistance, 1997-2000.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resist | 2003 |
Long-term follow-up of gastric metaplasia after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Cicatrix; Convalescence; Drug The | 2003 |
Mutations in Helicobacter pylori rdxA gene sequences may not contribute to metronidazole resistance.
Topics: DNA, Bacterial; Drug Resistance, Bacterial; Genes, Bacterial; Genotype; Helicobacter Infections; Hel | 2003 |
Analysis of the rdxA gene in high-level metronidazole-resistant clinical isolates confirms a limited use of rdxA mutations as a marker for prediction of metronidazole resistance in Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Drug Resistance, Bacterial; Genetic Markers; Genotype; He | 2003 |
[Antimicrobial susceptibility tests and resistant strain of Helicobacter pylori].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infecti | 2003 |
Reality and false premises of antimicrobial susceptibility testing for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter Infections; Helicobac | 2003 |
Gastric transitional zones, areas where Helicobacter treatment fails: results of a treatment trial using the Sydney strain mouse model.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disease Models, Anim | 2003 |
[Effectiveness of eradication anti-helicobacter therapy in patients with duodenal ulcer in different drug dosage regimens].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; | 2003 |
Antimicrobial resistance in Helicobacter pylori isolates from children.
Topics: Amoxicillin; Anti-Bacterial Agents; Australia; Child; Clarithromycin; Drug Resistance, Microbial; Fe | 2003 |
The QUADRATE study: a proposal for a change in the reporting of pharmaceutical supported trials.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infection | 2003 |
[Failure of Helicobacter pylori eradication--suggestions for further therapy].
Topics: Age Distribution; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bac | 2003 |
Antibiotic resistance of Helicobacter pylori: a cross-sectional study in consecutive patients, and relation to ethnicity.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Endoscopy, Gastrointestinal; Heli | 2003 |
[Pharmacotherapy in complex treatment of ulcerous stenosis].
Topics: Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Cimetidine; Drug Therapy, Combinati | 2003 |
Prevalence of Helicobacter pylori resistance to clarithromycin and metronidazole determined by 23S ribosomal RNA and rdxA gene analyses in Hiroshima, Japan.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistance, Microbial; Female; He | 2003 |
Effects of primary metronidazole and clarithromycin resistance to Helicobacter pylori on omeprazole, metronidazole, and clarithromycin triple-therapy regimen in a region with high rates of metronidazole resistance.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
The relationship among previous antimicrobial use, antimicrobial resistance, and treatment outcomes for Helicobacter pylori infections.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Fema | 2003 |
Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
Summaries for patients. Past antibiotic use affects resistance and outcomes of Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; Cohort Studies; Drug Resistance, Bacterial; Fema | 2003 |
Summaries for patients. Effects of antibiotic treatment for Helicobacter pylori on normal bowel bacteria.
Topics: Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, | 2003 |
Susceptibility of Helicobacter pylori to metronidazole.
Topics: Adult; Aged; Colony Count, Microbial; Culture Media; Drug Resistance, Microbial; Female; Gastroscopy | 2003 |
Metronidazole-resistant Helicobacter pylori is more prevalent in patients with nonulcer dyspepsia than in peptic ulcer patients in a multiethnic Asian population.
Topics: Asian People; Biopsy; Drug Resistance, Bacterial; Dyspepsia; Ethnicity; Female; Helicobacter Infecti | 2003 |
[Level of Helicobacter pylori infection of the gastric mucosa in the optimization of a daily dose of antihelicobacter drugs].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug | 2003 |
Geographical difference in antimicrobial resistance pattern of Helicobacter pylori clinical isolates from Indian patients: Multicentric study.
Topics: Amoxicillin; Anti-Infective Agents; Ciprofloxacin; Clarithromycin; Drug Resistance, Bacterial; Helic | 2003 |
Childhood Helicobacter pylori infection, clinical presentations, endoscopic, histologic features and results of treatment.
Topics: Adolescent; Amoxicillin; Child; Child, Preschool; Drug Therapy, Combination; Female; Gastroscopy; He | 2003 |
Frameshift mutations in frxA occur frequently and do not provide a reliable marker for metronidazole resistance in UK isolates of Helicobacter pylori.
Topics: Amino Acid Sequence; Anti-Infective Agents; Biomarkers; Drug Resistance, Bacterial; Frameshift Mutat | 2004 |
A national survey of primary care physicians' perceptions and practices related to Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combin | 2004 |
Primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Finnish population.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; Drug Resistan | 2004 |
Helicobacter pylori: antibiotic resistance and eradication rates in Suffolk, UK, 1991-2001.
Topics: Adult; Age Factors; Amoxicillin; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, Combinati | 2004 |
Long-term effect of Helicobacter pylori eradication on the reversibility of acid secretion in profound hypochlorhydria.
Topics: Achlorhydria; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combinat | 2004 |
Helicobacter pylori: a historical perspective 1983-2003.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Comorbidity; Drug Therapy, Combination; Esophagitis, Peptic | 2004 |
Treatment with omeprazole, metronidazole, and amoxicillin in captive South African cheetahs (Acinonyx jubatus) with spiral bacteria infection and gastritis.
Topics: Acinonyx; Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; | 2004 |
High level of resistance to metronidazole and clarithromycin in Helicobacter pylori isolated from pediatric patients in Poland (1997-2001).
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Multiple, Ba | 2004 |
DNA typing for Helicobacter pylori isolates from eradication-failed patients: comparison of the isolates before and after therapy.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clarithromycin; DNA | 2004 |
Resolution of Helicobacter pylori associated granulomatous gastritis in a child after eradication therapy.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combi | 2004 |
Effect of cyclo-oxygenase inhibitors on Helicobacter pylori susceptibility to metronidazole and clarithromycin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Cells, Cultured; Clarithromycin; Cyclooxygenase Inhibi | 2004 |
Effects of Helicobacter pylori eradication among adults with intellectual disability.
Topics: Adult; Amoxicillin; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Heli | 2004 |
Reversible cerebellar lesions induced by metronidazole therapy for helicobacter pylori.
Topics: Anti-Infective Agents; Cerebellar Diseases; Female; Helicobacter Infections; Helicobacter pylori; Hu | 2004 |
More about Helicobacter pylori, antibiotics and IBD.
Topics: Anti-Infective Agents; Antibodies, Bacterial; Ciprofloxacin; Drug Therapy, Combination; Helicobacter | 2004 |
[Efficacy of 14 day OBMT therapy as a second-line treatment for Helicobacter pylori infection].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Femal | 2004 |
Universal high-level primary metronidazole resistance in Helicobacter pylori isolated from children in Egypt.
Topics: Adolescent; Anti-Infective Agents; Child; Child, Preschool; Drug Resistance, Bacterial; Egypt; Endos | 2004 |
Antimicrobial susceptibility of Helicobacter pylori strains isolated in Bangladesh.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Bacterial Proteins; Bangladesh; Drug Resistance, Bac | 2004 |
Antibiotic resistance in Helicobacter pylori: is it a problem in New Zealand?
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Hum | 2004 |
Role of the rdxA and frxA genes in oxygen-dependent metronidazole resistance of Helicobacter pylori.
Topics: Amoxicillin; Anaerobiosis; Anti-Infective Agents; Bacterial Proteins; Chloramphenicol; Clarithromyci | 2004 |
[Resistance to antibiotics used in Helicobacter pylori infection in children].
Topics: Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Drug Therapy, | 2004 |
[Helicobacter pylori resistance to metronidazole and clarythromicin: descriptive analysis 1997-2000].
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Female; Helicobacter Infec | 2004 |
High levels of dual resistance to clarithromycin and metronidazole and in vitro activity of levofloxacin against Helicobacter pylori isolates from patients after failure of therapy.
Topics: Clarithromycin; Drug Resistance; Drug Therapy, Combination; Helicobacter Infections; Helicobacter py | 2004 |
Efficacy of metronidazole for the treatment of clarithromycin-resistant Helicobacter pylori infection in a Japanese population.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; | 2004 |
Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea.
Topics: Adult; Aged; Anti-Bacterial Agents; Clarithromycin; DNA, Bacterial; Drug Resistance, Bacterial; Fema | 2004 |
Results of triple eradication therapy in Japanese children: a retrospective multicenter study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Amoxicillin; Anti-Ulcer Agents; Benzimidazoles; | 2004 |
Second-line treatment for Helicobacter pylori infection in Japan: proton pump inhibitor-based amoxicillin and metronidazole regimen.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Drug | 2004 |
The predictive value of Helicobacter pylori in-vitro metronidazole resistance.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Hum | 2004 |
Recurrence of Helicobacter pylori infection 1 year after successful treatment: prospective cohort study in the Republic of Yemen.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Infective Agents; Chronic Disease; Clarithromyc | 2004 |
Standard treatment for Helicobacter pylori infection is suboptimal in non-ulcer dyspepsia compared with duodenal ulcer in Chinese.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Asian People; Clarithromycin; Drug Resistan | 2005 |
Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Infective Agents; Anti-Ulcer Agents; Drug Resistance, Bacter | 2005 |
Metronidazole and risk of acute pancreatitis: a population-based case-control study.
Topics: Acute Disease; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Case-Control Studies; Denmark; D | 2005 |
Helicobacter pylori infection in Greenlandic patients with dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Dyspepsia; Esomeprazole; Greenland; Helicobac | 2004 |
Long-term recurrence rate after treatment of Helicobacter pylori infection in children and adolescents in Estonia.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Estonia; Female; Follow-Up Studies; Helicobac | 2004 |
Susceptibilities to clarithromycin, amoxycillin and metronidazole of Helicobacter pylori isolates from the antrum and corpus in Tokyo, Japan, 1995-2001.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Biopsy; Child; Clarithromycin; Drug Res | 2005 |
[Study on metronidazole resistance to Helicobacter pylori from three populations with different ethnics in Yunnan].
Topics: Adult; China; Chronic Disease; Drug Resistance, Bacterial; Female; Gastritis; Helicobacter Infection | 2004 |
Antibiotic sensitivity of Helicobacter pylori in Jamaica.
Topics: Aged; Breath Tests; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pylori | 2004 |
Cultural recovery and determination of antimicrobial susceptibility in Helicobacter pylori by using commercial transport and isolation media.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Culture Media; Drug Resistance, Bacterial; Helic | 2005 |
Antibiotic resistance of Helicobacter pylori isolated in Split, Southern Croatia.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Croatia; Drug Resistance, Bacterial; Female; Helicobac | 2005 |
[Effect of acid suppression therapy for eradicating Helicobacter pylori infection on bismuth absorption from colloidal bismuth pectin].
Topics: Amoxicillin; Animals; Antacids; Bismuth; Colloids; Drug Therapy, Combination; Helicobacter Infection | 2005 |
Helicobacter pylori antibiotic-resistance patterns and risk factors in adult dyspeptic patients from ethnically diverse populations in central and south London during 2000.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Clarithromycin; Drug Re | 2005 |
Isogenic variation of Helicobacter pylori strain resulting in heteroresistant antibacterial phenotypes in a single host in vivo.
Topics: Anti-Bacterial Agents; Bacterial Proteins; Base Sequence; DNA Fingerprinting; Drug Resistance, Bacte | 2005 |
[The effect of Helicobacter pylori eradication therapy on bismuth absorption of colloidal bismuth subcitrate].
Topics: Absorption; Amoxicillin; Animals; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Infecti | 2005 |
A 10-day levofloxacin-based triple therapy in patients who have failed two eradication courses.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Evaluation; Drug Resistance, Bacterial; Drug Therapy, Combi | 2005 |
Most Helicobacter pylori strains of Kolkata in India are resistant to metronidazole but susceptible to other drugs commonly used for eradication and ulcer therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Infective Agents; Clarithromycin; Drug Resistance, Bacterial; Furazol | 2005 |
In vitro antimicrobial susceptibility testing of Helicobacter felis, H. bizzozeronii, and H. salomonis.
Topics: Animals; Anti-Bacterial Agents; Cat Diseases; Cats; Dog Diseases; Dogs; Drug Resistance, Bacterial; | 2005 |
Bactericidal and morphological effects of NE-2001, a novel synthetic agent directed against Helicobacter pylori.
Topics: Adult; Anti-Bacterial Agents; Biphenyl Compounds; Clarithromycin; Drug Resistance, Bacterial; Guanid | 2005 |
Eradication of Helicobacter spp. from a rat breeding colony.
Topics: Amoxicillin; Animal Feed; Animals; Animals, Laboratory; Clarithromycin; DNA Primers; Electrophoresis | 2005 |
[The trend of eradication rates of second-line quadruple therapy containing metronidazole for Helicobacter pylori infection: an analysis of recent eight years].
Topics: Adult; Antacids; Anti-Infective Agents; Bismuth; Drug Therapy, Combination; Female; Helicobacter Inf | 2005 |
[Impact of metronidazole resistance on eradication rate for Helicobacter pylori].
Topics: Anti-Infective Agents; Drug Resistance, Bacterial; Helicobacter Infections; Helicobacter pylori; Hum | 2005 |
Antimicrobial resistance of Helicobacter pylori in Poland: a multicentre study.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Bacterial; Helico | 2005 |
Heterogeneous susceptibility to metronidazole and clarithromycin of Helicobacter pylori isolates from a single biopsy in adults is confirmed in children.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Biopsy; Child; Clarithromycin; Drug Resistance, | 2005 |
Long-term results of anti-Helicobacter pylori therapy in early-stage gastric high-grade transformed MALT lymphoma.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Disease Progression; Disease-Fre | 2005 |
How effective are quadruple therapies as first-line H. pylori eradication therapies?
Topics: Adult; Anti-Infective Agents; Australia; Bismuth; Drug Therapy, Combination; Helicobacter Infections | 2005 |
Diverse phenotypes resulting from polyphosphate kinase gene (ppk1) inactivation in different strains of Helicobacter pylori.
Topics: Animals; Anti-Infective Agents; Disease Models, Animal; Gene Deletion; Genetic Complementation Test; | 2005 |
Up-expression of NapA and other oxidative stress proteins is a compensatory response to loss of major Helicobacter pylori stress resistance factors.
Topics: Acid Phosphatase; Animals; Bacterial Proteins; Catalase; DNA; DNA Damage; DNA Fragmentation; Drug Re | 2005 |
Mutation discovery in bacterial genomes: metronidazole resistance in Helicobacter pylori.
Topics: Anti-Infective Agents; Bacterial Proteins; DNA, Bacterial; Drug Resistance, Bacterial; Genome, Bacte | 2005 |
[The epidemiology of Helicobacter pylori resistance to antibiotics in Beijing].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; China; Clarithromyci | 2005 |
[Recent topics on important drugs for H. pylori eradication: Metronidazole (MNZ)].
Topics: Animals; Drug Resistance, Bacterial; Drug Therapy, Combination; Helicobacter Infections; Helicobacte | 2005 |
DNA sequence analysis of rdxA and frxA from paired metronidazole-sensitive and -resistant Helicobacter pylori isolates obtained from patients with heteroresistance.
Topics: Amino Acid Sequence; Anti-Bacterial Agents; Bacterial Proteins; DNA, Bacterial; Drug Resistance, Bac | 2006 |
Efficacy and safety of rifabutin-containing 'rescue therapy' for resistant Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial | 2006 |
Tetracycline, metronidazole and amoxicillin-metronidazole combinations in proton pump inhibitor-based triple therapies are equally effective as alternative therapies against Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; He | 2006 |
Efficacy of Helicobacter pylori eradication on the chronic mucosal inflammation of the remnant stomach after distal gastrectomy for early gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Infective Agents; Anti-Ulcer | 2005 |
[Medical, social, and economic effectiveness of treatment of day-case patients with peptic ulcer].
Topics: Adolescent; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Cost-Benefit An | 2006 |
Recurrence of Helicobacter pylori infection after several eradication therapies: long-term follow-up of 1000 patients.
Topics: Amoxicillin; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug Administration Schedule; | 2006 |
Review of successful treatment for Helicobacter species in laboratory mice.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Infective Agents; Bismuth; DNA, Bacterial; Drug The | 2006 |
Prospective multicentre study on antibiotic resistance of Helicobacter pylori strains obtained from children living in Europe.
Topics: Adolescent; Age Distribution; Amoxicillin; Anti-Infective Agents; Child; Child, Preschool; Clarithro | 2006 |
Drug susceptibility pattern of Helicobacter pylori in patients with dyspepsia at the Kenyatta National Hospital, Nairobi.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2005 |
Helicobacter pylori antimicrobial resistance and risk factors in Denmark 1998-2004: no need for concern?
Topics: Anti-Bacterial Agents; Clarithromycin; Denmark; Drug Resistance, Bacterial; Female; Helicobacter Inf | 2006 |
[Susceptibility of 36 Helicobacter pylori clinical isolates to four first-line antibiotics and virulence factors].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Child; Clarithro | 2006 |
Is there a role for sequential in sequential anti-H. pylori therapy?
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromycin; Dose-Response Relation | 2006 |
[Long term results of treatment by simple surgical closure of perforated gastroduodenal ulcer followed by eradication of Helicobacter pylori].
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromyc | 2006 |
[Successful platelet recovery after the second eradication of Helicobacter pylori with metronidazole in two patients with chronic idiopathic thrombocytopenic purpura].
Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Clarithromycin; | 2006 |
Esomeprazole-based 1-week triple therapy directed by susceptibility testing for eradication of Helicobacter pylori infection in children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Child; Child, Presc | 2006 |
Triple levofloxacin-based rescue therapy is an accepted empirical third-line treatment.
Topics: Amoxicillin; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Clarithromycin; Dru | 2006 |
Primary resistance and antibiotic minimum inhibitory concentrations for Helicobacter pylori strains, in Split, Croatia.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Azithromycin; Cells, Cultured; Clarithromycin; Croatia; D | 2006 |
Guidelines in the medical treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Clarithromycin; Dyspeps | 2006 |
[Prospective study of 420 biopsies realised in patients with duodenal ulcer with positive Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; D | 2006 |
[The trend of eradication rates of first-line triple therapy for Helicobacter pylori infection: single center experience for recent eight years].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Co | 2006 |
High prevalence and level of resistance to metronidazole, but lack of resistance to other antimicrobials in Helicobacter pylori, isolated from a multiracial population in Kuwait.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Female; Helicobacter Infections; Helicobacter pyl | 2006 |
Antimicrobial resistance of Helicobacter pylori isolates from Iranian adults and children.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Infective Agents; Child; Child, Preschool; Clarithromycin | 2006 |
Alaska sentinel surveillance for antimicrobial resistance in Helicobacter pylori isolates from Alaska native persons, 1999-2003.
Topics: Adult; Aged; Alaska; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Biopsy; Clarithromyc | 2006 |
Some fibrocystic breast change may be caused by sexually transmitted H. pylori during oral nipple contact: supporting literature and case report of resolution after gut H. pylori eradication treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Ulcer Agents; Clarithromycin; Female; Fibrocyst | 2007 |
Efficacy of two triple eradication regimens in children with Helicobacter pylori infection.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Clarithromycin; Dr | 2006 |
Chest pain during triple therapy for duodenal ulcer.
Topics: Adult; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Chest Pain; Clarithromycin; | 2007 |
Helicobacter pylori culture and antimicrobial resistance in Iran.
Topics: Adolescent; Anti-Bacterial Agents; Biopsy, Needle; Child; Child, Preschool; Drug Resistance, Bacteri | 2007 |
Metronidazole-induced aseptic meningitis during Helicobacter pylori eradication therapy.
Topics: Adult; Anti-Infective Agents; Helicobacter Infections; Helicobacter pylori; Humans; Male; Meningitis | 2007 |
Comparison of two invasive diagnostic tests for Helicobacter pylori after antimicrobial therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Clarithromycin; Drug Therapy, Combina | 2007 |
[Helicobacter pylori infection and eradication are not related to glycosylated hemoglobin levels (HbA1c) in young patients with type 1 diabetes].
Topics: Adolescent; Adult; Age Factors; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulce | 2007 |
Preparation, in vitro and in vivo evaluation of stomach-specific metronidazole-loaded alginate beads as local anti-Helicobacter pylori therapy.
Topics: Alginates; Animals; Anti-Infective Agents; Chemistry, Pharmaceutical; Delayed-Action Preparations; D | 2007 |
Resistance rate to antibiotics of Helicobacter pylori isolates in eastern Taiwan.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple, Bacterial; Female; He | 2007 |
What is the best first choice treatment option for Helicobacter pylori?
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Anti-Infective Agents; Anti-Ulcer Ag | 2007 |
Screening for metronidazole-resistance associated gene fragments of H pylori by suppression subtractive hybridization.
Topics: Anti-Infective Agents; DNA Fragmentation; DNA, Bacterial; Drug Resistance, Bacterial; Gene Dosage; G | 2007 |
[Prevalence of metronidazole, clarithromycin and tetracycline resistance in Helicobacter pylori isolated from Chilean patients].
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Chile; C | 2007 |
Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance; | 2007 |
Eradication rates of helicobacter pylori infection with second-line treatment: non-ulcer dyspepsia compared to peptic ulcer disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Dysp | 2007 |
Duodenal gastric metaplasia and Helicobacter pylori infection in patients with diffuse nodular duodenitis.
Topics: Adult; Aged; Case-Control Studies; Chronic Disease; Clarithromycin; Drug Therapy, Combination; Duode | 2007 |
Helicobacter pylori primary resistant strains over 11 years in French children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resist | 2007 |
Macrolide resistance in the normal microbiota after Helicobacter pylori treatment.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Bacteroides; Clarithromycin; Drug Resistance, | 2007 |
14-day quadruple therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure in Thailand.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Ag | 2006 |
Changing antimicrobial susceptibility epidemiology of Helicobacter pylori strains in Japan between 2002 and 2005.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Child; Clarithromyci | 2007 |
[Antimicrobial susceptibility of H pylori strains obtained from Paraguayan patients].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2007 |
[Preliminary study on in-vitro induction of antibiotic resistance in Helicobacter pylori strains isolated from children].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Biopsy; Child; Clarithromycin; Drug Resis | 2007 |
Levofloxacin-resistant Helicobacter pylori in Hong Kong.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA Gyrase; DNA Mutational Analysis; DNA, Bacter | 2008 |
[Changing patterns of antibiotic resistance of Helicobacter pylori in patients with peptic ulcer disease].
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Disk Diffusion Antimicrobial Tests; | 2007 |
A new eradication resistance index as a predictor of metronidazole-containing second-line treatment of Helicobacter pylori.
Topics: Aged; Amoxicillin; Anti-Infective Agents; Breath Tests; Female; Helicobacter Infections; Helicobacte | 2007 |
[Prevalence of resistance to metronidazole in Helicobacter pylori from children and induction of resistance in vitro].
Topics: Anti-Bacterial Agents; Child; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; M | 2007 |
The effect of Helicobacter pylori eradication on reducing the incidence of gastric cancer.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Aged, 80 and over; Amoxicillin; Anti-Infective Agents | 2008 |
[Sequential therapy regimen for Helicobacter pylori infection in children].
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Resistance | 2008 |
Effect of smoking on failure of H. pylori therapy and gastric histology in a high gastric cancer risk area of Colombia.
Topics: Amoxicillin; Anti-Infective Agents; Bismuth; Colombia; Drug Therapy, Combination; Female; Follow-Up | 2007 |
Helicobacter pylori isolates recovered from gastric biopsies of patients with gastro-duodenal pathologies in Cameroon: current status of antibiogram.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Biopsy; Cameroon; Clarithromycin; Drug | 2008 |
Chronic urticaria and Helicobacter pylori.
Topics: Adolescent; Adult; Amoxicillin; Case-Control Studies; Chronic Disease; Comorbidity; Drug Therapy, Co | 2008 |
Use of antibiotics to prevent hepatitis and typhlitis in male scid mice spontaneously infected with Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bismuth; Cecal Diseases; Cecum; Chronic Disease; Helico | 1995 |
Eradication rate of Helicobcter pylori.
Topics: Colony Count, Microbial; Drug Resistance, Microbial; Drug Therapy, Combination; Helicobacter Infecti | 1995 |
[Is measurement of basal levels of serum pepsinogen II useful in proving the eradication of Helicobacter pylori by treatment?].
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fe | 1995 |
[The importance of obtaining biopsies of the gastric body in the follow-up after eradicating treatment of Helicobacter pylori].
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Biopsy; Bismuth; Clavulanic Acid; Clavula | 1995 |
[Helicobacter pylori and peptic ulcer--1995 therapeutic indications and recommendations of a Munster Expert Group].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Dose-Response Relationship, Drug; Dr | 1995 |
[Omeprazole + clarithromycin + metronidazole--a new standard for eradication of Helicobacter pylori].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1995 |
Eczema responsive to treatment for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Eczema; Gastroenteritis; Helicobacter Inf | 1995 |
Metronidazole uptake in Helicobacter pylori.
Topics: Biological Transport, Active; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Drug Resistance, Microbial; | 1995 |
Evaluation of antibiotic therapies for eradication of Helicobacter hepaticus.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Dose-Response Relationship, Dru | 1995 |
Metronidazole, omeprazole and clarithromycin: an effective combination therapy for Helicobacter pylori infection.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infe | 1995 |
High Helicobacter pylori numbers are associated with low eradication rate after triple therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Breath Tests; Chronic Disease; Colony Count, | 1995 |
Helicobacter pylori infection in recurrent abdominal pain in childhood: comparison of diagnostic tests and therapy.
Topics: Abdominal Pain; Adolescent; Amoxicillin; Antibodies, Bacterial; Bismuth; Child; Child, Preschool; Du | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Breath Tests; Drug Administration Schedule; Drug Resistance, Microbial; Drug Ther | 1995 |
"Cure" of Helicobacter pylori and "cure" of peptic ulcer: do they mean the same thing?
Topics: Anti-Bacterial Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Follow-Up Studies; Helico | 1995 |
Helicobacter pylori infection and abnormalities of acid secretion in patients with duodenal ulcer disease.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal | 1995 |
Resolution of Helicobacter pylori-associated gastric lymphoproliferative disease in a child.
Topics: Adolescent; Amoxicillin; Bismuth; Chronic Disease; Drug Therapy, Combination; Female; Follow-Up Stud | 1995 |
90% cure: which anti-Helicobacter therapy can achieve this treatment goal?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1995 |
Recrudescence of Helicobacter pylori after apparently successful eradication: novel application of randomly amplified polymorphic DNA fingerprinting.
Topics: Adult; Anti-Ulcer Agents; Base Sequence; DNA Fingerprinting; DNA, Bacterial; Drug Therapy, Combinati | 1995 |
Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Helicobacter Infections; Helic | 1995 |
Cell proliferation in Helicobacter pylori associated gastritis and the effect of eradication therapy.
Topics: Adult; Cell Division; Chronic Disease; Drug Therapy, Combination; Gastric Mucosa; Gastritis; Helicob | 1995 |
Effect of Helicobacter pylori eradication on peptic ulcer healing.
Topics: Adult; Aged; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter Infections; Helicobacte | 1995 |
Helicobacter pylori infection in children with recurrent abdominal pain.
Topics: Abdominal Pain; Adolescent; Anti-Ulcer Agents; Biopsy; Child; Child, Preschool; Endoscopy, Gastroint | 1994 |
[The effect of "triple therapy" on the eradicating of H. pylori and the healing of a duodenal ulcer. The initial study and 6 months later].
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Evaluation; Drug Therapy, Combination; Duodenal Ulcer; Female; | 1995 |
Helicobacter pylori eradication and reinfection.
Topics: Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; | 1995 |
High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease.
Topics: Adult; Developing Countries; Drug Resistance, Microbial; Duodenal Diseases; Female; Helicobacter Inf | 1994 |
Treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1995 |
Fulminant pseudomembranous colitis (PMC) following triple therapy for Helicobacter pylori.
Topics: Amoxicillin; Drug Therapy, Combination; Enterocolitis, Pseudomembranous; Female; Helicobacter Infect | 1994 |
One-week low-dose triple therapy: new standards for Helicobacter pylori treatment.
Topics: Clarithromycin; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; He | 1995 |
[Low malignancy MALT lymphoma of the stomach: H. pyloric eradication as a therapeutic concept?].
Topics: Amoxicillin; Drug Therapy, Combination; Follow-Up Studies; Gastric Mucosa; Gastritis; Helicobacter I | 1994 |
Treatment of low-grade gastric MALT lymphoma with Helicobacter pylori eradication.
Topics: Amoxicillin; Biopsy; Gastrectomy; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B- | 1995 |
Helicobacter pylori infection and gastric juice vitamin C levels. Impact of eradication.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Ascorbic Acid; Bismuth; Drug Therapy, Combination; Female | 1995 |
Hitting H pylori for four.
Topics: Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Helicobacter Infections; | 1995 |
Low dose, short duration therapy for the eradication of Helicobacter pylori in patients with duodenal ulcer.
Topics: Adult; Aged; Anti-Ulcer Agents; Drug Administration Schedule; Drug Therapy, Combination; Duodenal Ul | 1994 |
Duodenal ulcer healing drugs.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastrin-Releasing Pep | 1994 |
Effect of Helicobacter pylori eradication on G-cell and D-cell density in children.
Topics: Adolescent; Amoxicillin; Cell Count; Child; Drug Therapy, Combination; Female; Furazolidone; Gastrin | 1994 |
Effect of eradication of Helicobacter pylori on gastric epithelial cell proliferation.
Topics: Adult; Aged; Bismuth; Cell Division; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Muco | 1994 |
Effective treatment after failure of omeprazole plus amoxycillin to eradicate Helicobacter pylori infection in peptic ulcer disease.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combinatio | 1994 |
Impact of metronidazole resistance on the eradication of Helicobacter pylori.
Topics: Adult; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Female; | 1994 |
[10 days of triple treatment of Helicobacter pylori infection and peptic ulcer. Status after treatment of 4 weeks and of one year].
Topics: Adult; Aged; Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Helicobacter Infections; | 1994 |
[A Norwegian conference on updating of the treatment of Helicobacter pylori in peptic ulcer. Interessegruppe for Gastroenterologi].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Follow-Up Studies; Helicobacter Infections; Helicob | 1994 |
Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer.
Topics: Anti-Ulcer Agents; Antibodies, Bacterial; Drug Therapy, Combination; Duodenal Ulcer; Enzyme-Linked I | 1994 |
[Eradication of Helicobacter pylori. Effectiveness of a combination of ranitidine and metronidazole/roxithromycin].
Topics: Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Duodenal | 1994 |
Ribotyping patterns and emergence of metronidazole resistance in paired clinical samples of Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; DNA, Bacterial; DNA, Ribosomal; Drug Resistance, Microbial; Drug The | 1994 |
Phospholipase A2 activity in gastric juice from patients with active and H. pylori-eradicated healed duodenal ulcer.
Topics: Adult; Aged; Bile Acids and Salts; Bismuth; Choline; Drug Therapy, Combination; Duodenal Ulcer; Fema | 1994 |
Preservation of gastric antral mucus is associated with failure of eradication of Helicobacter pylori by bismuth, metronidazole and tetracycline.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Administration Schedule; Female; Gastric Mucosa; Gastr | 1994 |
Peripheral neuropathy induced by metronidazole.
Topics: Aged; Aged, 80 and over; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Male; Metr | 1994 |
Helicobacter pylori infection and serum pepsinogen A, pepsinogen C, and gastrin in gastritis and peptic ulcer: significance of inflammation and effect of bacterial eradication.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastrins; Gastritis; Helicobacter Infection | 1994 |
[Alternative treatment of Helicobacter pylori infections].
Topics: Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Sto | 1994 |
Effect of eradication of Helicobacter pylori on serum pepsinogen I, gastrin, and insulin in duodenal ulcer patients: a 12-month follow-up study.
Topics: Amoxicillin; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-U | 1994 |
Resolution of protein-losing hypertrophic lymphocytic gastritis with therapeutic eradication of Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Female; Gastric Mucosa; Gastritis, Hypertrophic; He | 1994 |
Helicobacter pylori in patients with rosacea.
Topics: Antibodies, Bacterial; Duodenitis; Female; Gastritis; Helicobacter Infections; Helicobacter pylori; | 1994 |
[Helicobacter pylori resistance against metronidazole in Switzerland: implications for eradication therapy?].
Topics: Adult; Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Female; Helicobacter Infections; Hel | 1994 |
Role of Helicobacter pylori eradication in the prevention of peptic ulcer bleeding relapse.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Fem | 1994 |
Histology of the mucosa of gastric antrum and body before and after eradication of Helicobacter pylori.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Gastric Mucosa; | 1993 |
Vitamin C concentration in gastric juice before and after anti-Helicobacter pylori treatment.
Topics: Amoxicillin; Ascorbic Acid; Bismuth; Female; Gastric Juice; Gastritis; Helicobacter Infections; Heli | 1994 |
Short report: smoking habits and the acquisition of metronidazole resistance in patients with Helicobacter pylori-related gastritis.
Topics: Adult; Aged; Drug Resistance, Microbial; Female; Gastritis; Helicobacter Infections; Helicobacter py | 1993 |
[Antimicrobial sensitivity and treatment of Helicobacter pylori infections].
Topics: Amoxicillin; Anti-Bacterial Agents; Female; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 1994 |
Omeprazole/amoxicillin versus ranitidine/triple therapy for duodenal ulcer: when is the "same" the same?
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobact | 1994 |
Helicobacter pylori infection and exaggerated gastrin release. Effects of inflammation and progastrin processing.
Topics: Adult; Bismuth; Female; Food; Gastrins; Helicobacter Infections; Helicobacter pylori; Humans; Male; | 1993 |
Role of serology in monitoring treatment for Helicobacter pylori infection in elderly patients.
Topics: Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Antibodies, Bacterial; Drug Therapy, Co | 1993 |
Short report: treatment of Helicobacter pylori-associated duodenal ulcer with omeprazole plus antibiotics.
Topics: Adult; Aged; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infe | 1993 |
Serum pepsinogens as markers of response to therapy for Helicobacter pylori gastritis.
Topics: Adult; Biopsy; Bismuth; Female; Gastric Mucosa; Gastritis; Helicobacter Infections; Helicobacter pyl | 1993 |
[Helicobacter pylori infection and peptic ulcer].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Human | 1993 |
Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori.
Topics: Chromatography, High Pressure Liquid; Colony Count, Microbial; Culture Media; Drug Resistance, Micro | 1993 |
One week's anti-Helicobacter pylori treatment for duodenal ulcer.
Topics: Adolescent; Adult; Aged; Antacids; Anti-Ulcer Agents; Breath Tests; Drug Administration Schedule; Dr | 1994 |
[Oral triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease].
Topics: Administration, Oral; Adult; Aged; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; | 1993 |
Histamine content of the oxyntic mucosa from duodenal ulcer patients: effect of Helicobacter pylori eradication.
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Furazolidone; Gastric Mucosa; | 1993 |
Apparent reversal of early gastric mucosal atrophy after triple therapy for Helicobacter pylori.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Gastric Mucosa; Ga | 1993 |
Acid secretion and sensitivity to gastrin in patients with duodenal ulcer: effect of eradication of Helicobacter pylori.
Topics: Acute Disease; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Acid; Gastri | 1993 |
Eradication of Helicobacter pylori in recurrent duodenal ulcer.
Topics: Amoxicillin; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Re | 1993 |
One-day therapy for treatment of Helicobacter pylori infection.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Administration Schedule; Drug Therapy, | 1993 |
The role of Helicobacter pylori in peptic ulcer disease.
Topics: Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Gastric Mucosa; Helicobac | 1993 |
Long-term Helicobacter pylori recurrence after successful eradication with triple therapy.
Topics: Bismuth; Drug Therapy, Combination; Female; Follow-Up Studies; Gastritis; Helicobacter Infections; H | 1993 |
Evaluation of new therapy for eradication of H. pylori infection in nude mouse model.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Diterpenes; Drug Evaluation, Preclinical; Drug Therapy, Com | 1993 |
Biotype and molecular fingerprints of metronidazole-resistant strains of Helicobacter pylori from antral gastric mucosa.
Topics: Bacterial Proteins; Bacterial Typing Techniques; DNA, Bacterial; Drug Resistance, Microbial; Gastric | 1993 |
Treatment of peptic ulcers caused by Helicobacter pylori.
Topics: Amoxicillin; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metron | 1993 |
Metronidazole-resistant Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Developing Countries; Drug Resistance, Microbial; He | 1993 |
Eradication of Helicobacter pylori normalizes serum gastrin concentration and antral gastrin cell number in a patient with primary gastrin cell hyperplasia.
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Enterochromaffin Cells; Gastric Mucosa; Gastrins | 1993 |
Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Child; Drug Resistance, Microbial; Dyspepsia; Female; He | 1993 |
Local cellular and immune response by antral mucosa in patients undergoing treatment for eradication of Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastric Mucosa; | 1993 |
Two-week eradication regimen for metronidazole-resistant Helicobacter pylori.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Breath Tests; Ciprofloxacin; Drug Resistanc | 1993 |
In vitro susceptibility of Helicobacter pylori to several antimicrobial combinations.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Combinations; Drug Synergism; Gastritis; Helicobacter Infec | 1993 |
Metronidazole affects Helicobacter pylori related nonulcer dyspepsia and symptoms from carbohydrate malabsorption.
Topics: Anti-Bacterial Agents; Dyspepsia; Fructose; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 1995 |
What is the meaning of ranitidine in successful triple-therapy against Helicobacter pylori infection?
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Synergism; Drug Therapy, Combination; Helicobacter Infec | 1995 |
[Eradication of Helicobacter pylori and hemorrhagic recurrence of duodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Duodenal Ulcer; Follow-Up Studies; Helicobacter Infections | 1995 |
Evaluation of a new bismuth-free triple therapy in nude mice and humans.
Topics: Amoxicillin; Animals; Anti-Ulcer Agents; Antitrichomonal Agents; Bismuth; Colony Count, Microbial; C | 1995 |
[One week triple therapy for eradication of Helicobacter pylori infection: simple and effective].
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Dose-Response Relationship, Drug; Drug Adm | 1995 |
Resolution of gastric outlet obstruction after eradication of Helicobacter pylori.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; G | 1995 |
Cost-effectiveness of treatment regimens for the eradication of Helicobacter pylori in duodenal ulcer.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Cost-Benef | 1996 |
Azithromycin for the cure of Helicobacter pylori infection.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Azithromycin; Drug Therapy, Combina | 1996 |
[What factors influence healing of duodenal ulcer when Helicobacter pylori eradication treatment is used?].
Topics: Adult; Age Factors; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; | 1996 |
[New guidelines from the Medical Products Agency: the triple regime against Helicobacter pylori is necessary. Treat only if the ulcer is verified].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug | 1996 |
Verification of decreased basal and stimulated serum pepsinogen-I levels is a useful non-invasive method for determining the success of eradication therapy for Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Duodenal U | 1996 |
One-day combined therapy of children with Helicobacter pylori-associated peptic disease.
Topics: Adolescent; Amoxicillin; Anti-Ulcer Agents; Child; Child, Preschool; Drug Administration Schedule; D | 1996 |
Gastric mucosal hepatocyte growth factor in Helicobacter pylori gastritis and peptic ulcer disease.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Female; Gastric Mucosa; Ga | 1996 |
Regression of salivary gland MALT lymphoma after treatment for Helicobacter pylori.
Topics: Bismuth; Doxycycline; Female; Helicobacter Infections; Helicobacter pylori; Humans; Lymphoma, B-Cell | 1996 |
[Comment on the Stolte/Domschke letter-discussion].
Topics: Amoxicillin; Drug Therapy, Combination; Gastritis; Helicobacter Infections; Helicobacter pylori; Hum | 1996 |
[Triple combination antimicrobial therapy of Helicobacter pylori and basal levels of serum gastrin].
Topics: Adult; Amoxicillin; Drug Therapy, Combination; Female; Gastrins; Gastritis; Helicobacter Infections; | 1996 |
Pharmacology of the gastric mucosa: a rational approach to Helicobacter polytherapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Ga | 1996 |
Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong.
Topics: Anti-Ulcer Agents; Antitrichomonal Agents; Biopsy; Case-Control Studies; China; Drug Resistance, Mic | 1996 |
Helicobacter pylori reinfection after apparent eradication--the Ipswich experience.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Case-Control Studies; Drug T | 1996 |
Treatment of Helicobacter pylori infection by topical administration of antimicrobial agents.
Topics: Administration, Topical; Amoxicillin; Antacids; Bismuth; Drug Therapy, Combination; Helicobacter Inf | 1996 |
Antimicrobial resistance and Helicobacter pylori.
Topics: Anti-Bacterial Agents; Antitrichomonal Agents; Clarithromycin; Drug Resistance, Microbial; Helicobac | 1996 |
Evaluation of various oral antimicrobial formulations for eradication of Helicobacter hepaticus.
Topics: Administration, Oral; Amoxicillin; Animals; Anti-Bacterial Agents; Base Sequence; Bismuth; Diet; Dri | 1996 |
Use of PCR and culture to detect Helicobacter pylori in naturally infected cats following triple antimicrobial therapy.
Topics: Amoxicillin; Animals; Bacteriological Techniques; Cats; Cells, Cultured; Drug Therapy, Combination; | 1996 |
Metronidazole and clarithromycin resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. The Gastrointestinal Physiology Working Group of Universidad Peruana Cayetano He
Topics: Agar; Anti-Bacterial Agents; Clarithromycin; Color; Developing Countries; Drug Resistance, Microbial | 1996 |
Triple therapy with sucralfate, amoxycillin and metronidazole for healing duodenal ulcer and eradicating Helicobacter pylori infection.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antitrichomonal Agents; Drug Therapy | 1996 |
One-week triple therapy with omeprazole, amoxycillin and either clarithromycin or metronidazole for cure of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; A | 1996 |
The role of screening for Helicobacter pylori in patients with duodenal ulceration in the primary health care setting.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Antibodies, Bacterial; Drug Therapy, | 1996 |
Metronidazole resistance: a predictor of failure of Helicobacter pylori eradication by triple therapy.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therapy, Com | 1996 |
Short-term low-dose triple therapy with lansoprazole plus amoxycillin and clarithromycin for Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Th | 1996 |
[Which factors influence the success of the classical triple therapy in the eradication of Helicobacter pylori?].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combi | 1996 |
Multiple strain colonization and metronidazole resistance in Helicobacter pylori-infected patients: identification from sequential and multiple biopsy specimens.
Topics: Biopsy; DNA, Bacterial; Drug Resistance, Microbial; Genetic Variation; Helicobacter Infections; Heli | 1996 |
An audit of low dose triple therapy for eradication of Helicobacter pylori.
Topics: Adult; Aged; Anti-Bacterial Agents; Antitrichomonal Agents; Drug Therapy, Combination; Female; Gastr | 1996 |
Acne rosacea and Helicobacter pylori betrothed.
Topics: Administration, Oral; Animals; Antitrichomonal Agents; Helicobacter Infections; Helicobacter pylori; | 1996 |
Effect of omeprazole on movement of intravenously administered metronidazole into gastric juice and its significance in treatment of Helicobacter pylori.
Topics: Adult; Biological Transport, Active; Drug Therapy, Combination; Gastric Juice; Gastric Mucosa; Helic | 1996 |
[Triple-therapy treatment during 1 month versus 2 weeks in gastroduodenal disease due to Helicobacter pylori in children].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Bismuth; Child; Child, Preschool; Drug Evaluation; D | 1996 |
Resolution of a metaplastic duodenal polyp after cure of Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Duodenal Neoplasms; Helicobacter Infection | 1996 |
Heterogeneity in susceptibility to metronidazole among Helicobacter pylori isolates from patients with gastritis or peptic ulcer disease.
Topics: Drug Resistance, Microbial; Gastritis; Helicobacter Infections; Helicobacter pylori; Humans; Metroni | 1996 |
Metronidazole, ranitidine and clarithromycin combination for treatment of Helicobacter pylori infection (modified Bazzoli's triple therapy).
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug | 1996 |
Dysfunction in gastric myoelectric and motor activity in Helicobacter pylori positive gastritis patients with non-ulcer dyspesia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithrom | 1996 |
Insulin-like growth factor-I in Helicobacter pylori gastritis and response to eradication using bismuth based triple therapy.
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Case-Control Studies; Drug Therapy, Co | 1996 |
[Connection between Helicobacter pylori infection and chronic gastrointestinal urticaria].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Antacids; Bismuth; Chronic Disease; Female; | 1996 |
Relevance of the ferret model of Helicobacter-induced gastritis to evaluation of antibacterial therapies.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disease Models, Anim | 1996 |
Triple therapy in duodenal ulcer healing--a follow up study.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Duodenal Ulcer; F | 1996 |
Effect of lansoprazole in mono-, dual-, or triple therapy on Helicobacter pylori eradication.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; | 1996 |
Endoscopic topical therapy for the treatment of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Topical; Amoxicillin; Antacids; Anti-Ulcer | 1996 |
Eradication of helicobacter pylori among patients from a primary care practice.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Chronic Disease; Drug Therapy, Combination; Endosco | 1996 |
Bacterial density of Helicobacter pylori predicts the success of triple therapy in bleeding duodenal ulcer.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Biopsy; Drug Therapy, Combination; Duodenal Ulcer; Female; Ga | 1996 |
Six months' experience with a pharmacist-run Helicobacter pylori treatment clinic.
Topics: Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Bismuth; Cost of Illness; Drug Therapy, | 1996 |
Drugs for treatment of peptic ulcers.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Diarrhea; Drug Inte | 1997 |
Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in The Netherlands.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple; Female; Helicobacter Infections; H | 1996 |
[Breath test in the diagnosis of Helicobacter pylori infection: concordance with histological methods and correlation with anatomopathological lesions of the gastric mucosa].
Topics: Adult; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Drug T | 1996 |
[Good results with Helicobacter pylori eradication for treatment of non-ulcer dyspepsia].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; D | 1996 |
Life-threatening interaction between clarithromycin and disopyramide.
Topics: Aged; Anti-Arrhythmia Agents; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Disopyramide | 1997 |
[Time course of disappearance of Helicobacter pylori after topical therapy and new triple therapy].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Administration, Oral; Anti-Bacterial Agents; Clarithromycin | 1997 |
[The treatment of children with Helicobarter pylory by triple therapy can be shortened without the risk of losing it eradicating efficacy. Letter].
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Antitrichomonal Agents; Child; Child, Preschool; Dru | 1996 |
Treating Helicobacter pylori--the best is yet to come?
Topics: Anti-Ulcer Agents; Bismuth; Clinical Trials as Topic; Drug Therapy, Combination; Helicobacter Infect | 1996 |
Effective 2-wk therapy for Helicobacter pylori disease in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Evaluation; Drug T | 1997 |
A one-week quadruple eradication regimen for Helicobacter pylori in routine clinical practice.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Breath Tests; Dru | 1997 |
The stability of amoxycillin, clarithromycin and metronidazole in gastric juice: relevance to the treatment of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Buffers; Chromatography, High Pressure Liquid | 1997 |
Effect of eradication of Helicobacter pylori in patients with fundic atrophic gastritis.
Topics: Amoxicillin; Bismuth; Female; Gastritis, Atrophic; Helicobacter Infections; Helicobacter pylori; Hum | 1997 |
[Triple ranitidine therapy in Helicobacter pylori infection. Recommendation for effective, safe and cost effective combination for Helicobacter pylori eradication].
Topics: Amoxicillin; Anti-Ulcer Agents; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Drug Admini | 1996 |
[Helicobacter pylori eradication: finally clarity].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Gastritis; Helicobacter I | 1996 |
Resolution of protein-losing hypertrophic gastropathy by eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Chil | 1997 |
Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents | 1997 |
Triple-drug therapy of Helicobacter pylori infection in duodenal ulcer disease.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; | 1997 |
Regression of a large gastric MALT lymphoma with antibiotic treatment to eradicate Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1997 |
[Early results of treating Helicobacter pylori infections in patients with gastric ulcer and gastritis].
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Drug Administration Schedule; Dr | 1996 |
Chronic abdominal pain and Helicobacter pylori.
Topics: Abdominal Pain; Adolescent; Anti-Bacterial Agents; Chronic Disease; Gastric Mucosa; Gastritis; Gastr | 1997 |
[Helicobacter pylori: pretherapeutic resistance status in Germany (Ruhr area)].
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Multiple; Female; Gastritis; Ge | 1997 |
In vitro assessment of gastric mucosal transfer of anti-Helicobacter therapeutic agents.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Antitrichomonal Agents; Biological Transport; Carbachol | 1997 |
Relation of lactoferrin levels in gastric mucosa with Helicobacter pylori infection and with the degree of gastric inflammation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Biomarke | 1997 |
Eradication therapy in peptic ulcer disease.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Monitoring; Drug Therapy, Combination; Helicobacter I | 1997 |
Clarithromycin resistance in Helicobacter pylori: prevalence in untreated dyspeptic patients and stability in vitro.
Topics: Adult; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Dyspepsia; Erythromycin; F | 1996 |
Ranitidine in a twice daily triple therapy regimen for the eradication of Helicobacter pylori.
Topics: Amoxicillin; Antitrichomonal Agents; Drug Administration Schedule; Drug Therapy, Combination; Duoden | 1997 |
Reversal of long-standing iron deficiency anaemia after eradication of Helicobacter pylori infection.
Topics: Adult; Anemia, Iron-Deficiency; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; D | 1997 |
Treatment of Helicobacter pylori infection favourably affects gastric mucosal superoxide dismutases.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Clarithromycin; Drug | 1997 |
Serum 13C-bicarbonate assay for the diagnosis of gastric Helicobacter pylori infection and response to treatment.
Topics: Amoxicillin; Bicarbonates; Bismuth; Carbon Isotopes; Clarithromycin; Drug Therapy, Combination; Gast | 1997 |
Successful low-dose amoxycillin, metronidazole and omeprazole combination therapy in a population with a high frequency of metronidazole-resistant Helicobacter pylori.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Resistance, Microbial; Drug Therapy, Combination; | 1997 |
Identification and eradication of Helicobacter pylori in an isolated patient population.
Topics: Amoxicillin; Bismuth; Cost Savings; Drug Therapy, Combination; Helicobacter Infections; Helicobacter | 1997 |
Unhealed duodenal ulcers despite Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithromycin; Drug Ad | 1997 |
Effect of Helicobacter pylori eradication on subsequent development of cancer after endoscopic resection of early gastric cancer.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Biopsy; Clarithromycin; Combined Modality Therapy; Dose | 1997 |
Short-term eradication therapy for Helicobacter pylori does not reduce the incidence of gastric metaplasia in duodenal ulcer patients.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; Female; Heli | 1997 |
[Effectiveness of short-term triple therapy for healing Helicobacter pylori infection in ulcer disease].
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin | 1997 |
Sensitivity of Helicobacter pylori to metronidazole.
Topics: Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Mic | 1997 |
Is the sanctuary where Helicobacter pylori avoids antibacterial treatment intracellular?
Topics: Adult; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Antibodies, Monoclonal; Antitrichomon | 1997 |
Helicobacter pylori eradication.
Topics: Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Tre | 1997 |
Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance.
Topics: Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; D | 1997 |
One-day high-dose combined therapy of Helicobacter pylori infection.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Evaluation; Drug Therapy, Combination; | 1997 |
Treatment of gastritis in cheetahs (Acinonyx jubatus).
Topics: Acinonyx; Animals; Anti-Bacterial Agents; Antitrichomonal Agents; Biopsy; Bismuth; Dose-Response Rel | 1997 |
Ménétrièr's disease associated with Helicobacter pylori infection: resolution of enlarged gastric folds and hypoproteinemia after antibacterial treatment.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; | 1997 |
Treatment of Helicobacter pylori infection: summary of a meeting at the Fourth United European Gastroenterology Week, September 20, 1995.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Antacids; Bismuth; Clarithromycin; Drug Resist | 1996 |
Natural and experimental Helicobacter mustelae reinfection following successful antimicrobial eradication in ferrets.
Topics: Amoxicillin; Animals; Antacids; Bacterial Proteins; Biopsy; Bismuth; DNA, Bacterial; Drug Therapy, C | 1996 |
Characterization and therapy for experimental infection by Helicobacter mustelae in ferrets.
Topics: Amoxicillin; Animals; Antacids; Antibodies, Bacterial; Bismuth; Drug Therapy, Combination; Female; F | 1996 |
An increase in Helicobacter pylori strains resistant to metronidazole: a five-year study.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Ampicillin; Antacids; Anti-Bacterial Agents; Bismuth; DN | 1996 |
Helicobacter pylori populations in Peruvian patients.
Topics: Adult; Aged; Anti-Bacterial Agents; DNA Fingerprinting; Drug Resistance, Microbial; Female; Helicoba | 1997 |
Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and -sensitive strains.
Topics: Amoxicillin; Animals; Antitrichomonal Agents; Disease Models, Animal; Drug Resistance, Microbial; He | 1997 |
Interaction of drugs for eradication therapy against antibiotic-resistant strains of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Colony | 1997 |
Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
Topics: Adult; Aged; Aged, 80 and over; Antacids; Anti-Bacterial Agents; Bismuth; Drug Administration Schedu | 1998 |
Anti-Helicobacter pylori specific antibody immunohistochemistry improves the diagnostic accuracy of Helicobacter pylori in biopsy specimen from patients treated with triple therapy.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Biopsy; D | 1998 |
[Antibiotic resistance among strains of Helicobacter pylori in Gothenburg. Bacteria resistant to metronidazole].
Topics: Antitrichomonal Agents; Drug Resistance, Multiple; Female; Helicobacter Infections; Helicobacter pyl | 1998 |
Pragmatic eradication of H. pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Helicobacter In | 1997 |
Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland.
Topics: Anti-Bacterial Agents; Antitrichomonal Agents; Child; Drug Resistance, Microbial; Drug Resistance, M | 1997 |
Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome.
Topics: Amoxicillin; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicoba | 1998 |
New, improved Helicobacter pylori eradication therapy in children.
Topics: Adolescent; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Clarithromycin; Drug Therapy, Combinati | 1998 |
Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Drug Resistance, Microbial; | 1998 |
One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Clarithromycin; Drug Administ | 1998 |
Antimicrobial resistance and Helicobacter pylori: impacts on current and future therapies.
Topics: Anti-Bacterial Agents; Australia; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter | 1998 |
[Short-term triple therapy with pantoprazole, amoxicillin and metronidazole in Helicobacter pylori infection].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; An | 1998 |
[Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?].
Topics: Abdominal Pain; Adolescent; Adult; Age Factors; Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-U | 1998 |
Effect of metronidazole resistance on bacterial eradication of Helicobacter pylori in infected children.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Child; Drug Resistance, Microbial; Drug Therap | 1998 |
Clostridium difficile colitis associated with a 'triple' regimen, containing clarithromycin and metronidazole, to eradicate Helicobacter pylori.
Topics: Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulcer; Enterocolitis, Pseudom | 1998 |
The ideal therapy must be defined in each geographical area: experience with a quadruple therapy in Spain.
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Femal | 1998 |
Eradication of Helicobacter pylori restores elevation of serum gastrin concentrations in patients with end-stage renal disease.
Topics: Ammonia; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Gastric Juice; | 1998 |
[Polyneuropathy caused by vitamin B12 deficiency secondary to chronic atrophic gastritis and giardiasis].
Topics: Amoxicillin; Anemia, Pernicious; Anti-Bacterial Agents; Antiprotozoal Agents; Bismuth; Duodenitis; E | 1998 |
Assessment of symptomatic response as predictor of Helicobacter pylori status following eradication therapy in patients with ulcer.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Breath T | 1998 |
Transmission of canine gastric Helicobacter salomonis infection from dam to offspring and between puppies.
Topics: Animals; Anti-Bacterial Agents; Biopsy; Disease Models, Animal; Dog Diseases; Dogs; Electrophoresis, | 1998 |
Four-day quadruple therapy as a routine treatment for Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Aged; Anti-Bacterial Agents; Anti-Ulcer | 1997 |
Clostridium difficile colitis associated with treatment of Helicobacter pylori infection.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Bismuth; Clostridioides difficile; Diarrhea; Enterocolitis | 1998 |
Demonstration of unexpected antibiotic resistance of genotypically identical Helicobacter pylori isolates.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; DNA, Bacterial; Drug Resistance, Microbial; Duod | 1998 |
[Evaluation of results of surgical treatment of peptic ulcer associated with Helicobacter pylori].
Topics: Adult; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Duodenal Ulcer; Evaluation Studi | 1998 |
Getting to the route of Helicobacter pylori treatment.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Delivery Systems; Drug Res | 1998 |
Detection of Helicobacter pylori in stool specimens by PCR and antigen enzyme immunoassay.
Topics: Adult; Amoxicillin; Antigens, Bacterial; Child; DNA, Bacterial; Feces; Follow-Up Studies; Helicobact | 1998 |
Antimicrobial susceptibility of Helicobacter pylori determined by the E test using tetrazolium egg yolk agar.
Topics: Agar; Culture Media; Egg Yolk; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; | 1998 |
Delayed healing of chronic gastric ulcer after Helicobacter pylori infection in mice.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Helicobacter Infections; Helicobacter pylori; Metronida | 1998 |
One-week treatment with omeprazole, clarithromycin, and metronidazole in children with Helicobacter pylori infection.
Topics: Adolescent; Child; Child, Preschool; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; H | 1998 |
Characterization of clinical isolates of Helicobacter pylori in Singapore.
Topics: Amoxicillin; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Bacterial Typing Techni | 1998 |
Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.
Topics: Anti-Bacterial Agents; Dose-Response Relationship, Drug; Drug Resistance, Microbial; Helicobacter In | 1998 |
Contact granulomas.
Topics: Anti-Bacterial Agents; Antibodies, Bacterial; Clarithromycin; Granuloma, Laryngeal; Helicobacter Inf | 1998 |
Use of a [13C]urea breath test for detection of gastric infection with Helicobacter spp in dogs.
Topics: Amoxicillin; Animals; Anti-Infective Agents; Anti-Ulcer Agents; Biopsy; Breath Tests; Carbon Isotope | 1998 |
Effect of ranitidine and metronidazole on 1gG activity of patients with Helicobacter pylori infection.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Antibodies, Bacterial; Antibodies, Catalytic; Gastr | 1998 |
Metronidazole- and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites.
Topics: Adult; Aged; Anti-Bacterial Agents; Case-Control Studies; Clarithromycin; Drug Resistance, Microbial | 1998 |
Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Asia, Southeastern; Australia; Drug Resistance, Microbial; | 1998 |
In-vitro evaluation of nitrofurantoin as an alternative agent for metronidazole in combination antimicrobial therapy against Helicobacter pylori.
Topics: Antacids; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, | 1998 |
The pharmacoeconomic impact of antimicrobial therapy for peptic ulcer disease in a large urban jail.
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Female; Helicob | 1998 |
One-week low-dose triple therapy is effective in treating Helicobacter pylori-infected patients with bleeding peptic ulcers.
Topics: Adult; Aged; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Gastrointestinal | 1998 |
Influence of metronidazole resistance on efficacy of quadruple therapy for Helicobacter pylori eradication.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Hum | 1998 |
[Treatment of Helicobacter pylori infection].
Topics: Antacids; Anti-Bacterial Agents; Clarithromycin; Dyspepsia; Gastroesophageal Reflux; Helicobacter In | 1998 |
Long-term follow-up of duodenal ulcer in children before and after eradication of Helicobacter pylori.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Biopsy; Bismuth; Child; Disease Progression; Drug Th | 1999 |
A new intragastric delivery system for the treatment of Helicobacter pylori associated gastric ulcer: in vitro evaluation.
Topics: Algorithms; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Drug Combinations; Drug Del | 1999 |
[Triple treatment for the eradication of Helicobacter pylori infection].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1998 |
Helicobacter pylori eradication treatment reduces the severity of rosacea.
Topics: Adult; Aged; Amoxicillin; Antacids; Anti-Bacterial Agents; Antibodies, Bacterial; Bismuth; Female; H | 1999 |
Understanding peptic ulcer disease pharmacotherapeutics.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Female; Helicob | 1999 |
Exposure to metronidazole in vivo readily induces resistance in Helicobacter pylori and reduces the efficacy of eradication therapy in mice.
Topics: Animals; Anti-Bacterial Agents; Disease Models, Animal; Drug Resistance, Microbial; Helicobacter Inf | 1999 |
Duodenal ulcer disease: to treat H. pylori infection or not?
Topics: Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Hu | 1992 |
[Profile of the resistance to macrolides and imidazoles of Helicobacter pylori in a sample of the Portuguese population].
Topics: Anti-Bacterial Agents; Biopsy; Clarithromycin; Drug Resistance, Microbial; Gastroscopy; Helicobacter | 1998 |
Immunization with recombinant Helicobacter pylori urease decreases colonization levels following experimental infection of rhesus monkeys.
Topics: Adjuvants, Immunologic; Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Toxins; Bac | 1999 |
Effect of Helicobacter pylori eradication on the natural history of duodenal ulcer disease.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Drug Therapy, Combination; Duodenal Ulcer; Fo | 1998 |
Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases.
Topics: ABO Blood-Group System; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antigens, Bacterial; | 1998 |
Prospective evaluation of ranitidine bismuth citrate-based triple therapy for the treatment of Helicobacter pylori infection.
Topics: Adult; Aged; Anti-Ulcer Agents; Bismuth; Drug Administration Schedule; Drug Therapy, Combination; Fe | 1999 |
Prevalence of Helicobacter pylori resistance to metronidazole, clarithromycin, amoxycillin, tetracycline and trovafloxacin in The Netherlands.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Drug Resistance, Mul | 1999 |
Predominance of a single strain of Helicobacter pylori in gastric antrum.
Topics: Antibiosis; Biopsy; DNA Fingerprinting; DNA, Bacterial; Electrophoresis, Agar Gel; Helicobacter Infe | 1999 |
Metronidazole resistance and virulence factors in Helicobacter pylori as markers for treatment failure in a paediatric population.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Pr | 1999 |
A new quadruple therapy for Helicobacter pylori: influence of resistant strains on treatment outcome.
Topics: Adult; Aged; Amoxicillin; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacte | 1999 |
The effect of Helicobacter pylori eradication on gastro-oesophageal reflux.
Topics: Adult; Aged; Antacids; Anti-Bacterial Agents; Bismuth; Breath Tests; Drug Therapy, Combination; Esop | 1999 |
Two- to four-year histological follow-up of gastric mucosa after Helicobacter pylori eradication.
Topics: Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Female; Follow-Up Studies; Gast | 1999 |
Use of a urea breath test to evaluate short-term treatments for cats naturally infected with Helicobacter heilmannii.
Topics: Animals; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Antitrichomonal Agents; Azithromycin; B | 1999 |
Angioedema due to acquired C1-esterase inhibitor deficiency in a patient with Helicobacter pylori infection.
Topics: Adult; Angioedema; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Autoantibodies; C | 1999 |
My approach to Helicobacter pylori eradication.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Helicobacter Infections; Helicobacter pylori; Hu | 1999 |
Significance of anaerobic preincubation of Helicobacter pylori for measuring metronidazole susceptibility by the Etest.
Topics: Anaerobiosis; Gastric Mucosa; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; M | 1999 |
Evaluation of the factors influencing stomach-specific delivery of antibacterial agents for Helicobacter pylori infection.
Topics: Amoxicillin; Chitin; Chitosan; Drug Stability; Gastric Mucosa; Helicobacter Infections; Helicobacter | 1999 |
Efficacy of 1-week ranitidine-bismuth-citrate (RBC)-based triple therapy for eradication of Helicobacter pylori infection.
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clinical Trials as Topic; Drug Therapy, Combinat | 1999 |
[Symptomatic improvement of patients with nonulcer dyspepsia after Helicobacter pylori eradication].
Topics: Amoxicillin; Anti-Ulcer Agents; Breath Tests; Drug Therapy, Combination; Dyspepsia; Helicobacter Inf | 1999 |
Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States.
Topics: Anti-Bacterial Agents; Clarithromycin; Female; Helicobacter Infections; Helicobacter pylori; Hospita | 1999 |
Is there any difference in Helicobacter pylori eradication rates in patients with active peptic ulcer, inactive peptic ulcer and functional dyspepsia?
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Dy | 1999 |
Omeprazole, amoxycillin and metronidazole for the cure of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter Infec | 1999 |
What can be learnt from the new data about antibiotic resistance? Are there any practical clinical consequences of Helicobacter pylori antibiotic resistance?
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, | 1999 |
Re-treatment after Helicobacter pylori eradication failure.
Topics: Adult; Ampicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistanc | 1999 |
Simultaneous quantification of amoxycillin and metronidazole in plasma using high-performance liquid chromatography with photodiode array detection.
Topics: Amoxicillin; Chromatography, High Pressure Liquid; Helicobacter Infections; Humans; Metronidazole; S | 1999 |
Rapidly growing primary gastric B-cell lymphoma after eradication of Helicobacter pylori.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Gastrointestinal Neoplasms; Helicobacter I | 1999 |
Comparative evaluation of two methods for testing metronidazole susceptibility of Helicobacter pylori in routine practice.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Child; Child, Preschool; Drug Resistance, Microbial; | 1999 |
A survey of gastroenterologists' perceptions and practices related to Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Attitude of Health Personnel; Breath Tests; Carbon Isotopes; Car | 1999 |
CYP2C19 genotype-related efficacy of omeprazole for the treatment of infection caused by Helicobacter pylori.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Aryl Hydrocarbon Hydroxylases; Bism | 1999 |
Duodenal ulcer relapse is not always associated with recurrence of H. pylori infection: a prospective three-year follow-up study.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Drug Therapy, Combination; Duodenal Ulcer; | 1999 |
Regression of colonic low grade B cell lymphoma of the mucosa associated lymphoid tissue type after eradication of Helicobacter pylori.
Topics: Aged; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Colonic Neoplasms; Drug Therapy, Com | 2000 |
[Resolution of an autoimmune thrombocytopenic purpura after eradicating treatment of Helicobacter pylori].
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; Bismuth; Drug Therapy, Combination; Fema | 1999 |
Regression of high-grade gastric mucosa-associated lymphoid tissue lymphoma with Helicobacter pylori after triple antibiotic therapy.
Topics: Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Helicobacter | 2000 |
Relationship between eradication therapy and clarithromycin-resistant Helicobacter pylori in Japan.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clar | 2000 |
The long-term reinfection rate and the course of duodenal ulcer disease after eradication of Helicobacter pylori in a developing country.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Chile; Developing Countries; Drug Therapy, | 2000 |
Symptomatic benefit 1-3 years after H. pylori eradication in ulcer patients: impact of gastroesophageal reflux disease.
Topics: Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Femal | 2000 |
H. pylori: isolation and sensitivity from biopsy specimen of CLO positive patients.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Hum | 1999 |
Cell damage and proliferation in human gastric mucosa infected by Helicobacter pylori--a comparison before and after H pylori eradication in non-atrophic gastritis.
Topics: Anti-Bacterial Agents; Biopsy; Cell Division; Clarithromycin; DNA Damage; Gastric Mucosa; Gastritis; | 1999 |
Frequent association between alteration of the rdxA gene and metronidazole resistance in French and North African isolates of Helicobacter pylori.
Topics: Africa, Northern; Amino Acid Sequence; Anti-Bacterial Agents; Drug Resistance, Microbial; France; He | 2000 |
Unsuccessful treatment results in survival of less virulent genotypes of Helicobacter pylori in Colombian patients.
Topics: Amoxicillin; Antacids; Anti-Bacterial Agents; Bismuth; Chemoprevention; Colombia; Follow-Up Studies; | 2000 |
Inflammatory fibroid polyp and Helicobacter pylori. Aetiology or coincidence?
Topics: Amoxicillin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pylori; Humans | 2000 |
Helicobacter pylori: related to rosacea?
Topics: Amoxicillin; Anti-Bacterial Agents; Case-Control Studies; Drug Therapy, Combination; Helicobacter In | 2000 |
Does Helicobacter pylori have a role in the pathogenesis of rosacea?
Topics: Anti-Bacterial Agents; Case-Control Studies; Confounding Factors, Epidemiologic; Helicobacter Infect | 2000 |
Successful eradication of Helicobacter pylori as determined by ((13))C-urea breath test does not alter fibrinogen and acute phase response markers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acute-Phase Reaction; Adult; Aged; Anti-Bacterial Agents; A | 2000 |
A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule.
Topics: Adult; Aged; Anti-Ulcer Agents; Capsules; Female; Gastritis; Gastroscopy; Helicobacter Infections; H | 2000 |
Treatment of Helicobacter pylori infection in clinical practice in the United States: results from 224 patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Bacterial Agents; Bismuth; Clarithromycin; Drug Therap | 2000 |
Mucosal change of the stomach with low-grade mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori: follow-up study of 48 cases.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Drug Therapy, Combination; Female | 2000 |
Primary and combined resistance to four antimicrobial agents in Helicobacter pylori in Sofia, Bulgaria.
Topics: Adolescent; Adult; Aged; Anti-Bacterial Agents; Bulgaria; Child; Child, Preschool; Chronic Disease; | 2000 |
Distinctiveness of genotypes of Helicobacter pylori in Calcutta, India.
Topics: Adult; Aged; Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Base Sequence; Drug Res | 2000 |
Metronidazole resistance in Helicobacter pylori.
Topics: Anti-Bacterial Agents; Drug Resistance, Microbial; Helicobacter Infections; Helicobacter pylori; Hum | 1999 |
Metronidazole-resistant Helicobacter pylori in an urban Asian population.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Asia; Drug Resistance, Microbial; | 2000 |
Influence of age on the steady state disposition of drugs commonly used for the eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Age Factors; Aged; Amoxicillin; Anti-Bacterial Agent | 2000 |
[IgG and IgA immunoglobulins in helicobacter pylori infections of children with chronic dyspepsia before and after two week triple drug therapy].
Topics: Adolescent; Amoxicillin; Bismuth; Blotting, Western; Child; Chronic Disease; Drug Therapy, Combinati | 1999 |
Helicobacter pylori treatment and antibiotic susceptibility: results of a five-year audit.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resis | 1999 |
High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; DNA Mutational An | 2000 |
Iron-deficiency anemia associated with Helicobacter pylori gastritis.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Anemia, Iron-Deficiency; Anti-Bacterial Agents; | 2000 |
Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; F | 2000 |
[Quamatel application in three-drug eradication therapy of duodenal ulcer and gastroduodenal ulcerations associated with helicobacter pylori infection].
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Duodenal Ulcer; Fa | 2000 |
OAM for cure of Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Clarithromycin; Drug C | 2000 |
[The role of omeprazole in the eradication of Helicobacter pylori in patients with duodenal ulcers].
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combin | 2000 |
[Helicobacter pylori eradication in gastroduodenal ulcer: good, fine and not expensive].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Cost-Benefit Analysis; Drug T | 2000 |
Evaluation of nitrofurantoin combination therapy of metronidazole-sensitive and -resistant Helicobacter pylori infections in mice.
Topics: Animals; Anti-Infective Agents, Urinary; Antitrichomonal Agents; Bacterial Proteins; Cloning, Molecu | 2000 |
Efficacy of a 1-week pantoprazole triple therapy in eradicating Helicobacter pylori in Asian patients.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Helicobacter pylori and rosacea.
Topics: Administration, Topical; Anti-Bacterial Agents; Bacterial Toxins; Helicobacter Infections; Helicobac | 2000 |
Single drug therapy for Helicobacter pylori infection.
Topics: Bismuth; Capsules; Drug Combinations; Gastritis; Helicobacter Infections; Helicobacter pylori; Human | 2000 |
[Upgrading efficiency and safety of combined antihelicobacterial treatment of ulcer patients using modern clinicopharmacological approaches].
Topics: Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Dose-Response Relationship, Drug; Drug Therapy, Com | 2000 |
Isolation of a single strain of Helicobacter pylori from the antrum and body of individual patients.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Biopsy; DNA Fingerprinting; Female; Helicobac | 2000 |
Pooled analysis of Helicobacter pylori eradication regimes in Asia.
Topics: Asia; Bismuth; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pylori; Humans; Metr | 2000 |
Drug resistance in Helicobacter pylori infection.
Topics: Anti-Bacterial Agents; Antitrichomonal Agents; Clarithromycin; Drug Resistance, Microbial; Helicobac | 2000 |
Cure of Helicobacter pylori infection after failed primary treatment: one-center results from 120 patients.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Female; Follow-Up Studies; Helicob | 2000 |
Short-term infection with Helicobacter pylori and 1 week exposure to metronidazole does not enhance gastric mutation frequency in transgenic mice.
Topics: Animals; Anti-Bacterial Agents; Biotransformation; DNA Damage; Helicobacter Infections; Helicobacter | 2000 |
Endoscopic characteristics of low-grade gastric mucosa-associated lymphoid tissue lymphoma after eradication of Helicobacter pylori.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer | 2000 |
Efficacy of omeprazole plus two antimicrobials for the eradication of Helicobacter pylori in a Turkish population.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Therapy, Combination; Enzyme Inhibitors; He | 2000 |
Strategies to treat patients with antibiotic resistant Helicobacter pylori.
Topics: Amoxicillin; Anti-Bacterial Agents; Bismuth; Drug Resistance, Microbial; Drug Therapy; Drug Therapy, | 2000 |
Furazolidone- and nitrofurantoin-resistant Helicobacter pylori: prevalence and role of genes involved in metronidazole resistance.
Topics: Anti-Infective Agents, Urinary; Antitrichomonal Agents; Drug Resistance, Microbial; Furazolidone; Ge | 2001 |
High levels of resistance to metronidazole and clarithromycin in Helicobacter pylori strains in children.
Topics: Adolescent; Anti-Bacterial Agents; Child; Clarithromycin; Drug Resistance, Microbial; Female; Helico | 2001 |
[Efficacy of a multistep strategy for Helicobacter pylori eradication: quadruple therapy with omeprazole, metronidazole, tetracycline and bismuth after failure of a combination of omeprazole, clarithromycin and amoxycillin].
Topics: Anti-Ulcer Agents; Bismuth; Combined Modality Therapy; Drug Therapy, Combination; Female; Helicobact | 2000 |
[High eradication rates in Helicobacter pylori infection in patients with duodenal ulcer who failed previous eradication therapy].
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duodenal Ulc | 2000 |
Prevalence of Helicobacter pylori resistant strains in the southern part of Switzerland.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug | 2000 |
The use of AP-PCR and flaA-RFLP typing to investigate treatment failure in Helicobacter pylori infection.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Antigens, Bacterial; Bacterial Proteins; Clar | 2000 |
Antibiotic-resistance patterns of Helicobacter pylori in Croatia: cohort study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Amoxicillin; Benzimidazoles | 2001 |
Helicobacter pylori: changing patterns of ulcer disease and antibiotic resistance.
Topics: Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Australia; Clarit | 2000 |
Antibiotic resistance in Helicobacter pylori.
Topics: Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Microbial; Female; Gastroscopy; Helicobacter | 2000 |
Analysis of metronidazole, clarithromycin and tetracycline resistance of Helicobacter pylori isolates from Korea.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aging; Clarithromycin; Drug Resistance, Microbial; Femal | 2001 |
Evolution of metronidazole and tetracycline susceptibility pattern in Helicobacter pylori at a hospital in Saudi Arabia.
Topics: Anti-Bacterial Agents; Cross Infection; Drug Resistance, Microbial; Female; Helicobacter Infections; | 2001 |
High prevalence of mixed infections by Helicobacter pylori in Hong Kong: metronidazole sensitivity and overall genotype.
Topics: Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Biopsy; DNA Fingerprinting; DNA, Bacterial; D | 2001 |
[Principles of managing Helicobacter pylori infections. Guidelines of the European Society of Gastroenterology in Primary Health Care].
Topics: Amoxicillin; Biopsy; Clarithromycin; Drug Resistance, Microbial; Duodenoscopy; Enzyme-Linked Immunos | 2000 |
Beneficial effect of Helicobacter pylori eradication in dermatologic diseases.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Blotting, Western; Clarithromycin; D | 2001 |
Studies on the development and stability of resistance of Helicobacter pylori to metronidazole and clarithromycin.
Topics: Anti-Bacterial Agents; Cell Culture Techniques; Clarithromycin; Dose-Response Relationship, Drug; Dr | 2001 |
Eradication of Helicobacter pylori from the stomach and duodenum of patients with duodenal ulcers.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Duodenum; Enzyme-Linked Immunosorbent Assay; | 2001 |
Pattern of primary resistance of Helicobacter pylori to metronidazole or clarithromycin in the United States.
Topics: Adult; Age Factors; Aged; Anti-Bacterial Agents; Antitrichomonal Agents; Clarithromycin; Drug Resist | 2001 |
[Eradication therapy of Helicobacter pylori in antibiotic resistance].
Topics: Amoxicillin; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Microbial; Drug Therapy, Combinatio | 2001 |
Polycolonization of Helicobacter pylori among Chinese subjects.
Topics: Adult; Anti-Bacterial Agents; China; Clarithromycin; Drug Resistance, Microbial; Electrophoresis, Po | 2001 |
Amplified fragment length polymorphism genotyping of metronidazole-resistant Helicobacter pylori infecting dyspeptics in England.
Topics: Anti-Bacterial Agents; Cluster Analysis; Deoxyribonuclease HindIII; DNA, Bacterial; Drug Resistance, | 2001 |
In search of the Holy Grail of Heliocobacter pylori remedies.
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents; Anti-Ulcer Agents; Bismuth; Clarithromyci | 2001 |
Strategy for retreatment of therapeutic failure of eradication of Helicobacter pylori infection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agent | 2001 |
A prospective study of a one-week nonbismuth quadruple therapy for childhood Helicobacter pylori infection.
Topics: Adolescent; Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Child; Child, Preschool; C | 2001 |
Implications of the simultaneous presence of metronidazole-susceptible and -resistant Helicobacter pylori colonies within a single biopsy specimen.
Topics: Anti-Bacterial Agents; Biopsy; Digestive System; DNA Fingerprinting; DNA, Bacterial; Drug Resistance | 2001 |
A 9 year study of clarithromycin and metronidazole resistance in Helicobacter pylori from Spanish children.
Topics: Anti-Bacterial Agents; Chi-Square Distribution; Child; Child, Preschool; Clarithromycin; Confidence | 2001 |
Disappearance of antiphospholipid antibodies syndrome after Helicobacter pylori eradication.
Topics: Adult; Antiphospholipid Syndrome; Clarithromycin; Drug Therapy, Combination; Female; Gastritis; Heli | 2001 |
[Current principles of the use of laparoscopic surgery in gastroduodenal ulcer].
Topics: Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Therapy, Combination; Duode | 2001 |
Differentiation of metronidazole-sensitive and -resistant clinical isolates of Helicobacter pylori by immunoblotting with antisera to the RdxA protein.
Topics: Animals; Anti-Bacterial Agents; Antibodies, Bacterial; Bacterial Proteins; Drug Resistance, Bacteria | 2001 |
Eradication rates of Helicobacter pylori between metronidazole-sensitive and metronidazole-resistant strains with metronidazole containing regimen in Thai patients with peptic ulcer disease.
Topics: Adult; Aged; Chi-Square Distribution; Clarithromycin; Drug Resistance; Drug Therapy, Combination; Fe | 2001 |
Efficacy of Helicobacter pylori eradication therapies: a single centre observational study.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Bismuth; Clarithromycin; Drug Resistance, Bacterial; Drug | 2001 |
Healing of active, non-atrophic autoimmune gastritis by H. pylori eradication.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Autoimmune Diseases; Clarithromycin; | 2001 |
Influence of anti-Helicobacter triple-therapy with metronidazole, omeprazole and clarithromycin on intestinal microflora.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Case-Control Studies; Clarithromycin; Drug Therapy, Combin | 2001 |
Antibiotic susceptibility of Helicobacter pylori in the Chinese population.
Topics: China; Clarithromycin; DNA Fingerprinting; DNA, Bacterial; Drug Resistance, Multiple; Follow-Up Stud | 2001 |
Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults.
Topics: Adult; Amoxicillin; Anti-Ulcer Agents; Bangladesh; Body Mass Index; Breath Tests; Carbon Isotopes; D | 2001 |
Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole-amoxicillin-clarithromycin therapy.
Topics: Adolescent; Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Biopsy; Clarithromycin; DNA, Bacterial; Dru | 2001 |
First successful treatment of a primary high-grade gastric MALT lymphoma by eradication therapy for Helicobacter pylori.
Topics: Biopsy; Clarithromycin; Drug Therapy, Combination; Female; Helicobacter Infections; Helicobacter pyl | 2001 |
Identification of differentially regulated proteins in metronidozole resistant Helicobacter pylori by proteome techniques.
Topics: Bacterial Proteins; Drug Resistance, Bacterial; Electrophoresis, Gel, Two-Dimensional; Gene Expressi | 2001 |
Resolution of granulomatous rosacea after eradication of Helicobacter pylori with clarithromycin, metronidazole and pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Anti-Bacterial Agents; Anti-Ulcer Agents; Benzimidaz | 2001 |
The role of treatment with proton pump inhibitors and anti-Helicobacter therapy in functional dyspepsia.
Topics: Amoxicillin; Anti-Bacterial Agents; Drug Therapy, Combination; Dyspepsia; Enzyme Inhibitors; Helicob | 2001 |
[Prevalence of primary Helicobacter pylori resistance to eight antimicrobial agents in a hospital in Madrid].
Topics: Adult; Aged; Amoxicillin; Azithromycin; Cefotaxime; Ciprofloxacin; Clarithromycin; Clindamycin; Cros | 2001 |
Prospective study of Helicobacter pylori eradication therapy in stage I(E) high-grade mucosa-associated lymphoid tissue lymphoma of the stomach.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Female; Follo | 2001 |
Six-year follow-up after successful triple therapy for Helicobacter pylori infection in patients with peptic ulcer disease.
Topics: Aged; Antacids; Anti-Bacterial Agents; Anti-Ulcer Agents; Drug Therapy, Combination; Female; Follow- | 2001 |
Duodenal mucosa-associated lymphoid tissue lymphoma treated by eradication of Helicobacter pylori: report of 2 cases including EUS findings.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Benzimidazoles; Biopsy, Needle; Clarithr | 2001 |
European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori.
Topics: Amoxicillin; Clarithromycin; Confidence Intervals; Drug Resistance, Microbial; Europe; Helicobacter | 2001 |
Summaries for patients. Factors associated with Helicobacter pylori infections in the United States that are resistant to usual antibiotics.
Topics: Amoxicillin; Anti-Bacterial Agents; Clarithromycin; Drug Resistance, Bacterial; Gastritis; Helicobac | 2002 |
Drug combinations with amoxycillin reduce selection of clarithromycin resistance during Helicobacter pylori eradication therapy.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Amoxicillin; Anti-Bacterial Agents; Benzimidazoles; Clarith | 2002 |
Antibiotic resistance of Helicobacter pylori strains in Japanese children.
Topics: Adolescent; Amoxicillin; Anti-Bacterial Agents; Child; Child, Preschool; Clarithromycin; Drug Resist | 2002 |
Pyloricidins, novel anti-helicobacterpylori antibiotics produced by Bacillus sp. I. Taxonomy, fermentation and biological activity.
Topics: Amoxicillin; Animals; Anti-Bacterial Agents; Bacillus; Biological Assay; Clarithromycin; Fermentatio | 2001 |
[Dyspepsia and Helicobacter pylori infection in employees of a large industry. Results of a prospective BASF Helicobacter pylori prevention campaign].
Topics: Adolescent; Adult; Clarithromycin; Drug Therapy, Combination; Dyspepsia; Female; Gastritis; Germany; | 2002 |
Second-line Helicobacter pylori eradication with a furazolidone-based regimen in patients who have failed a metronidazole-based regimen.
Topics: Adult; Amoxicillin; Anti-Bacterial Agents; Anti-Infective Agents, Local; Drug Therapy, Combination; | 2001 |
In vitro activity of rifampicin against Helicobacter pylori isolated from children and adults.
Topics: Adolescent; Adult; Amoxicillin; Biopsy; Child; Child, Preschool; Clarithromycin; Drug Resistance, Mu | 2002 |
Resolution of collagenous colitis after treatment for Helicobacter pylori.
Topics: Aged; Biopsy, Needle; Clarithromycin; Colitis; Collagen; Diarrhea; Drug Therapy, Combination; Female | 2002 |
The effect of Helicobacter pylori eradication on the natural course of atrophic gastritis with dysplasia.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Amoxicillin; Anti-Bacterial Agents; Drug Combinations | 2002 |
Management of Helicobacter pylori infection. Eradication treatment can be tailored in patients undergoing endoscopy.
Topics: Anti-Bacterial Agents; Drug Resistance, Bacterial; Endoscopy, Gastrointestinal; Helicobacter Infecti | 2002 |
[Acquisition of secondary resistance after failure of a first treatment of Helicobacter pylori infection in children].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Age Factors; Amoxicillin; Anti-Bacterial Agents | 2002 |
Effects of metronidazole, tetracycline, and bismuth-metronidazole-tetracycline triple therapy in the Helicobacter pylori SS1 mouse model after 1 day of dosing: development of an H. pylori lead selection model.
Topics: Animals; Bismuth; Disease Models, Animal; Drug Therapy, Combination; Female; Helicobacter Infections | 2002 |
Association of metronidazole resistance and natural competence in Helicobacter pylori.
Topics: Anti-Bacterial Agents; Chloramphenicol O-Acetyltransferase; Drug Resistance, Bacterial; Helicobacter | 2002 |
[Evolution of the sensitivity of 235 strains of Helicobacter pylori from 1995 to 1998 and impact of antibiotic treatment].
Topics: Amoxicillin; Anti-Bacterial Agents; Anti-Ulcer Agents; Clarithromycin; Drug Resistance, Bacterial; D | 2002 |
Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil.
Topics: Anti-Bacterial Agents; Antigens, Bacterial; Bacterial Proteins; Brazil; Clarithromycin; DNA, Bacteri | 2002 |
Localization of antigen-presenting cells in Helicobacter pylori-infected gastric mucosa.
Topics: Anti-Bacterial Agents; Anti-Ulcer Agents; Antigen-Presenting Cells; CD28 Antigens; Cell Count; Clari | 2002 |
Resistance of Helicobacter pylori isolated in Israel to metronidazole, clarithromycin, tetracycline, amoxicillin and cefixime.
Topics: Amoxicillin; Cefixime; Chi-Square Distribution; Clarithromycin; Confidence Intervals; Drug Resistanc | 2002 |
Metronidazole: avoid it unless it's very much indicated (avoid its routine prescription).
Topics: Anti-Bacterial Agents; Drug Prescriptions; Drug Resistance, Bacterial; Helicobacter Infections; Heli | 2002 |
Prevalence of H. pylori-infection in family members of H. pylori positive and its influence on the reinfection rate after successful eradication therapy: a two-year follow-up.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Breath Tests; Child; Child, Preschool; Clarithromycin; D | 2002 |
In vitro anti-Helicobacter pylori activity of BAS-118, a new benzamide derivative.
Topics: Anti-Bacterial Agents; Benzamides; Clarithromycin; Drug Resistance, Bacterial; Helicobacter Infectio | 2002 |
Eradicating Helicobacter pylori.
Topics: Amoxicillin; Bismuth; Drug Resistance, Microbial; Drug Therapy, Combination; Dyspepsia; Helicobacter | 1992 |
Eradicating Helicobacter pylori.
Topics: Bismuth; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; Helico | 1992 |
Eradicating Helicobacter pylori.
Topics: Amoxicillin; Drug Administration Schedule; Drug Resistance, Microbial; Drug Therapy, Combination; He | 1992 |
Smoking does not contribute to duodenal ulcer relapse after Helicobacter pylori eradication.
Topics: Anti-Ulcer Agents; Duodenal Ulcer; Female; Follow-Up Studies; Helicobacter Infections; Helicobacter | 1992 |
Clinicopathological assessment of gastric biopsy samples of patients with Helicobacter pylori infection--metronidazole resistance and compliance problems in the United Arab Emirates.
Topics: Adolescent; Adult; Antacids; Bacteriological Techniques; Bismuth; Doxycycline; Drug Resistance, Micr | 1992 |
Eradication of Helicobacter pylori reduces gastric and duodenal ulcer recurrence.
Topics: Bismuth; Helicobacter Infections; Helicobacter pylori; Humans; Metronidazole; Organometallic Compoun | 1992 |
Mucosal peptic activity during Helicobacter pylori infection in pediatric patients.
Topics: Adolescent; Amoxicillin; Child; Child, Preschool; Female; Gastric Mucosa; Gastritis; Helicobacter In | 1992 |
Triple therapy of Helicobacter pylori infection in peptic ulcer. A 12-month follow-up study of 93 patients.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Dose-Response | 1992 |
pH-dependent secretion of gastrin in duodenal ulcer disease: effect of suppressing Helicobacter pylori.
Topics: Amoxicillin; Anti-Ulcer Agents; Duodenal Ulcer; Female; Gastric Acid; Gastrins; Helicobacter Infecti | 1992 |
Eradicating Helicobacter pylori in patients with duodenal ulcer.
Topics: Drug Resistance, Microbial; Duodenal Ulcer; Helicobacter Infections; Helicobacter pylori; Humans; Me | 1992 |
Is there a place for antacids in the treatment of Helicobacter pylori infection?
Topics: Adult; Aluminum Hydroxide; Antacids; Breath Tests; Carbonates; Clinical Enzyme Tests; Drug Therapy, | 1992 |
Halitosis and Helicobacter pylori. A possible link?
Topics: Antacids; Family Health; Female; Halitosis; Helicobacter Infections; Helicobacter pylori; Humans; Ma | 1992 |
Helicobacter pylori-related hypergastrinaemia is not due to elevated antral surface pH. Studies with antral alkalinisation.
Topics: Adult; Amoxicillin; Antacids; Duodenal Ulcer; Female; Gastrins; Helicobacter Infections; Helicobacte | 1992 |
Duodenal ulcer and eradication of Helicobacter pylori in a developing country. An 18-month follow-up study.
Topics: Amoxicillin; Brazil; Developing Countries; Drug Therapy, Combination; Duodenal Ulcer; Duodenoscopy; | 1992 |
Short report: short-term triple therapy for H. pylori-associated duodenal ulcer disease.
Topics: Adult; Anti-Ulcer Agents; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Helicobacter I | 1992 |
Secretion of intravenously administered antibiotics in gastric juice: implications for management of Helicobacter pylori.
Topics: Adult; Ampicillin; Erythromycin; Gastric Juice; Helicobacter Infections; Helicobacter pylori; Humans | 1992 |
The role of Helicobacter pylori in the pathogenesis of acid-peptic disease.
Topics: Adolescent; Adult; Anti-Bacterial Agents; Black or African American; Dyspepsia; Gastritis; Helicobac | 1992 |
Role of metronidazole resistance in therapy of Helicobacter pylori infections.
Topics: Adult; Aged; Aged, 80 and over; Amoxicillin; Anti-Ulcer Agents; Drug Resistance, Microbial; Female; | 1992 |
Does a previous course of tripotassium dicitrato bismuthate affect the subsequent chances of successful Helicobacter pylori eradication?
Topics: Adult; Aged; Drug Administration Schedule; Drug Resistance, Microbial; Duodenal Ulcer; Dyspepsia; Fe | 1992 |
[Helicobacter pylori: from harmless commensal to clinically significant disease factor].
Topics: Amoxicillin; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Dyspepsia; Gastritis; Helicobacter | 1992 |
Helicobacter pylori and non-ulcer dyspepsia.
Topics: Colloids; Drug Therapy, Combination; Dyspepsia; Helicobacter Infections; Helicobacter pylori; Humans | 1992 |
Suppression of Helicobacter pylori reduces gastrin releasing peptide stimulated gastrin release in duodenal ulcer patients.
Topics: Adult; Duodenal Ulcer; Female; Gastrin-Releasing Peptide; Gastrins; Helicobacter Infections; Helicob | 1992 |
Factors influencing the eradication of Helicobacter pylori with triple therapy.
Topics: Adult; Aged; Aged, 80 and over; Bismuth; Drug Therapy, Combination; Duodenal Ulcer; Female; Gastriti | 1992 |
[Helicobacter pylori and duodenal ulcer. Long-term results of triple sucralfate antibiotic therapy].
Topics: Adult; Aged; Amoxicillin; Drug Therapy, Combination; Duodenal Ulcer; Helicobacter Infections; Helico | 1991 |
[The treatment of patients with chronic gastritis].
Topics: Adult; Chronic Disease; Drug Evaluation; Female; Gastritis; Health Resorts; Helicobacter Infections; | 1991 |
Severe Helicobacter pylori infection in a patient with AIDS.
Topics: Acquired Immunodeficiency Syndrome; Adult; Ampicillin; Animals; Biopsy; Drug Therapy, Combination; G | 1991 |
Evaluation of a commercial latex test for serological diagnosis of Helicobacter pylori infection in treated and untreated patients.
Topics: Amoxicillin; Antibodies, Bacterial; Drug Therapy, Combination; Evaluation Studies as Topic; Helicoba | 1991 |
Plasma gastrin, daytime intragastric pH, and nocturnal acid output before and at 1 and 7 months after eradication of Helicobacter pylori in duodenal ulcer subjects.
Topics: Adult; Aged; Amoxicillin; Anti-Ulcer Agents; Bismuth; Circadian Rhythm; Duodenal Ulcer; Female; Gast | 1991 |
Five-day bismuth-free triple therapy for the eradication of Helicobacter pylori and reduction of duodenal ulcer relapse.
Topics: Adult; Amoxicillin; Breath Tests; Carbon Radioisotopes; Drug Administration Schedule; Drug Therapy, | 1991 |
Eradication of Helicobacter pylori abolishes 24-hour hypergastrinaemia: a prospective study in healthy subjects.
Topics: Adult; Amoxicillin; Circadian Rhythm; Duodenal Ulcer; Female; Gastric Acidity Determination; Gastrin | 1991 |
Therapy in Helicobacter pylori infection.
Topics: Amoxicillin; Drug Interactions; Drug Therapy, Combination; Helicobacter Infections; Helicobacter pyl | 1990 |
Helicobacter pylori and metronidazole resistance.
Topics: Adult; Antacids; Drug Resistance, Microbial; Drug Therapy, Combination; Female; Helicobacter Infecti | 1990 |
Helicobacter pylori infection treated with a tripotassium dicitrato bismuthate and metronidazole combination.
Topics: Aged; Anti-Ulcer Agents; Breath Tests; Drug Resistance, Microbial; Drug Therapy, Combination; Helico | 1990 |